7689-03-4 | (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
1g	98%	in stock	$16.00	$11.00
5g	98%	in stock	$72.00	$51.00
10g	98%	in stock	$138.00	$97.00
25g	98%	in stock	$288.00	$202.00
100g	98%	in stock	$997.00	$698.00

Description

• Catalog Number: AB54472
• Chemical Name: (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
• CAS Number: 7689-03-4
• Molecular Formula: C20H16N2O4
• Molecular Weight: 348.3520
• MDL Number: MFCD00081076
• SMILES: CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccccc4cc3Cn1c2=O
• NSC Number: 94600

Computed Properties

• Complexity: 742
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 1

Literature

• Plasma citrulline is a sensitive safety biomarker for small intestinal injury in rats.

  Toxicology letters 20181001

• Impact of diet on irinotecan toxicity in mice.

  Chemico-biological interactions 20180801

• Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells.

  Cell death & disease 20180801

• Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles.

  Archives of toxicology 20180401

• De novo transcriptome analyses reveals putative pathway genes involved in biosynthesis and regulation of camptothecin in Nothapodytes nimmoniana (Graham) Mabb.

  Plant molecular biology 20180101

• Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan.

  Toxicology and applied pharmacology 20170715

• Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

  Toxicology in vitro : an international journal published in association with BIBRA 20170601

• Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38.

  Environmental toxicology 20170201

• Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.

  Chemico-biological interactions 20161225

• Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.

  Nucleic acids research 20161201

• OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

  International journal of cancer 20161101

• Metabolite Diversity in Alkaloid Biosynthesis: A Multilane (Diastereomer) Highway for Camptothecin Synthesis in Camptotheca acuminata.

  The Plant cell 20160801

• Disruption of DNA Damage-Response by Propyl Gallate and 9-Aminoacridine.

  Toxicological sciences : an official journal of the Society of Toxicology 20160601

• New in vitro biomarkers to detect toxicity in human placental cells: The example of benzo[A]pyrene.

  Toxicology in vitro : an international journal published in association with BIBRA 20160401

• Identification of compounds that modulate retinol signaling using a cell-based qHTS assay.

  Toxicology in vitro : an international journal published in association with BIBRA 20160401

• Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols.

  European journal of medicinal chemistry 20160127

• The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

  Oncotarget 20160119

• Irinotecan (CPT-11)-induced elevation of bile acids potentiates suppression of IL-10 expression.

  Toxicology and applied pharmacology 20160115

• Different ATM Signaling in Response to Chromium(VI) Metabolism via Ascorbate and Nonascorbate Reduction: Implications for in Vitro Models and Toxicogenomics.

  Environmental health perspectives 20160101

• CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings.

  Toxicology and applied pharmacology 20151201

• The aryl hydrocarbon receptor-dependent disruption of contact inhibition in rat liver WB-F344 epithelial cells is linked with induction of survivin, but not with inhibition of apoptosis.

  Toxicology 20150703

• Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• PP2A-B56ϵ complex is involved in dephosphorylation of γ-H2AX in the repair process of CPT-induced DNA double-strand breaks.

  Toxicology 20150504

• A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression.

  Experimental hematology 20150501

• Cytotoxicity of obacunone and obacunone glucoside in human prostate cancer cells involves Akt-mediated programmed cell death.

  Toxicology 20150302

• Chemopreventive effects of standardized ethanol extract from the aerial parts of Artemisia princeps Pampanini cv. Sajabal via NF-κB inactivation on colitis-associated colon tumorigenesis in mice.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20150101

• Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.

  Drug design, development and therapy 20150101

• ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

  Cancer research 20141201

• Inhibition of autophagy enhances DNA damage-induced apoptosis by disrupting CHK1-dependent S phase arrest.

  Toxicology and applied pharmacology 20140801

• Myristicin from nutmeg induces apoptosis via the mitochondrial pathway and down regulates genes of the DNA damage response pathways in human leukaemia K562 cells.

  Chemico-biological interactions 20140725

• SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes.

  Toxicology and applied pharmacology 20140615

• Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.

  Molecules (Basel, Switzerland) 20140217

• Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.

  Toxicology and applied pharmacology 20140201

• Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity.

  Toxicology 20140106

• Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.

  The journal of obstetrics and gynaecology research 20140101

• Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum.

  PloS one 20140101

• Nicotine increases survival in human colon cancer cells treated with chemotherapeutic drugs.

  Toxicology in vitro : an international journal published in association with BIBRA 20131201

• Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).

  Proceedings of the National Academy of Sciences of the United States of America 20131119

• Antimycobacterial and herbicidal activity of ring-substituted 1-hydroxynaphthalene-2-carboxanilides.

  Bioorganic & medicinal chemistry 20131101

• Synthesis and evaluation of 7-chloro-4-(piperazin-1-yl)quinoline-sulfonamide as hybrid antiprotozoal agents.

  Bioorganic & medicinal chemistry 20130601

• Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.

  PloS one 20130101

• Characterization of DNA topoisomerase-1 in Spodoptera exigua for toxicity evaluation of camptothecin and hydoxy-camptothecin.

  PloS one 20130101

• Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.

  Investigational new drugs 20121201

• Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).

  Medical oncology (Northwood, London, England) 20121201

• Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.

  Investigational new drugs 20121201

• Fabrication of biodegradable micelles with sheddable poly(ethylene glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin.

  Colloids and surfaces. B, Biointerfaces 20121201

• Detection of apoptosis through the lipid order of the outer plasma membrane leaflet.

  Biochimica et biophysica acta 20121201

• The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep?

  The Journal of pharmacology and experimental therapeutics 20121201

• Molecular structure and vibrational spectra of Irinotecan: a density functional theoretical study.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20121201

• A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity.

  Biochimica et biophysica acta 20121201

• A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20121201

• A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.

  Journal of drug targeting 20121201

• Amidase-responsive controlled release of antitumoral drug into intracellular media using gluconamide-capped mesoporous silica nanoparticles.

  Nanoscale 20121121

• Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.

  Bioorganic & medicinal chemistry 20121115

• A novel fluorescence derivatization method combined with HPLC for determining the activities of endogenous caspase.

  The Analyst 20121107

• Electrosprayed polyelectrolyte complexes between mucoadhesive N,N,N,-trimethylchitosan-homocysteine thiolactone and alginate/carrageenan for camptothecin delivery.

  Carbohydrate polymers 20121106

• BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.

  Molecular pharmaceutics 20121105

• Synthesis of water-soluble camptothecin-polyoxetane conjugates via click chemistry.

  Molecular pharmaceutics 20121105

• Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.

  International journal of cancer 20121101

• Relapsed hepatoblastoma.

  Pediatric blood & cancer 20121101

• Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.

  Pediatric blood & cancer 20121101

• A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20121101

• Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.

  Biochimica et biophysica acta 20121101

• The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.

  International journal of molecular medicine 20121101

• In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy.

  Oncology reports 20121101

• Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20121101

• Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20121101

• RNF8 and RNF168 but not HERC2 are required for DNA damage-induced ubiquitylation in chicken DT40 cells.

  DNA repair 20121101

• Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.

  Cancer chemotherapy and pharmacology 20121101

• Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.

  Neuro-oncology 20121101

• Interaction between natural compounds and human topoisomerase I.

  Biological chemistry 20121101

• Enhanced in vitro antitumor efficacy and strong anti-cell-migration activity of a hydroxycamptothecin-encapsulated magnetic nanovehicle.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20121029

• Design of enzyme-mediated controlled release systems based on silica mesoporous supports capped with ester-glycol groups.

  Langmuir : the ACS journal of surfaces and colloids 20121016

• Camptothecins in tumor homing via an RGD sequence mimetic.

  Bioorganic & medicinal chemistry letters 20121015

• Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

  Cell cycle (Georgetown, Tex.) 20121015

• Azobenzene polyesters used as gate-like scaffolds in nanoscopic hybrid systems.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20121008

• Creation of pure nanodrugs and their anticancer properties.

  Angewandte Chemie (International ed. in English) 20121008

• Irinotecan induces senescence and apoptosis in colonic cells in vitro.

  Toxicology letters 20121002

• Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.

  Investigational new drugs 20121001

• Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20121001

• Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.

  Magnetic resonance in medicine 20121001

• Second-line chemotherapy for advanced gastric cancer in Korea.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20121001

• DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells.

  Leukemia & lymphoma 20121001

• UPLC and LC-MS studies on degradation behavior of irinotecan hydrochloride and development of a validated stability-indicating ultra-performance liquid chromatographic method for determination of irinotecan hydrochloride and its impurities in pharmaceutical dosage forms.

  Journal of chromatographic science 20121001

• Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20121001

• Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system.

  Journal of pharmaceutical sciences 20121001

• Expression of the hyperphosphorylated tau attenuates ER stress-induced apoptosis with upregulation of unfolded protein response.

  Apoptosis : an international journal on programmed cell death 20121001

• Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20121001

• Pharmacokinetics, tissue distribution, and the lactone/carboxylate equilibrium of hydroxycamptothecin delivered via aerosol in mice.

  Fitoterapia 20121001

• Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.

  Molecular oncology 20121001

• Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.

  Journal of vascular and interventional radiology : JVIR 20121001

• 2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani.

  Bioorganic & medicinal chemistry letters 20121001

• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20121001

• Dynamics of caspase-3 activation and inhibition in embryonic micromasses evaluated by a photon-counting chemiluminescence approach.

  In vitro cellular & developmental biology. Animal 20121001

• Suppression analysis of esa1 mutants in Saccharomyces cerevisiae links NAB3 to transcriptional silencing and nucleolar functions.

  G3 (Bethesda, Md.) 20121001

• Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.

  Molecular diagnosis & therapy 20121001

• Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents.

  European journal of medicinal chemistry 20121001

• Two- and three-dimensional live cell imaging of DNA damage response proteins.

  Journal of visualized experiments : JoVE 20120928

• The yeast Fun30 and human SMARCAD1 chromatin remodellers promote DNA end resection.

  Nature 20120927

• Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

  World journal of gastroenterology 20120921

• SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

  Oncogene 20120913

• New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.

  Journal of medicinal chemistry 20120913

• Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.

  Journal of controlled release : official journal of the Controlled Release Society 20120910

• Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.

  JOP : Journal of the pancreas 20120910

• FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

  World journal of gastroenterology 20120907

• Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.

  Journal of gastrointestinal cancer 20120901

• Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.

  British journal of pharmacology 20120901

• Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).

  Journal of cancer research and clinical oncology 20120901

• Preparation and in vitro evaluation of an ultrasound-triggered drug delivery system: 10-hydroxycamptothecin loaded PLA microbubbles.

  Ultrasonics 20120901

• N-glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells.

  Journal of cellular biochemistry 20120901

• Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20120901

• Network analysis of icb-1 gene function in human breast cancer cells.

  Journal of cellular biochemistry 20120901

• Anticancer activity of new haloalkyl camptothecin esters against human cancer cell lines and human tumor xenografts grown in nude mice.

  Anti-cancer agents in medicinal chemistry 20120901

• Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.

  Annals of surgical oncology 20120901

• AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

  Cancer chemotherapy and pharmacology 20120901

• Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.

  AAPS PharmSciTech 20120901

• MicroRNA changes in advanced radiotherapy techniques and its effect to secondary cancers.

  Medical hypotheses 20120901

• MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

  Experimental eye research 20120901

• Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).

  Acta oncologica (Stockholm, Sweden) 20120901

• CoMFA QSAR models of camptothecin analogues based on the distinctive SAR features of combined ABC, CD and E ring substitutions.

  Computers in biology and medicine 20120901

• S-1 for the treatment of gastrointestinal cancer.

  Expert opinion on pharmacotherapy 20120901

• Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola.

  Bioorganic & medicinal chemistry 20120901

• A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.

  Bioorganic & medicinal chemistry 20120901

• Disubstituted thiourea derivatives and their activity on CNS: synthesis and biological evaluation.

  European journal of medicinal chemistry 20120901

• Evaluation of predictive markers for patients with advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20120901

• [Hydroxycamptothecin inhibits proliferation of human lung carcinoma cell line A549 and down-regulates its Bcl-2 gene expression in vitro].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20120901

• Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.

  Anticancer research 20120901

• Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.

  Anticancer research 20120901

• [A patient with gastric small cell carcinoma who died from meningitis carcinomatosa after CDDP+CPT-11 chemotherapy with good response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120901

• [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].

  Magyar onkologia 20120901

• Inhibition of DNA topoisomerases I and II of compounds from Reynoutria japonica.

  Archives of pharmacal research 20120901

• pH-sensitive drug loading/releasing in amphiphilic copolymer PAE-PEG: integrating molecular dynamics and dissipative particle dynamics simulations.

  Journal of controlled release : official journal of the Controlled Release Society 20120820

• The RNA-binding protein CUG-BP1 increases survivin expression in oesophageal cancer cells through enhanced mRNA stability.

  The Biochemical journal 20120815

• Synthesis of benzo-annulated tryptanthrins and their biological properties.

  Bioorganic & medicinal chemistry 20120815

• Development and validation of a RP-HPLC method with fluorescence detection for simultaneous determination of 10-methoxycamptothecin and its metabolite 10-hydroxycamptothecin in rat plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120815

• Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120810

• Cytotoxic podophyllotoxin type-lignans from the steam bark of Bursera fagaroides var. fagaroides.

  Molecules (Basel, Switzerland) 20120809

• Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

  Investigational new drugs 20120801

• A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

  Investigational new drugs 20120801

• Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.

  International journal of clinical oncology 20120801

• Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.

  Investigational new drugs 20120801

• Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

  Cancer treatment reviews 20120801

• A preclinical and clinical review of aflibercept for the management of cancer.

  Cancer treatment reviews 20120801

• What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy?

  Annals of surgical oncology 20120801

• A two-step pH-dependent liquid-liquid extraction combined with HPLC-fluorescence method for the determination of 10-hydroxycamptothecin in mouse liver tissue.

  Pharmaceutical biology 20120801

• Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20120801

• Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

  Journal of biomolecular screening 20120801

• First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.

  Cancer science 20120801

• Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120801

• Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20120801

• Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy.

  International journal of pharmaceutics 20120801

• HSF4 is involved in DNA damage repair through regulation of Rad51.

  Biochimica et biophysica acta 20120801

• Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).

  Oncology reports 20120801

• Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug.

  Journal of the American Chemical Society 20120801

• Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

  Molecular cancer therapeutics 20120801

• The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.

  Cancer gene therapy 20120801

• Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.

  Japanese journal of clinical oncology 20120801

• Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.

  Cancer chemotherapy and pharmacology 20120801

• Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20120801

• Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis.

  Arteriosclerosis, thrombosis, and vascular biology 20120801

• Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.

  Japanese journal of clinical oncology 20120801

• Functional switching of ATM: sensor of DNA damage in proliferating cells and mediator of Akt survival signal in post-mitotic human neuron-like cells.

  Chinese journal of cancer 20120801

• Polynucleotide kinase/phosphatase, Pnk1, is involved in base excision repair in Schizosaccharomyces pombe.

  DNA repair 20120801

• Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety.

  Bioorganic & medicinal chemistry letters 20120801

• Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer.

  Anticancer research 20120801

• [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120801

• [A case of colon cancer with chronic renal dysfunction responding to effective retreatment with FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120801

• SLX-1 is required for maintaining genomic integrity and promoting meiotic noncrossovers in the Caenorhabditis elegans germline.

  PLoS genetics 20120801

• The utility of camptothecin as a synergist of Bacillus thuringiensis var. kurstaki and nucleopolyhedroviruses against Trichoplusia ni and Spodoptera exigua.

  Journal of economic entomology 20120801

• DNA topoisomerase I drugs and radiotherapy for lung cancer.

  Journal of thoracic disease 20120801

• Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia.

  The Indian journal of medical research 20120801

• The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.

  Journal of chemotherapy (Florence, Italy) 20120801

• Induction and mechanism of apoptosis by hydroxycamptothecin in human Tenon's capsule fibroblasts.

  Investigative ophthalmology & visual science 20120724

• Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

  British journal of cancer 20120724

• Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.

  International journal of cancer 20120715

• Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

  Pediatric blood & cancer 20120715

• The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.

  Biochemical pharmacology 20120715

• Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.

  Bioorganic & medicinal chemistry 20120715

• Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients.

  British journal of cancer 20120710

• A variant of the breast cancer type 2 susceptibility protein (BRC) repeat is essential for the RECQL5 helicase to interact with RAD51 recombinase for genome stabilization.

  The Journal of biological chemistry 20120706

• Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15.

  The Journal of clinical investigation 20120702

• In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20120701

• Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.

  Nanomedicine : nanotechnology, biology, and medicine 20120701

• Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

  Pharmaceutical research 20120701

• Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120701

• Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters.

  Xenobiotica; the fate of foreign compounds in biological systems 20120701

• Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.

  Acta oncologica (Stockholm, Sweden) 20120701

• Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines.

  Anti-cancer drugs 20120701

• Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics.

  Methods (San Diego, Calif.) 20120701

• Controlled drug delivery from composites of nanostructured porous silicon and poly(L-lactide).

  Nanomedicine (London, England) 20120701

• Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.

  Annals of surgical oncology 20120701

• Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.

  Anti-cancer drugs 20120701

• Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH-cortisol and renin-angiotensin-aldosterone.

  Journal of neuro-oncology 20120701

• Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway.

  Biochemical pharmacology 20120701

• Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

  Drug metabolism and disposition: the biological fate of chemicals 20120701

• Synthesis and antitumor activity of lapathoside D and its analogs.

  European journal of medicinal chemistry 20120701

• A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

  Acta oncologica (Stockholm, Sweden) 20120701

• A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.

  Journal of pharmaceutical and biomedical analysis 20120701

• Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells.

  International journal of molecular medicine 20120701

• Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways.

  Toxicology and applied pharmacology 20120701

• Differential expression and functional characterization of the NADPH cytochrome P450 reductase genes from Nothapodytes foetida.

  Plant science : an international journal of experimental plant biology 20120701

• Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.

  Cancer chemotherapy and pharmacology 20120701

• Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.

  Cancer chemotherapy and pharmacology 20120701

• Endophytic fungi: novel sources of anticancer lead molecules.

  Applied microbiology and biotechnology 20120701

• Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

  Anti-cancer drugs 20120701

• Fertility-sparing management for bulky cervical cancer using neoadjuvant transuterine arterial chemotherapy followed by vaginal trachelectomy.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120701

• Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients.

  Journal of vascular and interventional radiology : JVIR 20120701

• Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.

  Cell cycle (Georgetown, Tex.) 20120701

• [A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin as second-line].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120701

• FANCJ/BACH1 acetylation at lysine 1249 regulates the DNA damage response.

  PLoS genetics 20120701

• Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak.

  Oncogene 20120628

• Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.

  Cancer 20120615

• Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones.

  Biochemical pharmacology 20120615

• Triazine dendrimers as drug delivery systems: from synthesis to therapy.

  Advanced drug delivery reviews 20120615

• ADAM15 protein amplifies focal adhesion kinase phosphorylation under genotoxic stress conditions.

  The Journal of biological chemistry 20120615

• Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

  Journal of medicinal chemistry 20120614

• Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.

  British journal of cancer 20120605

• Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

  Investigational new drugs 20120601

• The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan.

  Investigational new drugs 20120601

• Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

  Cancer 20120601

• Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

  Clinical colorectal cancer 20120601

• TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

  Cancer chemotherapy and pharmacology 20120601

• Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20120601

• Mesoporous carbon@silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging.

  Biomaterials 20120601

• The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

  Oncology reports 20120601

• Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action.

  Phytochemistry 20120601

• Conventional chemotherapy of advanced pancreatic cancer.

  Current drug targets 20120601

• MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection.

  Biomaterials 20120601

• Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.

  European journal of medicinal chemistry 20120601

• Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.

  European journal of medicinal chemistry 20120601

• ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.

  Molecular oncology 20120601

• The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.

  Cancer chemotherapy and pharmacology 20120601

• Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.

  Cancer chemotherapy and pharmacology 20120601

• In-vivo pharmacokinetics, tissue distribution and anti-tumour effect of hydroxycamptothecin delivered in oil-in-water submicron emulsions.

  The Journal of pharmacy and pharmacology 20120601

• FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.

  Cancer chemotherapy and pharmacology 20120601

• Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20120601

• Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.

  Hepato-gastroenterology 20120601

• Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.

  Clinical therapeutics 20120601

• Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.

  Pharmacogenomics 20120601

• Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.

  Chemistry & biodiversity 20120601

• [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120601

• SN-38 loaded polymeric micelles to enhance cancer therapy.

  Nanotechnology 20120525

• Screening of anti-cancer agent using zebrafish: comparison with the MTT assay.

  Biochemical and biophysical research communications 20120525

• Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.

  International journal of cancer 20120515

• Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20120515

• Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120515

• Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel.

  International journal of pharmaceutics 20120510

• Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.

  Journal of medicinal chemistry 20120510

• Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.

  Journal of the American Chemical Society 20120509

• Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.

  British journal of cancer 20120508

• Progesterone and DNA damage encourage uterine cell proliferation and decidualization through up-regulating ribonucleotide reductase 2 expression during early pregnancy in mice.

  The Journal of biological chemistry 20120504

• Peptide-mediated targeted drug delivery.

  Medicinal research reviews 20120501

• Synthesis of camptothecin-amino acid carbamate linkers.

  Amino acids 20120501

• An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120501

• Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter?

  Journal of surgical oncology 20120501

• Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.

  The Journal of pathology 20120501

• Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.

  International journal of radiation oncology, biology, physics 20120501

• Interaction of human serum albumin with 10-hydroxycamptothecin: spectroscopic and molecular modeling studies.

  Molecular biology reports 20120501

• Clinical development of new formulations of cytotoxics in solid tumors.

  Current opinion in oncology 20120501

• A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer.

  Disease models & mechanisms 20120501

• A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20120501

• Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.

  Cancer chemotherapy and pharmacology 20120501

• FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

  Neuro-oncology 20120501

• EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120501

• Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120501

• Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120501

• Modulation of irinotecan-induced genomic DNA damage by theanine.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120501

• Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.

  Japanese journal of clinical oncology 20120501

• Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.

  The Journal of pharmacy and pharmacology 20120501

• Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120501

• Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

  British journal of clinical pharmacology 20120501

• Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20120501

• Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

  Neuro-oncology 20120501

• [Monitoring and evaluation tools for irinotecan and bevacizumab in glioblastoma: from prescription to patient's information].

  Bulletin du cancer 20120501

• Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.

  Cell cycle (Georgetown, Tex.) 20120501

• Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis.

  Protein & cell 20120501

• [A case of an advanced gastric cancer patient on hemodialysis achieving long-term progression-free survival after CPT-11+CDDP therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• [A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• [Two cases of CPT-11 and CDDP chemotherapy for advanced pancreatic cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120501

• Cetuximab in metastatic colorectal cancer.

  Expert review of anticancer therapy 20120501

• A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.

  Oncotarget 20120501

• Infused chemotherapy use in the elderly after patent expiration.

  The American journal of managed care 20120501

• [Study on in vitro microdialysis recovery of hydroxycamptothecine].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20120501

• Protein implicated in nonsyndromic mental retardation regulates protein kinase A (PKA) activity.

  The Journal of biological chemistry 20120427

• Bifunctionalized amphilectane diterpenes from the sponge Stylissa cf. massa.

  Journal of natural products 20120427

• Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells.

  Oncogene 20120426

• Targeting carbon nanotubes against cancer.

  Chemical communications (Cambridge, England) 20120425

• Zebrafish p53 protein enhances the translation of its own mRNA in response to UV irradiation and CPT treatment.

  FEBS letters 20120424

• Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20120416

• Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.

  Human molecular genetics 20120415

• Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.

  The Journal of biological chemistry 20120413

• Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.

  Journal of medicinal chemistry 20120412

• Antitumor activities of emulsion electrospun fibers with core loading of hydroxycamptothecin via intratumoral implantation.

  International journal of pharmaceutics 20120404

• DNA replication stress differentially regulates G1/S genes via Rad53-dependent inactivation of Nrm1.

  The EMBO journal 20120404

• Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

  The Journal of clinical investigation 20120402

• Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.

  Investigational new drugs 20120401

• Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  Investigational new drugs 20120401

• Irinotecan injures tight junction and causes bacterial translocation in rat.

  The Journal of surgical research 20120401

• A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

  Investigational new drugs 20120401

• A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.

  The British journal of radiology 20120401

• Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.

  International journal of clinical oncology 20120401

• Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?

  Annals of surgical oncology 20120401

• Effects of camptothecin and hydroxycamptothecin on insect cell lines Sf21 and IOZCAS-Spex-II.

  Pest management science 20120401

• Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation.

  Cancer chemotherapy and pharmacology 20120401

• Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.

  Journal of neuro-oncology 20120401

• Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.

  The Journal of pharmacology and experimental therapeutics 20120401

• Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.

  Oncology reports 20120401

• Structure-function studies of a plant tyrosyl-DNA phosphodiesterase provide novel insights into DNA repair mechanisms of Arabidopsis thaliana.

  The Biochemical journal 20120401

• Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

  Cancer chemotherapy and pharmacology 20120401

• Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.

  Anti-cancer drugs 20120401

• Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.

  Oncology reports 20120401

• Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.

  Oncology reports 20120401

• Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways.

  Molecular pharmacology 20120401

• Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20120401

• Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.

  European journal of gastroenterology & hepatology 20120401

• Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs.

  ChemMedChem 20120401

• Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles.

  European journal of medicinal chemistry 20120401

• Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.

  Bioorganic & medicinal chemistry 20120401

• First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.

  Journal of clinical gastroenterology 20120401

• Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401

• Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan.

  Neurosurgery clinics of North America 20120401

• In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles.

  Nanomedicine (London, England) 20120401

• [Successful management of liver metastasis from gastric adenosquamous carcinoma with adjuvant chemotherapy and radiofrequency ablation].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20120401

• Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.

  Anticancer research 20120401

• Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.

  Anticancer research 20120401

• Competition between replicative and translesion polymerases during homologous recombination repair in Drosophila.

  PLoS genetics 20120401

• A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

  Small (Weinheim an der Bergstrasse, Germany) 20120326

• Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

  Journal of pharmaceutical and biomedical analysis 20120325

• Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

  Journal of the National Cancer Institute 20120321

• PP4 dephosphorylates Maf1 to couple multiple stress conditions to RNA polymerase III repression.

  The EMBO journal 20120321

• Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20120315

• Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.

  Bioorganic & medicinal chemistry 20120315

• Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.

  World journal of gastroenterology 20120314

• Postoperative adjuvant chemotherapy in rectal cancer operated for cure.

  The Cochrane database of systematic reviews 20120314

• Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.

  British journal of cancer 20120313

• SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair.

  Nature communications 20120313

• A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX.

  The EMBO journal 20120307

• Fighting fire with fire: poisonous Chinese herbal medicine for cancer therapy.

  Journal of ethnopharmacology 20120306

• Topoisomerase I poisoning results in PARP-mediated replication fork reversal.

  Nature structural & molecular biology 20120304

• Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20120301

• Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

  Pediatric blood & cancer 20120301

• Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.

  Analytical and bioanalytical chemistry 20120301

• Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

  Clinical colorectal cancer 20120301

• Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.

  Clinical colorectal cancer 20120301

• Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

  Clinical colorectal cancer 20120301

• The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation.

  Cellular and molecular life sciences : CMLS 20120301

• Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

  Journal of neuro-oncology 20120301

• The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.

  Journal of surgical oncology 20120301

• Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.

  Cancer chemotherapy and pharmacology 20120301

• Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.

  Journal of gastroenterology 20120301

• Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer.

  AAPS PharmSciTech 20120301

• Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.

  Scandinavian journal of gastroenterology 20120301

• Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.

  Scandinavian journal of gastroenterology 20120301

• Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.

  Journal of cancer research and clinical oncology 20120301

• Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

  European journal of cancer (Oxford, England : 1990) 20120301

• Bakuchiol derivatives as novel and potent cytotoxic agents: a report.

  European journal of medicinal chemistry 20120301

• Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120301

• Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs.

  Acta pharmacologica Sinica 20120301

• Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat.

  The Journal of pharmacy and pharmacology 20120301

• Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer.

  Current drug delivery 20120301

• Uncoupling of RAD51 focus formation and cell survival after replication fork stalling in RAD51D null CHO cells.

  Environmental and molecular mutagenesis 20120301

• Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class.

  European journal of medicinal chemistry 20120301

• Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.

  European journal of medicinal chemistry 20120301

• The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20120301

• Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.

  Japanese journal of clinical oncology 20120301

• A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells.

  Bioorganic & medicinal chemistry letters 20120301

• Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.

  Pharmacogenomics 20120301

• Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.

  Advances in therapy 20120301

• SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.

  Anticancer research 20120301

• [A case of S-1-resistant resected advanced gastric cancer with para-aortic lymph node recurrence responding to bi-weekly CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120301

• A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

  Acta gastro-enterologica Belgica 20120301

• Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

  Journal of controlled release : official journal of the Controlled Release Society 20120227

• Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT.

  International journal of pharmaceutics 20120227

• In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.

  International journal of pharmaceutics 20120227

• Human DNA helicase B (HDHB) binds to replication protein A and facilitates cellular recovery from replication stress.

  The Journal of biological chemistry 20120224

• Cytotoxic phloroglucinols from the leaves of Myrtus communis.

  Journal of natural products 20120224

• A microchamber array for single cell isolation and analysis of intracellular biomolecules.

  Lab on a chip 20120221

• Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120220

• PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• Functionalized hydrophobic poly(glycerol-co-ε-caprolactone) depots for controlled drug release.

  Biomacromolecules 20120213

• RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide) (HPMA)-7-ethyl-10-hydroxycamptothecin (SN-38) conjugates.

  ChemMedChem 20120206

• Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery.

  Molecular pharmaceutics 20120206

• Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

  The Journal of biological chemistry 20120203

• Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

  Investigational new drugs 20120201

• Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.

  Investigational new drugs 20120201

• Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.

  International journal of radiation oncology, biology, physics 20120201

• Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis.

  International journal of colorectal disease 20120201

• In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.

  Phytotherapy research : PTR 20120201

• Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20120201

• In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification.

  Nanomedicine : nanotechnology, biology, and medicine 20120201

• Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease.

  Biogerontology 20120201

• Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.

  Annals of surgical oncology 20120201

• Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.

  Biochimie 20120201

• Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex.

  Biopolymers 20120201

• Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.

  Cancer science 20120201

• Avastin: more questions than answers. .

  Journal of neurosurgery 20120201

• Binding interactions of water-soluble camptothecin derivatives with bovine serum albumin.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20120201

• Rescue of replication failure by Fanconi anaemia proteins.

  Chromosoma 20120201

• The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles.

  Biomaterials 20120201

• Human neural stem cell tropism to metastatic breast cancer.

  Stem cells (Dayton, Ohio) 20120201

• The double-bromodomain proteins Bdf1 and Bdf2 modulate chromatin structure to regulate S-phase stress response in Schizosaccharomyces pombe.

  Genetics 20120201

• Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120201

• Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120201

• FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).

  Japanese journal of clinical oncology 20120201

• Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.

  Current medical research and opinion 20120201

• Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

  Cancer research 20120201

• Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201

• Design, synthesis and biological evaluation of new naphtalene diimides bearing isothiocyanate functionality.

  European journal of medicinal chemistry 20120201

• Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.

  Molecular cancer therapeutics 20120201

• Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120201

• Experimental and computational evidence for an inversion in guest capacity in high-generation triazine dendrimer hosts.

  Journal of the American Chemical Society 20120201

• An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120201

• [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].

  Bulletin du cancer 20120201

• Viewing metastatic colorectal cancer as a curable chronic disease.

  American journal of clinical oncology 20120201

• [A case of cecal cancer with abdominal wall abscess].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120201

• [A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120201

• [Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120201

• Negative supercoiling creates single-stranded patches of DNA that are substrates for AID-mediated mutagenesis.

  PLoS genetics 20120201

• Nucleolar disruption leads to the spatial separation of key 18S rRNA processing factors.

  RNA biology 20120201

• Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

  British journal of cancer 20120131

• Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120

• Fluorescence properties of the Na⁺/H⁺exchanger inhibitor HMA (5-(N,N-hexamethylene)amiloride) are modulated by intracellular pH.

  European journal of histochemistry : EJH 20120120

• Symmetric dimers of ent-kaurane diterpenoids with cytotoxic activity from Croton tonkinensis.

  Bioorganic & medicinal chemistry letters 20120115

• Comparison of the predictive ability of several second-order multivariate methods in the simultaneous determination of two therapeutic drugs in human urine.

  Talanta 20120115

• Sequence-specific base pair mimics are efficient topoisomerase IB inhibitors.

  Biochemistry 20120110

• Total synthesis of camptothecin and SN-38.

  The Journal of organic chemistry 20120106

• Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.

  International journal of radiation oncology, biology, physics 20120101

• Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

  International journal of radiation oncology, biology, physics 20120101

• A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120101

• A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

  Molecular biology reports 20120101

• Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.

  Cancer chemotherapy and pharmacology 20120101

• Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.

  Cancer chemotherapy and pharmacology 20120101

• Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.

  International journal of oncology 20120101

• Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.

  Oncology reports 20120101

• Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line.

  Molecular and cellular biochemistry 20120101

• First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

  Journal of cancer research and clinical oncology 20120101

• Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

  Biochemical pharmacology 20120101

• Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability.

  Oncology reports 20120101

• A plug and play polymeric template driven by supramolecular interactions.

  Journal of biomedical materials research. Part A 20120101

• Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.

  Cancer science 20120101

• The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals.

  Toxicological sciences : an official journal of the Society of Toxicology 20120101

• Glucan particles for macrophage targeted delivery of nanoparticles.

  Journal of drug delivery 20120101

• A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.

  Molecular cancer therapeutics 20120101

• Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.

  Neuro-oncology 20120101

• Carbon nanotubes in cancer therapy and drug delivery.

  Journal of drug delivery 20120101

• In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis.

  Molecular medicine (Cambridge, Mass.) 20120101

• Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.

  Molecular cancer therapeutics 20120101

• Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.

  Pharmacogenetics and genomics 20120101

• Kampo medicine 'Dai-kenchu-to' prevents CPT-11-induced small-intestinal injury in rats.

  Surgery today 20120101

• Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.

  Neoplasma 20120101

• Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro.

  European journal of medicinal chemistry 20120101

• The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.

  Surgery today 20120101

• Usefulness of multidisciplinary therapy combining neoadjuvant chemotherapy with S-1 plus cisplatin and postoperative sequential chemotherapy in patients with scirrhous gastric cancer.

  Hepato-gastroenterology 20120101

• Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120101

• Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120101

• TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.

  Scandinavian journal of gastroenterology 20120101

• Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

  Journal of drug delivery 20120101

• Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.

  Pharmacogenomics 20120101

• Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.

  Drug metabolism and pharmacokinetics 20120101

• Bioassay-Guided Isolation of Cytotoxic Cycloartane Triterpenoid Glycosides from the Traditionally Used Medicinal Plant Leea indica.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Greco-arab and islamic herbal-derived anticancer modalities: from tradition to molecular mechanisms.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.

  Anticancer research 20120101

• Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.

  Anticancer research 20120101

• Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2.

  Biological & pharmaceutical bulletin 20120101

• Strategy for synchronous and multiple liver metastasis.

  Hepato-gastroenterology 20120101

• Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120101

• The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101

• Cucurbitacin E Induces G(2)/M Phase Arrest through STAT3/p53/p21 Signaling and Provokes Apoptosis via Fas/CD95 and Mitochondria-Dependent Pathways in Human Bladder Cancer T24 Cells.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.

  Theranostics 20120101

• Multi-parametric analysis and modeling of relationships between mitochondrial morphology and apoptosis.

  PloS one 20120101

• In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells.

  Radiation oncology (London, England) 20120101

• Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

  Oncotarget 20120101

• [Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20120101

• Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress.

  Molecular systems biology 20120101

• Camptothecin fails to induce apoptosis in tumor necrosis factor-alpha-treated HaCaT cells.

  Pharmacology 20120101

• MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer?

  International journal of molecular sciences 20120101

• High-Dimensional descriptor selection and computational QSAR modeling for antitumor activity of ARC-111 analogues Based on Support Vector Regression (SVR).

  International journal of molecular sciences 20120101

• Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin.

  Journal of amino acids 20120101

• Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.

  Oncology 20120101

• Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy.

  International journal of nanomedicine 20120101

• Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system.

  Indian journal of pharmacology 20120101

• The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability.

  International journal of nanomedicine 20120101

• Defective cell cycle checkpoints as targets for anti-cancer therapies.

  Frontiers in pharmacology 20120101

• PGC-1α determines light damage susceptibility of the murine retina.

  PloS one 20120101

• Using DNA damage sensitivity phenotypes to characterize mutations affecting proteasome function.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest.

  PloS one 20120101

• Phosphorylation of CRN2 by CK2 regulates F-actin and Arp2/3 interaction and inhibits cell migration.

  Scientific reports 20120101

• Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses.

  Scientific reports 20120101

• Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.

  International journal of nanomedicine 20120101

• Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.

  Marine drugs 20120101

• Current approaches toward production of secondary plant metabolites.

  Journal of pharmacy & bioallied sciences 20120101

• In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.

  PloS one 20120101

• Bmi1 is down-regulated in the aging brain and displays antioxidant and protective activities in neurons.

  PloS one 20120101

• Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1.

  International journal of nanomedicine 20120101

• Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.

  International journal of nanomedicine 20120101

• Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells.

  PloS one 20120101

• Protease-activated drug development.

  Theranostics 20120101

• Advances in using PARP inhibitors to treat cancer.

  BMC medicine 20120101

• Biological activities of nitidine, a potential anti-malarial lead compound.

  Malaria journal 20120101

• Protein kinase CK2 localizes to sites of DNA double-strand break regulating the cellular response to DNA damage.

  BMC molecular biology 20120101

• Characterization of magnesium requirement of human 5'-tyrosyl DNA phosphodiesterase mediated reaction.

  BMC research notes 20120101

• Poractant alfa (Curosurf®) increases phagocytosis of apoptotic neutrophils by alveolar macrophages in vivo.

  Respiratory research 20120101

• The mTOR signalling pathway in human cancer.

  International journal of molecular sciences 20120101

• Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.

  BMC cancer 20120101

• In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy.

  International journal of nanomedicine 20120101

• Comparative mitochondrial proteomics: perspective in human diseases.

  Journal of hematology & oncology 20120101

• Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.

  BMC cancer 20120101

• Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.

  European journal of gynaecological oncology 20120101

• Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells.

  PloS one 20120101

• Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma.

  Journal of computer assisted tomography 20120101

• Biomedical applications of graphene.

  Theranostics 20120101

• Increased expression of DNA repair gene XPF enhances resistance to hydroxycamptothecin in bladder cancer.

  Medical science monitor : international medical journal of experimental and clinical research 20120101

• Combination therapy of surgical tumor resection with implantation of a hydrogel containing camptothecin-loaded poly(lactic-co-glycolic acid) microspheres in a C6 rat glioma model.

  Biological & pharmaceutical bulletin 20120101

• Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.

  Gastroenterology research and practice 20120101

• Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression.

  PloS one 20120101

• Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.

  PloS one 20120101

• Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.

  International journal of molecular sciences 20120101

• Curcumin: updated molecular mechanisms and intervention targets in human lung cancer.

  International journal of molecular sciences 20120101

• A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line.

  BMC complementary and alternative medicine 20120101

• Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.

  Journal of translational medicine 20120101

• Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.

  Journal of drug delivery 20120101

• PLGA Nanoparticles for Ultrasound-Mediated Gene Delivery to Solid Tumors.

  Journal of drug delivery 20120101

• The developing clinical problem of chemotherapy-induced hepatic injury.

  ANZ journal of surgery 20120101

• A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.

  Oncology 20120101

• Effects of depletion of dihydropyrimidine dehydrogenase on focus formation and RPA phosphorylation.

  Journal of radiation research 20120101

• Cyclin K goes with Cdk12 and Cdk13.

  Cell division 20120101

• Circulating MiR-125b as a marker predicting chemoresistance in breast cancer.

  PloS one 20120101

• The combination of olaparib and camptothecin for effective radiosensitization.

  Radiation oncology (London, England) 20120101

• Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.

  PloS one 20120101

• Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

  Frontiers in microbiology 20120101

• Growth inhibition of human gynecologic and colon cancer cells by Phyllanthus watsonii through apoptosis induction.

  PloS one 20120101

• Serum response factor modulates neuron survival during peripheral axon injury.

  Journal of neuroinflammation 20120101

• MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 expression in colonic smooth muscle cells.

  PloS one 20120101

• Antagonist effect of triptolide on AKT activation by truncated retinoid X receptor-alpha.

  PloS one 20120101

• Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells.

  Chinese medicine 20120101

• Implications of therapy-induced selective autophagy on tumor metabolism and survival.

  International journal of cell biology 20120101

• Current situation and perspectives of clinical study in integrative medicine in china.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.

  Oncology 20120101

• JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21.

  PloS one 20120101

• Sodium selenide toxicity is mediated by O2-dependent DNA breaks.

  PloS one 20120101

• Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.

  Clinical sarcoma research 20120101

• Non-antioxidant properties of α-tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitro.

  PloS one 20120101

• Mitochondria: redox metabolism and dysfunction.

  Biochemistry research international 20120101

• Study of drug metabolism by xanthine oxidase.

  International journal of molecular sciences 20120101

• Application of ionic liquids in the microwave-assisted extraction of proanthocyanidins from Larix gmelini bark.

  International journal of molecular sciences 20120101

• Preparation, characterization, and cytotoxicity of CPT/Fe₂O₃-embedded PLGA ultrafine composite fibers: a synergistic approach to develop promising anticancer material.

  International journal of nanomedicine 20120101

• The Fanconi anaemia components UBE2T and FANCM are functionally linked to nucleotide excision repair.

  PloS one 20120101

• Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

  International journal of nanomedicine 20120101

• Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide.

  International journal of nanomedicine 20120101

• Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite.

  International journal of nanomedicine 20120101

• Investigation of the biosynthetic potential of endophytes in traditional Chinese anticancer herbs.

  PloS one 20120101

• Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

  BMC cancer 20120101

• Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications.

  Journal of drug delivery 20120101

• The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm.

  Frontiers in oncology 20120101

• The chemotherapeutic potential of Terminalia ferdinandiana: Phytochemistry and bioactivity.

  Pharmacognosy reviews 20120101

• Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.

  PloS one 20120101

• Shifting the paradigm: the putative mitochondrial protein ABCB6 resides in the lysosomes of cells and in the plasma membrane of erythrocytes.

  PloS one 20120101

• Autophagic cell death is induced by acetone and ethyl acetate extracts from Eupatorium odoratum in vitro: effects on MCF-7 and vero cell lines.

  TheScientificWorldJournal 20120101

• Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.

  PloS one 20120101

• Nucleolin inhibits G4 oligonucleotide unwinding by Werner helicase.

  PloS one 20120101

• Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

  PloS one 20120101

• Metastasis of sigmoid colon cancer in cryptorchid testis: report of a case.

  Tumori 20120101

• A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation.

  International journal of nanomedicine 20120101

• Namitecan: a hydrophilic camptothecin with a promising preclinical profile.

  Current medicinal chemistry 20120101

• Preparation and in vivo evaluation of liposomal everolimus for lung carcinoma and thyroid carcinoma.

  Biological & pharmaceutical bulletin 20120101

• Kirenol production in hairy root culture of Siegesbeckea orientalis and its antimicrobial activity.

  Pharmacognosy magazine 20120101

• Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

  PloS one 20120101

• [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].

  Bulletin du cancer 20120101

• Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.

  World journal of surgical oncology 20120101

• XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.

  BMC cancer 20120101

• Metabolic difference of CZ48 in human and mouse liver microsomes.

  International journal of molecular sciences 20120101

• Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.

  Oncology 20120101

• DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.

  Current medicinal chemistry 20120101

• Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.

  Oncology 20120101

• Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

  PloS one 20120101

• Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.

  PloS one 20120101

• Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs.

  Biological & pharmaceutical bulletin 20120101

• Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.

  European journal of gynaecological oncology 20120101

• [Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].

  Voprosy onkologii 20120101

• Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.

  Oncology 20120101

• p53 Dimers associate with a head-to-tail response element to repress cyclin B transcription.

  PloS one 20120101

• Citrus limonin lacks the antichemotherapeutic effect in human models of breast cancer.

  Journal of nutrigenetics and nutrigenomics 20120101

• Preclinical combination therapy of thiarabine plus various clinical anticancer agents.

  Nucleosides, nucleotides & nucleic acids 20120101

• Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• Nedaplatin and irinotecan for patients with recurrent small cell lung cancer.

  Journal of experimental therapeutics & oncology 20120101

• Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

  Oncology 20120101

• Human serum albumin-modified Fe3O4 magnetic nanoparticles for affinity-SALDI-MS of small-molecule drugs in biological liquids.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20120101

• Alkaloids isolated from natural herbs as the anticancer agents.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.

  Onkologie 20120101

• EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

  PloS one 20120101

• α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis.

  PloS one 20120101

• Stress activated protein kinase pathway modulates homologous recombination in fission yeast.

  PloS one 20120101

• Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms.

  PloS one 20120101

• DNA repair factor MRE11/RAD50 cleaves 3'-phosphotyrosyl bonds and resects DNA to repair damage caused by topoisomerase 1 poisons.

  The Journal of biological chemistry 20111230

• Neurodevelopmental disorders. New hope for a devastating neurological disorder.

  Science (New York, N.Y.) 20111223

• Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice.

  Cancer letters 20111222

• Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.

  Journal of medicinal chemistry 20111222

• Rapid detection of apoptosis in mammalian cells by using intact cell MALDI mass spectrometry.

  The Analyst 20111221

• Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.

  Archives of biochemistry and biophysics 20111215

• Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.

  Bioorganic & medicinal chemistry 20111215

• Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.

  Journal of controlled release : official journal of the Controlled Release Society 20111210

• Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

  Cancer letters 20111208

• Mapping intact protein isoforms in discovery mode using top-down proteomics.

  Nature 20111208

• Abundance of prereplicative complexes (Pre-RCs) facilitates recombinational repair under replication stress in fission yeast.

  The Journal of biological chemistry 20111202

• Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.

  The pharmacogenomics journal 20111201

• High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.

  The Journal of surgical research 20111201

• Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.

  Medical oncology (Northwood, London, England) 20111201

• Apoptosis induced clustering of IP(3)R1 in nuclei of non-differentiated PC12 cells.

  Journal of cellular physiology 20111201

• Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

  Cancer 20111201

• SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

  Cell death and differentiation 20111201

• Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20111201

• Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

  Lung cancer (Amsterdam, Netherlands) 20111201

• Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20111201

• Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

  Journal of neuro-oncology 20111201

• Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.

  Current drug metabolism 20111201

• DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.

  Current drug metabolism 20111201

• Micropropagation and hairy root culture of Ophiorrhiza alata Craib for camptothecin production.

  Biotechnology letters 20111201

• Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.

  Biochemical pharmacology 20111201

• The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

  Cancer chemotherapy and pharmacology 20111201

• Higher DNA repair activity is related with longer replicative life span in mammalian embryonic fibroblast cells.

  Biogerontology 20111201

• Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.

  Clinics and research in hepatology and gastroenterology 20111201

• Novel activity of acriflavine against colorectal cancer tumor cells.

  Cancer science 20111201

• A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111201

• Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20111201

• Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.

  Annals of surgery 20111201

• Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111201

• Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111201

• The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

  Clinical colorectal cancer 20111201

• Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors.

  Bioorganic & medicinal chemistry 20111201

• 2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.

  Bioorganic & medicinal chemistry 20111201

• Quiescin sulfhydryl oxidase (QSOX) is expressed in the human atheroma core: possible role in apoptosis.

  In vitro cellular & developmental biology. Animal 20111201

• Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.

  Drug safety 20111201

• Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.

  American journal of clinical oncology 20111201

• Contrast-enhanced ultrasonography with intraarterial administration of SonoVue for guidance of transarterial chemoembolization: an initial experience.

  Medical ultrasonography 20111201

• Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma.

  Cell death & disease 20111201

• WRN helicase regulates the ATR-CHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes.

  Journal of cell science 20111201

• When do you need a validated assay?

  Bioanalysis 20111201

• DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death.

  Oncotarget 20111201

• [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20111201

• Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).

  Anticancer research 20111201

• Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study.

  Anticancer research 20111201

• Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel.

  Anticancer research 20111201

• TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.

  Oncotarget 20111201

• FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.

  Journal of chemotherapy (Florence, Italy) 20111201

• [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].

  Zhonghua fu chan ke za zhi 20111201

• Opposing role of condensin hinge against replication protein A in mitosis and interphase through promoting DNA annealing.

  Open biology 20111201

• Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Degradable water soluble hyperbranched polymers for drug delivery.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Preparation and characterization of camptothecin (CPT)-loaded folate-conjugated dextran nanoparticles for tumor-targeted drug delivery using supercritical antisolvent method.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Cucurbitane glucosides from the root of Machilus yaoshansis.

  Journal of natural products 20111128

• Disruption of serine/threonine protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for PP5 in the regulation of ultraviolet light-induced phosphorylation of serine/threonine protein kinase Chk1 (CHEK1).

  The Journal of biological chemistry 20111125

• Inflammatory macrophages induce Nrf2 transcription factor-dependent proteasome activity in colonic NCM460 cells and thereby confer anti-apoptotic protection.

  The Journal of biological chemistry 20111125

• Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.

  ACS nano 20111122

• Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin.

  ACS nano 20111122

• Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.

  British journal of cancer 20111122

• Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120

• Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.

  Biochemical and biophysical research communications 20111118

• MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.

  European journal of pharmacology 20111116

• MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells.

  FEBS letters 20111116

• Epigenetic regulation of motor neuron cell death through DNA methylation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20111116

• KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20111115

• Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115

• Synthesis of polyfunctionalized piperidone oxime ethers and their cytotoxicity on HeLa cells.

  Bioorganic & medicinal chemistry letters 20111115

• Early induction of c-Myc is associated with neuronal cell death.

  Neuroscience letters 20111114

• An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.

  British journal of cancer 20111108

• Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.

  International journal of radiation oncology, biology, physics 20111101

• Design and synthesis of novel camptothecin/5-fluorouracil conjugates as cytotoxic agents.

  Natural product research 20111101

• [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].

  Revue neurologique 20111101

• Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice.

  Basic & clinical pharmacology & toxicology 20111101

• The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.

  Journal of surgical oncology 20111101

• Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111101

• Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.

  European journal of cancer (Oxford, England : 1990) 20111101

• Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.

  Apoptosis : an international journal on programmed cell death 20111101

• PDZK1 regulates breast cancer resistance protein in small intestine.

  Drug metabolism and disposition: the biological fate of chemicals 20111101

• Identification of a checkpoint modulator with synthetic lethality to p53 mutants.

  Anti-cancer drugs 20111101

• Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111101

• The polypyrimidine/polypurine motif in the mouse mu opioid receptor gene promoter is a supercoiling-regulatory element.

  Gene 20111101

• Genistein, isoflavonoids in soybeans, prevents the formation of excess radiation-induced centrosomes via p21 up-regulation.

  Mutation research 20111101

• Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase.

  Cancer gene therapy 20111101

• Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery.

  Biomaterials 20111101

• Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.

  Cancer biology & therapy 20111101

• MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.

  Stem cells (Dayton, Ohio) 20111101

• Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors.

  Archiv der Pharmazie 20111101

• Hepatocellular necrosis, apoptosis, and proliferation after transcatheter arterial embolization or chemoembolization in a standardized rabbit model.

  Journal of vascular and interventional radiology : JVIR 20111101

• Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111101

• Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.

  Bioorganic & medicinal chemistry 20111101

• Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

  Expert opinion on investigational drugs 20111101

• Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.

  NMR in biomedicine 20111101

• Looking through the vascular normalization window: timing antiangiogenic treatment and chemotherapy with (99m)Tc-annexin A5.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20111101

• Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

  The oncologist 20111101

• [Neoadjuvant therapy concepts for liver metastases].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20111101

• (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20111101

• [Molecular determinants of response to topoisomerase I inhibitors].

  Bulletin du cancer 20111101

• Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

  Nanomedicine (London, England) 20111101

• Histone H3K56 acetylation, CAF1, and Rtt106 coordinate nucleosome assembly and stability of advancing replication forks.

  PLoS genetics 20111101

• [A case of advanced gastric cancer with splenic vein thrombus successfully treated with S-1 plus CPT-11 neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case of mucinous cystadenocarcinoma of the appendix with abdominal wall abscess successfully treated by percutaneous drainage and systemic chemotherapy-a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case of recurrent rectal cancer with paraaortic lymph node metastasis treated by FOLFIRI therapy leading to complete response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case report of pathologically complete response of rectal cancer after preoperative treatment of CPT-11, S-1, and radiation therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• Identification of carboxylesterases expressed in rat intestine and effects of their hydrolyzing activity in predicting first-pass metabolism of ester prodrugs.

  Die Pharmazie 20111101

• [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].

  Yao xue xue bao = Acta pharmaceutica Sinica 20111101

• Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration.

  Current drug delivery 20111101

• Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.

  Cancer letters 20111028

• Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.

  The Journal of biological chemistry 20111028

• Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark.

  Journal of natural products 20111028

• Bioreducible block copolymers based on poly(ethylene glycol) and poly(γ-benzyl L-glutamate) for intracellular delivery of camptothecin.

  Bioconjugate chemistry 20111019

• Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1.

  Nature 20111016

• Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111015

• Functionalized nanoscale oil bodies for targeted delivery of a hydrophobic drug.

  Nanotechnology 20111014

• NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines.

  Biochemical and biophysical research communications 20111014

• Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.

  British journal of cancer 20111011

• Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.

  Molecular pharmaceutics 20111003

• Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.

  Genetics and molecular research : GMR 20111003

• Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.

  Investigational new drugs 20111001

• Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.

  Investigational new drugs 20111001

• Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.

  Investigational new drugs 20111001

• Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.

  International journal of clinical oncology 20111001

• Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.

  Cancer chemotherapy and pharmacology 20111001

• A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.

  Cancer chemotherapy and pharmacology 20111001

• Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20111001

• Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.

  International journal of clinical oncology 20111001

• Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?

  Cancer 20111001

• Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.

  International journal of experimental pathology 20111001

• Upregulation of human autophagy-initiation kinase ULK1 by tumor suppressor p53 contributes to DNA-damage-induced cell death.

  Cell death and differentiation 20111001

• Iron/dextran sulfate multilayered microcapsules for controlled release of 10-hydroxycamptothecin.

  International journal of biological macromolecules 20111001

• An intranucleolar body associated with rDNA.

  Chromosoma 20111001

• Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

  Cancer science 20111001

• Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.

  Gynecologic oncology 20111001

• Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  European journal of cancer (Oxford, England : 1990) 20111001

• Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines.

  Molecular cancer therapeutics 20111001

• Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit.

  Molecular cancer therapeutics 20111001

• [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20111001

• RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

  Current cancer drug targets 20111001

• Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.

  Japanese journal of clinical oncology 20111001

• Allometric scaling of pegylated liposomal anticancer drugs.

  Journal of pharmacokinetics and pharmacodynamics 20111001

• Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin.

  The Annals of pharmacotherapy 20111001

• [Chemotherapy and rectal cancer].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20111001

• Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study.

  Techniques in coloproctology 20111001

• Production of camptothecin by hairy roots and regenerated transformed shoots of Ophiorrhiza rugosa var. decumbens.

  Natural product research 20111001

• FOLFIRINOX: a small step or a great leap forward?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111001

• Sequential chemotherapy for colorectal cancer.

  The Lancet. Oncology 20111001

• Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

  The Lancet. Oncology 20111001

• Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.

  Cancer biology & therapy 20111001

• Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

  Chinese journal of cancer 20111001

• ERas enhances resistance to CPT-11 in gastric cancer.

  Anticancer research 20111001

• Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer.

  Anticancer research 20111001

• A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20111001

• Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.

  Archives of dermatology 20111001

• A method for detecting genetic toxicity using the RNA synthesis response to DNA damage.

  The Journal of toxicological sciences 20111001

• Three structure-selective endonucleases are essential in the absence of BLM helicase in Drosophila.

  PLoS genetics 20111001

• Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.

  The Israel Medical Association journal : IMAJ 20111001

• Hydroxytyrosol protects against oxidative DNA damage in human breast cells.

  Nutrients 20111001

• Accurate determination of the anticancer prodrug simmitecan and its active metabolite chimmitecan in various plasma samples based on immediate deactivation of blood carboxylesterases.

  Journal of chromatography. A 20110923

• Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.

  Bioconjugate chemistry 20110921

• Synthesis of benzo[3,4]azepino[1,2-b]isoquinolin-9-ones from 3-arylisoquinolines via ring closing metathesis and evaluation of topoisomerase I inhibitory activity, cytotoxicity and docking study.

  Bioorganic & medicinal chemistry 20110915

• Characterization of novel antisense HIF-1α transcripts in human cancers.

  Cell cycle (Georgetown, Tex.) 20110915

• Camptothecin-20(s)-O-[N-(3'α,12'α-dihydroxy-24'-carbonyl-5'β-cholan)]-lysine, a novel camptothecin analogue, induces apoptosis towards hepatocellular carcinoma SMMC-7721 cells.

  Molecules (Basel, Switzerland) 20110913

• Camptothecin and thiocamptothecin: the role of sulfur in shifting the hydrolysis equilibrium towards the closed lactone form.

  ChemMedChem 20110905

• Total synthesis of 7-ethyl-10-hydroxycamptothecin (SN38) and its application to the development of C18-functionalized camptothecin derivatives.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110905

• Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.

  Journal of gastrointestinal cancer 20110901

• Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

  Critical reviews in oncology/hematology 20110901

• Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.

  Critical reviews in oncology/hematology 20110901

• Application of human pancreatic carcinoid BON cells for receptor-targeted drug development.

  Journal of drug targeting 20110901

• Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.

  Cancer chemotherapy and pharmacology 20110901

• The slow cell death response when screening chemotherapeutic agents.

  Cancer chemotherapy and pharmacology 20110901

• Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110901

• Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.

  Annals of surgical oncology 20110901

• Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

  Angiogenesis 20110901

• Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.

  Journal of surgical oncology 20110901

• Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20110901

• Activity of aspirin analogues and vanillin in a human colorectal cancer cell line.

  Oncology reports 20110901

• Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110901

• Effect of apoptosis-inducing antitumor agents on endocardial endothelial cells.

  Cardiovascular toxicology 20110901

• Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.

  Cancer science 20110901

• Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells.

  Free radical research 20110901

• Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle.

  Apoptosis : an international journal on programmed cell death 20110901

• The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration.

  Molecular biology of the cell 20110901

• The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs.

  Yonsei medical journal 20110901

• Suppression of autophagy by FIP200 deletion impairs DNA damage repair and increases cell death upon treatments with anticancer agents.

  Molecular cancer research : MCR 20110901

• Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a 'real world' analysis using Surveillance, Epidemiology, and End Results-Medicare data.

  Journal of the American Geriatrics Society 20110901

• A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.

  Japanese journal of clinical oncology 20110901

• Cell cycle regulation of DNA double-strand break end resection by Cdk1-dependent Dna2 phosphorylation.

  Nature structural & molecular biology 20110901

• Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.

  Japanese journal of clinical oncology 20110901

• An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

  Clinical colorectal cancer 20110901

• Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.

  Clinical colorectal cancer 20110901

• Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.

  Clinical colorectal cancer 20110901

• Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

  The oncologist 20110901

• Five hundred patients with Merkel cell carcinoma evaluated at a single institution.

  Annals of surgery 20110901

• Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.

  Anticancer research 20110901

• Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.

  Surgery today 20110901

• Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models.

  Cell death & disease 20110901

• [CPT-11 chemotherapy for a hemodialysis patient with small-cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• [Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• [A case of undifferentiated colon cancer responding to FOLFIRI therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• [A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• [Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

  PLoS computational biology 20110901

• Diarrhea.

  Disease-a-month : DM 20110901

• Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.

  Gan to kagaku ryoho. Cancer & chemotherapy 20110901

• Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer.

  The Korean journal of internal medicine 20110901

• [A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20110901

• Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.

  International journal of pharmaceutics 20110830

• Preparation and antitumor study of camptothecin nanocrystals.

  International journal of pharmaceutics 20110830

• Protein kinase Cη activates NF-κB in response to camptothecin-induced DNA damage.

  Biochemical and biophysical research communications 20110826

• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  The New England journal of medicine 20110825

• Camptothecin-induced downregulation of MLL5 contributes to the activation of tumor suppressor p53.

  Oncogene 20110818

• ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.

  Journal of the National Cancer Institute 20110817

• In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica.

  Bioorganic & medicinal chemistry 20110815

• Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism.

  Chemical communications (Cambridge, England) 20110814

• Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.

  Journal of controlled release : official journal of the Controlled Release Society 20110810

• Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810

• Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810

• [Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy].

  Zhonghua yi xue za zhi 20110809

• Direct analysis of camptothecin from Nothapodytes nimmoniana by desorption electrospray ionization mass spectrometry (DESI-MS).

  The Analyst 20110807

• Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

  Journal of the National Cancer Institute 20110803

• A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.

  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20110801

• Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.

  Investigational new drugs 20110801

• Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism.

  Investigational new drugs 20110801

• UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20110801

• The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.

  Cancer chemotherapy and pharmacology 20110801

• Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

  Cancer chemotherapy and pharmacology 20110801

• Calcium-induced cleavage of DNA topoisomerase I involves the cytoplasmic-nuclear shuttling of calpain 2.

  Cellular and molecular life sciences : CMLS 20110801

• Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.

  International journal of clinical oncology 20110801

• A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma.

  Digestive diseases and sciences 20110801

• Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110801

• Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.

  International journal of clinical oncology 20110801

• Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification.

  Cardiovascular research 20110801

• A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.

  Cancer letters 20110801

• Secalonic acid D as a novel DNA topoisomerase I inhibitor from marine lichen-derived fungus Gliocladium sp. T31.

  Pharmaceutical biology 20110801

• A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110801

• Trex2 enables spontaneous sister chromatid exchanges without facilitating DNA double-strand break repair.

  Genetics 20110801

• Proton MR spectroscopy of neural stem cells: does the proton-NMR peak at 1.28 ppm function as a biomarker for cell type or state?

  Rejuvenation research 20110801

• Second-line chemotherapy in patients with primary unknown cancer.

  Journal of cancer research and clinical oncology 20110801

• Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.

  Expert opinion on drug metabolism & toxicology 20110801

• Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.

  European journal of medicinal chemistry 20110801

• Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.

  European journal of medicinal chemistry 20110801

• Design and synthesis of spiro derivatives of parthenin as novel anti-cancer agents.

  European journal of medicinal chemistry 20110801

• Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

  Molecular cancer therapeutics 20110801

• Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

  Cancer research 20110801

• Pulmonary artery chemoembolization in a sheep model: Evaluation of performance and safety of irinotecan eluting beads (DEB-IRI).

  Journal of biomedical materials research. Part B, Applied biomaterials 20110801

• Phenylbutyrate inhibits homologous recombination induced by camptothecin and methyl methanesulfonate.

  Mutation research 20110801

• Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

  European journal of cancer (Oxford, England : 1990) 20110801

• Early gastric cancer combined with multiple metachronous osteosclerotic bone and bone marrow metastases that responded to chemoradiotherapy.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110801

• MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression.

  Molecular cancer research : MCR 20110801

• Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy.

  Molecular pharmaceutics 20110801

• Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.

  Cancer biology & therapy 20110801

• Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.

  Diseases of the colon and rectum 20110801

• Evolution of systemic therapy for metastatic colorectal cancer.

  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20110801

• Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.

  Annals of surgery 20110801

• Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.

  Surgery today 20110801

• Using bevacizumab in the fight against malignant glioma: first results in Asian patients.

  Hong Kong medical journal = Xianggang yi xue za zhi 20110801

• New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110801

• [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110801

• [A case of advanced gastric cancer with multiple liver metastasis responding to S-1 and irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110801

• [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110801

• [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20110801

• Increased RPA1 gene dosage affects genomic stability potentially contributing to 17p13.3 duplication syndrome.

  PLoS genetics 20110801

• 2-[(E)-4-(Dimethyl-amino)-benzyl-idene]indan-1-one.

  Acta crystallographica. Section E, Structure reports online 20110801

• Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

  Journal of medicinal chemistry 20110728

• Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells.

  Bioconjugate chemistry 20110720

• γ-Hydroxy-1,N2-propano-2'-deoxyguanosine DNA adduct conjugates the N-terminal amine of the KWKK peptide via a carbinolamine linkage.

  Chemical research in toxicology 20110718

• Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.

  Cancer 20110715

• Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.

  Journal of controlled release : official journal of the Controlled Release Society 20110715

• Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.

  Cancer research 20110715

• Design and synthesis of 4-amino-2-phenylquinazolines as novel topoisomerase I inhibitors with molecular modeling.

  Bioorganic & medicinal chemistry 20110715

• Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.

  Journal of medicinal chemistry 20110714

• Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.

  British journal of cancer 20110712

• Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110710

• 15-Deoxy-Δ12,14-prostaglandin J2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPARγ pathways.

  Biochemical and biophysical research communications 20110708

• Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?

  Nature reviews. Clinical oncology 20110705

• Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells.

  Small (Weinheim an der Bergstrasse, Germany) 20110704

• Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20110701

• Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.

  Cancer chemotherapy and pharmacology 20110701

• Synthesis of nanocarriers with remote magnetic drug release control and enhanced drug delivery for intracellular targeting of cancer cells.

  Acta biomaterialia 20110701

• Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.

  Gastroenterology 20110701

• New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots.

  Cancer science 20110701

• Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells.

  Disease models & mechanisms 20110701

• Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).

  Anti-cancer drugs 20110701

• Obacunone and obacunone glucoside inhibit human colon cancer (SW480) cells by the induction of apoptosis.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110701

• Adjuvant treatment of colon cancer: what is next?

  Current opinion in oncology 20110701

• Cetuximab in the treatment of patients with colorectal cancer.

  Expert opinion on biological therapy 20110701

• Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.

  Anti-cancer drugs 20110701

• Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

  Molecular cancer therapeutics 20110701

• Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.

  Journal of pediatric hematology/oncology 20110701

• Development of thermosensitive poly(n-isopropylacrylamide-co-((2-dimethylamino) ethyl methacrylate))-based nanoparticles for controlled drug release.

  Nanotechnology 20110701

• Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart.

  Anti-cancer drugs 20110701

• An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.

  Anti-cancer drugs 20110701

• A novel Rad18 ubiqitin ligase-mediated pathway for repair of camptothecin-induced DNA damage.

  Cell cycle (Georgetown, Tex.) 20110701

• Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.

  Nuclear medicine and biology 20110701

• Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.

  Chemistry & biodiversity 20110701

• [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110701

• [Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110701

• [A case of interstitial pneumonia induced by CPT-11 for local recurrence of rectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110701

• Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.

  Nature communications 20110701

• The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.

  PLoS genetics 20110701

• Epistatic relationships in the BRCA1-BRCA2 pathway.

  PLoS genetics 20110701

• Pharmacokinetics of hydroxycamptothecin nanosuspensions in rats.

  Die Pharmazie 20110701

• [Study on pharmacokinetics of HCPT nanosuspensions with ability of inhibiting P-gp in rats after oral administration].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20110701

• Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

  Toxins 20110701

• Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism.

  ACS nano 20110628

• A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

  British journal of cancer 20110628

• Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I.

  Science (New York, N.Y.) 20110624

• Stimulus-responsiveness and drug release from porous silicon films ATRP-grafted with poly(N-isopropylacrylamide).

  Langmuir : the ACS journal of surfaces and colloids 20110621

• The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110615

• Targeting tumor cells through chitosan-folate modified microcapsules loaded with camptothecin.

  Bioconjugate chemistry 20110615

• Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery.

  Small (Weinheim an der Bergstrasse, Germany) 20110606

• Machilusides A and B: structurally unprecedented homocucurbitane glycosides from the stem bark of Machilus yaoshansis.

  Organic letters 20110603

• Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents.

  Investigational new drugs 20110601

• Surgical therapies in metastatic colorectal cancer with a potential for cure.

  American journal of clinical oncology 20110601

• Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

  Critical reviews in oncology/hematology 20110601

• Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.

  Journal of liposome research 20110601

• A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

  Cancer chemotherapy and pharmacology 20110601

• Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.

  Journal of neuro-oncology 20110601

• Capecitabine-based chemotherapy for metastatic colorectal cancer.

  Journal of cancer research and clinical oncology 20110601

• Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.

  Annals of surgical oncology 20110601

• Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.

  International journal of clinical oncology 20110601

• Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110601

• Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110601

• Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110601

• Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.

  Cancer gene therapy 20110601

• Mediastinal infusion with tracheal necrosis: an unusual complication of Port-a-cath devices.

  Interactive cardiovascular and thoracic surgery 20110601

• USP1 deubiquitinase maintains phosphorylated CHK1 by limiting its DDB1-dependent degradation.

  Human molecular genetics 20110601

• Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions.

  Cancer science 20110601

• Glucose deprivation is associated with Chk1 degradation through the ubiquitin-proteasome pathway and effective checkpoint response to replication blocks.

  Biochimica et biophysica acta 20110601

• Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20110601

• Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.

  Biochemical pharmacology 20110601

• Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.

  European journal of medicinal chemistry 20110601

• Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.

  Molecular cancer therapeutics 20110601

• CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.

  Current cancer drug targets 20110601

• Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

  Molecular imaging 20110601

• Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.

  The Journal of pharmacy and pharmacology 20110601

• Cell fixation in zinc salt solution is compatible with DNA damage response detection by phospho-specific antibodies.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20110601

• O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110601

• Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

  The oncologist 20110601

• Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.

  The oncologist 20110601

• [Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• [Primary adenocarcinoma of small intestine with peritoneal dissemination treated with S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

  Anticancer research 20110601

• Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.

  Anti-cancer drugs 20110601

• Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.

  Anti-cancer drugs 20110601

• Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.

  Anti-cancer drugs 20110601

• A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

  Clinical colorectal cancer 20110601

• Spirocyclic lignans from Guaiacum (Zygophyllaceae) induce apoptosis in human breast cancer cell lines.

  Journal of natural products 20110527

• Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.

  Journal of natural products 20110527

• Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn.

  Biochemical and biophysical research communications 20110527

• Structural photodynamics of camptothecin, an anticancer drug in aqueous solutions.

  The journal of physical chemistry. A 20110526

• Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.

  British journal of cancer 20110524

• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• Nek6 suppresses the premature senescence of human cancer cells induced by camptothecin and doxorubicin treatment.

  Biochemical and biophysical research communications 20110520

• Use of irinotecan for treatment of small cell carcinoma of the prostate.

  The Prostate 20110515

• Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.

  Cell cycle (Georgetown, Tex.) 20110515

• Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.

  Cancer 20110515

• A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.

  Cancer 20110515

• Functionalized carbon nanomaterials as nanocarriers for loading and delivery of a poorly water-soluble anticancer drug: a comparative study.

  Chemical communications (Cambridge, England) 20110514

• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  The New England journal of medicine 20110512

• Human HEL308 localizes to damaged replication forks and unwinds lagging strand structures.

  The Journal of biological chemistry 20110506

• Total synthesis of the G2/M DNA damage checkpoint inhibitor psilostachyin C.

  The Journal of organic chemistry 20110506

• Drug target identification from protein dynamics using quantitative pathway analysis.

  Journal of proteome research 20110506

• Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs.

  Cancer chemotherapy and pharmacology 20110501

• Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20110501

• Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Correlation of camptothecin-producing ability and phylogenetic relationship in the genus Ophiorrhiza.

  Planta medica 20110501

• Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.

  Acta oncologica (Stockholm, Sweden) 20110501

• Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration.

  Drug delivery 20110501

• Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.

  Nucleic acids research 20110501

• Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

  European journal of cancer (Oxford, England : 1990) 20110501

• Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.

  European journal of cancer (Oxford, England : 1990) 20110501

• Anthocyanin-rich extracts suppress the DNA-damaging effects of topoisomerase poisons in human colon cancer cells.

  Molecular nutrition & food research 20110501

• Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi.

  International journal of antimicrobial agents 20110501

• Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.

  Japanese journal of clinical oncology 20110501

• Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.

  Oncology reports 20110501

• Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.

  Biochimica et biophysica acta 20110501

• Nitrate reductase-mediated nitric oxide generation is essential for fungal elicitor-induced camptothecin accumulation of Camptotheca acuminata suspension cell cultures.

  Applied microbiology and biotechnology 20110501

• Chk1 has an essential role in the survival of differentiated cortical neurons in the absence of DNA damage.

  Apoptosis : an international journal on programmed cell death 20110501

• Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.

  Investigative ophthalmology & visual science 20110501

• Regulation of JNK activity in the apoptotic response of intestinal epithelial cells.

  American journal of physiology. Gastrointestinal and liver physiology 20110501

• Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.

  Japanese journal of clinical oncology 20110501

• Expect the unexpected-screen your screens.

  Journal of pharmaceutical sciences 20110501

• Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.

  International journal of cancer 20110501

• Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110501

• Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells.

  Apoptosis : an international journal on programmed cell death 20110501

• Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks.

  Cell cycle (Georgetown, Tex.) 20110501

• Sequestration of camptothecin, an anticancer alkaloid, by chrysomelid beetles.

  Journal of chemical ecology 20110501

• Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20110501

• A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110501

• [A resected case of advanced gastric cancer with multiple liver metastasis successfully treated by preoperative and postoperative S-1/CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• [Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• The Saccharomyces cerevisiae telomerase subunit Est3 binds telomeres in a cell cycle- and Est1-dependent manner and interacts directly with Est1 in vitro.

  PLoS genetics 20110501

• Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.

  Anticancer research 20110501

• A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

  Clinical lung cancer 20110501

• Sex and dosing-time dependencies in irinotecan-induced circadian disruption.

  Chronobiology international 20110501

• [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110501

• The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes.

  Journal of natural products 20110425

• Effect of artificial reconstitution of the interaction between the plant Camptotheca acuminata and the fungal endophyte Fusarium solani on camptothecin biosynthesis.

  Journal of natural products 20110425

• DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

• An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts.

  Biochemical and biophysical research communications 20110415

• Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents.

  Journal of medicinal chemistry 20110414

• Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.

  World journal of gastroenterology 20110414

• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

  Nature chemical biology 20110413

• Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.

  British journal of cancer 20110412

• Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110410

• Few positives for triple-negative breast cancer.

  Journal of the National Cancer Institute 20110406

• Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.

  Molecular pharmaceutics 20110404

• A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity.

  The Journal of surgical research 20110401

• BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.

  Cancer chemotherapy and pharmacology 20110401

• A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20110401

• Dietary glycine protects from chemotherapy-induced hepatotoxicity.

  Amino acids 20110401

• Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110401

• Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20110401

• ERK mediates anti-apoptotic effect through phosphorylation and cytoplasmic localization of p21Waf1/Cip1/Sdi in response to DNA damage in normal human embryonic fibroblast (HEF) cells.

  Molecular biology reports 20110401

• ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.

  Neuroradiology 20110401

• Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.

  Pharmaceutical research 20110401

• Novel nanogels as drug delivery systems for poorly soluble anticancer drugs.

  Colloids and surfaces. B, Biointerfaces 20110401

• Irinotecan and radiosensitization in rectal cancer.

  Anti-cancer drugs 20110401

• The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.

  Pharmaceutical research 20110401

• Metabolic pathways of the camptothecin analog AR-67.

  Drug metabolism and disposition: the biological fate of chemicals 20110401

• A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20110401

• Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.

  Brain tumor pathology 20110401

• Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.

  European journal of cancer (Oxford, England : 1990) 20110401

• Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.

  Cancer science 20110401

• Correlations between camptothecin and related metabolites in Camptotheca acuminata reveal similar biosynthetic principles and in planta synergistic effects.

  Fitoterapia 20110401

• Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy.

  Japanese journal of clinical oncology 20110401

• R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20110401

• Cloning and biochemical characterization of Staphylococcus aureus type IA DNA topoisomerase comprised of distinct five domains.

  Archives of biochemistry and biophysics 20110401

• Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

  Japanese journal of clinical oncology 20110401

• Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.

  Japanese journal of clinical oncology 20110401

• Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.

  Japanese journal of clinical oncology 20110401

• Specific biomarkers for stochastic division patterns and starvation-induced quiescence under limited glucose levels in fission yeast.

  The FEBS journal 20110401

• Apoptotic microtubule network organization and maintenance depend on high cellular ATP levels and energized mitochondria.

  Apoptosis : an international journal on programmed cell death 20110401

• Synthesis and antitumor activity of 10-arylcamptothecin derivatives.

  Bioorganic & medicinal chemistry letters 20110401

• Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.

  Annals of biomedical engineering 20110401

• Barking up the wrong genome--we are not alone.

  Journal of clinical pharmacy and therapeutics 20110401

• Processing of joint molecule intermediates by structure-selective endonucleases during homologous recombination in eukaryotes.

  Chromosoma 20110401

• Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

  Expert opinion on pharmacotherapy 20110401

• RNA interference (RNAi) of Ufd1 protein can sensitize a hydroxycamptothecin-resistant colon cancer cell line SW1116/HCPT to hydroxycamptothecin.

  Journal of digestive diseases 20110401

• Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.

  Cancer 20110401

• Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.

  The American journal of pathology 20110401

• Sensitive detection of chemical-induced genotoxicity by the Cypridina secretory luciferase reporter assay, using DNA repair-deficient strains of Saccharomyces cerevisiae.

  Yeast (Chichester, England) 20110401

• [A case of recurrent gastric cancer with lymph node metastasis successfully treated by CPT-11/CDDP therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110401

• [A case report of primary duodenal adenocarcinoma responding to chemotherapy with S-1 and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110401

• DNA damage response in resting and proliferating peripheral blood lymphocytes treated by camptothecin or X-ray.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20110401

• Acneiform eruption following molecular targeted chemotherapy.

  Internal medicine journal 20110401

• [Second line chemotherapy for pancreatic cancer].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20110401

• APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.

  Pharmacogenomics 20110401

• [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110401

• Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

  Clinical therapeutics 20110401

• [The synergistic antitumor effects of berberine alpha-hydroxy-beta-decanoylethyl sulfonate with hydroxycamptothecine and its effect on topoisomerase].

  Yao xue xue bao = Acta pharmaceutica Sinica 20110401

• [Study on chemical constituents from leaves of Naudea officinalis].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20110401

• [Chemotherapy for advanced colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Importance and practice of UGT1A1 polymorphisms].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20110401

• G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity.

  Journal of controlled release : official journal of the Controlled Release Society 20110330

• Clinical reports of pulmonary metastasectomy for colorectal cancer: a citation network analysis.

  British journal of cancer 20110329

• Absorption of 10-hydroxycamptothecin on Fe3O4 magnetite nanoparticles with layer-by-layer self-assembly and drug release response.

  Dalton transactions (Cambridge, England : 2003) 20110328

• Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-κB pathway.

  Toxicology letters 20110325

• 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.

  Journal of medicinal chemistry 20110324

• Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.

  Advanced drug delivery reviews 20110318

• Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.

  International journal of radiation oncology, biology, physics 20110315

• Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38.

  International journal of pharmaceutics 20110315

• Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors.

  Bioorganic & medicinal chemistry 20110315

• Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110310

• Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110310

• Three-drug combination regimen in pancreatic cancer treatment: are we there yet?

  JOP : Journal of the pancreas 20110309

• Treatment for refractory pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011.

  JOP : Journal of the pancreas 20110309

• Cytokeratin expression patterns in multiple infundibulocystic basal cell carcinoma.

  Journal of cutaneous pathology 20110301

• Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20110301

• Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.

  Journal of neurosurgery 20110301

• Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.

  Cancer chemotherapy and pharmacology 20110301

• Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.

  Cancer chemotherapy and pharmacology 20110301

• Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

  Journal of liposome research 20110301

• Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.

  Journal of gastrointestinal cancer 20110301

• A new approach to determine camptothecin and its analogues affinity to human serum albumin.

  Journal of pharmaceutical sciences 20110301

• Bafilomycin A1 activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondria.

  Cellular and molecular life sciences : CMLS 20110301

• Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis.

  Amino acids 20110301

• Application of magnetic nanoparticles in pharmaceutical sciences.

  Pharmaceutical research 20110301

• Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.

  Annals of surgical oncology 20110301

• A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.

  International journal of radiation oncology, biology, physics 20110301

• High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

  Pediatric blood & cancer 20110301

• Effects of camptothecin, etoposide and Ca2+ on caspase-3 activity and myofibrillar disruption of chicken during postmortem ageing.

  Meat science 20110301

• Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.

  Pediatric blood & cancer 20110301

• Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer.

  Japanese journal of clinical oncology 20110301

• Anticancer properties of 10-hydroxycamptothecin in a murine melanoma pulmonary metastasis model in vitro and in vivo.

  Toxicology in vitro : an international journal published in association with BIBRA 20110301

• Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells.

  Carcinogenesis 20110301

• Activation of stress-regulated transcription factors by triethylene glycol dimethacrylate monomer.

  Biomaterials 20110301

• A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.

  Cancer chemotherapy and pharmacology 20110301

• Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2-dimethyl hydrazine induced colorectal carcinoma in rats.

  European journal of pharmacology 20110301

• Selective ploidy ablation, a high-throughput plasmid transfer protocol, identifies new genes affecting topoisomerase I-induced DNA damage.

  Genome research 20110301

• Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

  Cancer research 20110301

• The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.

  European journal of cancer (Oxford, England : 1990) 20110301

• Experimental and theoretical investigation of the molecular and electronic structure of anticancer drug camptothecin.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110301

• The role of DDX3 in regulating Snail.

  Biochimica et biophysica acta 20110301

• Feasibility of EUS-guided injection of irinotecan-loaded microspheres into the swine pancreas.

  Gastrointestinal endoscopy 20110301

• Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P.

  Bioorganic & medicinal chemistry letters 20110301

• Quantification of CPT13 in rat plasma using LC-MS/MS for a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110301

• Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.

  Asia-Pacific journal of clinical oncology 20110301

• Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.

  Plant signaling & behavior 20110301

• Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110301

• Spectrofluorimetric determination of SN-38, a promising new anti-tumor agent, in the presence and absence of organized media.

  Applied spectroscopy 20110301

• Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20110301

• Application of liposome-encapsulated hydroxycamptothecin in the prevention of epidural scar formation in New Zealand white rabbits.

  The spine journal : official journal of the North American Spine Society 20110301

• Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.

  Neoplasia (New York, N.Y.) 20110301

• [A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• [A case of drug-induced interstitial pneumonia caused by S-1 and CPT-11 combination therapy for advanced colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• SUMO-targeted ubiquitin ligase, Rad60, and Nse2 SUMO ligase suppress spontaneous Top1-mediated DNA damage and genome instability.

  PLoS genetics 20110301

• Caspase 3 blocking avoids the expression of autoantigens triggered by apoptosis in neonatal Balb/c mice skin.

  Reumatismo 20110301

• Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.

  Clinical colorectal cancer 20110301

• Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.

  Clinical colorectal cancer 20110301

• [10-Hydroxycamptothecin aerosol treatment inhibits lung metastases in B16F10 melanoma mice models].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20110301

• MCM3AP is transcribed from a promoter within an intron of the overlapping gene for GANP.

  Journal of molecular biology 20110225

• Electron paramagnetic resonance (EPR) study of spin-labeled camptothecin derivatives: a different look of the ternary complex.

  Journal of medicinal chemistry 20110224

• Hydrophilic mesoporous carbon nanoparticles as carriers for sustained release of hydrophobic anti-cancer drugs.

  Chemical communications (Cambridge, England) 20110221

• Effects of organic solvents on drug incorporation into polymeric carriers and morphological analyses of drug-incorporated polymeric micelles.

  International journal of pharmaceutics 20110214

• Proteome half-life dynamics in living human cells.

  Science (New York, N.Y.) 20110211

• Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

  Biochemistry 20110208

• Role of senataxin in DNA damage and telomeric stability.

  DNA repair 20110207

• Molecular cooperation between the Werner syndrome protein and replication protein A in relation to replication fork blockage.

  The Journal of biological chemistry 20110204

• Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.

  The pharmacogenomics journal 20110201

• Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.

  Cancer chemotherapy and pharmacology 20110201

• Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.

  Cardiovascular and interventional radiology 20110201

• Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.

  Annals of surgical oncology 20110201

• Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.

  Japanese journal of clinical oncology 20110201

• Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer.

  Molecular pharmacology 20110201

• Delayed elimination of SN-38 in cancer patients with severe renal failure.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Phosphatidylserine as an anchor for plasminogen and its plasminogen receptor, histone H2B, to the macrophage surface.

  Journal of thrombosis and haemostasis : JTH 20110201

• Application of recombinant and non-recombinant peptides in the determination of tumor response to cancer therapy.

  Current pharmaceutical biotechnology 20110201

• DNA double-strand break repair in Caenorhabditis elegans.

  Chromosoma 20110201

• In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.

  Apoptosis : an international journal on programmed cell death 20110201

• Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.

  Clinics and research in hepatology and gastroenterology 20110201

• Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

  Cancer research 20110201

• Camptothecin induces DNA strand breaks and is cytotoxic in stimulated normal lymphocytes.

  Oncology reports 20110201

• Protein kinase C-δ isoform mediates lysosome labilization in DNA damage-induced apoptosis.

  International journal of oncology 20110201

• Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy.

  Current gene therapy 20110201

• Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles.

  European journal of medicinal chemistry 20110201

• Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.

  International journal of colorectal disease 20110201

• Metronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft.

  Cancer science 20110201

• Plant-derived bioactive compounds produced by endophytic fungi.

  Mini reviews in medicinal chemistry 20110201

• Changing management and survival in patients with stage IV colorectal cancer.

  Diseases of the colon and rectum 20110201

• SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.

  Nature genetics 20110201

• Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110201

• hPuf-A/KIAA0020 modulates PARP-1 cleavage upon genotoxic stress.

  Cancer research 20110201

• A Blm-Recql5 partnership in replication stress response.

  Journal of molecular cell biology 20110201

• Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

  Neurology 20110201

• Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells.

  Acta pharmacologica Sinica 20110201

• [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110201

• Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker.

  Aging 20110201

• Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients.

  Acta medica Okayama 20110201

• Camptothecin distribution and content in Nothapodytes nimmoniana.

  Natural product communications 20110201

• Supramolecular assembly and antitumor activity of multiwalled carbon nanotube-camptothecin complexes.

  Journal of nanoscience and nanotechnology 20110201

• Fabrication and characterization of PSi smart particles containing 20(S)-camptothecin-functionalized germanium nanoparticles.

  Journal of nanoscience and nanotechnology 20110201

• [Study on preparation and tissue distribution of hydroxycamptothecin liposomes].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20110201

• Anticancer and anti-inflammatory activities of shallot (Allium ascalonicum) extract.

  Archives of medical science : AMS 20110201

• Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.

  International journal of pharmaceutics 20110117

• Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.

  Biochemical pharmacology 20110115

• A propionyloxy derivative of 11-keto-β-boswellic acid induces apoptosis in HL-60 cells mediated through topoisomerase I & II inhibition.

  Chemico-biological interactions 20110115

• 3-Arylisoquinolines as novel topoisomerase I inhibitors.

  Bioorganic & medicinal chemistry 20110115

• Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110110

• TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage.

  The Journal of biological chemistry 20110107

• High-content screening of drug-induced cardiotoxicity using quantitative single cell imaging cytometry on microfluidic device.

  Lab on a chip 20110107

• Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

  Journal of the National Cancer Institute 20110105

• Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.

  Journal of the National Cancer Institute 20110105

• Andrographolide: a new plant-derived antineoplastic entity on horizon.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.

  Cancer chemotherapy and pharmacology 20110101

• Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.

  Cancer chemotherapy and pharmacology 20110101

• Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.

  Cancer chemotherapy and pharmacology 20110101

• Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.

  Cancer chemotherapy and pharmacology 20110101

• Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.

  Cancer chemotherapy and pharmacology 20110101

• Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.

  Cancer chemotherapy and pharmacology 20110101

• Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.

  Surgical endoscopy 20110101

• A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids.

  Journal of pharmaceutical sciences 20110101

• p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells.

  The Prostate 20110101

• Effects of methimazole on the elimination of irinotecan.

  Cancer chemotherapy and pharmacology 20110101

• Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.

  Annals of surgical oncology 20110101

• A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.

  Japanese journal of clinical oncology 20110101

• Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.

  Apoptosis : an international journal on programmed cell death 20110101

• Development of chemiluminescence method for determination of 10-hydroxycamptothecin based on luminol-[Ag(HIO₆)₂]⁵⁻ reaction in alkaline solution.

  Luminescence : the journal of biological and chemical luminescence 20110101

• The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1.

  Cancer chemotherapy and pharmacology 20110101

• Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.

  The Journal of pathology 20110101

• Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.

  Biochemical pharmacology 20110101

• 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer.

  Journal of surgical oncology 20110101

• High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.

  European journal of cancer (Oxford, England : 1990) 20110101

• Anticancer Potential of Aqueous Ethanol Seed Extract of Ziziphus mauritiana against Cancer Cell Lines and Ehrlich Ascites Carcinoma.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• A sandwiched microarray platform for benchtop cell-based high throughput screening.

  Biomaterials 20110101

• Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20110101

• Synchronized turbo apoptosis induced by cold-shock.

  Apoptosis : an international journal on programmed cell death 20110101

• Somatostatin receptor-targeted anti-cancer therapy.

  Current drug delivery 20110101

• FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?

  The Lancet. Oncology 20110101

• Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates.

  European journal of medicinal chemistry 20110101

• Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives.

  Bioorganic & medicinal chemistry letters 20110101

• Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.

  Current medical research and opinion 20110101

• Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110101

• Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

  Sarcoma 20110101

• Camptothecin induces apoptosis of human retinoblastoma cells via activation of FOXO1.

  Current eye research 20110101

• A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.

  International journal of clinical pharmacology and therapeutics 20110101

• The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.

  The oncologist 20110101

• In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells.

  The American journal of Chinese medicine 20110101

• α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73.

  Breast cancer research : BCR 20110101

• Ubiquitin-proteasome genes as targets for modulation of cisplatin sensitivity in fission yeast.

  BMC genomics 20110101

• Shiga toxin and its use in targeted cancer therapy and imaging.

  Microbial biotechnology 20110101

• Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

  Anticancer research 20110101

• A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.

  BMC medicine 20110101

• Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis.

  Chemotherapy 20110101

• A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway.

  PloS one 20110101

• A specific inhibitor of protein kinase CK2 delays gamma-H2Ax foci removal and reduces clonogenic survival of irradiated mammalian cells.

  Radiation oncology (London, England) 20110101

• Histone deacetylase activity modulates alternative splicing.

  PloS one 20110101

• DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.

  PloS one 20110101

• Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20110101

• The use of endophytes to obtain bioactive compounds and their application in biotransformation process.

  Biotechnology research international 20110101

• [Analysis of gene expression patterns in an irinotecan-resistance colon cancer cell by cDNA microarray].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20110101

• Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development.

  Current medicinal chemistry 20110101

• Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.

  Cancer cell international 20110101

• [A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110101

• [Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110101

• Proteomic assessment of a cell model of spinal muscular atrophy.

  BMC neuroscience 20110101

• Camptothecin-induced death of amelanotic and melanotic melanoma cells in different phases of cell cycle.

  Neoplasma 20110101

• Comparative genotypic and pathogenic examination of Campylobacter concisus isolates from diarrheic and non-diarrheic humans.

  BMC microbiology 20110101

• Amyloid precursor protein binding protein Fe65 is cleaved by caspases during DNA damage-induced apoptosis.

  Biological & pharmaceutical bulletin 20110101

• EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.

  BMC cancer 20110101

• A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.

  Journal of hematology & oncology 20110101

• Monocrotophos induced apoptosis in PC12 cells: role of xenobiotic metabolizing cytochrome P450s.

  PloS one 20110101

• Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study.

  Chemotherapy 20110101

• Nanomedicine: making controllable magnetic drug delivery possible for the treatment of breast cancer.

  Breast cancer research : BCR 20110101

• Functional role of kallikrein 6 in regulating immune cell survival.

  PloS one 20110101

• A fully integrated and automated detection system for single nucleotide polymorphisms of UGT1A1 and CYP2C19.

  Oncology research 20110101

• Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

  BMC cancer 20110101

• A melanoma molecular disease model.

  PloS one 20110101

• Effects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal Doxorubicin in vitro.

  Journal of drug delivery 20110101

• Liposome technology for industrial purposes.

  Journal of drug delivery 20110101

• Apoptotic sphingolipid ceramide in cancer therapy.

  Journal of lipids 20110101

• C16-Ceramide Analog Combined with Pc 4 Photodynamic Therapy Evokes Enhanced Total Ceramide Accumulation, Promotion of DEVDase Activation in the Absence of Apoptosis, and Augmented Overall Cell Killing.

  Journal of lipids 20110101

• Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells.

  International journal of nanomedicine 20110101

• Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.

  Clinical Medicine Insights. Oncology 20110101

• Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells.

  Molecular cancer 20110101

• Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.

  Sarcoma 20110101

• Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Replication-fork stalling and processing at a single psoralen interstrand crosslink in Xenopus egg extracts.

  PloS one 20110101

• Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer: an analysis in Western patients.

  Tumori 20110101

• Activation of multiple apoptotic pathways in human nasopharyngeal carcinoma cells by the prenylated isoflavone, osajin.

  PloS one 20110101

• Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• Integrin Targeted MR Imaging.

  Theranostics 20110101

• Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design.

  International journal of nanomedicine 20110101

• A viable hypomorphic allele of the essential IMP3 gene reveals novel protein functions in Saccharomyces cerevisiae.

  PloS one 20110101

• Synthesis of 1-substituted carbazolyl-1,2,3,4-tetrahydro- and carbazolyl-3,4-dihydro-β-carboline analogs as potential antitumor agents.

  Marine drugs 20110101

• Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.

  BMC medical genomics 20110101

• Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability.

  Virology journal 20110101

• FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.

  PloS one 20110101

• Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees.

  PloS one 20110101

• Interaction of late apoptotic and necrotic cells with vitronectin.

  PloS one 20110101

• Oncogene addiction in gliomas: implications for molecular targeted therapy.

  Journal of experimental & clinical cancer research : CR 20110101

• Esophageal small-cell carcinoma with syndrome of inappropriate secretion of antidiuretic hormone.

  Internal medicine (Tokyo, Japan) 20110101

• Investigation of a potential scintigraphic tracer for imaging apoptosis: radioiodinated annexin V-Kunitz protease inhibitor fusion protein.

  Journal of biomedicine & biotechnology 20110101

• A formal MIM specification and tools for the common exchange of MIM diagrams: an XML-Based format, an API, and a validation method.

  BMC bioinformatics 20110101

• Recent advances of chitosan nanoparticles as drug carriers.

  International journal of nanomedicine 20110101

• Transcriptomic and proteomic profiling of maize embryos exposed to camptothecin.

  BMC plant biology 20110101

• Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.

  Chemotherapy 20110101

• Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20110101

• Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.

  Tumori 20110101

• New Topoisomerase I mutations are associated with resistance to camptothecin.

  Molecular cancer 20110101

• Expression of OATP family members in hormone-related cancers: potential markers of progression.

  PloS one 20110101

• Current developments in the therapy of protozoan infections.

  The open medicinal chemistry journal 20110101

• Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3.

  International journal of Alzheimer's disease 20110101

• Management of provoked seizure.

  Annals of Indian Academy of Neurology 20110101

• Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

  Clinics and research in hepatology and gastroenterology 20110101

• Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy.

  BMC biology 20110101

• Induction of SCEs and DNA fragmentation in bovine peripheral lymphocytes by in vitro exposure to tolylfluanid-based fungicide.

  Genetics and molecular biology 20110101

• High throughput ratio imaging to profile caspase activity: potential application in multiparameter high content apoptosis analysis and drug screening.

  PloS one 20110101

• Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus.

  PloS one 20110101

• A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.

  Current chemical genomics 20110101

• Transport processes of radiopharmaceuticals and -modulators.

  Radiation oncology (London, England) 20110101

• Rtt107 phosphorylation promotes localisation to DNA double-stranded breaks (DSBs) and recombinational repair between sister chromatids.

  PloS one 20110101

• The essential functions of NEDD8 are mediated via distinct surface regions, and not by polyneddylation in Schizosaccharomyces pombe.

  PloS one 20110101

• Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).

  Oncology 20110101

• The over-expression of the β2 catalytic subunit of the proteasome decreases homologous recombination and impairs DNA double-strand break repair in human cells.

  Journal of biomedicine & biotechnology 20110101

• Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.

  BMC cancer 20110101

• Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum.

  PloS one 20110101

• A practical strategy for constructing nanodrugs using carbon nanotubes as carriers.

  Methods in molecular biology (Clifton, N.J.) 20110101

• Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

  Oncology 20110101

• Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

  Oncology 20110101

• Network target for screening synergistic drug combinations with application to traditional Chinese medicine.

  BMC systems biology 20110101

• Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.

  PloS one 20110101

• Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofol.

  Nanoscale research letters 20110101

• Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents.

  International journal of nanomedicine 20110101

• Preparation and physicochemical properties of 10-hydroxycamptothecin (HCPT) nanoparticles by supercritical antisolvent (SAS) process.

  International journal of molecular sciences 20110101

• Redundant mechanisms prevent mitotic entry following replication arrest in the absence of Cdc25 hyper-phosphorylation in fission yeast.

  PloS one 20110101

• DNA-PK-dependent RPA2 hyperphosphorylation facilitates DNA repair and suppresses sister chromatid exchange.

  PloS one 20110101

• Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

  Molecular cancer 20110101

• In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20110101

• Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.

  Onkologie 20110101

• Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors.

  BMC medical genomics 20110101

• Mitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drug.

  PloS one 20110101

• TSPYL2 is important for G1 checkpoint maintenance upon DNA damage.

  PloS one 20110101

• First-order multivariate calibration applied to the simultaneous fluorometric determination of the anticancer agents CPT-11 and SN-38 in serum and urine samples.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20110101

• Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications.

  International journal of molecular sciences 20110101

• mTOR controls ovarian follicle growth by regulating granulosa cell proliferation.

  PloS one 20110101

• Common side effects and interactions of colorectal cancer therapeutic agents.

  The Journal of practical nursing 20110101

• Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

  Clinical and experimental gastroenterology 20110101

• First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Lipid-polymer composite microspheres for colon-specific drug delivery prepared using an ultrasonic spray freeze-drying technique.

  Journal of microencapsulation 20110101

• Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography.

  Cancer imaging : the official publication of the International Cancer Imaging Society 20110101

• Lithium not only stabilizes mood, it is also neuroprotective.

  Indian journal of psychiatry 20110101

• 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

  Oncology 20110101

• Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells.

  Journal of radiation research 20110101

• Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice.

  Tumori 20110101

• Irinotecan as a second-line monotherapy for small cell lung cancer.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• Development of antiproliferative nanohybrid compound with controlled release property using ellagic acid as the active agent.

  International journal of nanomedicine 20110101

• Application of supercritical antisolvent method in drug encapsulation: a review.

  International journal of nanomedicine 20110101

• siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer.

  PloS one 20110101

• [Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101

• [Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].

  Voprosy onkologii 20110101

• Broad-spectrum antiviral therapeutics.

  PloS one 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• Bromophenols in marine algae and their bioactivities.

  Marine drugs 20110101

• Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts.

  Arthritis research & therapy 20110101

• Pancreatic β-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis.

  PloS one 20110101

• Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4.

  PloS one 20110101

• Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer.

  Clinical Medicine Insights. Oncology 20110101

• A novel preparation method for camptothecin (CPT) loaded folic acid conjugated dextran tumor-targeted nanoparticles.

  International journal of molecular sciences 20110101

• Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.

  International journal of molecular sciences 20110101

• Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.

  International journal of molecular sciences 20110101

• Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.

  BMC cancer 20110101

• A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1.

  Genome biology 20110101

• Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.

  BMC cancer 20110101

• Human RAD18 interacts with ubiquitylated chromatin components and facilitates RAD9 recruitment to DNA double strand breaks.

  PloS one 20110101

• Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation.

  PloS one 20110101

• Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy.

  Chinese medicine 20110101

• New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors.

  Current medicinal chemistry 20110101

• A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

  BMC cancer 20110101

• Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia.

  Molecular cancer 20110101

• Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.

  Biological & pharmaceutical bulletin 20110101

• Oral and fecal Campylobacter concisus strains perturb barrier function by apoptosis induction in HT-29/B6 intestinal epithelial cells.

  PloS one 20110101

• Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan.

  Oxidative medicine and cellular longevity 20110101

• The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs.

  Journal of nucleic acids 20110101

• High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease model.

  PloS one 20110101

• Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.

  PloS one 20110101

• In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs.

  Radiation oncology (London, England) 20110101

• Endothelial induced EMT in breast epithelial cells with stem cell properties.

  PloS one 20110101

• Primary myoepithelial carcinoma of palate.

  World journal of surgical oncology 20110101

• A new class of IMP dehydrogenase with a role in self-resistance of mycophenolic acid producing fungi.

  BMC microbiology 20110101

• The conservation and uniqueness of the caspase family in the basal chordate, amphioxus.

  BMC biology 20110101

• Acetonic extract of Buxus sempervirens induces cell cycle arrest, apoptosis and autophagy in breast cancer cells.

  PloS one 20110101

• The efficacy of chemotherapy in patients with high-grade metastatic colon cancer.

  Hepato-gastroenterology 20110101

• Apoptosis in cancer: from pathogenesis to treatment.

  Journal of experimental & clinical cancer research : CR 20110101

• Targets in epigenetics: inhibiting the methyl writers of the histone code.

  Current chemical genomics 20110101

• Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.

  PloS one 20110101

• Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.

  Oncology 20110101

• Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.

  Vascular cell 20110101

• Inhibition of unwinding and ATPase activities of Plasmodium falciparum Dbp5/DDX19 homolog.

  Communicative & integrative biology 20110101

• Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).

  Onkologie 20110101

• New insight into the molecular mechanisms of the biological effects of DNA minor groove binders.

  PloS one 20110101

• Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Tumor suppressors and cell-cycle proteins in lung cancer.

  Pathology research international 20110101

• High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity.

  International journal of molecular sciences 20110101

• Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery.

  International journal of molecular sciences 20110101

• The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit.

  Hepato-gastroenterology 20110101

• A case of marked response to preoperative chemoradiotherapy for rectal cancer with para-aortic lymph node metastasis.

  International surgery 20110101

• Pyrosequencing of the Camptotheca acuminata transcriptome reveals putative genes involved in camptothecin biosynthesis and transport.

  BMC genomics 20110101

• Nek family of kinases in cell cycle, checkpoint control and cancer.

  Cell division 20110101

• Cytotoxic and apoptotic effects of six herbal plants against the human hepatocarcinoma (HepG2) cell line.

  Chinese medicine 20110101

• [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101

• [Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101

• Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism.

  PloS one 20110101

• Methanosarcina acetivorans C2A topoisomerase IIIα, an archaeal enzyme with promiscuity in divalent cation dependence.

  PloS one 20110101

• Initiation but no execution - modulation of peripheral blood lymphocyte apoptosis in rheumatoid arthritis - a potential role for heat shock protein 70.

  Journal of inflammation (London, England) 20110101

• Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?

  European journal of gynaecological oncology 20110101

• MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells.

  Journal of biomedical science 20110101

• Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.

  PloS one 20110101

• Immunogenicity of panitumumab in combination chemotherapy clinical trials.

  BMC clinical pharmacology 20110101

• Generation of micronuclei during interphase by coupling between cytoplasmic membrane blebbing and nuclear budding.

  PloS one 20110101

• Long-term survival and improved quality of life after chemoradiotherapy to treat esophageal small cell carcinoma: a report of two cases.

  Hepato-gastroenterology 20110101

• The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.

  PloS one 20110101

• Differential effects of alpha-particle radiation and x-irradiation on genes associated with apoptosis.

  Radiology research and practice 20110101

• Cryptolepine-Induced Cell Death of Leishmania donovani Promastigotes Is Augmented by Inhibition of Autophagy.

  Molecular biology international 20110101

• Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum.

  Molecular biology international 20110101

• Evaluation of Maternal Toxicity in Rats Exposed to Multi-Wall Carbon Nanotubes during Pregnancy.

  Environmental health and toxicology 20110101

• Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression.

  PloS one 20110101

• Modulation of the host interferon response and ISGylation pathway by B. pertussis filamentous hemagglutinin.

  PloS one 20110101

• A quantitative method for the specific assessment of caspase-6 activity in cell culture.

  PloS one 20110101

• Attenuation of cytotoxic natural product DNA intercalating agents by caffeine.

  Scientia pharmaceutica 20110101

• Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.

  Drug metabolism and drug interactions 20110101

• Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report.

  Tumori 20110101

• Preparation of hippurate-zinc layered hydroxide nanohybrid and its synergistic effect with tamoxifen on HepG2 cell lines.

  International journal of nanomedicine 20110101

• Biosensing with quantum dots: a microfluidic approach.

  Sensors (Basel, Switzerland) 20110101

• Recruitment of Oct4 protein to UV-damaged chromatin in embryonic stem cells.

  PloS one 20110101

• Development of derivatives of 3, 3'-diindolylmethane as potent Leishmania donovani bi-subunit topoisomerase IB poisons.

  PloS one 20110101

• IT-141, a Polymer Micelle Encapsulating SN-38, Induces Tumor Regression in Multiple Colorectal Cancer Models.

  Journal of drug delivery 20110101

• 9-methoxycamptothecin from Nothapodytes foetida induces apoptosis in murine sarcoma S180 cells.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20110101

• A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.

  Chang Gung medical journal 20110101

• Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

  Journal of drug delivery 20110101

• Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.

  World journal of surgical oncology 20110101

• SN-38:β-cyclodextrin inclusion complex for in situ solidifying injectable polymer implants.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20110101

• Drug-polyester conjugated nanoparticles for cancer drug delivery.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20110101

• Enhanced antiproliferative and apoptotic response of HT-29 adenocarcinoma cells to combination of photoactivated hypericin and farnesyltransferase inhibitor manumycin A.

  International journal of molecular sciences 20110101

• Modeling natural anti-inflammatory compounds by molecular topology.

  International journal of molecular sciences 20110101

• The prospective role of plant products in radiotherapy of cancer: a current overview.

  Frontiers in pharmacology 20110101

• MicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer.

  Frontiers in genetics 20110101

• Preparation of carboxymethylchitosan nanoparticles with Acid-sensitive bond based on solid dispersion of 10-hydroxycamptothecin.

  ISRN pharmaceutics 20110101

• HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.

  Asian Pacific journal of cancer prevention : APJCP 20110101

• RNA Polymerase II Elongation at the Crossroads of Transcription and Alternative Splicing.

  Genetics research international 20110101

• Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Cell death signaling and anticancer therapy.

  Frontiers in oncology 20110101

• Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.

  Cancer 20101215

• Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20.

  Bioorganic & medicinal chemistry 20101215

• Synthesis of 4β-N-polyaromatic substituted podophyllotoxins: DNA topoisomerase inhibition, anticancer and apoptosis-inducing activities.

  Bioorganic & medicinal chemistry 20101215

• Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.

  World journal of gastroenterology 20101214

• Guesstimates are not good enough for determining what is happening in routine care.

  British journal of cancer 20101207

• Structure-activity relationship study of 16 a-thiocamptothecins: an integrated in vitro and in silico approach.

  ChemMedChem 20101203

• Antimetastatic activity of MONCPT in preclinical melanoma mice model.

  Investigational new drugs 20101201

• MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.

  Medical oncology (Northwood, London, England) 20101201

• Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation.

  Pharmaceutical development and technology 20101201

• Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan.

  Medical oncology (Northwood, London, England) 20101201

• A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.

  American journal of clinical oncology 20101201

• Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.

  International journal of cancer 20101201

• Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.

  European journal of cancer (Oxford, England : 1990) 20101201

• p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20101201

• Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin.

  Cancer letters 20101201

• P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

  Drug metabolism letters 20101201

• Autophagy and tumorigenesis.

  Seminars in immunopathology 20101201

• Neurotoxic activity of a topoisomerase-I inhibitor, camptothecin, in cultured cerebellar granule neurons.

  Neurotoxicology 20101201

• Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity.

  Biochimica et biophysica acta 20101201

• Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.

  European journal of clinical pharmacology 20101201

• CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Outcomes in the management of obstructive unresectable stage IV colorectal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20101201

• Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8.

  Clinical & experimental metastasis 20101201

• Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.

  Cancer investigation 20101201

• Lifetime imaging of FRET between red fluorescent proteins.

  Journal of biophotonics 20101201

• RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer.

  Carcinogenesis 20101201

• [Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].

  Cirugia espanola 20101201

• Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101201

• Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.

  Oncology reports 20101201

• An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.

  Oncology reports 20101201

• DNA end resection by CtIP and exonuclease 1 prevents genomic instability.

  EMBO reports 20101201

• Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.

  Cancer science 20101201

• A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20101201

• The DAC system and associations with acute leukemias and myelodysplastic syndromes.

  Investigational new drugs 20101201

• Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.

  Molecular cancer therapeutics 20101201

• [A case of liver metastases from rectal cancer showed a complete response by FOLFIRI and bevacizumab chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101201

• Histone H2A C-terminus regulates chromatin dynamics, remodeling, and histone H1 binding.

  PLoS genetics 20101201

• Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.

  Anticancer research 20101201

• Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

  Clinical colorectal cancer 20101201

• Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

  Journal of biosciences 20101201

• Examination of camptothecin and 10-hydroxycamptothecin in Camptotheca acuminata plant and cell culture, and the affected yields under several cell culture treatments.

  Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al 20101201

• A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.

  Biochemistry 20101130

• Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata.

  Journal of natural products 20101129

• Abietane and C20-norabietane diterpenes from the stem bark of Fraxinus sieboldiana and their biological activities.

  Journal of natural products 20101129

• The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination.

  Molecular cell 20101124

• Identification of the MMS22L-TONSL complex that promotes homologous recombination.

  Molecular cell 20101124

• A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability.

  Molecular cell 20101124

• DDK phosphorylates checkpoint clamp component Rad9 and promotes its release from damaged chromatin.

  Molecular cell 20101124

• [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].

  Orvosi hetilap 20101121

• Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery.

  Journal of controlled release : official journal of the Controlled Release Society 20101120

• Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.

  Bioconjugate chemistry 20101117

• Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.

  Vaccine 20101116

• Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules.

  Bioinformatics (Oxford, England) 20101115

• Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.

  Talanta 20101115

• Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.

  Journal of medicinal chemistry 20101111

• Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.

  Journal of medicinal chemistry 20101111

• Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.

  British journal of cancer 20101109

• A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.

  British journal of cancer 20101109

• Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.

  British journal of cancer 20101109

• Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.

  British journal of cancer 20101109

• Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit.

  JOP : Journal of the pancreas 20101109

• Cancer. Targeting bacteria to improve cancer therapy.

  Science (New York, N.Y.) 20101105

• Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

  Science (New York, N.Y.) 20101105

• The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.

  European journal of cancer care 20101101

• Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.

  Breast cancer research and treatment 20101101

• Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.

  Head & neck 20101101

• Molecular predictive and prognostic markers in colon cancer.

  Cancer treatment reviews 20101101

• Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20101101

• In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer.

  Cancer letters 20101101

• PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cells.

  Pharmaceutical research 20101101

• Toxicity study of a new camptothecin anti-cancer agent CKD-602 in dogs: 4-week continuous intravenous dose by infusion pump and 4-week repeated intravenous dose.

  Regulatory toxicology and pharmacology : RTP 20101101

• Nanomicelle with long-term circulation and enhanced stability of camptothecin based on mPEGylated alpha,beta-poly (L-aspartic acid)-camptothecin conjugate.

  Colloids and surfaces. B, Biointerfaces 20101101

• Nanodiamonds as intracellular transporters of chemotherapeutic drug.

  Biomaterials 20101101

• Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers.

  Pharmaceutical research 20101101

• Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer--irinotecan and platinum chemotherapy.

  Gynecologic oncology 20101101

• Glycolytic flux occurs in Drosophila melanogaster recovering from camptothecin treatment.

  Anti-cancer drugs 20101101

• Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

  Cellular and molecular life sciences : CMLS 20101101

• Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs.

  Anti-cancer drugs 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells.

  Molecular cancer research : MCR 20101101

• Novel single-platform multiparameter FCM analysis of apoptosis: Significant differences between wash and no-wash procedure.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20101101

• Identification of tyrosyl-DNA phosphodiesterase as a novel DNA damage repair enzyme in Arabidopsis.

  Plant physiology 20101101

• EGFR antibodies in colorectal cancer: where do they belong?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101

• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101

• Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis.

  Pathology international 20101101

• A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.

  Cancer chemotherapy and pharmacology 20101101

• Cotranscriptional exon skipping in the genotoxic stress response.

  Nature structural & molecular biology 20101101

• DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue.

  Cancer research 20101101

• DNA methylation and normal chromosome behavior in Neurospora depend on five components of a histone methyltransferase complex, DCDC.

  PLoS genetics 20101101

• [Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of complete resection of a squamous cell lung cancer invading diaphragm after neoadjuvant chemotherapy of nedaplatin and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron after chemotherapy including irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20101101

• Synthesis and in vitro anticancer activities of some selenadiazole derivatives.

  Archiv der Pharmazie 20101101

• XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.

  Anticancer research 20101101

• Maintenance therapy in colon cancer.

  Cancer treatment reviews 20101101

• Update on capecitabine alone and in combination regimens in colorectal cancer patients.

  Cancer treatment reviews 20101101

• Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.

  Chinese medical journal 20101101

• [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of small cell carcinoma of esophagus treated by chemotherapy with CDDP plus CPT-11 and radiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of pneumocystis pneumonia during chemotherapy for gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A successful case with CPT-11 + CDDP chemotherapy for recurrent gastric cancer of the remnant stomach].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Two cases of gastric endocrine cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of gastric endocrine cell carcinoma with liver metastases treated with S-1/CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [The efficacy of cetuximab for metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Adrenalectomy for solitary adrenal metastasis from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of sigmoid colon cancer with synchronous multiple liver and lung metastases, who survived 25-month after combination of chemotherapy and metastasectomy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

  British journal of cancer 20101026

• Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.

  British journal of cancer 20101026

• Antioxidant-prooxidant properties of a new organoselenium compound library.

  Molecules (Basel, Switzerland) 20101021

• Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.

  Bioconjugate chemistry 20101020

• Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020

• Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

  International journal of cancer 20101015

• The role of apoptosis in mineralizing murine versus avian micromass culture systems.

  Journal of cellular biochemistry 20101015

• Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors.

  Cancer research 20101015

• Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

• Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells.

  Oncogene 20101014

• Cetuximab in small bowel adenocarcinoma: a new friend?

  British journal of cancer 20101012

• ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress.

  Molecular cell 20101008

• Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells.

  Chemico-biological interactions 20101006

• Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).

  Critical reviews in oncology/hematology 20101001

• A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20101001

• Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

  Cancer chemotherapy and pharmacology 20101001

• The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.

  Cancer chemotherapy and pharmacology 20101001

• Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.

  Lung cancer (Amsterdam, Netherlands) 20101001

• Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.

  American journal of clinical oncology 20101001

• Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.

  The pharmacogenomics journal 20101001

• Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101001

• Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.

  Annals of surgical oncology 20101001

• Electrochemical reduction mechanism of camptothecin at glassy carbon electrode.

  Bioelectrochemistry (Amsterdam, Netherlands) 20101001

• Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.

  Annals of surgical oncology 20101001

• Evaluation of cytotoxic activity of Schisandra chinensis lignans.

  Planta medica 20101001

• Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.

  Japanese journal of clinical oncology 20101001

• A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).

  Japanese journal of clinical oncology 20101001

• FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.

  Cellular signalling 20101001

• The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.

  Cancer 20101001

• Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.

  International journal of colorectal disease 20101001

• A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20101001

• A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes.

  Molecular microbiology 20101001

• Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.

  Cardiovascular and interventional radiology 20101001

• Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat.

  Experimental biology and medicine (Maywood, N.J.) 20101001

• Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype.

  Therapeutic drug monitoring 20101001

• The R438W polymorphism of human DNA polymerase lambda triggers cellular sensitivity to camptothecin by compromising the homologous recombination repair pathway.

  Carcinogenesis 20101001

• Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101001

• Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.

  Pharmaceutical research 20101001

• [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].

  RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20101001

• Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101001

• Experimental evaluation of inhibitory effect of 10-hydroxycamptothecin on hypoxia-inducible factor-1α expression and angiogenesis in liver tumors after transcatheter arterial embolization.

  Journal of vascular and interventional radiology : JVIR 20101001

• Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.

  Oncology reports 20101001

• The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects.

  Oncology reports 20101001

• [mRNA quantification. The next challenge in routine diagnostics].

  Der Pathologe 20101001

• An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood.

  Biomedical chromatography : BMC 20101001

• Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101001

• Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20101001

• Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.

  The oncologist 20101001

• [A case of high CEA colon cancer responding to neoadjuvant chemotherapy with FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101001

• Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).

  Best practice & research. Clinical gastroenterology 20101001

• Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.

  PLoS genetics 20101001

• Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor.

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20101001

• Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.

  Anticancer research 20101001

• Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

  Anticancer research 20101001

• Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.

  Anticancer research 20101001

• A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

  Anticancer research 20101001

• Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery.

  Nanomedicine (London, England) 20101001

• [A rare case of large cell neuroendocrine carcinoma of the thymus].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20101001

• [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101001

• [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101001

• Chemotherapy of metastatic colorectal cancer.

  Prescrire international 20101001

• A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.

  British journal of cancer 20100928

• Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation.

  International journal of pharmaceutics 20100915

• Cholic acid-modified dendritic multimolecular micelles and enhancement of anticancer drug therapeutic efficacy.

  Bioconjugate chemistry 20100915

• p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals.

  The Journal of biological chemistry 20100910

• Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS).

  Journal of chromatography. A 20100910

• Human SIRT6 promotes DNA end resection through CtIP deacetylation.

  Science (New York, N.Y.) 20100910

• Proficient repair in chromatin remodeling defective ino80 mutants of Saccharomyces cerevisiae highlights replication defects as the main contributor to DNA damage sensitivity.

  DNA repair 20100904

• Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.

  Medical oncology (Northwood, London, England) 20100901

• The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.

  Medical oncology (Northwood, London, England) 20100901

• Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.

  Medical oncology (Northwood, London, England) 20100901

• Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.

  Medical oncology (Northwood, London, England) 20100901

• Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.

  Current stem cell research & therapy 20100901

• Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents.

  International journal of cancer 20100901

• Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.

  Journal of neuro-oncology 20100901

• Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.

  Cancer chemotherapy and pharmacology 20100901

• Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.

  Journal of neuro-oncology 20100901

• Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma.

  Journal of neuro-oncology 20100901

• Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Bevacizumab in recurrent high-grade pediatric gliomas.

  Neuro-oncology 20100901

• Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

  Neuro-oncology 20100901

• Oxidative stress-based cytotoxicity of delphinidin and cyanidin in colon cancer cells.

  Archives of biochemistry and biophysics 20100901

• Nek1 silencing slows down DNA repair and blocks DNA damage-induced cell cycle arrest.

  Mutagenesis 20100901

• Defective p53 antiangiogenic signaling in glioblastoma.

  Neuro-oncology 20100901

• Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.

  The Journal of pharmacology and experimental therapeutics 20100901

• Ultrasound-enhanced drug transport and distribution in the brain.

  AAPS PharmSciTech 20100901

• Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.

  Cancer 20100901

• pH-Dependent biodegradable silica nanotubes derived from Gd(OH)3 nanorods and their potential for oral drug delivery and MR imaging.

  Biomaterials 20100901

• Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

  Cancer science 20100901

• Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

  Journal of materials science. Materials in medicine 20100901

• Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity.

  European journal of medicinal chemistry 20100901

• Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage.

  Cell research 20100901

• Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.

  Anti-cancer drugs 20100901

• Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues.

  European journal of medicinal chemistry 20100901

• Synthesis and antiproliferative activity of indolizinophthalazine-5,12-dione derivatives, DNA topoisomerase IB inhibitors.

  European journal of medicinal chemistry 20100901

• Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.

  Anti-cancer drugs 20100901

• A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901

• Oxidative stimuli-responsive nanoprodrug of camptothecin kills glioblastoma cells.

  Bioorganic & medicinal chemistry letters 20100901

• Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression.

  International journal of oncology 20100901

• Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.

  The American journal of surgical pathology 20100901

• Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

  The Lancet. Oncology 20100901

• Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

  The Lancet. Oncology 20100901

• Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.

  British journal of clinical pharmacology 20100901

• Treatment of rat brain tumors using sustained-release of camptothecin from poly(lactic-co-glycolic acid) microspheres in a thermoreversible hydrogel.

  Chemical & pharmaceutical bulletin 20100901

• [A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100901

• [A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100901

• [Metastatic gastric cancer: does second-line chemotherapy make sense?].

  Deutsche medizinische Wochenschrift (1946) 20100901

• The SR protein B52/SRp55 is required for DNA topoisomerase I recruitment to chromatin, mRNA release and transcription shutdown.

  PLoS genetics 20100901

• Critical functions of Rpa3/Ssb3 in S-phase DNA damage responses in fission yeast.

  PLoS genetics 20100901

• Novel chemoradiosensitizers for cancer therapy.

  Anticancer research 20100901

• Inhibition of DNA topoisomerases I and II and cytotoxicity of compounds from Ulmus davidiana var. japonica.

  Archives of pharmacal research 20100901

• Expression of coxsackie and adenovirus receptor distinguishes transitional cancer states in therapy-induced cellular senescence.

  Cell death & disease 20100901

• 7'-Methyl-5'-oxo-2',3'-dihydro-spiro-[1,3-dioxolane-2,1'(5'H)-indolizine]-6'-carbonitrile.

  Acta crystallographica. Section E, Structure reports online 20100901

• Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.

  Journal of medicinal chemistry 20100826

• Rapid resolution liquid chromatography-mass spectrometry and high-performance liquid chromatography-fluorescence detection for metabolism and pharmacokinetic studies of ergosta-4,6,8(14),22-tetraen-3-one.

  Analytica chimica acta 20100824

• Are herbal medicines ripe for the cancer clinic?

  Science translational medicine 20100818

• The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity.

  Science translational medicine 20100818

• Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells.

  Cancer biology & therapy 20100815

• The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.

  Cancer research 20100815

• Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes.

  Life sciences 20100814

• Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.

  World journal of gastroenterology 20100814

• Identification of a coiled coil in werner syndrome protein that facilitates multimerization and promotes exonuclease processivity.

  The Journal of biological chemistry 20100813

• Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100810

• UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

  British journal of cancer 20100810

• Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.

  American journal of clinical oncology 20100801

• A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

  American journal of clinical oncology 20100801

• Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.

  Cancer chemotherapy and pharmacology 20100801

• Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.

  Cancer chemotherapy and pharmacology 20100801

• Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.

  Journal of neuro-oncology 20100801

• Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.

  Journal of drug targeting 20100801

• The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.

  Cancer chemotherapy and pharmacology 20100801

• A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.

  International journal of clinical oncology 20100801

• Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.

  Acta oncologica (Stockholm, Sweden) 20100801

• Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

  Cancer chemotherapy and pharmacology 20100801

• Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801

• Pharmacogenetics of irinotecan disposition and toxicity: a review.

  Current clinical pharmacology 20100801

• Different DNA immobilization strategies for the interaction of anticancer drug irinotecan with DNA based on electrochemical DNA biosensors.

  Combinatorial chemistry & high throughput screening 20100801

• Acute lung injury: apoptosis in effector and target cells of the upper and lower airway compartment.

  Clinical and experimental immunology 20100801

• Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons.

  Journal of neurochemistry 20100801

• BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.

  Cancer science 20100801

• Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100801

• Targeted cancer therapy with novel high drug-loading nanocrystals.

  Journal of pharmaceutical sciences 20100801

• Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20100801

• The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.

  Bioorganic & medicinal chemistry 20100801

• S phase entry causes homocysteine-induced death while ataxia telangiectasia and Rad3 related protein functions anti-apoptotically to protect neurons.

  Brain : a journal of neurology 20100801

• Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.

  British journal of pharmacology 20100801

• Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

  British journal of clinical pharmacology 20100801

• Consequences of chemotherapy on resection of colorectal liver metastases.

  Journal of visceral surgery 20100801

• Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

  Assay and drug development technologies 20100801

• Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).

  The Journal of pharmacy and pharmacology 20100801

• Overexpression of CD133 promotes drug resistance in C6 glioma cells.

  Molecular cancer research : MCR 20100801

• Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20100801

• Control of TrkA-induced cell death by JNK activation and differential expression of TrkA upon DNA damage.

  Molecules and cells 20100801

• When more is worse in clinical research and clinical practice.

  American journal of clinical oncology 20100801

• Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.

  Cell cycle (Georgetown, Tex.) 20100801

• Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801

• [A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100801

• [A case of irinotecan-induced interstitial pneumonia during treatment of recurrent colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100801

• Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects.

  Nanomedicine (London, England) 20100801

• Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20100801

• Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20100801

• A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs.

  Oncotarget 20100801

• Minor groove orientation of the KWKK peptide tethered via the N-terminal amine to the acrolein-derived 1,N2-gamma-hydroxypropanodeoxyguanosine lesion with a trimethylene linkage.

  Biochemistry 20100727

• Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.

  British journal of cancer 20100727

• Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.

  European journal of pharmacology 20100725

• Antifungal and cytotoxic activity of withanolides from Acnistus arborescens.

  Journal of natural products 20100723

• DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1.

  Chemical research in toxicology 20100719

• Synthesis and antiproliferative evaluation of certain iminonaphtho[2,3-b]furan derivatives.

  Bioorganic & medicinal chemistry 20100715

• Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

  World journal of gastroenterology 20100707

• Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.

  Cancer chemotherapy and pharmacology 20100701

• Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression.

  International journal of colorectal disease 20100701

• Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.

  Leukemia research 20100701

• Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20100701

• Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.

  Biochemical pharmacology 20100701

• Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line.

  The Journal of thoracic and cardiovascular surgery 20100701

• Trifluoromethyl-promoted homocamptothecins: synthesis and biological activity.

  European journal of medicinal chemistry 20100701

• Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.

  Japanese journal of clinical oncology 20100701

• Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.

  European journal of cancer (Oxford, England : 1990) 20100701

• Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

  Anti-cancer drugs 20100701

• Cytotoxicity and topo I targeting activity of substituted 10--nitrogenous heterocyclic aromatic group derivatives of SN-38.

  European journal of medicinal chemistry 20100701

• Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells.

  Cancer investigation 20100701

• Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.

  Pediatric blood & cancer 20100701

• Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

  Pharmaceutical research 20100701

• Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.

  Expert opinion on pharmacotherapy 20100701

• Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701

• The molecular cell death machinery in the simple cnidarian Hydra includes an expanded caspase family and pro- and anti-apoptotic Bcl-2 proteins.

  Cell research 20100701

• Sustained release of hydroxycamptothecin after subcutaneous administration using a novel phospholipid complex-DepoFoam technology.

  Drug development and industrial pharmacy 20100701

• Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.

  Advances in therapy 20100701

• Liquid chromatographic analysis of the anticancer alkaloid luotonin A and some new derivatives in human serum samples.

  Journal of separation science 20100701

• MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

  Molecular cancer therapeutics 20100701

• Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.

  Journal of surgical oncology 20100701

• The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

  European journal of cancer (Oxford, England : 1990) 20100701

• Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.

  Japanese journal of clinical oncology 20100701

• Irinotecan pharmacogenomics.

  Pharmacogenomics 20100701

• Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan.

  Journal of vascular and interventional radiology : JVIR 20100701

• Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

  Clinical lung cancer 20100701

• Cytokines shape chemotherapy-induced and 'bystander' senescence.

  Aging 20100701

• [Recent developments of pharmacogenomics in the treatment of colorectal cancers].

  Annales pharmaceutiques francaises 20100701

• [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• [A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Rad3 decorates critical chromosomal domains with gammaH2A to protect genome integrity during S-Phase in fission yeast.

  PLoS genetics 20100701

• Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer.

  Anticancer research 20100701

• [Synthesis of polyrotaxane-camptothecin conjugates and evaluation of its anti-tumor effect].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100701

• Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin.

  International journal of pharmaceutics 20100630

• ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.

  Cancer letters 20100628

• Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.

  The New England journal of medicine 20100624

• DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery.

  Proceedings. Biological sciences 20100622

• Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

• Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.

  International journal of cancer 20100615

• Prevention of in vivo lung tumor growth by prolonged local delivery of hydroxycamptothecin using poly(ester-carbonate)-collagen composites.

  Journal of controlled release : official journal of the Controlled Release Society 20100615

• Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions.

  International journal of pharmaceutics 20100615

• Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid.

  Bioorganic & medicinal chemistry 20100615

• Modularity and directionality in genetic interaction maps.

  Bioinformatics (Oxford, England) 20100615

• Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites.

  DNA repair 20100604

• Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.

  Investigational new drugs 20100601

• A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100601

• Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100601

• Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.

  American journal of clinical oncology 20100601

• Review role of topotecan in gynaecological cancers: current indications and perspectives.

  Critical reviews in oncology/hematology 20100601

• A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.

  American journal of clinical oncology 20100601

• Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.

  Lung cancer (Amsterdam, Netherlands) 20100601

• A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.

  American journal of clinical oncology 20100601

• Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines.

  Nanomedicine : nanotechnology, biology, and medicine 20100601

• The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

  Journal of cancer research and clinical oncology 20100601

• Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.

  International journal of radiation oncology, biology, physics 20100601

• Bax deficiency mediated drug resistance can be reversed by endoplasmic reticulum stress induced death signaling.

  Biochemical pharmacology 20100601

• Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy.

  Journal of controlled release : official journal of the Controlled Release Society 20100601

• Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I.

  European journal of medicinal chemistry 20100601

• Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20100601

• Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.

  International journal of clinical oncology 20100601

• Diet, microRNAs and prostate cancer.

  Pharmaceutical research 20100601

• Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11).

  International journal of clinical oncology 20100601

• A novel molecule, SLURP-1, enhances the survival of periodontal ligament fibroblasts.

  Journal of periodontal research 20100601

• Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.

  American journal of clinical oncology 20100601

• Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

  European journal of cancer (Oxford, England : 1990) 20100601

• Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy.

  The American journal of surgical pathology 20100601

• Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells.

  International journal of oncology 20100601

• Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.

  Oncology reports 20100601

• 'In vivo' optical approaches to angiogenesis imaging.

  Angiogenesis 20100601

• Pharmacokinetics of intraperitoneal irinotecan in a pig model.

  Journal of surgical oncology 20100601

• Efficient total synthesis of (S)-14-azacamptothecin.

  Chemistry, an Asian journal 20100601

• Induced endogenous autotoxicity in Camptotheca.

  Frontiers in bioscience (Elite edition) 20100601

• A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100601

• DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer.

  Future oncology (London, England) 20100601

• [Transition of chemotherapy for metastatic colorectal cancer and recent advances].

  Nihon rinsho. Japanese journal of clinical medicine 20100601

• Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

  Chemotherapy 20100601

• The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.

  Journal of chemotherapy (Florence, Italy) 20100601

• [Third-line CPT-11 chemotherapy for gastric cancer cases of non-curative gastrectomy or recurrence].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• [Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• [A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100601

• Minor groove dimeric bisbenzimidazoles inhibit in vitro DNA binding to eukaryotic DNA topoisomerase I.

  Biochemistry. Biokhimiia 20100601

• Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.

  Anticancer research 20100601

• [Alkaloids from the leaves of Nauclea officinalis].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100601

• Toxicity of perfluorinated carboxylic acids for aquatic organisms.

  Interdisciplinary toxicology 20100601

• Release modulation and cytotoxicity of hydroxycamptothecin-loaded electrospun fibers with 2-hydroxypropyl-beta-cyclodextrin inoculations.

  International journal of pharmaceutics 20100531

• The development of a dense gas solvent exchange process for the impregnation of pharmaceuticals into porous chitosan.

  International journal of pharmaceutics 20100531

• DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

  Chemistry & biology 20100528

• Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100520

• Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.

  Cancer 20100515

• Does interference between replication and transcription contribute to genomic instability in cancer cells?

  Cell cycle (Georgetown, Tex.) 20100515

• Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage.

  The Journal of biological chemistry 20100514

• Transcription-dependent activation of ataxia telangiectasia mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.

  The Journal of biological chemistry 20100514

• Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions.

  The journal of physical chemistry. B 20100506

• Role for ionic fluxes on cell death and apoptotic volume decrease in cultured cerebellar granule neurons.

  Neuroscience 20100505

• Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.

  Cancer chemotherapy and pharmacology 20100501

• The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• The novel proapoptotic activity of nonnatural enantiomer of Lentiginosine.

  Glycobiology 20100501

• Irinotecan as maintenance therapy in high-risk hepatoblastoma.

  Pediatric blood & cancer 20100501

• Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?

  Pediatric blood & cancer 20100501

• 10-Hydroxycamptothecin produced by a new endophytic Xylaria sp., M20, from Camptotheca acuminata.

  Biotechnology letters 20100501

• Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells.

  Pancreas 20100501

• Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20100501

• A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.

  Drug metabolism and disposition: the biological fate of chemicals 20100501

• Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles.

  Biomaterials 20100501

• Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53.

  Carcinogenesis 20100501

• [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review].

  Bulletin du cancer 20100501

• Operating characteristics of two independent sample design in phase I trials in paediatric oncology.

  European journal of cancer (Oxford, England : 1990) 20100501

• ADAM15 exerts an antiapoptotic effect on osteoarthritic chondrocytes via up-regulation of the X-linked inhibitor of apoptosis.

  Arthritis and rheumatism 20100501

• Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.

  Gynecologic oncology 20100501

• Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenation.

  Genetica 20100501

• Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501

• Smart particles for noble drug delivery system.

  Journal of nanoscience and nanotechnology 20100501

• A role for topoisomerase I in Fusarium graminearum and F. culmorum pathogenesis and sporulation.

  Molecular plant-microbe interactions : MPMI 20100501

• Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities.

  Bioorganic & medicinal chemistry 20100501

• Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation.

  International journal of oncology 20100501

• Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.

  Bioorganic & medicinal chemistry 20100501

• Mutation of the RAD51C gene in a Fanconi anemia-like disorder.

  Nature genetics 20100501

• Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

  Neuro-oncology 20100501

• Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.

  International journal of clinical pharmacology and therapeutics 20100501

• Diverse effects on mitochondrial and nuclear functions elicited by drugs and genetic knockdowns in bloodstream stage Trypanosoma brucei.

  PLoS neglected tropical diseases 20100501

• Cucurbitane-type triterpenes with anti-proliferative effects on U937 cells from an egyptian natural medicine, Bryonia cretica: structures of new triterpene glycosides, bryoniaosides A and B.

  Chemical & pharmaceutical bulletin 20100501

• [Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100501

• [A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-11 proved very effective].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100501

• [Mechanism of combined use of cyclopamine and hydroxycamptothecin in inducing the apoptosis of human oral squamous cell carcinoma cell line].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100501

• [Hematological toxicity of some combined chemotherapy schemes involving aranoza].

  Eksperimental'naia i klinicheskaia farmakologiia 20100501

• Cytotoxic activities of several geranyl-substituted flavanones.

  Journal of natural products 20100423

• Humulane and germacrane sesquiterpenes from Ferula lycia.

  Journal of natural products 20100423

• Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

  Journal of the National Cancer Institute 20100421

• Irinotecan in the adjuvant treatment of colon cancer: is the story finished or does personalized therapy open new opportunities?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100420

• Chemotherapeutic drugs inhibit ribosome biogenesis at various levels.

  The Journal of biological chemistry 20100416

• Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.

  Biochemical pharmacology 20100415

• Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100415

• The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.

  Cancer research 20100415

• Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

  Molecular pharmaceutics 20100405

• The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release.

  Organic letters 20100402

• Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.

  Biochemical and biophysical research communications 20100402

• Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.

  Cancer chemotherapy and pharmacology 20100401

• Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100401

• Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.

  The pharmacogenomics journal 20100401

• Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100401

• NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.

  The Journal of investigative dermatology 20100401

• Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20100401

• Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin.

  Colloids and surfaces. B, Biointerfaces 20100401

• Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.

  Pediatric blood & cancer 20100401

• Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.

  Annals of surgical oncology 20100401

• Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks.

  Human molecular genetics 20100401

• An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles.

  Biomaterials 20100401

• MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.

  Cancer biology & therapy 20100401

• DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region.

  Human mutation 20100401

• Insulin-like growth factors are more effective than progastrin in reversing proapoptotic effects of curcumin: critical role of p38MAPK.

  American journal of physiology. Gastrointestinal and liver physiology 20100401

• Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.

  Cancer 20100401

• Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.

  Cancer 20100401

• Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.

  The American journal of pathology 20100401

• Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.

  Journal of materials science. Materials in medicine 20100401

• Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.

  International journal of clinical oncology 20100401

• Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

  Acta oncologica (Stockholm, Sweden) 20100401

• The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines.

  Oncology reports 20100401

• Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.

  Journal of clinical gastroenterology 20100401

• Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100401

• Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

  Nature reviews. Clinical oncology 20100401

• Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100401

• Palliative chemotherapy for pancreatic malignancies.

  The Surgical clinics of North America 20100401

• Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

  Molecular cancer therapeutics 20100401

• [Optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients (2nd report)-influence of temperature on outflow speed of the medicinal solution].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20100401

• A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.

  Clinical colorectal cancer 20100401

• [Prognostic factors and survival of metastatic colorectal cancer in the Sousse University Hospital (Tunisia): comparative study of two treatment period of 200 patients].

  Bulletin du cancer 20100401

• Anti-HSV activity of camptothecin analogues.

  Natural product research 20100401

• Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.

  Expert review of anticancer therapy 20100401

• Upregulation of phagocytic clearance of apoptotic cells by autoimmune regulator.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20100401

• [Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100401

• [Survey on the compliance of patients with continuous infusion of 5-fluorouracil via portable infusion pumps].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100401

• [A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100401

• [Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100401

• Insecticidal activity of camptothecin against Nilaparvata lugens, Brevicoryne brassicae, and Chilo suppressalis.

  Journal of economic entomology 20100401

• Glutathione modulators reverse the pro-tumour effect of growth factors enhancing WiDr cell response to chemotherapeutic agents.

  Anticancer research 20100401

• Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.

  Cancer science 20100401

• Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.

  Cancer science 20100401

• Hepatocyte growth factor (HGF), heat shock proteins (HSPs) and multidrug resistance protein (MRP) expression in co-culture of colon tumor spheroids with normal cells after incubation with interleukin-1beta (IL-1beta) and/or camptothecin (CPT-11).

  Indian journal of experimental biology 20100401

• [Preparation and in vitro drug release study of long-circulating hydroxycamptothecin nanoparticles].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20100401

• Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery.

  Journal of the American Chemical Society 20100331

• An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells.

  Cancer letters 20100328

• MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM.

  Molecular cell 20100326

• Chemotherapy for advanced gastric cancer.

  The Cochrane database of systematic reviews 20100317

• Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.

  British journal of cancer 20100316

• Simple liquid chromatography method for the quantification of irinotecan and SN38 in sheep plasma: application to in vivo pharmacokinetics after pulmonary artery chemoembolization using drug eluting beads.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100315

• Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.

  Bioorganic & medicinal chemistry 20100315

• The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth.

  The Journal of biological chemistry 20100312

• PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA.

  The Journal of biological chemistry 20100312

• Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.

  Journal of medicinal chemistry 20100311

• MEPE/OF45 as a new target for sensitizing human tumour cells to DNA damage inducers.

  British journal of cancer 20100302

• An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.

  Medical oncology (Northwood, London, England) 20100301

• Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20100301

• N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?

  European journal of cancer care 20100301

• Synthesis and characterization of thermoresponsive polyamidoamine-polyethylene glycol-poly(D,L-lactide) core-shell nanoparticles.

  Acta biomaterialia 20100301

• P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549.

  Journal of cancer research and clinical oncology 20100301

• Genotoxicity of irinotecan and its modulation by vitamins A, C and E in human lymphocytes from healthy individuals and cancer patients.

  Toxicology in vitro : an international journal published in association with BIBRA 20100301

• HPTLC densitometric evaluation of tissue culture extracts of Nothapodytes foetida compared to conventional extracts for camptothecin content and antimicrobial activity.

  Planta medica 20100301

• Neurodegenerative, with expression ATF-2 by p38 in cortical neurons.

  Neurological research 20100301

• Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells.

  Carcinogenesis 20100301

• Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.

  Cancer science 20100301

• Peroxisome proliferator-activated receptor-gamma mediates bisphenol A inhibition of FSH-stimulated IGF-1, aromatase, and estradiol in human granulosa cells.

  Environmental health perspectives 20100301

• Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.

  Cancer 20100301

• Simultaneous confidence intervals to compare gene expression profiles using ABC transporter TaqMan microfluidic cards.

  Oncology reports 20100301

• Histone H3 Thr 45 phosphorylation is a replication-associated post-translational modification in S. cerevisiae.

  Nature cell biology 20100301

• FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.

  Cancer research 20100301

• Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.

  Biotechnology journal 20100301

• An overview of the recent progress in irinotecan pharmacogenetics.

  Pharmacogenomics 20100301

• [A case of small cell lung cancer (extensive disease) with liver metastasis acquiring stable disease by hepatic arterial infusion chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• [A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• [A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• Assessment of cyto/genotoxicity of irinotecan in v79 cells using the comet, micronucleus, and chromosome aberration assay.

  Arhiv za higijenu rada i toksikologiju 20100301

• Exoerythrocytic Plasmodium parasites secrete a cysteine protease inhibitor involved in sporozoite invasion and capable of blocking cell death of host hepatocytes.

  PLoS pathogens 20100301

• [Effect of hydroxycamptothecin (HCPT) on proliferation and apoptosis of rat hepatic stellate cells].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20100301

• Establishment and characterization of multidrug-resistant gastric cancer cell lines.

  Anticancer research 20100301

• Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog.

  Anticancer research 20100301

• Antiproliferative cardenolides from Pentopetia androsaemifolia Decne. from the Madagascar rain forest.

  Indian journal of experimental biology 20100301

• Screening of natural products for therapeutic activity against solid tumors.

  Indian journal of experimental biology 20100301

• 2-Ethyl-6-(2-pyrid-yl)-5,6,6a,11b-tetra-hydro-7H-indeno[2,1-c]quinoline.

  Acta crystallographica. Section E, Structure reports online 20100301

• Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract.

  Toxicology 20100227

• Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.

  Molecular cell 20100226

• Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs.

  Small (Weinheim an der Bergstrasse, Germany) 20100222

• Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

• Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.

  Advanced drug delivery reviews 20100217

• Treatment options for small cell lung cancer - do we have more choice?

  British journal of cancer 20100216

• Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.

  Biochemical pharmacology 20100215

• Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.

  Toxicology letters 20100215

• Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.

  Journal of immunology (Baltimore, Md. : 1950) 20100215

• DNA damage response links calpain to cellular senescence.

  Cell cycle (Georgetown, Tex.) 20100215

• Extending the use of 'Inverted Chirality Columns Approach' for enantiomeric excess determination in absence of reference samples: Application to a water-soluble camptothecin derivative.

  Journal of chromatography. A 20100212

• A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity.

  Journal of medicinal chemistry 20100211

• Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.

  Investigational new drugs 20100201

• Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.

  Cancer chemotherapy and pharmacology 20100201

• Characterization of two novel SETX mutations in AOA2 patients reveals aspects of the pathophysiological role of senataxin.

  Neurogenetics 20100201

• Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.

  Cancer chemotherapy and pharmacology 20100201

• A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.

  Pharmacological research 20100201

• Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.

  Cancer immunology, immunotherapy : CII 20100201

• Ultrasound-enhanced drug dispersion through solid tumours and its possible role in aiding ultrasound-targeted cancer chemotherapy.

  Cancer letters 20100201

• Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.

  Journal of cancer research and clinical oncology 20100201

• A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.

  American journal of clinical oncology 20100201

• Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.

  American journal of clinical oncology 20100201

• Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.

  The Prostate 20100201

• Differential modulation of BRCA1 and BARD1 nuclear localisation and foci assembly by DNA damage.

  Cellular signalling 20100201

• Fabrication of nanomicelle with enhanced solubility and stability of camptothecin based on alpha,beta-poly[(N-carboxybutyl)-L-aspartamide]-camptothecin conjugate.

  Colloids and surfaces. B, Biointerfaces 20100201

• Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine.

  The Journal of pharmacology and experimental therapeutics 20100201

• The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.

  Carcinogenesis 20100201

• Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100201

• Irinotecan and mismatch repair deficiency.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

  European journal of cancer (Oxford, England : 1990) 20100201

• Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

  Annals of surgery 20100201

• Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.

  European journal of cancer (Oxford, England : 1990) 20100201

• Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.

  Bulletin du cancer 20100201

• New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers.

  Bioorganic & medicinal chemistry 20100201

• Amifostine metabolite WR-1065 disrupts homologous recombination in mammalian cells.

  Radiation research 20100201

• Activation of AMP-activated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon-gamma-induced apoptosis.

  Arthritis and rheumatism 20100201

• [Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100201

• [A case of early poorly-differentiated neuroendocrine carcinoma of stomach].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100201

• [Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100201

• Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20100201

• Proteasome nuclear activity affects chromosome stability by controlling the turnover of Mms22, a protein important for DNA repair.

  PLoS genetics 20100201

• Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.

  The journal of obstetrics and gynaecology research 20100201

• [Clinical features of patients with brain metastasis from testicular germ cell tumor].

  Hinyokika kiyo. Acta urologica Japonica 20100201

• Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.

  Cancer treatment reviews 20100201

• Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer.

  Acta medica Okayama 20100201

• Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.

  Acta medica Okayama 20100201

• [A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100201

• The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.

  Anticancer research 20100201

• Aristolactams, 1-(2-C-methyl-beta-D-ribofuranosyl)-uracil and other bioactive constituents of Toussaintia orientalis.

  Natural product communications 20100201

• [Prediction of absorption of 10-hydroxycamptothecin in small intestines of rats with its partition coefficients in phases of liposomes and water].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20100201

• Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20100201

• Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.

  HPB : the official journal of the International Hepato Pancreato Biliary Association 20100201

• Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.

  The Journal of biological chemistry 20100122

• Metabolite fingerprinting of Camptotheca acuminata and the HPLC-ESI-MS/MS analysis of camptothecin and related alkaloids.

  Journal of pharmaceutical and biomedical analysis 20100120

• Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120

• A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.

  Bioorganic & medicinal chemistry 20100115

• Individualizing dosing of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Chemotherapy induces NEDP1-mediated destabilization of MDM2.

  Oncogene 20100114

• Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

  Neurology 20100112

• PTEN status in advanced colorectal cancer treated with cetuximab.

  British journal of cancer 20100105

• Development of a highly stable and targetable nanoliposomal formulation of topotecan.

  Journal of controlled release : official journal of the Controlled Release Society 20100104

• Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.

  Journal of controlled release : official journal of the Controlled Release Society 20100104

• Proteasome inhibition suppresses DNA-dependent protein kinase activation caused by camptothecin.

  DNA repair 20100102

• p21 Expression by human urothelial carcinoma cells modulates the phenotypic response to BCG.

  Urologic oncology 20100101

• Quantitative structure–property relationships of camptothecins in humans.

  Cancer chemotherapy and pharmacology 20100101

• A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.

  Cancer chemotherapy and pharmacology 20100101

• Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

  Cancer chemotherapy and pharmacology 20100101

• Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.

  Cancer chemotherapy and pharmacology 20100101

• Incorporation of ionic ligands accelerates drug release from LDI-glycerol polyurethanes.

  Acta biomaterialia 20100101

• The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.

  Phytotherapy research : PTR 20100101

• Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.

  Glycoconjugate journal 20100101

• A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Differential regulation of Apak by various DNA damage signals.

  Molecular and cellular biochemistry 20100101

• Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.

  Annals of surgical oncology 20100101

• A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.

  Japanese journal of clinical oncology 20100101

• Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11).

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20100101

• Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives.

  Biomedical chromatography : BMC 20100101

• Endophytic fungal strains of Fusarium solani, from Apodytes dimidiata E. Mey. ex Arn (Icacinaceae) produce camptothecin, 10-hydroxycamptothecin and 9-methoxycamptothecin.

  Phytochemistry 20100101

• No effect of irinotecan in patients with resistant desmoplastic small round cell tumor.

  Pediatric blood & cancer 20100101

• An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate.

  Cancer 20100101

• Pim-1 kinase as activator of the cell cycle pathway in neuronal death induced by DNA damage.

  Journal of neurochemistry 20100101

• Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.

  Cancer 20100101

• Genetic evidence for a role of Saccharomyces cerevisiae Mph1 in recombinational DNA repair under replicative stress.

  Yeast (Chichester, England) 20100101

• Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.

  Bioorganic & medicinal chemistry 20100101

• Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

  The Lancet. Oncology 20100101

• Improved first-line chemotherapy: a better chance for surgery?

  The Lancet. Oncology 20100101

• Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells.

  The American journal of pathology 20100101

• 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.

  Bioorganic & medicinal chemistry letters 20100101

• CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.

  Oncology reports 20100101

• Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores.

  Bioorganic & medicinal chemistry 20100101

• Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model.

  Anti-cancer drugs 20100101

• Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens.

  Cancer investigation 20100101

• Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates.

  Bioconjugate chemistry 20100101

• Diversity-oriented synthesis of quinolines via Friedländer annulation reaction under mild catalytic conditions.

  Journal of combinatorial chemistry 20100101

• Palliative treatment of unresectable metastatic colorectal cancer.

  Expert opinion on pharmacotherapy 20100101

• Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.

  Methods in molecular biology (Clifton, N.J.) 20100101

• Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model.

  PloS one 20100101

• Residual gammaH2AX foci as an indication of lethal DNA lesions.

  BMC cancer 20100101

• The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

  Molecular cancer therapeutics 20100101

• Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

  PloS one 20100101

• The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.

  The oncologist 20100101

• Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.

  Zeitschrift fur Gastroenterologie 20100101

• Identification of possible targets of the Aspergillus fumigatus CRZ1 homologue, CrzA.

  BMC microbiology 20100101

• [Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Evaluation of bevacizumab for advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [A case of advanced gastric cancer with a complete response to S-1 plus CPT-11 chemotherapy for eight years].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [S-1 + CPT-11 combination therapy with continuing 30-month CR in a recurrent gastric cancer with para-aortic lymph node metastasis in adjuvant chemotherapy with S-1--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [A case of S-1-resistant gastric cancer with multiple bone metastases and disseminated intravascular coagulation--effective treatment by combined chemotherapy with CDDP and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• [Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100101

• Unbiased transcriptional comparisons of generalist and specialist herbivores feeding on progressively defenseless Nicotiana attenuata plants.

  PloS one 20100101

• Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.

  BMC molecular biology 20100101

• Expression profiling of S. pombe acetyltransferase mutants identifies redundant pathways of gene regulation.

  BMC genomics 20100101

• ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation.

  Breast cancer research : BCR 20100101

• [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20100101

• A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.

  Acta oncologica (Stockholm, Sweden) 20100101

• Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.

  Molecular cancer 20100101

• Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair.

  PLoS genetics 20100101

• Usefulness of staging laparoscopy for advanced gastric cancer.

  Surgery today 20100101

• Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage.

  PloS one 20100101

• Rothmund-Thomson syndrome.

  Orphanet journal of rare diseases 20100101

• Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.

  BMC cancer 20100101

• Tau dephosphorylation potentiates apoptosis by mechanisms involving a failed dephosphorylation/activation of Bcl-2.

  Journal of Alzheimer's disease : JAD 20100101

• Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines.

  International journal of nanomedicine 20100101

• Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.

  Onkologie 20100101

• Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.

  Cancer journal (Sudbury, Mass.) 20100101

• Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment.

  Current medicinal chemistry 20100101

• Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype.

  BMC developmental biology 20100101

• Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.

  BMC cancer 20100101

• GSK3 and p53 - is there a link in Alzheimer's disease?

  Molecular neurodegeneration 20100101

• Gene expression profile of colon cancer cell lines treated with SN-38.

  Chemotherapy 20100101

• Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

  Molecular cancer 20100101

• Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

  Journal of experimental & clinical cancer research : CR 20100101

• DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression.

  BMC molecular biology 20100101

• Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.

  Drug metabolism and pharmacokinetics 20100101

• [Prognostic analysis of patients with liver metastases from colorectal cancer treated with different modes of therapy].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100101

• Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.

  Clinical drug investigation 20100101

• The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.

  Oncology research 20100101

• Cell-specific expression of tryptophan decarboxylase and 10-hydroxygeraniol oxidoreductase, key genes involved in camptothecin biosynthesis in Camptotheca acuminata Decne (Nyssaceae).

  BMC plant biology 20100101

• Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.

  Chemotherapy 20100101

• Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors.

  Journal of Alzheimer's disease : JAD 20100101

• Polysaccharopeptides derived from Coriolus versicolor potentiate the S-phase specific cytotoxicity of Camptothecin (CPT) on human leukemia HL-60 cells.

  Chinese medicine 20100101

• Dual inhibition of topoisomerases enhances apoptosis in melanoma cells.

  Neoplasma 20100101

• ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy.

  Molecular cancer 20100101

• Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

  Breast cancer research : BCR 20100101

• MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients.

  BMC medical genomics 20100101

• Toxicology and drug delivery by cucurbit[n]uril type molecular containers.

  PloS one 20100101

• Simultaneous quantitative monitoring of drug-induced caspase cascade pathways in carcinoma cells.

  Integrative biology : quantitative biosciences from nano to macro 20100101

• Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents.

  PloS one 20100101

• Metastatic colorectal cancer: from improved survival to potential cure.

  Oncology 20100101

• Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.

  Onkologie 20100101

• Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).

  Onkologie 20100101

• The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.

  Oncology research 20100101

• Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.

  Oncology research 20100101

• Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.

  BMC cancer 20100101

• Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.

  PloS one 20100101

• Global fitness profiling of fission yeast deletion strains by barcode sequencing.

  Genome biology 20100101

• Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitors.

  Journal of biomedical science 20100101

• Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model.

  Journal of experimental & clinical cancer research : CR 20100101

• Identifying interactions in the time and frequency domains in local and global networks - A Granger Causality Approach.

  BMC bioinformatics 20100101

• Caffeine prevents transcription inhibition and P-TEFb/7SK dissociation following UV-induced DNA damage.

  PloS one 20100101

• Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

  BMC cancer 20100101

• Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro.

  Biological & pharmaceutical bulletin 20100101

• Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition.

  Molecular cancer 20100101

• Inhibition of FOXO3 tumor suppressor function by betaTrCP1 through ubiquitin-mediated degradation in a tumor mouse model.

  PloS one 20100101

• Host lung gene expression patterns predict infectious etiology in a mouse model of pneumonia.

  Respiratory research 20100101

• Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101

• Role of the ATM-checkpoint kinase 2 pathway in CDT-mediated apoptosis of gingival epithelial cells.

  PloS one 20100101

• Up-regulation of p21 and TNF-alpha is mediated in lycorine-induced death of HL-60 cells.

  Cancer cell international 20100101

• Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.

  Transactions of the American Clinical and Climatological Association 20100101

• A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract.

  Oncology 20100101

• Treatment of colorectal cancer with and without bevacizumab: a phase III study.

  Oncology 20100101

• Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis.

  BMC systems biology 20100101

• Polymorphic nucleic Acid binding of bioactive isoquinoline alkaloids and their role in cancer.

  Journal of nucleic acids 20100101

• Effect of cAMP derivates on assembly and maintenance of tight junctions in human umbilical vein endothelial cells.

  BMC cell biology 20100101

• Increased expression of bcl11b leads to chemoresistance accompanied by G1 accumulation.

  PloS one 20100101

• Fluorescence in situ hybridization in combination with the comet assay and micronucleus test in genetic toxicology.

  Molecular cytogenetics 20100101

• Vitamin D in combination cancer treatment.

  Journal of Cancer 20100101

• [Pharmacogenomics and chemotherapy].

  Recenti progressi in medicina 20100101

• Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• [Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report].

  Il Giornale di chirurgia 20100101

• Pharmacoeconomic aspects of FOLFIRI or FOLFOX regimens administered with a fully ambulatory pump compared to the day hospital setting.

  Tumori 20100101

• Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab.

  Tumori 20100101

• Metastatic colorectal carcinoma and kidney tumors: a report of four cases.

  Tumori 20100101

• Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy.

  BMC cancer 20100101

• The Role of PCNA Posttranslational Modifications in Translesion Synthesis.

  Journal of nucleic acids 20100101

• Differential Dynamics of ATR-Mediated Checkpoint Regulators.

  Journal of nucleic acids 20100101

• Cytotoxicity screening of Bangladeshi medicinal plant extracts on pancreatic cancer cells.

  BMC complementary and alternative medicine 20100101

• Renal Dnase1 enzyme activity and protein expression is selectively shut down in murine and human membranoproliferative lupus nephritis.

  PloS one 20100101

• Phosphatases in the cellular response to DNA damage.

  Cell communication and signaling : CCS 20100101

• Molecular targets for the protodynamic action of cis-urocanic acid in human bladder carcinoma cells.

  BMC cancer 20100101

• Nano to micro delivery systems: targeting angiogenesis in brain tumors.

  Journal of angiogenesis research 20100101

• Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant.

  Journal of nucleic acids 20100101

• BLM Deficiency Is Not Associated with Sensitivity to Hydroxyurea-Induced Replication Stress.

  Journal of nucleic acids 20100101

• Early Steps in the DNA Base Excision Repair Pathway of a Fission Yeast Schizosaccharomyces pombe.

  Journal of nucleic acids 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients.

  International journal of nanomedicine 20100101

• 'Poker' association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

  BMC cancer 20100101

• Checkpoint-dependent and -independent roles of Swi3 in replication fork recovery and sister chromatid cohesion in fission yeast.

  PloS one 20100101

• Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis.

  PloS one 20100101

• Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.

  Tumori 20100101

• Generation of double-labeled reporter cell lines for studying co-dynamics of endogenous proteins in individual human cells.

  PloS one 20100101

• Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.

  PloS one 20100101

• DNA damage responses in human induced pluripotent stem cells and embryonic stem cells.

  PloS one 20100101

• Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells.

  Cancer cell international 20100101

• In the absence of Sonic hedgehog, p53 induces apoptosis and inhibits retinal cell proliferation, cell-cycle exit and differentiation in zebrafish.

  PloS one 20100101

• Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate.

  International journal of nanomedicine 20100101

• MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in Saccharomyces cerevisiae.

  PloS one 20100101

• Apoptotic markers in protozoan parasites.

  Parasites & vectors 20100101

• Aberrant WNT/β-catenin signaling in parathyroid carcinoma.

  Molecular cancer 20100101

• Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death.

  Parasites & vectors 20100101

• Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.

  Oncology 20100101

• Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells.

  Pharmacological reports : PR 20100101

• PI 3 kinase related kinases-independent proteolysis of BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells.

  PloS one 20100101

• Promotion of tumor development in prostate cancer by progerin.

  Cancer cell international 20100101

• Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells.

  Molecular cancer 20100101

• Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.

  Onkologie 20100101

• Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation.

  PloS one 20100101

• 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer.

  BMC cancer 20100101

• Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

  BMC cancer 20100101

• Advances in the field of nanooncology.

  BMC medicine 20100101

• Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

  PloS one 20100101

• Recent advances in PEG-PLA block copolymer nanoparticles.

  International journal of nanomedicine 20100101

• Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.

  BMC cancer 20100101

• Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action.

  Molecular systems biology 20100101

• Antiproliferative activity of plant extracts used against cancer in traditional medicine.

  Scientia pharmaceutica 20100101

• Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma.

  PloS one 20100101

• Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.

  BMC biology 20100101

• 6-Nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-dione, a potent antitumor agent, induces cell cycle arrest and apoptosis.

  Journal of experimental & clinical cancer research : CR 20100101

• Development and Validation of a RP-Ultra performance liquid chromatographic Method for Quantification of Topotecan Hydrochloride in Bulk and Injection Dosage Form.

  Indian journal of pharmaceutical sciences 20100101

• A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report.

  Journal of experimental therapeutics & oncology 20100101

• Irinotecan as a maintenance therapy for hepatoblastoma: a comment.

  Journal of cancer research and therapeutics 20100101

• Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.

  Oncology 20100101

• Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports.

  Hepato-gastroenterology 20100101

• Anticancer drugs from marine flora: an overview.

  Journal of oncology 20100101

• Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20100101

• Production of camptothecin in cultures of Chonemorpha grandiflora.

  Pharmacognosy research 20100101

• Ethnopharmacology in the 21st century - grand challenges.

  Frontiers in pharmacology 20100101

• Cyclodextrins in delivery systems: Applications.

  Journal of pharmacy & bioallied sciences 20100101

• Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment.

  Toxins 20100101

• Secondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs.

  Pharmacognosy reviews 20100101

• The role of funding and policies on innovation in cancer drug development.

  Ecancermedicalscience 20100101

• A multiwell electrochemical biosensor for real-time monitoring of the behavioural changes of cells in vitro.

  Sensors (Basel, Switzerland) 20100101

• En bloc resection for right colon cancer directly invading duodenum or pancreatic head.

  Yonsei medical journal 20091231

• The anti-HIV actions of 7- and 10-substituted camptothecins.

  Molecules (Basel, Switzerland) 20091231

• The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

  International journal of cancer 20091215

• Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?

  Pediatric blood & cancer 20091215

• Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.

  British journal of cancer 20091215

• KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210

• Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.

  Biochemical and biophysical research communications 20091204

• Mms1-Mms22 complex protects genome integrity in Schizosaccharomyces pombe.

  DNA repair 20091203

• Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20091201

• Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20091201

• Quinoline alkaloids as intercalative topoisomerase inhibitors.

  Journal of molecular modeling 20091201

• Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

  Journal of neuro-oncology 20091201

• Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.

  International journal of radiation oncology, biology, physics 20091201

• A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091201

• Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.

  Archives of disease in childhood 20091201

• Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

  Endocrine-related cancer 20091201

• Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma.

  Leukemia & lymphoma 20091201

• Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.

  Pediatric blood & cancer 20091201

• Irinotecan side effects relieved by the use of HI-6 oxime: in vivo experimental approach.

  Basic & clinical pharmacology & toxicology 20091201

• In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.

  Cytokine 20091201

• Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.

  Cancer treatment reviews 20091201

• Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

  The Journal of pharmacology and experimental therapeutics 20091201

• A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.

  Japanese journal of clinical oncology 20091201

• Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.

  Japanese journal of clinical oncology 20091201

• Treatment of metastatic colorectal cancer in the elderly.

  Current treatment options in oncology 20091201

• Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors.

  Bioorganic & medicinal chemistry letters 20091201

• Comeback for the camptothecins?

  Leukemia & lymphoma 20091201

• Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

• The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells.

  International journal of oncology 20091201

• NOA36/ZNF330 is a conserved cystein-rich protein with proapoptotic activity in human cells.

  Biochimica et biophysica acta 20091201

• Polymeric phosphorylcholine-camptothecin conjugates prepared by controlled free radical polymerization and click chemistry.

  Bioconjugate chemistry 20091201

• Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.

  Targeted oncology 20091201

• Chemical constituents of the bark of Machilus wangchiana and their biological activities.

  Journal of natural products 20091201

• KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

• Medicinally important secondary metabolites in recombinant microorganisms or plants: progress in alkaloid biosynthesis.

  Biotechnology journal 20091201

• SUMO modification regulates BLM and RAD51 interaction at damaged replication forks.

  PLoS biology 20091201

• [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].

  Ai zheng = Aizheng = Chinese journal of cancer 20091201

• [Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• [A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea.

  PLoS pathogens 20091201

• Poly(ADP-ribose) Glycohydrolase deficiency sensitizes mouse ES cells to DNA damaging agents.

  Current cancer drug targets 20091201

• [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].

  Bulletin du cancer 20091201

• Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

  Anticancer research 20091201

• Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.

  Journal of chemotherapy (Florence, Italy) 20091201

• [Validation study of KRAS mutation in colorectal cancer].

  Magyar onkologia 20091201

• Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11.

  Journal of biosciences 20091201

• MONCPT exerts anti-cancer activities via inducing G2/M arrest and apoptosis in human bladder cancer.

  Die Pharmazie 20091201

• The antinociceptive and anti-inflammatory activities of caulerpin, a bisindole alkaloid isolated from seaweeds of the genus Caulerpa.

  Marine drugs 20091201

• Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.

  The American journal of geriatric pharmacotherapy 20091201

• [Allicin enhances cytotoxicity of CPT-11 to colon cancer LoVo cell in vitro].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20091201

• Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription.

  Viruses 20091201

• 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors.

  Journal of medicinal chemistry 20091126

• Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Mechanisms of cascade reactions in the syntheses of camptothecin-family alkaloids: intramolecular [4(+) + 2] reactions of N-arylimidates and alkynes.

  Organic letters 20091119

• Pro-apoptotic activities of novel synthetic quinones in human cancer cell lines.

  Cancer letters 20091118

• A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

  British journal of cancer 20091117

• Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

  International journal of cancer 20091115

• Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction.

  Experimental cell research 20091115

• Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin.

  Advanced drug delivery reviews 20091112

• XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

  Advanced drug delivery reviews 20091112

• Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.

  Advanced drug delivery reviews 20091112

• Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts.

  Macromolecular bioscience 20091110

• Antineoplastic activity of idazoxan hydrochloride.

  Cancer chemotherapy and pharmacology 20091101

• Experimental study of combination therapy with S-1 against pancreatic cancer.

  Cancer chemotherapy and pharmacology 20091101

• Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091101

• PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.

  Cancer letters 20091101

• Recent development in nano-sized dosage forms of plant alkaloid camptothecin-derived drugs.

  Recent patents on anti-cancer drug discovery 20091101

• Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts.

  Cancer science 20091101

• Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

  Cancer science 20091101

• Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

  Clinical pharmacology and therapeutics 20091101

• Incorporation methods for cholic acid chitosan-g-mPEG self-assembly micellar system containing camptothecin.

  Colloids and surfaces. B, Biointerfaces 20091101

• Overexpression of mitochondrial Leishmania major ascorbate peroxidase enhances tolerance to oxidative stress-induced programmed cell death and protein damage.

  Eukaryotic cell 20091101

• Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20091101

• UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?

  Anti-cancer drugs 20091101

• Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78.

  Naunyn-Schmiedeberg's archives of pharmacology 20091101

• Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors.

  Bioorganic & medicinal chemistry 20091101

• Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.

  International journal of radiation oncology, biology, physics 20091101

• Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

  The Lancet. Oncology 20091101

• Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.

  Cancer investigation 20091101

• Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen).

  Journal of natural products 20091101

• Asterolaurins A-F, xenicane diterpenoids from the Taiwanese soft coral Asterospicularia laurae.

  Journal of natural products 20091101

• Treatment of gastric cancer in Asia: the missing link.

  The Lancet. Oncology 20091101

• [Intestinal absorption and secretion mechanism of carboxylate drugs].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20091101

• Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.

  Molecular cancer therapeutics 20091101

• [Histological complete response in a case of advanced gastric endocrine carcinoma treated by irinotecan plus cisplatin].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20091101

• Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.

  Journal of natural products 20091101

• The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20091101

• Hypoxia-induced downregulation of autophagy mediator Beclin 1 reduces the susceptibility of malignant intestinal epithelial cells to hypoxia-dependent apoptosis.

  Autophagy 20091101

• [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Huge ascending colon carcinoma, treated successfully with S-1 plus CPT-11, followed by significant tumor reduction and curative resection--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of advanced rectal cancer that responded to S-1 with an extended complete response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• Caenorhabditis elegans HIM-18/SLX-4 interacts with SLX-1 and XPF-1 and maintains genomic integrity in the germline by processing recombination intermediates.

  PLoS genetics 20091101

• [The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of rectal cancer with lung metastases responding to cetuximab].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Intermittent hepatic arterial infusion with systemic chemotherapy for metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case report of multiple liver metastases from colorectal cancer effectively treated with systemic chemotherapy and hepatic arterial infusion].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Neoadjuvant chemotherapy and pancreatoduodenectomy for locally advanced colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Treatment for intrapelvic recurrence of rectal cancer--resection versus chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [Ovarian metastasis after complete response of colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A long term survivor of advanced gastric cancer treated with multi-drug combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• [A case of bilateral pulmonary metastasis from gastric cancer performed radical thoracoscopic lobectomy after neoadjuvant chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091101

• Anticancer agents derived from natural products.

  Mini reviews in medicinal chemistry 20091101

• UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

  World journal of gastroenterology 20091028

• Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

  Journal of the National Cancer Institute 20091021

• Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020

• Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection.

  Journal of pharmaceutical and biomedical analysis 20091015

• Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

  Bioorganic & medicinal chemistry 20091015

• Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents.

  The Journal of biological chemistry 20091009

• Alpha4 is an essential regulator of PP2A phosphatase activity.

  Molecular cell 20091009

• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.

  Journal of medicinal chemistry 20091008

• Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.

  Chemico-biological interactions 20091007

• Intercepting the synthesis of triazine dendrimers with nucleophilic pharmacophores: a general strategy toward drug delivery vehicles.

  Chemical communications (Cambridge, England) 20091007

• Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.

  British journal of cancer 20091006

• TREX1 acts in degrading damaged DNA from drug-treated tumor cells.

  DNA repair 20091002

• Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.

  Cancer chemotherapy and pharmacology 20091001

• Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20091001

• Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.

  Cancer chemotherapy and pharmacology 20091001

• Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.

  Journal of cancer research and clinical oncology 20091001

• Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives.

  European journal of medicinal chemistry 20091001

• Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity.

  Journal of leukocyte biology 20091001

• Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.

  Xenobiotica; the fate of foreign compounds in biological systems 20091001

• Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20091001

• Improvement of aqueous solubility of fenretinide and other hydrophobic anti-tumor drugs by complexation with amphiphilic dextrins.

  Drug delivery 20091001

• Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery.

  Biomaterials 20091001

• Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms.

  Anti-cancer drugs 20091001

• Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

  Cancer 20091001

• Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.

  European journal of pharmacology 20091001

• Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells.

  Biomaterials 20091001

• Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.

  Journal of human genetics 20091001

• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001

• Long-term outcome of unresectable metastatic colorectal cancer: does 'adjuvant' chemotherapy play a role after resection?

  Annals of surgery 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• A Flp-nick system to study repair of a single protein-bound nick in vivo.

  Nature methods 20091001

• [Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].

  Bulletin du cancer 20091001

• Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.

  International journal of experimental pathology 20091001

• Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.

  Nature reviews. Clinical oncology 20091001

• Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?

  Nature reviews. Clinical oncology 20091001

• CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091001

• Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.

  Haematologica 20091001

• A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage.

  Nature 20091001

• [Progress in chemotherapy for advanced gastric cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20091001

• The elongator complex interacts with PCNA and modulates transcriptional silencing and sensitivity to DNA damage agents.

  PLoS genetics 20091001

• [A case of recurrent rectal cancer with multiple lung metastases successfully treated with S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• [A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• [A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• [A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091001

• Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

  International journal of clinical oncology 20091001

• Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20091001

• Small cell carcinoma of the breast.

  Journal of the National Medical Association 20091001

• [Combination with SN-38 on human colon cancer LoVo cells].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20091001

• The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.

  Cancer letters 20090928

• Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.

  Journal of medicinal chemistry 20090924

• Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity.

  ACS nano 20090922

• Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).

  British journal of cancer 20090915

• Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.

  World journal of gastroenterology 20090914

• PKCeta confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells.

  Experimental cell research 20090910

• Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.

  International journal of pharmaceutics 20090908

• Summary of the american college for advancement in medicine november 2007 conference on integrative medicine: advancing science and clinical practice.

  Evidence-based complementary and alternative medicine : eCAM 20090901

• Molecular characterization and expression analysis of a new cDNA encoding strictosidine synthase from Ophiorrhiza japonica.

  Molecular biology reports 20090901

• Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7.

  Shock (Augusta, Ga.) 20090901

• Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.

  Cancer chemotherapy and pharmacology 20090901

• In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090901

• Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.

  European journal of medicinal chemistry 20090901

• Simultaneous drug release at different rates from biodegradable polyurethane foams.

  Acta biomaterialia 20090901

• Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090901

• Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver.

  Drug metabolism and disposition: the biological fate of chemicals 20090901

• Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.

  Acta radiologica (Stockholm, Sweden : 1987) 20090901

• Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

  Cancer 20090901

• A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.

  Japanese journal of clinical oncology 20090901

• Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20090901

• Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

• Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.

  Oncology reports 20090901

• Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells.

  Apoptosis : an international journal on programmed cell death 20090901

• Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?

  European journal of cancer (Oxford, England : 1990) 20090901

• Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.

  The British journal of surgery 20090901

• Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

• Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901

• Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization.

  Cell cycle (Georgetown, Tex.) 20090901

• Combined arterial infusion and stent implantation compared with metal stent alone in treatment of malignant gastroduodenal obstruction.

  Cardiovascular and interventional radiology 20090901

• Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090901

• Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors.

  Journal of natural products 20090901

• Chemical Constituents of the Roots of Euphorbia micractina.

  Journal of natural products 20090901

• Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?

  Nature reviews. Gastroenterology & hepatology 20090901

• Neuroendocrine tumor of the rectum.

  American journal of surgery 20090901

• Is there a role for second-line chemotherapy in advanced gastric cancer?

  The Lancet. Oncology 20090901

• [Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20090901

• [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].

  Ai zheng = Aizheng = Chinese journal of cancer 20090901

• [Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• [A case of superficial small cell carcinoma of the esophagus].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090901

• Chemotherapy, which drugs and when.

  European journal of cancer (Oxford, England : 1990) 20090901

• [The development of the first line treatment of metastatic colorectal cancer (mCRC)].

  Magyar onkologia 20090901

• [Metachronous metastasis from rectal adenocarcinoma to the penis--case report].

  Magyar onkologia 20090901

• Direct inhibition of RNA polymerase II transcription by RECQL5.

  The Journal of biological chemistry 20090828

• HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response.

  The Journal of biological chemistry 20090828

• The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.

  Molecular cell 20090828

• Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

  Journal of medicinal chemistry 20090827

• Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.

  World journal of gastroenterology 20090821

• Proteomic analysis of enriched lysosomes at early phase of camptothecin-induced apoptosis in human U-937 cells.

  Journal of proteomics 20090820

• Metastatic colorectal cancer: is surgery necessary?

  Journal of the National Cancer Institute 20090819

• Bruceine D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase.

  Cancer letters 20090818

• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

  British journal of cancer 20090818

• Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.

  International journal of cancer 20090815

• Preparation and properties of hydroxycamptothecin-loaded nanoparticles made of amphiphilic copolymer and normal polymer.

  Journal of colloid and interface science 20090815

• Microfabricated electrospun collagen membranes for 3-D cancer models and drug screening applications.

  Biomacromolecules 20090810

• Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.

  World journal of gastroenterology 20090807

• DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

  Cell stem cell 20090807

• Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.

  British journal of cancer 20090804

• MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea.

  British journal of cancer 20090804

• Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.

  Investigational new drugs 20090801

• A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090801

• A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.

  Cancer chemotherapy and pharmacology 20090801

• Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

  International journal of radiation oncology, biology, physics 20090801

• alpha-ENaC is a functional element of the hypertonicity-induced cation channel in HepG2 cells and it mediates proliferation.

  Pflugers Archiv : European journal of physiology 20090801

• Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour.

  The British journal of nutrition 20090801

• Photochemical electrocyclisation of 3-vinylindoles to pyrido[2,3-a]-, pyrido[4,3-a]- and thieno[2,3-a]-carbazoles: design, synthesis, DNA binding and antitumor cell cytotoxicity.

  European journal of medicinal chemistry 20090801

• STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner.

  Biochemical pharmacology 20090801

• Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.

  Anti-cancer drugs 20090801

• Innate immunity turned inside-out: antimicrobial defense by phagocyte extracellular traps.

  Journal of molecular medicine (Berlin, Germany) 20090801

• The Campoletis sonorensis ichnovirus vankyrin protein P-vank-1 inhibits apoptosis in insect Sf9 cells.

  Insect molecular biology 20090801

• Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

  Annals of oncology : official journal of the European Society for Medical Oncology 20090801

• Perforating dermatosis in a patient receiving bevacizumab.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20090801

• Human RIF1 encodes an anti-apoptotic factor required for DNA repair.

  Carcinogenesis 20090801

• Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.

  Anti-cancer drugs 20090801

• On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.

  Bioorganic & medicinal chemistry letters 20090801

• Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.

  Expert opinion on biological therapy 20090801

• 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.

  Bioorganic & medicinal chemistry letters 20090801

• Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks.

  EMBO reports 20090801

• Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1.

  Mechanisms of ageing and development 20090801

• Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation.

  Cancer research 20090801

• Irinotecan use during pregnancy.

  Obstetrics and gynecology 20090801

• Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.

  Annals of surgery 20090801

• Candenatenins A-F, phenolic compounds from the heartwood of Dalbergia candenatensis.

  Journal of natural products 20090801

• Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.

  Anticancer research 20090801

• A novel K-ras mutation in colorectal cancer. A case report and literature review.

  Anticancer research 20090801

• Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

  Molecular cancer therapeutics 20090801

• [Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [A case of advanced colon cancer treated with preoperative chemotherapy (IRIS) leading to clinical complete response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• [Effectiveness of S-1 plus CPT-11 therapy for an elderly patient with recurrent colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090801

• Pseudomonas aeruginosa eliminates natural killer cells via phagocytosis-induced apoptosis.

  PLoS pathogens 20090801

• Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.

  Annals of the New York Academy of Sciences 20090801

• Quinolones: action and resistance updated.

  Current topics in medicinal chemistry 20090801

• The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.

  British journal of cancer 20090721

• Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.

  British journal of cancer 20090721

• Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090720

• Naphtho[2,3-d]isoxazole-4,9-dione-3-carboxylates: potent, non-cytotoxic, antiapoptotic agents.

  Chemico-biological interactions 20090715

• Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090715

• The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry.

  Current biology : CB 20090714

• Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair.

  Cell 20090710

• Electrokinetic dispersion of a cancer chemotherapeutic drug for the treatment of solid tumours.

  Cancer letters 20090708

• Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells.

  The EMBO journal 20090708

• High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.

  British journal of cancer 20090707

• Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.

  JOP : Journal of the pancreas 20090706

• Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.

  The Journal of biological chemistry 20090703

• Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M.

  Blood 20090702

• Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.

  Cancer chemotherapy and pharmacology 20090701

• Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.

  Cancer chemotherapy and pharmacology 20090701

• Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.

  Cancer chemotherapy and pharmacology 20090701

• Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.

  Journal of neuro-oncology 20090701

• Can cetuximab affect paraneoplastic myopathy?

  Journal of neuro-oncology 20090701

• Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.

  Pediatric blood & cancer 20090701

• Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090701

• A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.

  Anti-cancer drugs 20090701

• Intracellular dynamics of topoisomerase I inhibitor, CPT-11, by slit-scanning confocal Raman microscopy.

  Histochemistry and cell biology 20090701

• Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles.

  Biomaterials 20090701

• Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

  Cancer 20090701

• Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090701

• Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.

  Anti-cancer drugs 20090701

• Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

  European journal of cancer (Oxford, England : 1990) 20090701

• A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

  European journal of cancer (Oxford, England : 1990) 20090701

• DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

  Chemical reviews 20090701

• Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.

  Oncology reports 20090701

• Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.

  Molecular cancer therapeutics 20090701

• Genetic prognostic and predictive markers in colorectal cancer.

  Nature reviews. Cancer 20090701

• Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid.

  Annals of plastic surgery 20090701

• Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Cetuximab, chemotherapy and KRAS status in mCRC.

  Nature reviews. Clinical oncology 20090701

• Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.

  The Annals of pharmacotherapy 20090701

• [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].

  Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20090701

• Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

  Pharmacogenomics 20090701

• Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride.

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• [A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule.

  Journal of hematopathology 20090701

• Telomere length regulates ISG15 expression in human cells.

  Aging 20090701

• TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.

  Cancer letters 20090628

• Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.

  Journal of medicinal chemistry 20090625

• NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.

  Cancer letters 20090618

• Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.

  Oncogene 20090618

• Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation.

  British journal of cancer 20090616

• Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.

  Cancer 20090615

• Conjugated eicosapentaenoic acid inhibits human topoisomerase IB with a mechanism different from camptothecin.

  Archives of biochemistry and biophysics 20090615

• Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090610

• Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.

  Cancer letters 20090608

• Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.

  Chinese medical journal 20090605

• Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin.

  DNA repair 20090604

• A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.

  British journal of cancer 20090602

• A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

  Investigational new drugs 20090601

• Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.

  Investigational new drugs 20090601

• Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.

  Cancer chemotherapy and pharmacology 20090601

• Irinotecan-induced mucositis is associated with changes in intestinal mucins.

  Cancer chemotherapy and pharmacology 20090601

• DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.

  International journal of cancer 20090601

• Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.

  International journal of cancer 20090601

• Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.

  International journal of colorectal disease 20090601

• Degradable poly(beta-amino ester) nanoparticles for cancer cytoplasmic drug delivery.

  Nanomedicine : nanotechnology, biology, and medicine 20090601

• Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.

  The Journal of pharmacology and experimental therapeutics 20090601

• Polysaccharide surface modified Fe3O4 nanoparticles for camptothecin loading and release.

  Acta biomaterialia 20090601

• Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.

  Cancer chemotherapy and pharmacology 20090601

• A landmark point analysis with cytotoxic agents for advanced NSCLC.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090601

• The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis.

  American journal of physiology. Cell physiology 20090601

• Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.

  Journal of cancer research and clinical oncology 20090601

• Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin.

  ChemMedChem 20090601

• Irinogenetics: how many stars are there in the sky?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.

  Annals of surgical oncology 20090601

• PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types.

  Journal of molecular medicine (Berlin, Germany) 20090601

• Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.

  Therapeutic drug monitoring 20090601

• CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.

  Oncology reports 20090601

• Chemical constituents of Heteroplexis micocephala.

  Journal of natural products 20090601

• Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts.

  Cancer research 20090601

• Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.

  Bioconjugate chemistry 20090601

• A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

  Cancer prevention research (Philadelphia, Pa.) 20090601

• DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin.

  Protein science : a publication of the Protein Society 20090601

• Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine.

  Biological & pharmaceutical bulletin 20090601

• Cathepsin D and eukaryotic translation elongation factor 1 as promising markers of cellular senescence.

  Cancer research 20090601

• [Pharmacogenomics].

  Nihon rinsho. Japanese journal of clinical medicine 20090601

• The antiproliferative cytostatic effects of a self-activating viridin prodrug.

  Molecular cancer therapeutics 20090601

• Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors.

  Mini reviews in medicinal chemistry 20090601

• Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.

  Anticancer research 20090601

• [A case of marked response to CPT-11+CDDP neoadjuvant chemotherapy for advanced gastric cancer with paraaortic lymph node metastasis enabling curative resection and over 10-year survival].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090601

• [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090601

• Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.

  Acta pharmaceutica (Zagreb, Croatia) 20090601

• Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis.

  Journal of chemical biology 20090601

• [Chemotherapy of elderly patients with colorectal cancer].

  Magyar onkologia 20090601

• Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

  Diseases of the colon and rectum 20090601

• Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.

  Electrophoresis 20090601

• Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).

  International journal of clinical oncology 20090601

• Deoxyamphimedine, a pyridoacridine alkaloid, damages DNA via the production of reactive oxygen species.

  Marine drugs 20090601

• [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20090601

• [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090601

• Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair.

  Current genomics 20090601

• Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.

  Journal of controlled release : official journal of the Controlled Release Society 20090521

• Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• UGT1A and irinotecan toxicity: keeping it in the family.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• Dose escalation methods in phase I cancer clinical trials.

  Journal of the National Cancer Institute 20090520

• Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.

  British journal of cancer 20090519

• Analysis of 7,8-dihydro-8-oxo-2'-deoxyguanosine in cellular DNA during oxidative stress.

  Chemical research in toxicology 20090518

• Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog.

  Bioorganic & medicinal chemistry letters 20090515

• 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro.

  International journal of pharmaceutics 20090508

• PU.1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells.

  Biochemical and biophysical research communications 20090508

• Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

  Neurology 20090505

• Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.

  Cancer chemotherapy and pharmacology 20090501

• Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.

  Cancer chemotherapy and pharmacology 20090501

• Formulation and comparative characterization of chitosan, gelatin, and chitosan-gelatin-coated liposomes of CPT-11-HCl.

  Drug development and industrial pharmacy 20090501

• Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.

  Cancer chemotherapy and pharmacology 20090501

• De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma.

  The international journal of biochemistry & cell biology 20090501

• The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090501

• DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin.

  Mutagenesis 20090501

• Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.

  Cancer investigation 20090501

• Different inhibitory effects in rat and human carboxylesterases.

  Drug metabolism and disposition: the biological fate of chemicals 20090501

• Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

  World journal of surgery 20090501

• Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera.

  European journal of cancer (Oxford, England : 1990) 20090501

• Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter.

  American journal of physiology. Cell physiology 20090501

• A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.

  Japanese journal of clinical oncology 20090501

• Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).

  Japanese journal of clinical oncology 20090501

• Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study.

  Bioorganic & medicinal chemistry letters 20090501

• Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.

  Biochimica et biophysica acta 20090501

• Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors.

  Bioorganic & medicinal chemistry letters 20090501

• Nuclear translocation of dihydrofolate reductase is not a pre-requisite for DNA damage induced apoptosis.

  Apoptosis : an international journal on programmed cell death 20090501

• PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090501

• The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

  Molecular cancer therapeutics 20090501

• Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.

  Nature reviews. Clinical oncology 20090501

• RAD18 transmits DNA damage signalling to elicit homologous recombination repair.

  Nature cell biology 20090501

• Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.

  Japanese journal of clinical oncology 20090501

• High therapeutic effectiveness of postoperative irinotecan chemotherapy in a typical case of radiographically and pathologically diagnosed pleuropulmonary blastoma.

  Journal of pediatric hematology/oncology 20090501

• A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells.

  PLoS pathogens 20090501

• Novel camptothecin derivatives as topoisomerase I inhibitors.

  Expert opinion on therapeutic patents 20090501

• UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

  Pharmacogenomics 20090501

• [Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [A case of recurrent endocrine cell carcinoma of the common bile duct successfully treated by hepatic artery infusion with CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [Efficacy of chemotherapy using 10-hydroxycamptothecin on recurrent or refractory neuroblastoma in children].

  Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20090501

• Current mathematical methods used in QSAR/QSPR studies.

  International journal of molecular sciences 20090501

• UV-vis spectra of the anticancer camptothecin family drugs in aqueous solution: specific spectroscopic signatures unraveled by a combined computational and experimental study.

  The journal of physical chemistry. B 20090423

• Methodological approaches in application of synthetic lethality screening towards anticancer therapy.

  British journal of cancer 20090421

• Control of alternative splicing by signal-dependent degradation of splicing-regulatory proteins.

  The Journal of biological chemistry 20090417

• Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.

  Cancer 20090415

• Camptothecin releases P-TEFb from the inactive 7SK snRNP complex.

  Cell cycle (Georgetown, Tex.) 20090415

• Second-line chemotherapy in advanced and metastatic CRC.

  The Cochrane database of systematic reviews 20090415

• Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.

  Biochemistry 20090414

• Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410

• Human CtIP mediates cell cycle control of DNA end resection and double strand break repair.

  The Journal of biological chemistry 20090403

• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  The New England journal of medicine 20090402

• 'Natural history' of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090401

• Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.

  Cancer chemotherapy and pharmacology 20090401

• A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.

  Cancer chemotherapy and pharmacology 20090401

• A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.

  Cancer chemotherapy and pharmacology 20090401

• The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.

  Cancer chemotherapy and pharmacology 20090401

• A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.

  Investigational new drugs 20090401

• Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

  Investigational new drugs 20090401

• A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20090401

• The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes.

  The Journal of investigative dermatology 20090401

• Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

  European radiology 20090401

• Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones.

  European journal of medicinal chemistry 20090401

• Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?

  Biomedical chromatography : BMC 20090401

• An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.

  Journal of neuro-oncology 20090401

• A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.

  Pharmaceutical research 20090401

• Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.

  Journal of neuro-oncology 20090401

• Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.

  International journal of colorectal disease 20090401

• Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells.

  Cellular signalling 20090401

• Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.

  Anti-cancer drugs 20090401

• Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.

  Anti-cancer drugs 20090401

• A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

  Annals of oncology : official journal of the European Society for Medical Oncology 20090401

• Suppression of the double-strand-break-repair defect of the Saccharomyces cerevisiae rad57 mutant.

  Genetics 20090401

• Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer.

  Anti-cancer drugs 20090401

• Synthesis of new camptothecin analogs with improved antitumor activities.

  Bioorganic & medicinal chemistry letters 20090401

• Cytotoxic oleanane triterpene saponins from Albizia chinensis.

  Journal of natural products 20090401

• Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.

  Anti-cancer drugs 20090401

• Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase.

  International journal of oncology 20090401

• Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.

  Oncology reports 20090401

• MicroRNA-125b is a novel negative regulator of p53.

  Genes & development 20090401

• Phagocytosis of bacteria is enhanced in macrophages undergoing nutrient deprivation.

  The FEBS journal 20090401

• 12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents.

  Bioorganic & medicinal chemistry 20090401

• Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.

  Bioconjugate chemistry 20090401

• Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090401

• Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

  Journal of the National Cancer Institute 20090401

• NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.

  Proteomics 20090401

• Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.

  Nature reviews. Clinical oncology 20090401

• Heterozygous disruption of the DNA topoisomerase I gene confers cellular resistance to camptothecin in human cells.

  Biological & pharmaceutical bulletin 20090401

• [Colorectal cancers: prognostic and predictive factors of response to treatment].

  Bulletin du cancer 20090401

• Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.

  Molecular cancer therapeutics 20090401

• [Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090401

• UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

  International journal of clinical oncology 20090401

• Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.

  Canadian journal of surgery. Journal canadien de chirurgie 20090401

• What's new in ... colorectal cancer. Meaningful progress in therapy options.

  JAAPA : official journal of the American Academy of Physician Assistants 20090401

• [Preparation and characterization of hydroxycamptothecin nanoparticles of amphiphilic block copolymer].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20090401

• Antitumor Effects of Camptothecin Combined with Conventional Anticancer Drugs on the Cervical and Uterine Squamous Cell Carcinoma Cell Line SiHa.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20090401

• The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer's disease.

  Aging 20090401

• Preparation, pharmacokinetics and tissue distribution of micelles made of reverse thermo-responsive polymers.

  International journal of pharmaceutics 20090331

• Calothrixins, a new class of human DNA topoisomerase I poisons.

  Journal of natural products 20090327

• Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.

  British journal of cancer 20090324

• Irinotecan toxicity: genes or intestinal microflora?

  British journal of cancer 20090324

• Cooperativity of Mus81.Mms4 with Rad54 in the resolution of recombination and replication intermediates.

  The Journal of biological chemistry 20090320

• Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• Bioactivity-guided isolation of cytotoxic constituents of Brucea javanica collected in Vietnam.

  Bioorganic & medicinal chemistry 20090315

• The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP).

  The Biochemical journal 20090315

• Apoptosis in fresh and cryopreserved buffalo sperm.

  Theriogenology 20090315

• The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310

• Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090304

• Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090302

• Apoptotic effect of CKD-602 (Camtobell) on oral squamous cell carcinoma cell lines.

  Oral oncology 20090301

• A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer.

  Journal of cancer research and clinical oncology 20090301

• Leishmania mexicana: inhibition of camptothecin-induced apoptosis of monocyte-derived dendritic cells.

  Experimental parasitology 20090301

• Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.

  Endocrine-related cancer 20090301

• Monitoring of cell death in epithelial cells using high frequency ultrasound spectroscopy.

  Ultrasound in medicine & biology 20090301

• Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• Delocalization of nucleolar poly(ADP-ribose) polymerase-1 to the nucleoplasm and its novel link to cellular sensitivity to DNA damage.

  DNA repair 20090301

• Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan.

  Environmental and molecular mutagenesis 20090301

• Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.

  Cancer science 20090301

• Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090301

• Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells.

  International journal of oncology 20090301

• Decrease in chemosensitivity against anticancer drugs by an esophageal squamous cell carcinoma SEREX antigen, AISEC.

  International journal of oncology 20090301

• Salt stress-induced cell death in the unicellular green alga Micrasterias denticulata.

  Journal of experimental botany 20090301

• cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation.

  Cancer research 20090301

• Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.

  Annals of surgery 20090301

• [The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20090301

• Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease.

  The Korean journal of internal medicine 20090301

• FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.

  The oncologist 20090301

• [Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090301

• [A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090301

• Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.

  Journal of pediatric surgery 20090301

• [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].

  Bulletin du cancer 20090301

• Semisynthesis, biological activity, and molecular modeling studies of C-ring-modified camptothecins.

  Journal of medicinal chemistry 20090226

• Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine.

  Cancer research 20090215

• Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.

  The Journal of biological chemistry 20090213

• Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090210

• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090210

• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090210

• Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.

  Cancer letters 20090208

• Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

  Cancer chemotherapy and pharmacology 20090201

• Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.

  Cancer chemotherapy and pharmacology 20090201

• Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.

  Cancer chemotherapy and pharmacology 20090201

• Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan.

  Clinical pharmacology and therapeutics 20090201

• Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Experience with irinotecan for the treatment of malignant glioma.

  Neuro-oncology 20090201

• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

  Journal of neuro-oncology 20090201

• Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

  Pharmaceutical research 20090201

• Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.

  Drug metabolism and disposition: the biological fate of chemicals 20090201

• Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.

  Annals of surgical oncology 20090201

• Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.

  Annals of surgical oncology 20090201

• Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.

  Journal of surgical oncology 20090201

• Monolithic osmotic tablet containing solid dispersion of 10-hydroxycamptothecin.

  Drug development and industrial pharmacy 20090201

• Irinotecan in cancer patients with end-stage renal failure.

  The Annals of pharmacotherapy 20090201

• A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.

  American journal of clinical oncology 20090201

• Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.

  American journal of clinical oncology 20090201

• Dynamic proteomics for investigating the response of individual cancer cells under drug action.

  Expert review of proteomics 20090201

• [A case of recurrence after curative total gastrectomy for gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090201

• [Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090201

• Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.

  International journal of clinical oncology 20090201

• Role of glucocorticoid receptor in the regulation of cellular sensitivity to irinotecan hydrochloride.

  Journal of pharmacological sciences 20090201

• The CAIRO and FOCUS studies: which lesson is to be learned?

  The oncologist 20090201

• The European contribution to 'Sugarbaker's protocol' for the treatment of colorectal peritoneal carcinomatosis.

  Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20090201

• [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].

  Recenti progressi in medicina 20090201

• Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells.

  Biochemical and biophysical research communications 20090130

• A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.

  European journal of pharmacology 20090128

• Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.

  World journal of gastroenterology 20090128

• The spliceosome as target for anticancer treatment.

  British journal of cancer 20090127

• Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.

  British journal of cancer 20090127

• Down-regulation of adenine nucleotide translocase 3 and its role in camptothecin-induced apoptosis in human hepatoma QGY7703 cells.

  FEBS letters 20090122

• Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.

  Journal of controlled release : official journal of the Controlled Release Society 20090119

• Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.

  Molecular cell 20090116

• Synthesis and antitumor activity of novel 20s-camptothecin analogues.

  Bioorganic & medicinal chemistry letters 20090115

• Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

  Cancer research 20090115

• Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090115

• Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.

  British journal of cancer 20090113

• Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110

• Synthesis of 6-amino-6-deoxyhyaluronan as an intermediate for conjugation with carboxylate-containing compounds: application to hyaluronan-camptothecin conjugates.

  Carbohydrate research 20090105

• Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20090101

• Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?

  Cancer chemotherapy and pharmacology 20090101

• NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells.

  Cancer chemotherapy and pharmacology 20090101

• A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

  Cancer chemotherapy and pharmacology 20090101

• Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

  Medical oncology (Northwood, London, England) 20090101

• Primary small cell carcinoma of the breast.

  Breast cancer (Tokyo, Japan) 20090101

• Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.

  Ultrasonics 20090101

• Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20090101

• A photo-activated targeting chemotherapy using glutathione sensitive camptothecin-loaded polymeric micelles.

  Pharmaceutical research 20090101

• How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?

  Pediatric blood & cancer 20090101

• 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

  Molecular pharmacology 20090101

• Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.

  Annals of surgical oncology 20090101

• IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis.

  International immunology 20090101

• Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

  Acta oncologica (Stockholm, Sweden) 20090101

• Diflomotecan, a promising homocamptothecin for cancer therapy.

  Expert opinion on investigational drugs 20090101

• A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.

  Chemotherapy 20090101

• The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.

  Medical oncology (Northwood, London, England) 20090101

• Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.

  Chemotherapy 20090101

• Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.

  Cancer 20090101

• Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.

  Radiology 20090101

• Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.

  Journal of hepato-biliary-pancreatic surgery 20090101

• Camptothecins: a SAR/QSAR study.

  Chemical reviews 20090101

• Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090101

• Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231.

  Cancer cell international 20090101

• An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues.

  Journal of natural products 20090101

• Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells.

  BMC cancer 20090101

• Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

  Genetics in medicine : official journal of the American College of Medical Genetics 20090101

• Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

  Genetics in medicine : official journal of the American College of Medical Genetics 20090101

• Collective cell migration drives morphogenesis of the kidney nephron.

  PLoS biology 20090101

• Chemotherapy for small-bowel Adenocarcinoma at a single institution.

  Surgery today 20090101

• The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

  The oncologist 20090101

• Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.

  Molecular cancer research : MCR 20090101

• Pharmacogenetics and pharmacogenomics of anticancer agents.

  CA: a cancer journal for clinicians 20090101

• The role of capecitabine in the management of tumors of the digestive system.

  Reviews on recent clinical trials 20090101

• Treatment of colorectal liver metastases: a review.

  Reviews on recent clinical trials 20090101

• [Advanced gastric cancer showing complete response to neoadjuvant chemotherapy with CPT-11 and S-1-a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090101

• [A case of simultaneous double cancers with multiple liver metastases responding to S-1+CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090101

• Antiphospholipid antibodies: paradigm in transition.

  Journal of neuroinflammation 20090101

• The internally truncated LRP5 receptor presents a therapeutic target in breast cancer.

  PloS one 20090101

• A microhomology-mediated break-induced replication model for the origin of human copy number variation.

  PLoS genetics 20090101

• Genetic evidence for single-strand lesions initiating Nbs1-dependent homologous recombination in diversification of Ig v in chicken B lymphocytes.

  PLoS genetics 20090101

• A newly identified essential complex, Dre2-Tah18, controls mitochondria integrity and cell death after oxidative stress in yeast.

  PloS one 20090101

• Activation of DNA-PK by ionizing radiation is mediated by protein phosphatase 6.

  PloS one 20090101

• Does celecoxib have a role in the treatment of patients with colorectal cancer?

  Clinical colorectal cancer 20090101

• Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.

  Clinical colorectal cancer 20090101

• Binding of PFOS to serum albumin and DNA: insight into the molecular toxicity of perfluorochemicals.

  BMC molecular biology 20090101

• Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies.

  Lipids in health and disease 20090101

• GSK3 beta N-terminus binding to p53 promotes its acetylation.

  Molecular cancer 20090101

• Chemical probes that competitively and selectively inhibit Stat3 activation.

  PloS one 20090101

• HIV gp120 induces, NF-kappaB dependent, HIV replication that requires procaspase 8.

  PloS one 20090101

• S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.

  PloS one 20090101

• A new dawn for the use of traditional Chinese medicine in cancer therapy.

  Molecular cancer 20090101

• Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.

  Oncology 20090101

• Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.

  Oncology 20090101

• A functional type I topoisomerase from Pseudomonas aeruginosa.

  BMC molecular biology 20090101

• Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.

  Anticancer research 20090101

• Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells.

  Anticancer research 20090101

• [Drug discovery based on classic natural products].

  Yao xue xue bao = Acta pharmaceutica Sinica 20090101

• Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.

  American journal of therapeutics 20090101

• A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.

  BMC cancer 20090101

• Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.

  Tumori 20090101

• Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

  BMC cancer 20090101

• Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.

  In vivo (Athens, Greece) 20090101

• Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.

  BMC cancer 20090101

• Cell survival from chemotherapy depends on NF-kappaB transcriptional up-regulation of coenzyme Q biosynthesis.

  PloS one 20090101

• In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context.

  Xenotransplantation 20090101

• A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent.

  PloS one 20090101

• Protein kinase C activation disrupts epithelial apical junctions via ROCK-II dependent stimulation of actomyosin contractility.

  BMC cell biology 20090101

• Early assessment of therapeutic response using FDG PET in small cell lung cancer.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20090101

• Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20090101

• Increased susceptibility of spinal muscular atrophy fibroblasts to camptothecin is p53-independent.

  BMC cell biology 20090101

• Polymeric micelles of ammonium palmitoyl glycol chitosan and solubilization of camptothecin.

  PDA journal of pharmaceutical science and technology 20090101

• A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.

  BMC cancer 20090101

• Anti-angiogenic effects of pterogynidine alkaloid isolated from Alchornea glandulosa.

  BMC complementary and alternative medicine 20090101

• Porphyromonas gingivalis induce apoptosis in human gingival epithelial cells through a gingipain-dependent mechanism.

  BMC microbiology 20090101

• A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.

  PloS one 20090101

• Transcriptional down-regulation and rRNA cleavage in Dictyostelium discoideum mitochondria during Legionella pneumophila infection.

  PloS one 20090101

• Near infrared planar tumor imaging and quantification using nanosized Alexa 750-labeled phospholipid micelles.

  International journal of nanomedicine 20090101

• Numerical analysis of etoposide induced DNA breaks.

  PloS one 20090101

• Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

  Journal of translational medicine 20090101

• Camptothecin production by in vitro cultures and plant regeneration in Ophiorrhiza species.

  Methods in molecular biology (Clifton, N.J.) 20090101

• Comparative studies and identification of camptothecin produced by an endophyte at shake flask and bioreactor.

  Natural product research 20090101

• [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20090101

• [Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20090101

• Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab.

  Journal of cancer research and therapeutics 20090101

• Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity.

  Drug metabolism and pharmacokinetics 20090101

• dRecQ4 is required for DNA synthesis and essential for cell proliferation in Drosophila.

  PloS one 20090101

• Regulation of DNA replication by the S-phase DNA damage checkpoint.

  Cell division 20090101

• Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.

  BMC genomics 20090101

• The Schizosaccharomyces pombe checkpoint kinases Chk1 and Cds1 are important for cell survival in response to cisplatin.

  PloS one 20090101

• Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates.

  Molecular pharmaceutics 20090101

• Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

  Oncology 20090101

• Evolving treatment of advanced colon cancer.

  Annual review of medicine 20090101

• Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.

  Arzneimittel-Forschung 20090101

• Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum.

  Journal of biomedicine & biotechnology 20090101

• Evaluation of the possible benefits of post-radiotherapy surgery after concomitant chemoradiotherapy with a new radio-sensitizing regimen (irinotecan / CPT-11, interferon A2b and amifostine) for advanced-stage cervical carcinoma. Preliminary results of a pilot phase-II study.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101

• Polymer-drug interactions in tyrosine-derived triblock copolymer nanospheres: a computational modeling approach.

  Molecular pharmaceutics 20090101

• Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells.

  PloS one 20090101

• [Pre-clinical study of combined aranosa, cisplatin and irinotecan in the treatment of experimental lung cancer].

  Voprosy onkologii 20090101

• RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.

  PloS one 20090101

• Network-assisted protein identification and data interpretation in shotgun proteomics.

  Molecular systems biology 20090101

• Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin.

  Biochimica et biophysica acta 20090101

• Expression and functional studies of ubiquitin C-terminal hydrolase L1 regulated genes.

  PloS one 20090101

• SUMO chain formation is required for response to replication arrest in S. pombe.

  PloS one 20090101

• A survival strategy: the coevolution of the camptothecin biosynthetic pathway and self-resistance mechanism.

  Phytochemistry 20090101

• TJ-41 Induces Apoptosis and Potentiates the Apoptotic Effects of 5-FU in Breast Cancer Cell Lines.

  Journal of oncology 20090101

• UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

  Molecular diagnosis & therapy 20090101

• Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.

  BMC cancer 20090101

• Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.

  Digestion 20090101

• Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.

  Cancer biomarkers : section A of Disease markers 20090101

• Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.

  Oncology 20090101

• Networking of differentially expressed genes in human cancer cells resistant to methotrexate.

  Genome medicine 20090101

• The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

  Oncology 20090101

• The cellular phenotype of Roberts syndrome fibroblasts as revealed by ectopic expression of ESCO2.

  PloS one 20090101

• The G-quadruplex ligand telomestatin impairs binding of topoisomerase IIIalpha to G-quadruplex-forming oligonucleotides and uncaps telomeres in ALT cells.

  PloS one 20090101

• A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

  PloS one 20090101

• Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin.

  PloS one 20090101

• Structural similarity assessment for drug sensitivity prediction in cancer.

  BMC bioinformatics 20090101

• Binding of DNA topoisomerases I and II to replication origins.

  Methods in molecular biology (Clifton, N.J.) 20090101

• Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

  BMC cancer 20090101

• Single-step therapy -- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies.

  In vivo (Athens, Greece) 20090101

• Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.

  BMC cancer 20090101

• Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

  PloS one 20090101

• Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.

  Oncology research 20090101

• Activation of cyclin-dependent kinase 5 is a consequence of cell death.

  Journal of biomedicine & biotechnology 20090101

• Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin A.

  Aging 20090101

• A pilot study of irinotecan combined with 5-fluorouracil and leucovorin for the treatment of Chinese patients with locally advanced and metastatic gastric cancer.

  Tumori 20090101

• Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report.

  World journal of surgical oncology 20090101

• Insilico analysis of homocamptothecin (hCPT) analogues for anti-tumour activity.

  International journal of bioinformatics research and applications 20090101

• Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.

  European journal of gynaecological oncology 20090101

• Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.

  Molecular cancer 20090101

• Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.

  Drug design, development and therapy 20090101

• G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies.

  PloS one 20090101

• Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.

  Journal of gastrointestinal cancer 20090101

• Chemo-diversion strategy for unresectable colorectal carcinoma: report of two cases.

  Hepato-gastroenterology 20090101

• The SNF2-family member Fun30 promotes gene silencing in heterochromatic loci.

  PloS one 20090101

• Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

  PloS one 20090101

• Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell.

  Reproductive biology and endocrinology : RB&E 20090101

• A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.

  Chemotherapy 20090101

• The synthetic inhibitor of fibroblast growth factor receptor PD166866 controls negatively the growth of tumor cells in culture.

  Journal of experimental & clinical cancer research : CR 20090101

• Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

  Journal of oncology 20090101

• Chemogenomic profiling predicts antifungal synergies.

  Molecular systems biology 20090101

• The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.

  Trials 20090101

• Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20090101

• Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM).

  International journal of nanomedicine 20090101

• Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.

  The Kurume medical journal 20090101

• Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.

  Clinical therapeutics 20090101

• Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.

  Journal of oncology 20090101

• Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.

  Journal of cancer research and therapeutics 20090101

• Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38.

  PDA journal of pharmaceutical science and technology 20090101

• Induction of apoptosis in the human Leukemic U937 cell line by Kaempferia parviflora Wall.ex.Baker extract and effects of paclitaxel and camptothecin.

  Asian Pacific journal of cancer prevention : APJCP 20090101

• InPACdb--Indian plant anticancer compounds database.

  Bioinformation 20090101

• Irinotecan plus S-1 for liver metastases of gastric cancer.

  Hepato-gastroenterology 20090101

• Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.

  International surgery 20090101

• Cytoprotective effect of lithium against spontaneous and induced apoptosis of lymphoid cell line MOLT-4.

  Folia histochemica et cytobiologica 20090101

• Solid lipid nanoparticles: a modern formulation approach in drug delivery system.

  Indian journal of pharmaceutical sciences 20090101

• When transcription meets recombination: a lesson from the human RECQ protein complexes.

  F1000 biology reports 20090101

• Current status of maintenance therapy for advanced ovarian cancer.

  International journal of women's health 20090101

• Effect of organic tomato (Lycopersicon esculentum) extract on the genotoxicity of doxorubicin in the Drosophila wing spot test.

  Genetics and molecular biology 20090101

• Logical network of genotoxic stress-induced NF-κB signal transduction predicts putative target structures for therapeutic intervention strategies.

  Advances and applications in bioinformatics and chemistry : AABC 20090101

• Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study.

  Journal of the American Chemical Society 20081231

• PCNA damage caused by antineoplastic drugs.

  Biochemical pharmacology 20081215

• Micronucleus induction in V79 cells by the anabolic doping steroids desoxymethyltestosterone (madol) and 19-norandrostenedione.

  Toxicology letters 20081215

• Semi-synthesis and biological activity of gamma-lactones analogs of camptothecin.

  Bioorganic & medicinal chemistry letters 20081215

• Overexpression of OATP1B3 confers apoptotic resistance in colon cancer.

  Cancer research 20081215

• Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081210

• Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.

  Biochemical and biophysical research communications 20081205

• Dynamic proteomics of individual cancer cells in response to a drug.

  Science (New York, N.Y.) 20081205

• Expeditious total syntheses of camptothecin and 10-hydroxycamptothecin.

  Organic letters 20081204

• CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901.

  Investigational new drugs 20081201

• A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20081201

• Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.

  Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 20081201

• Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

  Investigational new drugs 20081201

• Deletion of MAG1 and MRE11 enhances the sensitivity of the Saccharomyces cerevisiae HUG1P-GFP promoter-reporter construct to genotoxicity.

  Biosensors & bioelectronics 20081201

• The comparison of biophysical properties of DB-67 and its ester DB-67-4ABTFA determined by fluorescence spectroscopy methods.

  Bio Systems 20081201

• The HSA affinity of warfarin and flurbiprofen determined by fluorescence anisotropy measurements of camptothecin.

  Bio Systems 20081201

• Irinotecan in the treatment of elderly patients with advanced colorectal cancer.

  Critical reviews in oncology/hematology 20081201

• Fanconi anemia proteins stabilize replication forks.

  DNA repair 20081201

• MgLig4, a homolog of Neurospora crassa Mus-53 (DNA ligase IV), is involved in, but not essential for, non-homologous end-joining events in Magnaporthe grisea.

  Fungal genetics and biology : FG & B 20081201

• Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats.

  Cancer biology & therapy 20081201

• Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081201

• Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.

  Japanese journal of clinical oncology 20081201

• Polymeric micellar delivery systems in oncology.

  Japanese journal of clinical oncology 20081201

• What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?

  Current opinion in neurology 20081201

• Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.

  Chemical & pharmaceutical bulletin 20081201

• Pharmacogenomics of tamoxifen and irinotecan therapies.

  Clinics in laboratory medicine 20081201

• [Report from the 44th Congress of the American Society of Clinical Oncology].

  Magyar onkologia 20081201

• Fhit tumor suppressor: guardian of the preneoplastic genome.

  Future oncology (London, England) 20081201

• Topoisomerase 3alpha and RMI1 suppress somatic crossovers and are essential for resolution of meiotic recombination intermediates in Arabidopsis thaliana.

  PLoS genetics 20081201

• Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells.

  Experimental oncology 20081201

• [Investigations on preparation and release behavior in vitro of 9-nitro camptothecin encapsulated micelles].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20081201

• Anticancer alkaloid lamellarins inhibit protein kinases.

  Marine drugs 20081201

• Acetylcholinesterase-inhibiting activity of pyrrole derivatives from a novel marine gliding bacterium, Rapidithrix thailandica.

  Marine drugs 20081201

• Vinflunine in the treatment of bladder cancer.

  Therapeutics and clinical risk management 20081201

• A case of primary small cell carcinoma of the liver that was treated with chemotherapy.

  Hepatology international 20081201

• First-line therapeutic strategies in metastatic colorectal cancer.

  Oncology (Williston Park, N.Y.) 20081130

• Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line.

  Chemico-biological interactions 20081125

• Systems biology. Cast of 1000 proteins shines in movies of cancer cells.

  Science (New York, N.Y.) 20081121

• Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• The role of polyamine architecture on the pharmacological activity of open lactone camptothecin-polyamine conjugates.

  Bioconjugate chemistry 20081119

• Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

  Cancer 20081115

• Efficient one-cycle affinity selection of binding proteins or peptides specific for a small-molecule using a T7 phage display pool.

  Bioorganic & medicinal chemistry 20081115

• A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115

• Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.

  Cancer research 20081115

• Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

  Journal of medicinal chemistry 20081113

• Drosophila pico and its mammalian ortholog lamellipodin activate serum response factor and promote cell proliferation.

  Developmental cell 20081111

• Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.

  British journal of cancer 20081104

• Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.

  Cancer chemotherapy and pharmacology 20081101

• Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.

  Cancer chemotherapy and pharmacology 20081101

• The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs.

  European journal of medicinal chemistry 20081101

• Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.

  Cancer chemotherapy and pharmacology 20081101

• First synthesis of novel spin-labeled derivatives of camptothecin as potential antineoplastic agents.

  European journal of medicinal chemistry 20081101

• Use of hydrodynamic flow focusing for the generation of biodegradable camptothecin-loaded polymer microspheres.

  Journal of pharmaceutical sciences 20081101

• Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.

  Cancer chemotherapy and pharmacology 20081101

• Initiation of caspase-independent death in mouse mesangial cells by Cd2+: involvement of p38 kinase and CaMK-II.

  Journal of cellular physiology 20081101

• Clinical and pharmacogenetic factors associated with irinotecan toxicity.

  Cancer treatment reviews 20081101

• Effect of cyclodextrin complexation on the liposome permeability of a model hydrophobic weak Acid.

  Pharmaceutical research 20081101

• Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.

  Pharmaceutical research 20081101

• A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

  Journal of neuro-oncology 20081101

• A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081101

• Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.

  Cancer science 20081101

• A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).

  European journal of cancer (Oxford, England : 1990) 20081101

• Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.

  Japanese journal of clinical oncology 20081101

• Antiangiogenic therapy in malignant gliomas.

  Current opinion in oncology 20081101

• Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.

  Xenobiotica; the fate of foreign compounds in biological systems 20081101

• Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs.

  Acta pharmacologica Sinica 20081101

• Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).

  Biological & pharmaceutical bulletin 20081101

• Low-dose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma.

  Journal of pediatric hematology/oncology 20081101

• [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20081101

• [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [Marked response to combination chemotherapy using S-1, CPT-11 for lymph node metastasis of gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• Race does not explain genetic heterogeneity in pharmacogenomic pathways.

  Pharmacogenomics 20081101

• Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

  Clinical colorectal cancer 20081101

• Chemical-genetic profiling of imidazo[1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells.

  PLoS genetics 20081101

• [New perspectives in predicting response to chemotherapy in colorectal cancer].

  Gastroenterologia y hepatologia 20081101

• [Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [A case of ovarian cancer in which a remarkable effect was seen with intrathoracic administration of CDDP and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• [Isolation and purification of 10-hydroxycamptothecin and vincoside-lactam from Camptotheca acuminata seed by polyamide].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20081101

• A novel co-polymer based on hydroxypropyl alpha-cyclodextrin conjugated to low molecular weight polyethylenimine as an in vitro gene delivery vector.

  International journal of molecular sciences 20081101

• Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA.

  Biochemistry 20081028

• Interplay between Np95 and Eme1 in the DNA damage response.

  Biochemical and biophysical research communications 20081024

• RecQ4 facilitates UV light-induced DNA damage repair through interaction with nucleotide excision repair factor xeroderma pigmentosum group A (XPA).

  The Journal of biological chemistry 20081024

• GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.

  British journal of cancer 20081021

• Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.

  British journal of cancer 20081021

• Regulation of proliferating cell nuclear antigen ubiquitination in mammalian cells.

  Proceedings of the National Academy of Sciences of the United States of America 20081021

• Requirement of a functional spindle checkpoint for arsenite-induced apoptosis.

  Journal of cellular biochemistry 20081015

• DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy.

  Neuroscience 20081015

• Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents.

  Bioorganic & medicinal chemistry 20081015

• Clinical determinants of response to irinotecan-based therapy derived from cell line models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

• A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

• The FANCM ortholog Fml1 promotes recombination at stalled replication forks and limits crossing over during DNA double-strand break repair.

  Molecular cell 20081010

• CDK targets Sae2 to control DNA-end resection and homologous recombination.

  Nature 20081002

• Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

  Investigational new drugs 20081001

• Physicochemical characterization and membrane binding properties of camptothecin.

  Journal of pharmaceutical sciences 20081001

• Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.

  Gastroenterologie clinique et biologique 20081001

• Management and survival trends in advanced colorectal cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20081001

• Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081001

• The 9-1-1 DNA clamp is required for immunoglobulin gene conversion.

  Molecular and cellular biology 20081001

• Caspase-3 activation as a key factor for HBx-transformed cell death.

  Cell proliferation 20081001

• Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.

  Cancer 20081001

• Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

  The Annals of pharmacotherapy 20081001

• Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

  Journal of pharmacokinetics and pharmacodynamics 20081001

• Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.

  Oncology reports 20081001

• New lessons from 'old' chemotherapy in colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.

  American journal of clinical oncology 20081001

• Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

  Japanese journal of clinical oncology 20081001

• Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.

  Molecular cancer therapeutics 20081001

• Cisplatin abrogates the geldanamycin-induced heat shock response.

  Molecular cancer therapeutics 20081001

• An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.

  Journal of the National Comprehensive Cancer Network : JNCCN 20081001

• [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• [A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• [A case of successful control for primary duodenal cancer with combined CPT-11, CDDP and DOC chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.

  Gan to kagaku ryoho. Cancer & chemotherapy 20081001

• Mutation of the zebrafish nucleoporin elys sensitizes tissue progenitors to replication stress.

  PLoS genetics 20081001

• In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.

  Biomedical research (Tokyo, Japan) 20081001

• [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].

  Bulletin du cancer 20081001

• [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].

  Bulletin du cancer 20081001

• Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.

  Journal of chemotherapy (Florence, Italy) 20081001

• [Advances in the study of small peptides in targeted drug delivery system].

  Yao xue xue bao = Acta pharmaceutica Sinica 20081001

• The effect of 10-hydroxycamptothecine in preventing fibroblast proliferation and epidural scar adhesion after laminectomy in rats.

  European journal of pharmacology 20080928

• 18beta-Glycyrrhetinic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity.

  Life sciences 20080926

• SMT3IP1, a nucleolar SUMO-specific protease, deconjugates SUMO-2 from nucleolar and cytoplasmic nucleophosmin.

  Biochemical and biophysical research communications 20080919

• Checkpoint-dependent phosphorylation of Exo1 modulates the DNA damage response.

  The EMBO journal 20080917

• Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies.

  Talanta 20080915

• 11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents.

  Bioorganic & medicinal chemistry 20080915

• Cleavage-mediated activation of Chk1 during apoptosis.

  The Journal of biological chemistry 20080912

• Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080910

• Modelling in vitro growth of dense root networks.

  Journal of theoretical biology 20080907

• Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I.

  Journal of molecular biology 20080905

• Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

  British journal of cancer 20080902

• Apoptosis-induced inhibition of CD1d-mediated antigen presentation: different roles for caspases and signal transduction pathways.

  Immunology 20080901

• Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

  Critical reviews in oncology/hematology 20080901

• Pharmacogenetic pathway analysis of irinotecan.

  Clinical pharmacology and therapeutics 20080901

• DNA damage-inducing agents elicit gamma-secretase activation mediated by oxidative stress.

  Cell death and differentiation 20080901

• Catalyst-dependent drug loading of LDI-glycerol polyurethane foams leads to differing controlled release profiles.

  Acta biomaterialia 20080901

• CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.

  Journal of neuro-oncology 20080901

• Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

  Molecular pharmacology 20080901

• Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080901

• Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation.

  Pharmaceutical research 20080901

• Conventional and dense gas techniques for the production of liposomes: a review.

  AAPS PharmSciTech 20080901

• Mutational study of the 'catalytic tetrad' of DNA topoisomerase IB from the hemoflagellate Leishmania donovani: Role of Asp-353 and Asn-221 in camptothecin resistance.

  Biochemical pharmacology 20080901

• Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.

  Journal of biomolecular screening 20080901

• Synthesis and structure-activity relationship studies of theophylline analogs on population responses in the rat hippocampus in vitro.

  Bioorganic & medicinal chemistry 20080901

• 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.

  Anti-cancer drugs 20080901

• Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.

  International journal of oncology 20080901

• Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma.

  Oncology reports 20080901

• Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.

  Oncology 20080901

• Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.

  Acta pharmacologica Sinica 20080901

• Modifications of human carboxylesterase for improved prodrug activation.

  Expert opinion on drug metabolism & toxicology 20080901

• Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080901

• Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?

  Expert review of anticancer therapy 20080901

• Arylamine N-acetyltransferases: a new inhibitor of apoptosis in HepG2 cells.

  Journal of Zhejiang University. Science. B 20080901

• Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080901

• Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.

  Japanese journal of clinical oncology 20080901

• Segmental duplications arise from Pol32-dependent repair of broken forks through two alternative replication-based mechanisms.

  PLoS genetics 20080901

• Frajunolides E-K, briarane diterpenes from Junceella fragilis.

  Journal of natural products 20080901

• Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.

  The oncologist 20080901

• An autopsy case of acute pulmonary toxicity related to irinotecan.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080901

• [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• [A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• 2,2-dimethyl-2H-pyran-derived alkaloids I. Practical synthesis of acronycine and benzo[b]acronycine and their biological properties.

  Archives of pharmacal research 20080901

• Effects of nutritional support in patients with colorectal cancer during chemotherapy.

  Collegium antropologicum 20080901

• Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy.

  International journal of nanomedicine 20080901

• A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.

  Biochemical and biophysical research communications 20080829

• Novel amidino-substituted thienyl- and furylvinylbenzimidazole: derivatives and their photochemical conversion into corresponding diazacyclopenta[c]fluorenes. synthesis, interactions with DNA and RNA, and antitumor evaluation. 4.

  Journal of medicinal chemistry 20080828

• Necdin regulates p53 acetylation via Sirtuin1 to modulate DNA damage response in cortical neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080827

• Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission.

  The Journal of biological chemistry 20080822

• PEGylated nanographene oxide for delivery of water-insoluble cancer drugs.

  Journal of the American Chemical Society 20080820

• Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.

  British journal of cancer 20080819

• Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.

  Life sciences 20080815

• Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).

  Bioorganic & medicinal chemistry 20080815

• Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080815

• Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

  Journal of medicinal chemistry 20080814

• Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.

  Chemico-biological interactions 20080811

• Enhancing ultrasound-mediated cell membrane permeabilisation (sonoporation) using a high frequency pulse regime and implications for ultrasound-aided cancer chemotherapy.

  Cancer letters 20080808

• Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.

  British journal of cancer 20080805

• Resistance to chemotherapy: new treatments and novel insights into an old problem.

  British journal of cancer 20080805

• Factors affecting the clearance and biodistribution of polymeric nanoparticles.

  Molecular pharmaceutics 20080804

• Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

  The pharmacogenomics journal 20080801

• Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.

  Cancer chemotherapy and pharmacology 20080801

• Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20080801

• A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.

  Cancer chemotherapy and pharmacology 20080801

• Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.

  Cancer chemotherapy and pharmacology 20080801

• Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies.

  European journal of medicinal chemistry 20080801

• Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080801

• Renal function as a predictor of irinotecan-induced neutropenia.

  Clinical pharmacology and therapeutics 20080801

• Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20080801

• Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080801

• Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.

  Journal of neuro-oncology 20080801

• Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice.

  Diabetes 20080801

• Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.

  Molecular pharmacology 20080801

• MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer.

  Cancer biology & therapy 20080801

• Arylstibonic acids: novel inhibitors and activators of human topoisomerase IB.

  Bioorganic chemistry 20080801

• Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.

  Nature clinical practice. Oncology 20080801

• Telithromycin inhibits the production of proinflammatory mediators and the activation of NF-kappaB in in vitro-stimulated murine cells.

  FEMS immunology and medical microbiology 20080801

• Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080801

• Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

  Neuro-oncology 20080801

• Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.

  Anti-cancer drugs 20080801

• A DNA damage signal activates and derepresses exon inclusion in Drosophila TAF1 alternative splicing.

  RNA (New York, N.Y.) 20080801

• Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells.

  Bioconjugate chemistry 20080801

• Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20080801

• A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.

  European journal of cancer (Oxford, England : 1990) 20080801

• PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.

  The Journal of pharmacy and pharmacology 20080801

• Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.

  Neoplasia (New York, N.Y.) 20080801

• Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.

  Journal of neurosurgery 20080801

• Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• Structural and functional analysis of the Crb2-BRCT2 domain reveals distinct roles in checkpoint signaling and DNA damage repair.

  Genes & development 20080801

• Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity.

  Cancer research 20080801

• FLEX data, KRAS and ERCC1 testing in oncology.

  Future oncology (London, England) 20080801

• Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection.

  Drug development and industrial pharmacy 20080801

• Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting.

  The oncologist 20080801

• [Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080801

• [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080801

• KRAS status predicts response to cetuximab for metastatic colorectal cancer.

  ONS connect 20080801

• Inference of protein complex activities from chemical-genetic profile and its applications: predicting drug-target pathways.

  PLoS computational biology 20080801

• Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.

  American journal of clinical oncology 20080801

• A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes.

  The Journal of biological chemistry 20080725

• Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets.

  Journal of the American Chemical Society 20080723

• UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

  British journal of cancer 20080722

• Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin.

  Colloids and surfaces. B, Biointerfaces 20080715

• Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.

  Cancer 20080715

• Uniform threshold intensity distribution-based quantitative multivariate imaging cytometry.

  Analytical chemistry 20080715

• Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring.

  Bioorganic & medicinal chemistry letters 20080715

• Histone H1 dephosphorylation is not a general feature in early apoptosis.

  Biochemistry 20080715

• Identification of a minimal functional linker in human topoisomerase I by domain swapping with Cre recombinase.

  Biochemistry 20080708

• Preparation and characterization of novel polymeric micelles for 9-nitro-20(S)-camptothecin delivery.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080703

• Phase II study of rubitecan in recurrent or metastatic head and neck cancer.

  Cancer chemotherapy and pharmacology 20080701

• Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.

  Cancer chemotherapy and pharmacology 20080701

• Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

  Cancer chemotherapy and pharmacology 20080701

• Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.

  Cancer chemotherapy and pharmacology 20080701

• Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.

  Cancer immunology, immunotherapy : CII 20080701

• Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080701

• Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.

  Lung cancer (Amsterdam, Netherlands) 20080701

• Activated charcoal to prevent irinotecan-induced diarrhea in children.

  Pediatric blood & cancer 20080701

• Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.

  Pharmaceutical research 20080701

• A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.

  Pharmaceutical research 20080701

• LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas.

  Acta biomaterialia 20080701

• Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.

  Cancer 20080701

• Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.

  Archives of toxicology 20080701

• Sensitivity of RECQL4-deficient fibroblasts from Rothmund-Thomson syndrome patients to genotoxic agents.

  Human genetics 20080701

• Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs.

  Cancer biology & therapy 20080701

• Microfabrication of an asymmetric, multi-layered microdevice for controlled release of orally delivered therapeutics.

  Lab on a chip 20080701

• ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells.

  Cancer research 20080701

• Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.

  Onkologie 20080701

• A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.

  Nature clinical practice. Urology 20080701

• Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?

  The oncologist 20080701

• [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [Combination chemotherapy composed of mFOLFOX 6, FOLFIRI 2 and surgery and radiation therapy for locoregional recurrences and multiple lung metastases from rectal cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.

  Molecular cancer therapeutics 20080701

• Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.

  Molecular cancer therapeutics 20080701

• Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.

  The Tohoku journal of experimental medicine 20080701

• DNA topoisomerase I inhibitory alkaloids from Corydalis saxicola.

  Chemistry & biodiversity 20080701

• Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.

  Clinical colorectal cancer 20080701

• Regional chemotherapy for liver-limited metastatic colorectal cancer.

  Clinical colorectal cancer 20080701

• A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.

  Clinical colorectal cancer 20080701

• [Case report of malignant sertoli cell tumor].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20080701

• [Effects of nitrogen forms on camptothecin content and its metabolism-related enzymes activities in Camptotheca acuminata seedlings].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20080701

• Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.

  World journal of gastroenterology 20080628

• KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.

  Journal of the National Cancer Institute 20080618

• Camptothecinoids from the seeds of Taiwanese Nothapodytes foetida.

  Molecules (Basel, Switzerland) 20080616

• Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.

  Bioorganic & medicinal chemistry letters 20080615

• Down-regulation of Na+/H+ exchanger regulatory factor 1 increases expression and function of multidrug resistance protein 4.

  Cancer research 20080615

• Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I.

  The Journal of biological chemistry 20080613

• Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.

  The pharmacogenomics journal 20080601

• Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.

  Cancer chemotherapy and pharmacology 20080601

• Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20080601

• Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080601

• Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

  Investigational new drugs 20080601

• BCRP/ABCG2 in the placenta: expression, function and regulation.

  Pharmaceutical research 20080601

• Effects of isocamptothecin, a novel camptothecin analogue, on proliferation, apoptosis and telomerase activity in HaCaT cells.

  Experimental dermatology 20080601

• Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells.

  Gut 20080601

• Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Advances in neoadjuvant therapy for colorectal cancer with liver metastases.

  Cancer treatment reviews 20080601

• Inhibition of nucleolar transcription as a trigger for neuronal apoptosis.

  Journal of neurochemistry 20080601

• Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.

  Cancer biology & therapy 20080601

• Identification and characterization of a Drosophila ortholog of WRN exonuclease that is required to maintain genome integrity.

  Aging cell 20080601

• ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin.

  Molecular pharmacology 20080601

• Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.

  Cancer science 20080601

• Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.

  Gynecologic oncology 20080601

• EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase.

  Cellular signalling 20080601

• Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080601

• Determination of anticarcinogenic and rescue therapy drugs in urine by photoinduced spectrofluorimetry using multivariate calibration: comparison of several second-order methods.

  Analytical and bioanalytical chemistry 20080601

• Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor.

  Cancer science 20080601

• Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080601

• Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.

  European journal of cancer (Oxford, England : 1990) 20080601

• Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.

  Journal of surgical oncology 20080601

• Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.

  Oncology reports 20080601

• Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.

  International journal of oncology 20080601

• Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080601

• Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

  Pharmacotherapy 20080601

• Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080601

• Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.

  Japanese journal of clinical oncology 20080601

• Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.

  American journal of clinical oncology 20080601

• Population-based phase I trial of irinotecan and epirubicin.

  American journal of clinical oncology 20080601

• ISG15 as a novel tumor biomarker for drug sensitivity.

  Molecular cancer therapeutics 20080601

• Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins.

  Molecular cancer therapeutics 20080601

• Promotive effects of hyperthermia on the cytostatic activity to Ehrlich ascites tumor cells by diverse delta-alkyllactones.

  Experimental oncology 20080601

• The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice.

  Journal of chemotherapy (Florence, Italy) 20080601

• Neoadjuvant chemoradiation for rectal cancer: is more better?

  Oncology (Williston Park, N.Y.) 20080601

• [Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [CR obtained by CPT-11 and CDDP combination-therapy in a small-cell lung-cancer patient through effective pharmaceutical care].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [A case of interstitial pneumonia induced by S-1/irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080601

• [A case of small cell carcinoma of the ureter].

  Hinyokika kiyo. Acta urologica Japonica 20080601

• Redistribution of cell death-inducing DNA fragmentation factor-like effector-a (CIDEa) from mitochondria to nucleus is associated with apoptosis in HeLa cells.

  General physiology and biophysics 20080601

• Polymeric micelles modified by folate-PEG-lipid for targeted drug delivery to cancer cells in vitro.

  Journal of nanoscience and nanotechnology 20080601

• Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.

  Advanced drug delivery reviews 20080522

• Thiocamptothecin.

  Journal of medicinal chemistry 20080522

• CITED2 signals through peroxisome proliferator-activated receptor-gamma to regulate death of cortical neurons after DNA damage.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080521

• Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.

  British journal of cancer 20080520

• A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.

  British journal of cancer 20080520

• Proteome response in HT-29 human colorectal cancer cells to two apoptosis-inducing compounds with different mode of action.

  International journal of cancer 20080515

• Microcavity array (MCA)-based biosensor chip for functional drug screening of 3D tissue models.

  Biosensors & bioelectronics 20080515

• Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.

  Cancer 20080515

• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.

  Journal of controlled release : official journal of the Controlled Release Society 20080508

• In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin.

  Journal of controlled release : official journal of the Controlled Release Society 20080508

• Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20080501

• Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.

  International journal of cancer 20080501

• A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080501

• Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition.

  The Biochemical journal 20080501

• UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

  Cancer 20080501

• Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells.

  Cancer science 20080501

• A highly efficient gene-targeting system for Aspergillus parasiticus.

  Letters in applied microbiology 20080501

• Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.

  Cancer 20080501

• Development and validation of a reverse-phase HPLC with fluorescence detector method for simultaneous determination of CZ48 and its active metabolite camptothecin in mouse plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080501

• A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model.

  Cell cycle (Georgetown, Tex.) 20080501

• Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.

  Expert opinion on pharmacotherapy 20080501

• E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.

  Bioorganic & medicinal chemistry letters 20080501

• A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis.

  International journal of oncology 20080501

• Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.

  Oncology reports 20080501

• Synthesis and cytotoxic activity of new 9-substituted camptothecins.

  Bioorganic & medicinal chemistry letters 20080501

• Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.

  Journal of neurosurgery 20080501

• Artificial lipids stabilized camptothecin incorporated in liposomes.

  Biological & pharmaceutical bulletin 20080501

• The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20080501

• Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.

  Pharmacogenomics 20080501

• [Non-resectable metastases from colorectal cancers].

  Gastroenterologie clinique et biologique 20080501

• Topoisomerase I inhibitors for the treatment of brain tumors.

  Expert review of anticancer therapy 20080501

• Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.

  Expert review of anticancer therapy 20080501

• Systemic treatment of colorectal cancer.

  Gastroenterology 20080501

• Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.

  Neoplasia (New York, N.Y.) 20080501

• Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers.

  Drug development and industrial pharmacy 20080501

• Polynucleotide kinase as a potential target for enhancing cytotoxicity by ionizing radiation and topoisomerase I inhibitors.

  Anti-cancer agents in medicinal chemistry 20080501

• Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy.

  Anti-cancer agents in medicinal chemistry 20080501

• [A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• [Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• [A case of advanced rectal cancer responding to neoadjuvant chemotherapy with CPT-11, 5-FU and l-LV after coronary artery bypass graft].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).

  Onkologie 20080501

• Human DNA topoisomerase inhibitors from Potentilla argentea and their cytotoxic effect against MCF-7.

  Die Pharmazie 20080501

• Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.

  Clinical colorectal cancer 20080501

• Colon cancer: update on adjuvant therapy.

  Clinical colorectal cancer 20080501

• [The study of dynamic acccumulation of camptothecin in Camptotheca acuminata fruit by TLCS].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20080501

• Protein arginine (N)-methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins.

  FEBS letters 20080430

• Is MutaMouse insensitive to clastogens?

  Mutation research 20080430

• Detecting genotoxic effects of potential clastogens: an in vivo study using the transgenic lacZ plasmid and the MutaMouse model.

  Mutation research 20080430

• A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

  British journal of cancer 20080422

• Synthesis, cytotoxic activities and structure-activity relationships of topoisomerase I inhibitors: indolizinoquinoline-5,12-dione derivatives.

  Bioorganic & medicinal chemistry 20080415

• Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions.

  Cancer 20080415

• Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080410

• Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.

  British journal of cancer 20080408

• Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.

  Journal of controlled release : official journal of the Controlled Release Society 20080407

• [Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20080401

• Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.

  Cancer chemotherapy and pharmacology 20080401

• Alternative pathways of programmed cell death are activated in cells with defective caspase-dependent apoptosis.

  Leukemia research 20080401

• Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.

  Cancer chemotherapy and pharmacology 20080401

• Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities.

  European journal of medicinal chemistry 20080401

• Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.

  Clinical pharmacology and therapeutics 20080401

• Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

  Pediatric blood & cancer 20080401

• Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.

  International journal of cancer 20080401

• Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080401

• Tasumatrols U-Z, taxane diterpene esters from Taxus sumatrana.

  Journal of natural products 20080401

• A novel ATP-binding cassette transporter, ABCG6 is involved in chemoresistance of Leishmania.

  Molecular and biochemical parasitology 20080401

• Ionizing radiation can induce GSK-3beta phosphorylation and NF-kappaB transcriptional transactivation in ATM-deficient fibroblasts.

  Cellular signalling 20080401

• Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.

  Basic & clinical pharmacology & toxicology 20080401

• Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

  Current medical research and opinion 20080401

• Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells.

  Carcinogenesis 20080401

• A new isopentenyl diphosphate isomerase gene from Camptotheca acuminata: cloning, characterization and functional expression in Escherichia coli.

  DNA sequence : the journal of DNA sequencing and mapping 20080401

• The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.

  Cancer science 20080401

• Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

  Neuro-oncology 20080401

• Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.

  Oncology reports 20080401

• Development of efficient RNA interference system using EGF-displaying phagemid particles.

  Acta pharmacologica Sinica 20080401

• Synthesis and antitumor activity of aromatic camptothecin esters.

  International journal of molecular medicine 20080401

• Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.

  Cancer biology & therapy 20080401

• Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.

  Bioconjugate chemistry 20080401

• [Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20080401

• Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080401

• DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions.

  Cancer research 20080401

• The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.

  Cancer research 20080401

• DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080401

• Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines.

  Phytotherapy research : PTR 20080401

• Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

  American journal of clinical oncology 20080401

• Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.

  Leukemia & lymphoma 20080401

• Prospecting for Camptothecines from Nothapodytes nimmoniana in the Western Ghats, South India: identification of high-yielding sources of camptothecin and new families of camptothecines.

  Journal of chromatographic science 20080401

• [Combined irinotecan (CPT-11) and nedaplatin (254-S) therapy for advanced and/or recurrent cervical cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080401

• [Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080401

• Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.

  Seminars in oncology 20080401

• [Antibody treatment in colorectal cancer--what the surgeon needs to know].

  Zentralblatt fur Chirurgie 20080401

• Chemotherapy in elderly patients with colorectal cancer.

  The oncologist 20080401

• Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.

  International journal of clinical oncology 20080401

• UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

  Journal of chemotherapy (Florence, Italy) 20080401

• Effects of mitofusin-2 gene on cell proliferation and chemotherapy sensitivity of MCF-7.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20080401

• [Hydrocamptothecin promotes the mRNA expression of Wnt signaling inhibitor DKK-1].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080401

• [Quantitative analysis of nuclear proteome in apoptosis hepatoma cells induced by hydroxycamptothecin].

  Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology 20080401

• Metronomic chemotherapy and tumor immunomodulation.

  Cancer biology & therapy 20080401

• Characterization of mre11 loss following HSV-1 infection.

  Virology 20080330

• Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.

  Journal of medicinal chemistry 20080327

• Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67.

  International journal of pharmaceutics 20080320

• Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

  Cancer letters 20080318

• Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.

  Biochemical pharmacology 20080315

• Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives.

  Bioorganic & medicinal chemistry 20080315

• Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects.

  Biochemical pharmacology 20080315

• Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression.

  Cancer research 20080315

• Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to genotoxic stresses.

  Cancer research 20080315

• Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Activation of ubiquitin-dependent DNA damage bypass is mediated by replication protein a.

  Molecular cell 20080314

• Evidence-based Chinese medicine for cancer therapy.

  Journal of ethnopharmacology 20080305

• Osteosarcoma metastatic to the kidney and iatrogenic hemorrhage.

  Pediatric blood & cancer 20080301

• Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.

  Pediatric blood & cancer 20080301

• Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20080301

• Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20080301

• Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.

  Cancer chemotherapy and pharmacology 20080301

• Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: a case report.

  Lung cancer (Amsterdam, Netherlands) 20080301

• A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080301

• ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080301

• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080301

• Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment.

  Cancer biology & therapy 20080301

• Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080301

• An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.

  Cancer gene therapy 20080301

• Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.

  Cancer investigation 20080301

• Topoisomerase inhibitors as anti-arthritic agents.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080301

• Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.

  European journal of cancer (Oxford, England : 1990) 20080301

• Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice.

  Arthritis and rheumatism 20080301

• Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20080301

• U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.

  Onkologie 20080301

• [A case of multidrug-resistant squamous cell lung carcinoma responding to S-1 plus CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• [A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• [A long survival case of advanced colon cancer with lung metastasis and cancerous pleuritis responding to CPT-11 and S-1 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080301

• Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20080301

• Sequential vs combination colorectal cancer therapy sparks debate.

  British journal of hospital medicine (London, England : 2005) 20080301

• Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly(D,L-lactide) micelles.

  Biomedical materials (Bristol, England) 20080301

• Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

  International journal of nanomedicine 20080301

• Tumor targeting using liposomal antineoplastic drugs.

  International journal of nanomedicine 20080301

• Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.

  Clinical colorectal cancer 20080301

• Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.

  Clinical colorectal cancer 20080301

• Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.

  Clinical genitourinary cancer 20080301

• [Current therapeutic options for liver metastasis].

  Revista medica de Chile 20080301

• Broken beyond repair. Damaging DNA in glioblastoma cells with radiation and camptothecin.

  Cancer biology & therapy 20080301

• [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080301

• Anti-cancer effects of xanthones from pericarps of mangosteen.

  International journal of molecular sciences 20080301

• Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

  British journal of cancer 20080226

• Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.

  British journal of cancer 20080226

• Bevacizumab plus irinotecan in recurrent glioblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220

• Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.

  Cancer letters 20080218

• New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor.

  Bioorganic & medicinal chemistry letters 20080215

• Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.

  Cancer 20080215

• Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080215

• Spectrofluorimetric determination of irinotecan in the presence of oxidant agents and metal ions.

  Talanta 20080215

• G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

  British journal of cancer 20080212

• Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.

  The Journal of biological chemistry 20080208

• Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

  Journal of the National Cancer Institute 20080206

• Injectable block copolymer hydrogels for sustained release of a PEGylated drug.

  International journal of pharmaceutics 20080204

• Molecular cloning, expression profiling and functional analysis of a DXR gene encoding 1-deoxy-D-xylulose 5-phosphate reductoisomerase from Camptotheca acuminata.

  Journal of plant physiology 20080201

• Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20080201

• A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20080201

• Reducing irinotecan-associated diarrhea in children.

  Pediatric blood & cancer 20080201

• Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.

  Cancer chemotherapy and pharmacology 20080201

• Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080201

• Clinical relevance of the homologous recombination machinery in cancer therapy.

  Cancer science 20080201

• Nucleosomes represent a physical barrier for cleavage activity of DNA topoisomerase I in vivo.

  The Biochemical journal 20080201

• Effects of recombinant human PLD2 on proliferation and apoptosis of HL-60 cells.

  Cell biology international 20080201

• Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

  Molecular pharmacology 20080201

• Fragment responsible for translocation in the N-terminal domain of human topoisomerase I.

  Biochemical and biophysical research communications 20080201

• From bench to drug: human seizure modeling using Drosophila.

  Progress in neurobiology 20080201

• Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan.

  Cancer gene therapy 20080201

• Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

  Cancer investigation 20080201

• New homocamptothecins: synthesis, antitumor activity, and molecular modeling.

  Bioorganic & medicinal chemistry 20080201

• Histone deimination as a response to inflammatory stimuli in neutrophils.

  Journal of immunology (Baltimore, Md. : 1950) 20080201

• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201

• Withangulatin I, a new cytotoxic withanolide from Physalis angulata.

  Chemical & pharmaceutical bulletin 20080201

• The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition.

  Cancer research 20080201

• Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.

  Molecular cancer therapeutics 20080201

• [CPT-11 (Irinotecan)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• [Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• [A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080201

• [A quantitative analysis of mitochondrial protein differential expressions in hydroxycamptothecin-treated hepatoma cells].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20080201

• Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

  The oncologist 20080201

• Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors.

  Journal of enzyme inhibition and medicinal chemistry 20080201

• A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.

  American journal of clinical oncology 20080201

• Genetic analysis of the Neurospora crassa RAD14 homolog mus-43 and the RAD10 homolog mus-44 reveals that they belong to the mus-38 pathway of two nucleotide excision repair systems.

  Genes & genetic systems 20080201

• Vertebrate WRNIP1 and BLM are required for efficient maintenance of genome stability.

  Genes & genetic systems 20080201

• DNA damage activates the SAC in an ATM/ATR-dependent manner, independently of the kinetochore.

  PLoS genetics 20080201

• [Effect of nitrogen on camptothecin content in Camptotheca acuminata seedlings].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20080201

• A review of topotecan in combination chemotherapy for advanced cervical cancer.

  Therapeutics and clinical risk management 20080201

• Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models.

  British journal of cancer 20080129

• Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.

  British journal of cancer 20080129

• [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080117

• An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3'-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme.

  The Biochemical journal 20080115

• Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation.

  Bioorganic & medicinal chemistry letters 20080115

• Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20080101

• A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20080101

• A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.

  Cancer chemotherapy and pharmacology 20080101

• Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin.

  Digestive diseases and sciences 20080101

• Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes.

  Pulmonary pharmacology & therapeutics 20080101

• A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation.

  Journal of biomedical materials research. Part A 20080101

• Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study.

  Journal of cancer research and clinical oncology 20080101

• Protection of halogenated DNA from strand breakage and sister-chromatid exchange induced by the topoisomerase I inhibitor camptothecin.

  Mutation research 20080101

• Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080101

• A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20080101

• Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080101

• Determination of camptothecins in DMSO extracts of Nothapodytes foetida by direct injection capillary electrophoresis.

  Phytochemical analysis : PCA 20080101

• Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101

• Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67.

  Journal of pharmaceutical sciences 20080101

• Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.

  Annals of surgical oncology 20080101

• Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.

  Journal of pharmaceutical sciences 20080101

• Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.

  Acta oncologica (Stockholm, Sweden) 20080101

• Preparation and properties of mixed micelles made of Pluronic polymer and PEG-PE.

  Journal of colloid and interface science 20080101

• Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats.

  Pharmaceutical research 20080101

• Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.

  Acta oncologica (Stockholm, Sweden) 20080101

• Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.

  Acta oncologica (Stockholm, Sweden) 20080101

• Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin.

  Cell death and differentiation 20080101

• Polymer-drug conjugates: current status and future trends.

  Frontiers in bioscience : a journal and virtual library 20080101

• The large subunit of Leishmania topoisomerase I functions as the 'molecular steer' in type IB topoisomerase.

  Molecular microbiology 20080101

• Carbon beam therapy in recurrent ovarian cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080101

• Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents.

  The Journal of pharmacy and pharmacology 20080101

• Cytotoxic triterpenoid saponins acylated with monoterpenic acid from Pithecellobium lucidum.

  Journal of natural products 20080101

• Treatment of metastatic urachal carcinoma in an elderly woman.

  Nature clinical practice. Oncology 20080101

• Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.

  Acta oncologica (Stockholm, Sweden) 20080101

• Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.

  Journal of the American College of Surgeons 20080101

• Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

  Annals of surgery 20080101

• Phosphorylation of beta-actin by protein kinase C-delta in camptothecin analog-induced leukemic cell apoptosis.

  Acta pharmacologica Sinica 20080101

• Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080101

• Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• Importance of a C-terminal conserved region of Chk1 for checkpoint function.

  PloS one 20080101

• Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development.

  Developmental cell 20080101

• [A pilot study of irinotecan hydrochloride(CPT-11)and cisplatin(CDDP)combination chemotherapy for previously treated non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• [Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• [An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080101

• Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles.

  Drug delivery 20080101

• Using generalized procrustes analysis (GPA) for normalization of cDNA microarray data.

  BMC bioinformatics 20080101

• Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.

  Molecular cancer 20080101

• [Predictive factors of response to anti-EGFR treatments in colorectal cancer].

  Bulletin du cancer 20080101

• Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.

  The oncologist 20080101

• Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin.

  Clinical & experimental metastasis 20080101

• Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20080101

• Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.

  Clinical colorectal cancer 20080101

• Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation.

  Clinical colorectal cancer 20080101

• Chemotherapy for brain metastases in small-cell lung cancer.

  Clinical lung cancer 20080101

• Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.

  Chemotherapy 20080101

• [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080101

• PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.

  Breast cancer research : BCR 20080101

• Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.

  Medical oncology (Northwood, London, England) 20080101

• Small cell carcinoma of the extrahepatic bile duct diagnosed with EUS-FNA and effectively treated with chemoradiation.

  Internal medicine (Tokyo, Japan) 20080101

• Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.

  Anticancer research 20080101

• Successful treatment with S-1 plus CPT-11 for lymph node metastasis from colon cancer: report of a case.

  Anticancer research 20080101

• The influence of nicotine on granulocytic differentiation - inhibition of the oxidative burst and bacterial killing and increased matrix metalloproteinase-9 release.

  BMC cell biology 20080101

• Insulin inhibits caspase-3 activity in human renal tubular epithelial cells via the PI3-kinase/Akt pathway.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20080101

• Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect.

  BMC biotechnology 20080101

• Design, synthesis and development of novel camptothecin drugs.

  Current pharmaceutical design 20080101

• Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil.

  Anticancer research 20080101

• Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer.

  Oncology 20080101

• High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?

  Oncology 20080101

• Drug interaction prediction using ontology-driven hypothetical assertion framework for pathway generation followed by numerical simulation.

  BMC bioinformatics 20080101

• A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

  BMC cancer 20080101

• Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.

  Oncology 20080101

• Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.

  PloS one 20080101

• [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].

  Revue neurologique 20080101

• Development and validation of an HPLC method to quantify camptothecin in polymeric nanocapsule suspensions.

  Journal of AOAC International 20080101

• Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells.

  Molecular cancer 20080101

• Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania major.

  BMC microbiology 20080101

• Topoisomerase II inhibition involves characteristic chromosomal expression patterns.

  BMC genomics 20080101

• Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.

  BMC cancer 20080101

• A phase I trial of CPT-11 and S-1 combination chemotherapy in patients with metastatic colorectal cancer.

  Hepato-gastroenterology 20080101

• Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice.

  BMC cancer 20080101

• The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer.

  Breast cancer research : BCR 20080101

• Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.

  Anticancer research 20080101

• Complete response obtained and maintained by combination of S-1 and CPT-11 in hepatic metastases of colon cancer: a case report.

  Anticancer research 20080101

• Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.

  Anticancer research 20080101

• Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes' C colorectal cancer.

  Anticancer research 20080101

• A new hTopo I isomerase inhibitor produced by a mangrove endophytic fungus no. 2240.

  Journal of Asian natural products research 20080101

• An endophytic Neurospora sp. from Nothapodytes foetida producing camptothecin.

  Prikladnaia biokhimiia i mikrobiologiia 20080101

• Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.

  Molecular cancer 20080101

• Weekly irinotecan plus protracted venous fluorouracil infusion (WI-FI) in advanced colorectal cancer: a phase II study.

  Anticancer research 20080101

• Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.

  Oncology 20080101

• Bortezomib as a therapeutic candidate for neuroblastoma.

  Journal of experimental therapeutics & oncology 20080101

• Micropropagation and production of Camptothecin from in vitro plants of Ophiorrhiza rugosa var. decumbens.

  Natural product research 20080101

• Inhibition of cell growth and invasion by epidermal growth factor-targeted phagemid particles carrying siRNA against focal adhesion kinase in the presence of hydroxycamptothecin.

  BMC biotechnology 20080101

• Heat stress-responsive transcriptome analysis in heat susceptible and tolerant wheat (Triticum aestivum L.) by using Wheat Genome Array.

  BMC genomics 20080101

• NF-kappaB mediates the survival of human bronchial epithelial cells exposed to cigarette smoke extract.

  Respiratory research 20080101

• Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.

  World journal of surgical oncology 20080101

• Intestinal permeability and toxicity of second-line therapeutic agents in ovarian cancer.

  Tumori 20080101

• Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.

  Chemotherapy 20080101

• Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.

  Cancer journal (Sudbury, Mass.) 20080101

• Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.

  Oncology 20080101

• DNA cleavage assay for the identification of topoisomerase I inhibitors.

  Nature protocols 20080101

• Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.

  BMC cancer 20080101

• Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.

  Journal of gastroenterology 20080101

• Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).

  Anticancer research 20080101

• Phase I study of irinotecan combined with mitomycin-C and 5-fluorouracil for gynecological malignancies: the JGOG study.

  Anticancer research 20080101

• Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients.

  Anticancer research 20080101

• Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.

  Anticancer research 20080101

• [Colorectal carcinoma--primary treatment in case of advanced metastization].

  Onkologie 20080101

• KEGG spider: interpretation of genomics data in the context of the global gene metabolic network.

  Genome biology 20080101

• Sequential or combination chemotherapy for a patient with mCRC?

  Cancer treatment reviews 20080101

• A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.

  Cancer treatment reviews 20080101

• Recurrent disease four years after surgery and adjuvant chemotherapy.

  Cancer treatment reviews 20080101

• A DNA topoisomerase IB in Thaumarchaeota testifies for the presence of this enzyme in the last common ancestor of Archaea and Eucarya.

  Biology direct 20080101

• Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20080101

• Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.

  Anticancer research 20080101

• Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.

  The International journal of biological markers 20080101

• The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.

  Acta chirurgica Iugoslavica 20080101

• Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan.

  Journal of oncology 20080101

• Chromosome 20q amplification regulates in vitro response to Kinesin-5 inhibitor.

  Cancer informatics 20080101

• TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects.

  Hepato-gastroenterology 20080101

• Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.

  Journal of gastrointestinal cancer 20080101

• Docetaxel and irinotecan as first-line chemotherapy in patients with advanced non-small-cell lung cancer: a pilot study.

  Le Journal medical libanais. The Lebanese medical journal 20080101

• Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells.

  Drug design, development and therapy 20080101

• Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

  Drug design, development and therapy 20080101

• Antifungals: need to search for a new molecular target.

  Indian journal of pharmaceutical sciences 20080101

• Induced differentiation of hepatocellular carcinoma by natural products.

  African journal of traditional, complementary, and alternative medicines : AJTCAM 20080101

• Topotecan in the treatment of relapsed small cell lung cancer.

  OncoTargets and therapy 20080101

• A review on plant-derived natural products and their analogs with anti-tumor activity.

  Indian journal of pharmacology 20080101

• Response Surface Methodology for the Optimization of Celecoxib Self-microemulsifying Drug delivery System.

  Indian journal of pharmaceutical sciences 20080101

• Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice.

  Clinical medicine. Oncology 20080101

• Increased alpha2,3-sialylation and hyperglycosylation of N-glycans in embryonic rat cortical neurons during camptothecin-induced apoptosis.

  Molecules and cells 20071231

• Synthesis and characterization of novel internal surface reversed-phase silica supports for high-performance liquid chromatography.

  Journal of chromatography. A 20071228

• Diffusion of camptothecin immobilized with cationic surfactant into agarose hydrogel containing anionic carrageenan.

  Journal of biomedical materials research. Part A 20071215

• Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70.

  International journal of cancer 20071215

• Identification of C10 biotinylated camptothecin (CPT-10-B) binding peptides using T7 phage display screen on a QCM device.

  Bioorganic & medicinal chemistry 20071215

• A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.

  Cancer 20071215

• Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death.

  Cancer research 20071215

• Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.

  World journal of gastroenterology 20071214

• Trf4 targets ncRNAs from telomeric and rDNA spacer regions and functions in rDNA copy number control.

  The EMBO journal 20071212

• Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.

  Biochemistry 20071211

• Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair.

  The Journal of biological chemistry 20071207

• Preparation, characterization, and controlled release of novel nanoparticles based on MMA/beta-CD copolymers.

  Macromolecular bioscience 20071206

• Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.

  Journal of cancer research and clinical oncology 20071201

• Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

  International journal of cancer 20071201

• Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

  Lung cancer (Amsterdam, Netherlands) 20071201

• Susceptibility of Autographa californica multiple nucleopolyhedrovirus to inhibitors of DNA replication.

  Journal of virological methods 20071201

• A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• Bevacizumab-associated reversible hypotension.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20071201

• A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20071201

• 20-(S)-camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study.

  ChemMedChem 20071201

• Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani.

  Biochimie 20071201

• Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• Role of DNA mismatch repair and double-strand break repair in genome stability and antifungal drug resistance in Candida albicans.

  Eukaryotic cell 20071201

• A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.

  Oncology reports 20071201

• [Systemic treatment of peritoneal metastases].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20071201

• Treatment of advanced colorectal cancer in the elderly.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071201

• Human mitochondrial transcription factor A possesses multiple subcellular targeting signals.

  The FEBS journal 20071201

• Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20071201

• AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.

  IDrugs : the investigational drugs journal 20071201

• Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071201

• Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.

  Japanese journal of clinical oncology 20071201

• Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.

  Biological & pharmaceutical bulletin 20071201

• Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.

  Onkologie 20071201

• CPT accumulation in the fruit and during early phases of plant development in Camptotheca acuminata Decaisne (Nyssaceae).

  Natural product research 20071201

• Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.

  Journal of natural products 20071201

• Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report.

  Chest 20071201

• Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer.

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• [Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• [A case report--combination chemotherapy with oral UFT and CPT-11, 5-FU, l-LV by hepatic arterial infusion for multiple hepatic metastasis from sigmoid colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071201

• Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.

  Neoplasia (New York, N.Y.) 20071201

• Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells.

  Radiation research 20071201

• Additive immunosuppressive effect of hydroxycamptothecin and cyclosporine on rejection of heart transplantation in rats.

  Transplantation proceedings 20071201

• Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.

  Molecular cancer therapeutics 20071201

• In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

  Molecular cancer therapeutics 20071201

• Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.

  International journal of nanomedicine 20071201

• Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.

  Journal of chemotherapy (Florence, Italy) 20071201

• Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.

  Journal of chemotherapy (Florence, Italy) 20071201

• Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro-quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA.

  Archives of pharmacal research 20071201

• Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus.

  Hepato-gastroenterology 20071201

• Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.

  Clinical colorectal cancer 20071201

• Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.

  Clinical colorectal cancer 20071201

• A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.

  Clinical colorectal cancer 20071201

• Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.

  Journal of experimental & clinical cancer research : CR 20071201

• [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071201

• Drug-eluting particles for interventional pharmacology.

  Techniques in vascular and interventional radiology 20071201

• A case of late-onset severe cardiotoxicity from 5-fluorouracil therapy resulting in death.

  The New Zealand medical journal 20071130

• p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis.

  The Journal of biological chemistry 20071123

• Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity.

  Biochemical pharmacology 20071115

• The mammalian DNA replication elongation checkpoint: implication of Chk1 and relationship with origin firing as determined by single DNA molecule and single cell analyses.

  Cell cycle (Georgetown, Tex.) 20071115

• TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo.

  The EMBO journal 20071114

• Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?

  The EMBO journal 20071114

• Synthesis and molecular structure of ethyl [N-tosyl-(R)-prolyloxy]-2(S)-[4-cyano-8,8-ethylenedioxy-5-oxo-5,6,7,8-tetrahydroindolizin-3-yl] acetate, a key intermediate in the total synthesis of (20S)-camptothecins.

  Molecules (Basel, Switzerland) 20071113

• [Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20071110

• Apoptotic actions of p53 require transcriptional activation of PUMA and do not involve a direct mitochondrial/cytoplasmic site of action in postnatal cortical neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20071107

• A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20071101

• Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia.

  Leukemia research 20071101

• Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20071101

• Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.

  Cellular signalling 20071101

• Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071101

• Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.

  The Journal of urology 20071101

• The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.

  European journal of cancer (Oxford, England : 1990) 20071101

• Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071101

• [Research advance of nanometric traditional Chinese herbal drugs for cancer treatment].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20071101

• [Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of cytology-positive, stage IV gastric cancer, alive with no recurrence for 4 years, curatively treated with combination chemotherapy using S-1, CPT-11 and subsequent total gastrectomy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Progress of chemotherapy in colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• Effect of probenecid on the biliary excretion of belotecan.

  Archives of pharmacal research 20071101

• Cetuximab efficacy in patients treated routinely in university hospitals.

  Gastroenterologie clinique et biologique 20071101

• Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20071101

• Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles.

  Journal of cellular and molecular medicine 20071101

• [A long-term surviving patient with unresectable lung metastasis from colon cancer treated with intravenous administration of activated autologous lymphocytes and low-dose chemotherapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Transarterial chemoembolization with irinotecan (CPT-11) and degradable starch microspheres (DSM) in patients with liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Evaluation of bronchial arterial infusion (BAI) for lung cancer with carcinomatous pleuritis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Carboplatin and CPT-11 chemotherapy in a hemodialysis patient with small-cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of unresectable gastric cancer successfully treated with combination chemotherapy of S-1 + CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [A case of S-1 resistant multiple lung metastases after curative total gastrectomy for gastric cancer successfully treated by S-1 combined with CPT-11 as the third-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• Molecular mechanics and DNA replication regulation.

  HFSP journal 20071101

• [Prediction of adverse drug reactions based on genomic information].

  Nihon rinsho. Japanese journal of clinical medicine 20071028

• Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.

  British journal of cancer 20071022

• Taming glioblastoma: targeting angiogenesis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core.

  Journal of controlled release : official journal of the Controlled Release Society 20071018

• Role of kinase suppressor of Ras-1 in neuronal survival signaling by extracellular signal-regulated kinase 1/2.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20071017

• Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling.

  International journal of cancer 20071015

• Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy.

  International journal of cancer 20071015

• Camptothecin-incorporating N-phthaloylchitosan-g-mPEG self-assembly micellar system: effect of degree of deacetylation.

  Colloids and surfaces. B, Biointerfaces 20071015

• Complex N-glycan and metabolic control in tumor cells.

  Cancer research 20071015

• The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.

  Cancer research 20071015

• Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage.

  Cancer research 20071015

• A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071015

• Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010

• Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010

• Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010

• First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action.

  British journal of cancer 20071008

• Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.

  The pharmacogenomics journal 20071001

• Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20071001

• Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model.

  Cancer chemotherapy and pharmacology 20071001

• MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.

  Digestive diseases and sciences 20071001

• Isolated metastasis of lung cancer to the thyroid gland.

  Lung cancer (Amsterdam, Netherlands) 20071001

• Expression and characterization of a human carboxylesterase 2 splice variant.

  The Journal of pharmacology and experimental therapeutics 20071001

• Haplotypes and a novel defective allele of CES2 found in a Japanese population.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

  Neuro-oncology 20071001

• From old organisms to new molecules: integrative biology and therapeutic targets in accelerated human ageing.

  Cellular and molecular life sciences : CMLS 20071001

• Acute toxicity of irinotecan in the ex-vivo isolated perfused human lung model--high-dose therapy during isolated perfusion without acute toxic lung edema.

  Interactive cardiovascular and thoracic surgery 20071001

• Changes in the protein spectrum of mitochondria isolated from hydroxycamptothecin-treated hepatoma cells.

  Anti-cancer drugs 20071001

• Effect of betulinic acid on anticancer drug-resistant colon cancer cells.

  Basic & clinical pharmacology & toxicology 20071001

• Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.

  Annals of surgery 20071001

• Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.

  Therapeutic drug monitoring 20071001

• Human Mus81 and FANCB independently contribute to repair of DNA damage during replication.

  Genes to cells : devoted to molecular & cellular mechanisms 20071001

• Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071001

• Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma.

  The Journal of pharmacy and pharmacology 20071001

• Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase.

  Biological & pharmaceutical bulletin 20071001

• A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.

  Japanese journal of clinical oncology 20071001

• [A case of unresectable gastric cancer complicated by serious pyloric stenosis in which S-1 administration after gastrojejunostomy proved effective].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• [A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• [Neoadjuvant chemotherapy with combination of S-1 and CPT-11 in advanced rectal cancer - a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071001

• Recent advances with topotecan in the treatment of lung cancer.

  The oncologist 20071001

• Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis.

  Neoplasia (New York, N.Y.) 20071001

• Two new benzofurans from Gastrodia elata and their DNA topoisomerases I and II inhibitory activities.

  Planta medica 20071001

• [Hydroxycamptothecin promotes the apoptosis of prostate cancer cell line PC-3].

  Zhonghua nan ke xue = National journal of andrology 20071001

• Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an 'off-target' effect?

  Mini reviews in medicinal chemistry 20071001

• FOLFIRI chemotherapy for metastatic colorectal cancer patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20071001

• Inhibitory effect of HCPT on expression of HIF-1alpha and downstream genes in hypoxic human cervical SiHa cancer cells.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20071001

• Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay.

  Journal of chemotherapy (Florence, Italy) 20071001

• Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.

  Journal of chemotherapy (Florence, Italy) 20071001

• The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.

  Journal of chemotherapy (Florence, Italy) 20071001

• Local-regional approach to diffuse malignant peritoneal mesothelioma.

  Gastroenterologie clinique et biologique 20071001

• Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.

  Gastroenterologie clinique et biologique 20071001

• [Studies on the separation and purificaton of pumiloside from Nauclea officinalis by macroreticular resin].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20071001

• Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.

  Journal of molecular biology 20070928

• Synthesis of ferulic ester dimers, functionalisation and biological evaluation as potential antiatherogenic and antiplasmodial agents.

  Bioorganic & medicinal chemistry 20070915

• Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.

  Cancer research 20070915

• Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.

  Cancer research 20070915

• Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Chemoradiation in the management of esophageal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070910

• Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.

  Journal of medicinal chemistry 20070906

• Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.

  Journal of medicinal chemistry 20070906

• UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

  Journal of the National Cancer Institute 20070905

• Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.

  Cancer chemotherapy and pharmacology 20070901

• Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.

  Molecular pharmacology 20070901

• Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• Rapid down-regulation of Ret following exposure of dopaminergic neurons to neurotoxins.

  Journal of neurochemistry 20070901

• Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.

  Peptides 20070901

• Dumbbell-shaped circular oligonucleotides as inhibitors of human topoisomerase I.

  Bioorganic & medicinal chemistry letters 20070901

• Two optimized combination assays to examine apoptosis pathways in clinical samples.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20070901

• [Role of pharmacogenetics in chemotherapy of colorectal cancers].

  La Revue de medecine interne 20070901

• Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

  Cancer science 20070901

• Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells.

  Journal of proteome research 20070901

• Mms22 preserves genomic integrity during DNA replication in Schizosaccharomyces pombe.

  Genetics 20070901

• A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.

  Anti-cancer drugs 20070901

• Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.

  Anti-cancer drugs 20070901

• Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

  Cancer 20070901

• Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.

  Current medical research and opinion 20070901

• An automated method for in vitro anticancer drug efficacy monitoring based on cell viability measurement using a portable photodiode array chip.

  Lab on a chip 20070901

• Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

  Japanese journal of clinical oncology 20070901

• Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Strain-dependent induction of epithelial cell oncosis by Campylobacter jejuni is correlated with invasion ability and is independent of cytolethal distending toxin.

  Microbiology (Reading, England) 20070901

• PKCeta expression contributes to the resistance of Hodgkin's lymphoma cell lines to apoptosis.

  Cancer biology & therapy 20070901

• Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Dicer-related drh-3 gene functions in germ-line development by maintenance of chromosomal integrity in Caenorhabditis elegans.

  Genes to cells : devoted to molecular & cellular mechanisms 20070901

• Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.

  Biological & pharmaceutical bulletin 20070901

• Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070901

• Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.

  Cancer biology & therapy 20070901

• [A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070901

• Immunomodulatory activity of an extract of the novel fungal endophyte Entrophospora infrequens isolated from Nothapodytes foetida (Wight) Sleumer.

  Acta microbiologica et immunologica Hungarica 20070901

• Photochemical properties of camptothecin in the presence of copper(II) ions: the role of radicals as prospective species in photodynamic therapy.

  Molecular biotechnology 20070901

• Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.

  Clinical lung cancer 20070901

• A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.

  Journal of Korean medical science 20070901

• The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.

  Clinical colorectal cancer 20070901

• Combined-modality therapy for rectal cancer: future prospects.

  Clinical colorectal cancer 20070901

• Metachronous metastasis to the penis from a rectal adenocarcinoma.

  Clinical colorectal cancer 20070901

• Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.

  International journal of nanomedicine 20070901

• Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.

  British journal of cancer 20070828

• Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

  Journal of medicinal chemistry 20070823

• 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.

  Journal of medicinal chemistry 20070823

• A renewed call for equipoise.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: a promising new approach to the treatment of multidrug resistant cancer.

  Cancer letters 20070808

• Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.

  British journal of cancer 20070806

• Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3.

  The Journal of biological chemistry 20070803

• Short and efficient total synthesis of luotonin A and 22-hydroxyacuminatine using a common cascade strategy.

  The Journal of organic chemistry 20070803

• Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20070801

• Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

  Pediatric blood & cancer 20070801

• Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070801

• A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

  Lung cancer (Amsterdam, Netherlands) 20070801

• Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.

  International journal of pharmaceutics 20070801

• NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin.

  Cellular signalling 20070801

• Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity.

  Cell death and differentiation 20070801

• Chemical radiosensitizers for use in radiotherapy.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801

• Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles.

  International journal of pharmaceutics 20070801

• Activation of the extrinsic caspase pathway in cultured cortical neurons requires p53-mediated down-regulation of the X-linked inhibitor of apoptosis protein to induce apoptosis.

  Journal of neurochemistry 20070801

• Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.

  Molecular pharmacology 20070801

• Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.

  Gynecologic oncology 20070801

• Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.

  Cancer 20070801

• Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.

  Small (Weinheim an der Bergstrasse, Germany) 20070801

• Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.

  Cancer 20070801

• Combination of HPLC 'inverted chirality columns approach' and MS/MS detection for extreme enantiomeric excess determination even in absence of reference samples. Application to camptothecin derivatives.

  Analytical chemistry 20070801

• Synthetic lethality of Drosophila in the absence of the MUS81 endonuclease and the DmBlm helicase is associated with elevated apoptosis.

  Genetics 20070801

• UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.

  Pharmacogenetics and genomics 20070801

• DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties.

  Human reproduction (Oxford, England) 20070801

• Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.

  Biological & pharmaceutical bulletin 20070801

• [A case of small cell carcinoma of the esophagus with remarkable response to chemotherapy with CPT-11 and CDDP].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070801

• [Bevacizumab (Avastin)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• [Cetuximab].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• [Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• Camptothecin: therapeutic potential and biotechnology.

  Current pharmaceutical biotechnology 20070801

• [Effects of mitofusin-2 gene on proliferation and chemosensitivity of human breast carcinoma cell line MCF-7].

  Ai zheng = Aizheng = Chinese journal of cancer 20070801

• [Effects of hydroxycamptothecin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823].

  Ai zheng = Aizheng = Chinese journal of cancer 20070801

• [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20070801

• The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

  Molecular cancer therapeutics 20070801

• Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.

  International journal of clinical oncology 20070801

• Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor.

  Journal of pediatric surgery 20070801

• [Proteomic analysis of mitochondrial proteins in hydroxycamptothecin-treated SMMC-7721 cells].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20070801

• Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.

  American journal of clinical oncology 20070801

• Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.

  American journal of clinical oncology 20070801

• Optimizing combination chemotherapy by controlling drug ratios.

  Molecular interventions 20070801

• [Chemotherapy in lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070801

• Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20070801

• Targeted therapy in rectal cancer.

  Oncology (Williston Park, N.Y.) 20070801

• The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

  Current genomics 20070801

• Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from Poncirus trifoliata (L.) Raf.

  Bioorganic & medicinal chemistry 20070715

• TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070715

• Human polynucleotide kinase participates in repair of DNA double-strand breaks by nonhomologous end joining but not homologous recombination.

  Cancer research 20070715

• Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?

  Lancet (London, England) 20070714

• Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

  Lancet (London, England) 20070714

• Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

  Lancet (London, England) 20070714

• Antitumour drugs impede DNA uncoiling by topoisomerase I.

  Nature 20070712

• Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.

  Cancer letters 20070708

• Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress.

  Biochemistry 20070703

• Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20070701

• A generalised age- and phase-structured model of human tumour cell populations both unperturbed and exposed to a range of cancer therapies.

  Bulletin of mathematical biology 20070701

• Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma.

  Cell death and differentiation 20070701

• Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors.

  Bioorganic & medicinal chemistry letters 20070701

• Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

  Cancer 20070701

• Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20070701

• Anti-proliferative and antioxidant activities of Saposhnikovia divaricata.

  Oncology reports 20070701

• Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

  Pharmacogenetics and genomics 20070701

• Cigarette smoking and the personalization of irinotecan therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070701

• Anticancer carrier-linked prodrugs in clinical trials.

  Expert opinion on investigational drugs 20070701

• Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.

  Journal of neurochemistry 20070701

• Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.

  Journal of pharmacological sciences 20070701

• [Surgery and chemotherapy for colorectal cancer: current status and perspective].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070701

• Radiotherapy for localized rectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• [Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• [Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• [Complete remission of hepatic metastasis of gastric cancer with CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070701

• Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.

  Japanese journal of clinical oncology 20070701

• Capecitabine and irinotecan in advanced gastric cancer.

  The Lancet. Oncology 20070701

• Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.

  Clinical colorectal cancer 20070701

• Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.

  Japanese journal of clinical oncology 20070701

• Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

  Anti-cancer drugs 20070701

• [Are antiangiogenic antibodies universal for solid tumor?].

  Bulletin du cancer 20070701

• Hydroxycamptothecin deactivation rates and binding to model membranes and HSA determined by fluorescence spectra analysis.

  Combinatorial chemistry & high throughput screening 20070701

• Determination of hydroxycamptothecin affinities to albumin and membranes by steady-state fluorescence anisotropy measurements.

  Combinatorial chemistry & high throughput screening 20070701

• C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

  Biochemical pharmacology 20070630

• UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070620

• Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.

  Bioorganic & medicinal chemistry 20070615

• NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia.

  Oncogene 20070614

• Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes.

  International journal of pharmaceutics 20070607

• [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].

  Zhonghua yi xue za zhi 20070605

• 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice.

  Journal of controlled release : official journal of the Controlled Release Society 20070604

• Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.

  Cancer chemotherapy and pharmacology 20070601

• Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.

  Cancer chemotherapy and pharmacology 20070601

• A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.

  Investigational new drugs 20070601

• Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.

  Investigational new drugs 20070601

• Development of a mechanistically-based genetically engineered PC12 cell system to detect p53-mediated cytotoxicity.

  Toxicology in vitro : an international journal published in association with BIBRA 20070601

• The novel gene mus7(+) is involved in the repair of replication-associated DNA damage in fission yeast.

  DNA repair 20070601

• A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance.

  Cell death and differentiation 20070601

• Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.

  Annals of surgical oncology 20070601

• Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling.

  Mutation research 20070601

• Chemotherapy of advanced gastric cancer.

  Cancer treatment reviews 20070601

• A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20070601

• Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20070601

• Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.

  Anti-cancer drugs 20070601

• Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.

  Anti-cancer drugs 20070601

• DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation.

  Cancer science 20070601

• Comparison of three methods for genotyping the UGT1A1 (TA)n repeat polymorphism.

  Clinical biochemistry 20070601

• The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT-11 in human bronchogenic carcinoma cell lines.

  International journal of oncology 20070601

• Timing of apoptosis onset depends on cell cycle progression in peripheral blood lymphocytes and lymphocytic leukemia cells.

  Oncology reports 20070601

• UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers.

  Basic & clinical pharmacology & toxicology 20070601

• Insights, challenges, and future directions in irinogenetics.

  Therapeutic drug monitoring 20070601

• Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting.

  Cancer biology & therapy 20070601

• Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070601

• Curcumin in cell death processes: a challenge for CAM of age-related pathologies.

  Evidence-based complementary and alternative medicine : eCAM 20070601

• Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.

  American journal of clinical oncology 20070601

• Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of Alvaradoa haitiensis.

  Journal of natural products 20070601

• [Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• [Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• [A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• [Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070601

• Role of repeated hepatectomy in the multimodal treatment of hepatic colorectal metastases.

  Archives of surgery (Chicago, Ill. : 1960) 20070601

• Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.

  Journal of chemotherapy (Florence, Italy) 20070601

• UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

  Current opinion in molecular therapeutics 20070601

• Controlled release camptothecin tablets based on pluronic and poly(acrylic acid) copolymer. Effect of fabrication technique on drug stability, tablet structure, and release mode.

  Drug development and industrial pharmacy 20070601

• Chemotherapy-induced mucositis: focusing on diarrhea.

  The journal of supportive oncology 20070601

• In vitro simulation study of individualized chemotherapy in lung cancer.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20070601

• Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.

  The Israel Medical Association journal : IMAJ 20070601

• Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.

  Fukuoka igaku zasshi = Hukuoka acta medica 20070601

• Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.

  Acta chirurgica Belgica 20070601

• Role of flexibility and long range communication on the function of human topoisomerase I.

  The Italian journal of biochemistry 20070601

• Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.

  Journal of experimental & clinical cancer research : CR 20070601

• WTH3 is a direct target of the p53 protein.

  British journal of cancer 20070521

• A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.

  British journal of cancer 20070521

• Synthesis, DNA binding, and Leishmania topoisomerase inhibition activities of a novel series of anthra[1,2-d]imidazole-6,11-dione derivatives.

  Journal of medicinal chemistry 20070517

• Antitumor agents. 256. Conjugation of paclitaxel with other antitumor agents: evaluation of novel conjugates as cytotoxic agents.

  Bioorganic & medicinal chemistry letters 20070515

• The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma.

  Cancer 20070515

• Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.

  Cancer research 20070515

• Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505.

  The Journal of biological chemistry 20070511

• Highly efficient and mild cascade reactions triggered by bis(triphenyl)oxodiphosphonium trifluoromethanesulfonate and a concise total synthesis of camptothecin.

  Organic letters 20070510

• A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.

  British journal of cancer 20070507

• Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

  Journal of medicinal chemistry 20070503

• A Fhit-ing role in the DNA damage checkpoint response.

  Cell cycle (Georgetown, Tex.) 20070502

• Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.

  International journal of colorectal disease 20070501

• Thrombotic microangiopathy and anti-VEGF agents.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070501

• Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.

  Annals of surgical oncology 20070501

• Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.

  Biochemical pharmacology 20070501

• Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070501

• Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer.

  Cancer 20070501

• CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

  Virchows Archiv : an international journal of pathology 20070501

• Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.

  Oncology reports 20070501

• Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20070501

• Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.

  Oncology reports 20070501

• Cells lacking DNA topoisomerase II beta are resistant to genistein.

  Journal of natural products 20070501

• Analysis of nucleolar protein dynamics reveals the nuclear degradation of ribosomal proteins.

  Current biology : CB 20070501

• Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

  Gastroenterology 20070501

• Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.

  Leukemia & lymphoma 20070501

• [Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• [A case of ascending colon cancer with enlarged metastatic lymph nodes around superior mesenteric arterial root that responded dramatically to S-1 and CPT-11 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• [Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070501

• Integration of novel agents into combined-modality treatment for rectal cancer patients.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20070501

• Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials.

  Molecular cancer therapeutics 20070501

• Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.

  Molecular cancer therapeutics 20070501

• Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.

  Human gene therapy 20070501

• p53 activation by knockdown technologies.

  PLoS genetics 20070501

• Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.

  Japanese journal of clinical oncology 20070501

• Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.

  Human cell 20070501

• Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

  Clinical colorectal cancer 20070501

• Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.

  Japanese journal of clinical oncology 20070501

• Anti-tumor and anti-invasive effects of diverse delta-alkyllactones: dependence on molecular side-chain length, action period and intracellular uptake.

  Life sciences 20070424

• Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways.

  The Journal of biological chemistry 20070420

• Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells.

  FEBS letters 20070417

• [Diagnosis of and therapy for pancreatic neoplasms].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070410

• WRN counteracts the NHEJ pathway upon camptothecin exposure.

  Biochemical and biophysical research communications 20070406

• Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.

  Journal of medicinal chemistry 20070405

• Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.

  Pediatric blood & cancer 20070401

• Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.

  Cancer chemotherapy and pharmacology 20070401

• Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.

  Journal of neuro-oncology 20070401

• Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070401

• Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil.

  Lung cancer (Amsterdam, Netherlands) 20070401

• Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives.

  Colloids and surfaces. B, Biointerfaces 20070401

• Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070401

• RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair.

  Molecular and cellular biology 20070401

• St. John's wort and irinotecan-induced diarrhea.

  Toxicology and applied pharmacology 20070401

• Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties.

  Bioorganic & medicinal chemistry 20070401

• Cooperative roles of vertebrate Fbh1 and Blm DNA helicases in avoidance of crossovers during recombination initiated by replication fork collapse.

  Molecular and cellular biology 20070401

• Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.

  Bioorganic & medicinal chemistry 20070401

• Topoisomerase inhibition accelerates gene expression after adeno-associated virus-mediated gene transfer to the mammalian heart.

  Molecular therapy : the journal of the American Society of Gene Therapy 20070401

• Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.

  Cancer 20070401

• Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.

  European journal of cancer (Oxford, England : 1990) 20070401

• The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I.

  Biochimie 20070401

• Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data.

  Anti-cancer drugs 20070401

• Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

  Pharmacogenomics 20070401

• A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.

  Onkologie 20070401

• Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).

  The journal of gene medicine 20070401

• Cetuximab plus irinotecan in refractory colorectal cancer patients.

  Expert review of anticancer therapy 20070401

• S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.

  Molecular cancer therapeutics 20070401

• [Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [Outpatient chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• [A case of effective regimen of tegafur and uracil (UFT)/leucovorin (LV) plus irinotecan (CPT-11) for advanced rectal carcinoma with severe pelvic infiltration to be performed curative resection].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070401

• Adjuvant treatment of colon cancer: past, present and future.

  Journal of chemotherapy (Florence, Italy) 20070401

• Adjuvant therapy for stage II and III colorectal cancer.

  Seminars in oncology 20070401

• Developing strategies for liver metastases from colorectal cancer.

  Seminars in oncology 20070401

• Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.

  Scandinavian journal of gastroenterology 20070401

• Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.

  Cancer biology & therapy 20070401

• Size matters. What can we learn from a small randomized trial?

  Onkologie 20070401

• A case of small cell carcinoma of the kidney.

  Hinyokika kiyo. Acta urologica Japonica 20070401

• Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.

  Oncology (Williston Park, N.Y.) 20070401

• [Lethal effect of adenovirus-mediated HSV-TK gene in combination with hydroxycamptothecin on human bladder cancer in vitro].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070401

• [Preparation and characterization of 7-ethyl-10-hydroxycamptothecin-loaded hypomicron of amphiphilic block copolymer].

  Yao xue xue bao = Acta pharmaceutica Sinica 20070401

• Irinotecan toxicity.

  Current opinion in supportive and palliative care 20070401

• Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.

  The Journal of biological chemistry 20070330

• A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.

  British journal of cancer 20070326

• Apoptosis assays with lymphoma cell lines: problems and pitfalls.

  British journal of cancer 20070326

• Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.

  Journal of molecular biology 20070316

• Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assays.

  Analytical biochemistry 20070315

• Seizure suppression by top1 mutations in Drosophila.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070314

• Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.

  Journal of pharmaceutical and biomedical analysis 20070312

• Chl1 and Ctf4 are required for damage-induced recombinations.

  Biochemical and biophysical research communications 20070302

• Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20070301

• A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer.

  Cancer chemotherapy and pharmacology 20070301

• Autophagy delays apoptotic death in breast cancer cells following DNA damage.

  Cell death and differentiation 20070301

• Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20070301

• Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.

  Journal of molecular modeling 20070301

• Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20070301

• Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair.

  DNA repair 20070301

• Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.

  Biochemical pharmacology 20070301

• Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

  Biochimica et biophysica acta 20070301

• Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.

  Cancer science 20070301

• WRN exonuclease activity is blocked by DNA termini harboring 3' obstructive groups.

  Mechanisms of ageing and development 20070301

• Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.

  Diseases of the colon and rectum 20070301

• Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.

  European journal of medicinal chemistry 20070301

• Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

  Anti-cancer drugs 20070301

• Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector.

  Anti-cancer drugs 20070301

• Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.

  Oncology reports 20070301

• Synthesis of alginic acid-poly[2-(diethylamino)ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system.

  Biomacromolecules 20070301

• The activity of caspases in spontaneous and camptothecin-induced death of melanotic and amelanotic melanoma cell.

  Cancer biology & therapy 20070301

• A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• [Lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• [Chemotherapy for elderly patients with colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• [A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070301

• Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.

  Journal of neurosurgery 20070301

• Inhibition of DNA topoisomerase I by natural and synthetic mono- and dimeric protoberberine alkaloids.

  Chemistry & biodiversity 20070301

• Correction of proliferation and drug sensitivity defects in the progeroid Werner's Syndrome by Holliday junction resolution.

  Rejuvenation research 20070301

• Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

  The oncologist 20070301

• Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070301

• Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20070301

• Validation of rapid polymerase chain reaction-based detection of all length polymorphisms in the UGT 1A1 gene promoter.

  Diagnostic molecular pathology : the American journal of surgical pathology, part B 20070301

• Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20070301

• Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.

  Clinical colorectal cancer 20070301

• [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070301

• A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.

  British journal of cancer 20070226

• Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.

  British journal of cancer 20070226

• Monoubiquitylation promotes mitochondrial p53 translocation.

  The EMBO journal 20070221

• The thermodynamic dissociation constants of the anticancer drugs camptothecine, 7-ethyl-10-hydroxycamptothecine, 10-hydroxycamptothecine and 7-ethylcamptothecine by the least-squares nonlinear regression of multiwavelength spectrophotometric pH-titration data.

  Analytica chimica acta 20070219

• Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones.

  Bioorganic & medicinal chemistry 20070215

• Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• Biodistribution and pharmacokinetics of colon-specific HPMA copolymer--9-aminocamptothecin conjugate in mice.

  Journal of controlled release : official journal of the Controlled Release Society 20070212

• Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.

  British journal of cancer 20070212

• Use of interfering RNA to investigate the role of endogenous gastrin in the survival of gastrointestinal cancer cells.

  British journal of cancer 20070212

• [Standard chemotherapy for colonic neoplasms].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070210

• A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.

  Cancer letters 20070208

• Morphology control of polylactide microspheres enclosing irinotecan hydrochloride with polylactide based polymer surfactant for reduction of initial burst.

  International journal of pharmaceutics 20070207

• Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle.

  Mutation research 20070203

• Rtt109 acetylates histone H3 lysine 56 and functions in DNA replication.

  Science (New York, N.Y.) 20070202

• Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.

  Pediatric blood & cancer 20070201

• Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.

  Cancer chemotherapy and pharmacology 20070201

• A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.

  Cancer chemotherapy and pharmacology 20070201

• Irinotecan changes gene expression in the small intestine of the rat with breast cancer.

  Cancer chemotherapy and pharmacology 20070201

• Comparison of antitumor activities in tumor xenograft treatment.

  Contemporary clinical trials 20070201

• Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

  Investigational new drugs 20070201

• Reproductive toxicity evaluation of a new camptothecin anticancer agent, CKD-602, in pregnant/lactating female rats and their offspring.

  Cancer chemotherapy and pharmacology 20070201

• Downregulation of hnRNP C1/C2 by siRNA sensitizes HeLa cells to various stresses.

  Molecular and cellular biochemistry 20070201

• Leishmania donovani: dyskinetoplastid cells survive and proliferate in the presence of pyruvate and uridine but do not undergo apoptosis after treatment with camptothecin.

  Experimental parasitology 20070201

• Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070201

• Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.

  International journal of cancer 20070201

• Effects of green tea compounds on irinotecan metabolism.

  Drug metabolism and disposition: the biological fate of chemicals 20070201

• Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa.

  Bioorganic & medicinal chemistry 20070201

• Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.

  Anti-cancer drugs 20070201

• Role of p53 in irinotecan-induced intestinal cell death and mucosal damage.

  Anti-cancer drugs 20070201

• Prolidase-independent mechanism of camptothecin-induced inhibition of collagen biosynthesis in cultured human skin fibroblasts.

  Journal of biochemistry 20070201

• Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas.

  Journal of neurochemistry 20070201

• Automated laser scanning cytometry: a powerful tool for multi-parameter analysis of drug-induced apoptosis.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20070201

• 3D-QSAR study of 20 (S)-camptothecin analogs.

  Acta pharmacologica Sinica 20070201

• Topotecan in the management of cervical cancer.

  Expert opinion on pharmacotherapy 20070201

• EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway.

  Prostaglandins & other lipid mediators 20070201

• Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070201

• Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070201

• Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.

  Onkologie 20070201

• [Basic strategies on first- and second-line chemotherapy for advanced gastric cancers].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070201

• [Up to date chemotherapy for colon cancer].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070201

• [Clinical development of chemotherapy for advanced gastric cancer].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20070201

• Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070201

• Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.

  Cancer science 20070201

• [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.

  Current drug metabolism 20070201

• Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function.

  Molecular cancer research : MCR 20070201

• [Small cell carcinoma of the urinary bladder treated with neo-adjuvant cp chemotherapy (CPT-11 and CDDP): a case report].

  Hinyokika kiyo. Acta urologica Japonica 20070201

• Characteristics of the microbial community in rhizosphere of Camptotheca acuminata cultured with exotic invasive plant Eupatorium adenophorum.

  Science in China. Series C, Life sciences 20070201

• [Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070201

• Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.

  British journal of cancer 20070129

• Resolution of Holliday junction substrates by human topoisomerase I.

  Journal of molecular biology 20070126

• Impaired kinetics of Bax-GFP and Smac/DIABLO-GFP in caspase-8- and bid-silenced and Bcl-2 overexpressed breast cancer MCF-7 cells exposed to camptothecin.

  Cellular and molecular biology (Noisy-le-Grand, France) 20070121

• Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site.

  Journal of molecular biology 20070119

• Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid state.

  Journal of pharmaceutical and biomedical analysis 20070117

• Inducible functional expression of Bcl-2 in human astrocytes derived from NTera-2 cells.

  Journal of neuroscience methods 20070115

• Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.

  British journal of cancer 20070115

• Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.

  British journal of cancer 20070115

• A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.

  Cancer chemotherapy and pharmacology 20070101

• Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.

  Cancer chemotherapy and pharmacology 20070101

• DNA damage-inducing agent-elicited gamma-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades.

  Cell death and differentiation 20070101

• Leishmania promastigotes activate PI3K/Akt signalling to confer host cell resistance to apoptosis.

  Cellular microbiology 20070101

• Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.

  The Journal of pharmacology and experimental therapeutics 20070101

• A theoretical study of some new analogues of the anti-cancer drug camptothecin.

  Journal of molecular modeling 20070101

• Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20070101

• Synthesis of 6-chloroisoquinoline-5,8-diones and pyrido[3,4-b]phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity.

  Bioorganic & medicinal chemistry 20070101

• Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.

  European journal of cancer (Oxford, England : 1990) 20070101

• Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.

  Cancer science 20070101

• Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.

  Journal of surgical oncology 20070101

• Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

  European journal of cancer (Oxford, England : 1990) 20070101

• Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin.

  Neuro-oncology 20070101

• Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria.

  Apoptosis : an international journal on programmed cell death 20070101

• Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

  Cancer 20070101

• Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

  Clinical pharmacology and therapeutics 20070101

• The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

  Journal of clinical pharmacology 20070101

• Corneal activation of prothrombin to form thrombin, independent of vascular injury.

  Investigative ophthalmology & visual science 20070101

• Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.

  Experimental biology and medicine (Maywood, N.J.) 20070101

• Mitochondrial transmembrane potential in spontaneous and camptothecin-induced apoptosis of melanotic and amelanotic melanoma cells.

  Neoplasma 20070101

• Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.

  Cancer research 20070101

• [Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [A case of stage IV gastric cancer treated sequentially for over two years by TS-1, paclitaxel, and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• [CR of rectal cancer and synchronous liver and lung metastases obtained with TS-1 plus CPT-11 combination therapy--case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Leishmania donovani bisubunit topoisomerase I gene fusion leads to an active enzyme with conserved type IB enzyme function.

  The FEBS journal 20070101

• Soluble camptothecin derivatives prepared by click cycloaddition chemistry on functional aliphatic polyesters.

  Bioconjugate chemistry 20070101

• Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression.

  Molecular cancer 20070101

• Reduction of gene repair by selenomethionine with the use of single-stranded oligonucleotides.

  BMC molecular biology 20070101

• A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents.

  Molecular cancer research : MCR 20070101

• Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.

  Pharmacogenetics and genomics 20070101

• Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance.

  Molecular cancer 20070101

• Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.

  Clinical colorectal cancer 20070101

• Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors.

  Planta medica 20070101

• Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity.

  Anticancer research 20070101

• Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features.

  Anticancer research 20070101

• Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.

  Chemotherapy 20070101

• Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.

  Bioconjugate chemistry 20070101

• Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.

  Digestive diseases (Basel, Switzerland) 20070101

• [A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity].

  Medicina 20070101

• Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070101

• siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs.

  Clinical and experimental pharmacology & physiology 20070101

• The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer.

  Anticancer research 20070101

• CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression.

  Anticancer research 20070101

• Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.

  Anticancer research 20070101

• Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.

  Anticancer research 20070101

• Bevacizumab in the treatment of colorectal cancer.

  Clinical advances in hematology & oncology : H&O 20070101

• Panitumumab in metastatic colorectal cancer.

  Clinical advances in hematology & oncology : H&O 20070101

• Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.

  Chemotherapy 20070101

• Enhanced nuclear delivery and cytotoxic activity of hydroxycamptothecin using o/w emulsions.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20070101

• Adjuvant treatment of colorectal cancer.

  CA: a cancer journal for clinicians 20070101

• Antitumor effects of hydroxycamptothecin-loaded poly[ethylene glycol]-poly [gamma-benzyl-L-glutamate] micelles against oral squamous cell carcinoma.

  Oncology research 20070101

• Development and clinical indications of cetuximab.

  The International journal of biological markers 20070101

• Cetuximab in colon cancer.

  The International journal of biological markers 20070101

• A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.

  Cancer investigation 20070101

• Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors.

  Journal of experimental therapeutics & oncology 20070101

• Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.

  Acta oncologica (Stockholm, Sweden) 20070101

• Differential expression and role of p21cip/waf1 and p27kip1 in TNF-alpha-induced inhibition of proliferation in human glioma cells.

  Molecular cancer 20070101

• [Irinotecan and liver dysfunctions].

  Therapie 20070101

• Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer.

  Anticancer research 20070101

• Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070101

• Improved cyclodextrin-based receptors for camptothecin by inverse virtual screening.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20070101

• Molecular biology of cantharidin in cancer cells.

  Chinese medicine 20070101

• HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.

  Cancer treatment and research 20070101

• Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

  Cancer treatment and research 20070101

• Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival.

  Retrovirology 20070101

• Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug.

  Angewandte Chemie (International ed. in English) 20070101

• p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion.

  PloS one 20070101

• Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.

  PloS one 20070101

• Tumor-targeted induction of oxystress for cancer therapy.

  Journal of drug targeting 20070101

• A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.

  Tumori 20070101

• Targeted proapoptotic anticancer drug delivery system.

  Molecular pharmaceutics 20070101

• Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine.

  Current medicinal chemistry 20070101

• Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.

  Anticancer research 20070101

• Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer.

  Anticancer research 20070101

• Complete remission of ovarian small cell carcinoma treated with irinotecan and cisplatin: a case report.

  Anticancer research 20070101

• Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix.

  Anticancer research 20070101

• A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer.

  Anticancer research 20070101

• Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.

  Anticancer research 20070101

• Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases.

  Anticancer research 20070101

• STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.

  Anticancer research 20070101

• Irinotecan and S-1 neoadjuvant chemoradiation therapy in patients with advanced rectal cancer.

  Hepato-gastroenterology 20070101

• Transbilayer phospholipid movements in ABCA1-deficient cells.

  PloS one 20070101

• Establishment of a single-dose irinotecan model of gastrointestinal mucositis.

  Chemotherapy 20070101

• Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro.

  Acta biochimica Polonica 20070101

• Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20070101

• Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.

  Cancer journal (Sudbury, Mass.) 20070101

• Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.

  ONS connect 20070101

• A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.

  Medical oncology (Northwood, London, England) 20070101

• Bench-to-bedside review: High-mobility group box 1 and critical illness.

  Critical care (London, England) 20070101

• Transport of camptothecin in hairy roots of Ophiorrhiza pumila.

  Phytochemistry 20070101

• Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.

  Oncology research 20070101

• Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library.

  Bioconjugate chemistry 20070101

• Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20070101

• Conjugation to increase treatment volume during local therapy: a case study with PEGylated camptothecin.

  Bioconjugate chemistry 20070101

• Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer.

  Indian journal of cancer 20070101

• Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors.

  Journal of biomaterials science. Polymer edition 20070101

• Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.

  Chemotherapy 20070101

• [Angiogenesis targeting in gastro-intestinal cancers].

  Bulletin du cancer 20070101

• [Drug therapy for inoperable gastric cancer: current possibilities and perspectives of development].

  Voprosy onkologii 20070101

• A novel camptothecin analog with enhanced antitumor activity.

  Anticancer research 20070101

• Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth.

  PloS one 20070101

• The 'new' chemosystematics: phylogeny and phytochemistry.

  Phytochemistry 20070101

• BRCA1: a novel prognostic factor in resected non-small-cell lung cancer.

  PloS one 20070101

• Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma.

  Oncology 20070101

• Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.

  Oncology 20070101

• Deletion study of DNA topoisomerase IB from Leishmania donovani: searching for a minimal functional heterodimer.

  PloS one 20070101

• On the ease of predicting the thermodynamic properties of beta-cyclodextrin inclusion complexes.

  Chemistry Central journal 20070101

• Determination of hydroxycamptothecinum by flow injection analysis with chemiluminescence detection.

  Journal of clinical laboratory analysis 20070101

• Development of novel oxygen-independent photosensitizers.

  Nucleic acids symposium series (2004) 20070101

• Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.

  International surgery 20070101

• Impact of light on Hypocrea jecorina and the multiple cellular roles of ENVOY in this process.

  BMC genomics 20070101

• Human RECQ1 is a DNA damage responsive protein required for genotoxic stress resistance and suppression of sister chromatid exchanges.

  PloS one 20070101

• Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling.

  PloS one 20070101

• Aluminium blunts the proliferative response and increases apoptosis of cultured human cells: putative relationship to Alzheimer's disease.

  Bioinformation 20070101

• Decrease in CD93 (C1qRp) expression in a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances.

  Microbiology and immunology 20070101

• The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20070101

• Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway.

  PloS one 20070101

• Effects of mutations in SGS1 and in genes functionally related to SGS1 on inverted repeat-stimulated spontaneous unequal sister-chromatid exchange in yeast.

  BMC molecular biology 20070101

• Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.

  Oncology 20070101

• Breast tumour angiogenesis.

  Breast cancer research : BCR 20070101

• Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study.

  In vivo (Athens, Greece) 20070101

• Long-term survivors after chemotherapy in advanced non-small cell lung cancer.

  Anticancer research 20070101

• A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.

  Oncology 20070101

• Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).

  Oncology 20070101

• Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.

  Oncology 20070101

• [The choice of treatment in advanced gastric cancer].

  Tumori 20070101

• Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.

  Acta clinica Belgica 20070101

• [Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer].

  Voprosy onkologii 20070101

• Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.

  Oncology 20070101

• [Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs].

  Medicina 20070101

• XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.

  Oncology 20070101

• ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.

  Drug metabolism letters 20070101

• Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design.

  Drug target insights 20070101

• A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.

  British journal of cancer 20061218

• Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.

  British journal of cancer 20061218

• Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

  International journal of cancer 20061215

• Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro.

  Cancer research 20061215

• Endonuclease G promotes cell death of non-invasive human breast cancer cells.

  Experimental cell research 20061210

• Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes.

  DNA repair 20061209

• KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.

  Biochemical and biophysical research communications 20061208

• Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061201

• The extracellular release of HMGB1 during apoptotic cell death.

  American journal of physiology. Cell physiology 20061201

• Novel colon-specific microspheres with highly dispersed hydroxycamptothecin cores: their preparation, release behavior, and therapeutic efficiency against colonic cancer.

  Journal of pharmaceutical sciences 20061201

• Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.

  Bioorganic & medicinal chemistry letters 20061201

• Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.

  International journal of radiation oncology, biology, physics 20061201

• Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination.

  Mutation research 20061201

• Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061201

• A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061201

• Contribution of growth and cell cycle checkpoints to radiation survival in Drosophila.

  Genetics 20061201

• Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation.

  Pharmaceutical research 20061201

• A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

  Cancer 20061201

• Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.

  Oncology reports 20061201

• Chiral capillary electrophoretic determination of the enantiomeric purity of homocamptothecin derivatives, promising antitumor topoisomerase I inhibitors, using highly sulfated CDs and fluorescence detection.

  Electrophoresis 20061201

• Adding pharmacogenetics information to drug labels: lessons learned.

  Pharmacogenetics and genomics 20061201

• Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells.

  Cancer research 20061201

• Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.

  The American journal of pathology 20061201

• [Thymic basaloid carcinoma].

  Kyobu geka. The Japanese journal of thoracic surgery 20061201

• Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.

  Pharmacogenomics 20061201

• [Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).

  Onkologie 20061201

• Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.

  Journal of gastroenterology 20061201

• Activation of nuclear factor kappa B by different agents: influence of culture conditions in a cell-based assay.

  Annals of the New York Academy of Sciences 20061201

• Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis.

  Annals of the New York Academy of Sciences 20061201

• [Outpatient chemotherapy of an advanced or metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [Present status of home therapy cancer patients using an infusor].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [Our outpatient cases for home anti-cancer chemotherapy using a CV port and a portable pump system].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [A case report of a patient with advanced rectal cancer who was administered chemotherapy in collaboration with a clinical pathway and visiting nursing care].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• [Outpatient chemotherapy in gynecologic oncology].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061201

• Enrichment of non-synchronized cells in the G1, S and G2 phases of the cell cycle for the study of apoptosis.

  Biochemical pharmacology 20061130

• Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment.

  Oncogene 20061130

• Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases.

  Journal of controlled release : official journal of the Controlled Release Society 20061128

• In vitro anti-proliferative and antioxidant studies on Devil's Club Oplopanax horridus.

  Journal of ethnopharmacology 20061124

• A bacterial protein enhances the release and efficacy of liposomal cancer drugs.

  Science (New York, N.Y.) 20061124

• Validation of an HPLC method for analysis of DB-67 and its water soluble prodrug in mouse plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061121

• Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120

• Phosphorylation status of the Kep1 protein alters its affinity for its protein binding partner alternative splicing factor ASF/SF2.

  The Biochemical journal 20061115

• Molecular determinants of irinotecan efficacy.

  International journal of cancer 20061115

• Pharmacogenetics and irinotecan therapy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061115

• Searching for the Holy Grail of oncology.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061115

• Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.

  Cancer research 20061115

• Induction of transcriptionally active Jun proteins regulates drug-induced senescence.

  The Journal of biological chemistry 20061110

• Fractionated administration of irinotecan and cisplatin in Japanese patients with extensive-stage-disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061110

• A novel Rad18 function involved in protection of the vertebrate genome after exposure to camptothecin.

  DNA repair 20061108

• Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.

  Chinese medical journal 20061105

• BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20061101

• Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

  Cancer chemotherapy and pharmacology 20061101

• Incorporation of camptothecin into N-phthaloyl chitosan-g-mPEG self-assembly micellar system.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20061101

• Synthesis and antitumor activity of novel 10-substituted camptothecin analogues.

  Bioorganic & medicinal chemistry 20061101

• Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20061101

• Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin.

  Pharmacological research 20061101

• Irinotecan in the treatment of colorectal cancer.

  Cancer treatment reviews 20061101

• Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

  Cancer science 20061101

• Real-time imaging and quantification of brain delivery of liposomes.

  Pharmaceutical research 20061101

• Irinotecan cytotoxicity does not necessarily depend on the UGT1A1 polymorphism but on fluoropyrimidine: a molecular case report.

  Oncology reports 20061101

• Topoisomerases of kinetoplastid parasites: why so fascinating?

  Molecular microbiology 20061101

• Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate.

  Anti-cancer drugs 20061101

• Functional relationships between Rad18 and WRNIP1 in vertebrate cells.

  Biological & pharmaceutical bulletin 20061101

• The role of DNA double-strand breaks in spontaneous homologous recombination in S. cerevisiae.

  PLoS genetics 20061101

• Exatecan and gemcitabine: no better than gemcitabine only.

  The Lancet. Oncology 20061101

• [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [What happened during these 12 years since CPT-11 was launched in Japan ?].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo.

  PLoS genetics 20061101

• Pharmacogenetic approach for cancer treatment-tailored medicine in practice.

  Annals of the New York Academy of Sciences 20061101

• 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20061101

• [Evaluation of bronchial arterial infusion (BAI) for lung cancer with brain metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• [A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061101

• Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20061101

• A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.

  World journal of gastroenterology 20061028

• Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.

  World journal of gastroenterology 20061028

• Novel, efficient total synthesis of natural 20(S)-camptothecin.

  Organic & biomolecular chemistry 20061021

• Amphiphilic poly(D,L-lactic acid)/poly(ethylene glycol)/poly(D,L-lactic acid) nanogels for controlled release of hydrophobic drugs.

  Macromolecular bioscience 20061020

• Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• Cortisol can be pro- or anti-apoptotic in sea bream cells: potential role of HSP70 induction for cytoprotection.

  Molecular and cellular endocrinology 20061019

• A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance.

  Proceedings of the National Academy of Sciences of the United States of America 20061017

• Synthesis and activity of a folate peptide camptothecin prodrug.

  Bioorganic & medicinal chemistry letters 20061015

• St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.

  Toxicology and applied pharmacology 20061015

• Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.

  Cancer research 20061015

• Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.

  The Journal of biological chemistry 20061013

• Human topoisomerase I forms double cleavage complexes on natural DNA.

  Biochemical and biophysical research communications 20061013

• CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage.

  Science (New York, N.Y.) 20061013

• Maoecrystal Z, a cytotoxic diterpene from Isodon eriocalyx with a unique skeleton.

  Organic letters 20061012

• Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines.

  British journal of cancer 20061009

• Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.

  Cancer chemotherapy and pharmacology 20061001

• The tumor specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam.

  Cancer chemotherapy and pharmacology 20061001

• Characterization of the activities of p21Cip1/Waf1 promoter-driven reporter systems during camptothecin-induced senescence-like state of BHK-21 cells.

  Molecular and cellular biochemistry 20061001

• Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.

  Endocrinology 20061001

• A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.

  The Journal of pharmacology and experimental therapeutics 20061001

• Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20061001

• Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20061001

• Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement by Bartlett et al.

  Annals of surgical oncology 20061001

• Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.

  Annals of surgical oncology 20061001

• Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.

  Cancer 20061001

• The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells.

  Biochimica et biophysica acta 20061001

• Topoisomerase I inhibitors: camptothecins and beyond.

  Nature reviews. Cancer 20061001

• Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061001

• Effect of S-1 on pharmacokinetics of irinotecan in a patient with colorectal cancer.

  Clinical pharmacology and therapeutics 20061001

• Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

  Cancer research 20061001

• The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein.

  Cancer research 20061001

• Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.

  American journal of clinical oncology 20061001

• New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.

  Future oncology (London, England) 20061001

• Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

  Archives of neurology 20061001

• Transcriptome analysis of Aspergillus nidulans exposed to camptothecin-induced DNA damage.

  Eukaryotic cell 20061001

• [A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• [Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemotherapy with 5-FU].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20061001

• Bcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin.

  Acta biochimica et biophysica Sinica 20061001

• Development of a screening assay for surrogate markers of CHK1 inhibitor-induced cell cycle release.

  Journal of biomolecular screening 20061001

• Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.

  Neurologia medico-chirurgica 20061001

• Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.

  Oncology (Williston Park, N.Y.) 20061001

• Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.

  Journal of chemotherapy (Florence, Italy) 20061001

• A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.

  Journal of chemotherapy (Florence, Italy) 20061001

• Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.

  Journal of chemotherapy (Florence, Italy) 20061001

• Inhibition of human glutathione transferases by multidrug resistance chemomodulators in vitro.

  Journal of enzyme inhibition and medicinal chemistry 20061001

• [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061001

• [Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061001

• [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061001

• Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061001

• Practical formal total syntheses of the homocamptothecin derivative and anticancer agent diflomotecan via asymmetric acetate aldol additions to pyridine ketone substrates.

  The Journal of organic chemistry 20060929

• Synthesis of the parent and substituted tetracyclic ABCD ring cores of camptothecins via 1-(3-aryl-2-propynyl)- 1,6-dihydro-6-oxo-2-pyridinecarbonitriles.

  Organic letters 20060928

• RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060927

• Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060920

• CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.

  British journal of cancer 20060918

• Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.

  British journal of cancer 20060918

• Synthesis and biological assays of E-ring analogs of camptothecin and homocamptothecin.

  Bioorganic & medicinal chemistry 20060915

• Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910

• Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910

• Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

  British journal of cancer 20060904

• A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

  British journal of cancer 20060904

• Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.

  Cancer chemotherapy and pharmacology 20060901

• Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

  Investigational new drugs 20060901

• Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.

  The Journal of pharmacology and experimental therapeutics 20060901

• Gut myoelectrical activity induces heat shock response in Escherichia coli and Caco-2 cells.

  Experimental physiology 20060901

• In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.

  The Journal of pharmacology and experimental therapeutics 20060901

• Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.

  Journal of pharmaceutical sciences 20060901

• Phorbol 12-myristate 13-acetate protects against tumor necrosis factor (TNF)-induced necrotic cell death by modulating the recruitment of TNF receptor 1-associated death domain and receptor-interacting protein into the TNF receptor 1 signaling complex: Implication for the regulatory role of protein kinase C.

  Molecular pharmacology 20060901

• Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.

  Molecular pharmacology 20060901

• Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.

  Cancer science 20060901

• A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.

  International journal of radiation oncology, biology, physics 20060901

• Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060901

• Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.

  Oncology reports 20060901

• Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.

  Oncology reports 20060901

• Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.

  Japanese journal of clinical oncology 20060901

• A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060901

• Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.

  Pharmacogenetics and genomics 20060901

• Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells.

  Nature structural & molecular biology 20060901

• A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat.

  Cancer biology & therapy 20060901

• Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.

  Anti-cancer drugs 20060901

• Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060901

• [Pharmacokinetic study of cancer chemotherapy].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20060901

• Linear cyclodextrin-containing polymers and their use as delivery agents.

  Expert opinion on drug delivery 20060901

• Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

  The oncologist 20060901

• [Malignant mesothelioma--diagnosis and treatment strategies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [Hepatic arterial infusion chemotherapy for liver metastases from digestive cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of non-curatively resected colon cancer with liver and lymph node metastases treated by TS-1/CPT-11 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• [A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060901

• Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.

  Cancer biology & therapy 20060901

• Protocol consisting of cisplatin, etoposide and irinotecan induced complete pathological remission of primary small cell carcinoma of the bladder.

  International journal of urology : official journal of the Japanese Urological Association 20060901

• Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.

  Molecular cancer therapeutics 20060901

• Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.

  Clinical colorectal cancer 20060901

• Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

  Clinical colorectal cancer 20060901

• Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.

  Experimental oncology 20060901

• Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.

  Journal of experimental & clinical cancer research : CR 20060901

• [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060901

• Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060901

• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.

  International journal of nanomedicine 20060901

• Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.

  Current clinical pharmacology 20060901

• Synthesis and cytotoxic activity of polyamine analogues of camptothecin.

  Journal of medicinal chemistry 20060824

• The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060823

• Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.

  Bioorganic & medicinal chemistry letters 20060815

• A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy.

  Cancer 20060815

• Copper-topotecan complexation mediates drug accumulation into liposomes.

  Journal of controlled release : official journal of the Controlled Release Society 20060810

• Structural basis for specificity in the poxvirus topoisomerase.

  Molecular cell 20060804

• Synthesis and biological evaluation of 10,11-methylenedioxy-14-azacamptothecin.

  Organic letters 20060803

• Hexosomes formed from glycerate surfactants--formulation as a colloidal carrier for irinotecan.

  International journal of pharmaceutics 20060802

• [Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20060801

• Human primary renal cells as a model for toxicity assessment of chemo-therapeutic drugs.

  Toxicology in vitro : an international journal published in association with BIBRA 20060801

• A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20060801

• Short-chain fatty acid mediated phosphorylation of heat shock protein 25: effects on camptothecin-induced apoptosis.

  American journal of physiology. Gastrointestinal and liver physiology 20060801

• Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20060801

• Predicting the outcome of chemotherapy for colorectal cancer.

  Current opinion in pharmacology 20060801

• Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.

  Lung cancer (Amsterdam, Netherlands) 20060801

• First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060801

• Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Determinants of chemosensitivity in gastric cancer.

  Current opinion in pharmacology 20060801

• Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.

  Current opinion in pharmacology 20060801

• A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060801

• Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats.

  Regulatory toxicology and pharmacology : RTP 20060801

• TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

  Trends in pharmacological sciences 20060801

• Targeting atypical trypanosomatid DNA topoisomerase I.

  Drug discovery today 20060801

• Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.

  Pediatric transplantation 20060801

• A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.

  Cancer research 20060801

• In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060801

• [Lung cancer with bone metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• [Multiple hepatic metastases of colon cancer responding to combined therapy with TS-1 and CPT-11--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060801

• Hydroxycamptothecin-induced apoptosis in hepatoma SMMC-7721 cells and the role of mitochondrial pathway.

  Mitochondrion 20060801

• Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.

  Anti-cancer drugs 20060801

• [Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line].

  Zhongguo shi yan xue ye xue za zhi 20060801

• Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.

  Molecular cancer therapeutics 20060801

• Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

  Molecular cancer therapeutics 20060801

• Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20060801

• [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20060801

• The role of targeted therapy in the treatment of colorectal cancer.

  Clinical advances in hematology & oncology : H&O 20060801

• [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801

• [Application of Camptosar in neoadjuvant chemotherapy for rectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801

• Cellular stress increases RGS2 mRNA and decreases RGS4 mRNA levels in SH-SY5Y cells.

  Neuroscience letters 20060724

• Antitumor quinols: role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets.

  Biochemical and biophysical research communications 20060721

• Turning point for colorectal cancer clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Sensitization of cancer cells to DNA damaging agents by imidazolines.

  Journal of the American Chemical Society 20060719

• Hepatocyte growth factor increases mitochondrial mass in glioblastoma cells.

  Biochemical and biophysical research communications 20060714

• Histone acetyltransferase 1 is dispensable for replication-coupled chromatin assembly but contributes to recover DNA damages created following replication blockage in vertebrate cells.

  Biochemical and biophysical research communications 20060714

• Analyses of the interaction of WRNIP1 with Werner syndrome protein (WRN) in vitro and in the cell.

  DNA repair 20060713

• Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.

  Journal of medicinal chemistry 20060713

• p44/42 MAP kinase and c-Jun N-terminal kinase contribute to the up-regulation of caspase-3 in manganese-induced apoptosis in PC12 cells.

  Brain research 20060712

• Effects of modification of the active site tyrosine of human DNA topoisomerase I.

  Biochemistry 20060711

• Identification of conserved pathways of DNA-damage response and radiation protection by genome-wide RNAi.

  Current biology : CB 20060711

• Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut.

  British journal of cancer 20060703

• Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.

  Cancer chemotherapy and pharmacology 20060701

• Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.

  Investigational new drugs 20060701

• SLURP-2: A novel cholinergic signaling peptide in human mucocutaneous epithelium.

  Journal of cellular physiology 20060701

• The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.

  Drug metabolism and disposition: the biological fate of chemicals 20060701

• A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.

  Molecular pharmacology 20060701

• Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors.

  Molecular pharmacology 20060701

• Salvage chemotherapy with CPT-11 for recurrent meningioma.

  Journal of neuro-oncology 20060701

• Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.

  Lung cancer (Amsterdam, Netherlands) 20060701

• Irinotecan-eluting stents inhibited neointimal proliferation in hypercholesterolemic rabbit aortas.

  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20060701

• Biological agents versus chemotherapy in the treatment of colorectal cancer.

  Expert opinion on pharmacotherapy 20060701

• The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060701

• 4-nitroquinoline-1-oxide induces the formation of cellular topoisomerase I-DNA cleavage complexes.

  Cancer research 20060701

• Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.

  Expert review of molecular diagnostics 20060701

• [Blood supply of pulmonary metastases and its clinical significance].

  Ai zheng = Aizheng = Chinese journal of cancer 20060701

• [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• [24 hour infusion of CPT-11/oral UFT/LV].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• [FOLFIRI regimen for metastatic or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• [IFL].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• [A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060701

• The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.

  British journal of clinical pharmacology 20060701

• [Adjuvant treatment of colorectal cancer].

  Bulletin du cancer 20060701

• Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin.

  Drug development and industrial pharmacy 20060701

• The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

  Molecular cancer therapeutics 20060701

• Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

  Molecular cancer therapeutics 20060701

• [Effects of cu2+ on biosynthesis of camptothecin in cell cultures of Camptotheca acuminata].

  Sheng wu gong cheng xue bao = Chinese journal of biotechnology 20060701

• Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.

  Clinical colorectal cancer 20060701

• [Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701

• Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli.

  The Journal of biological chemistry 20060630

• Analysis of resonance chemotherapy in leukemia treatment via multi-staged population balance models.

  Journal of theoretical biology 20060621

• Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

• Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060615

• Development and validation of a sensitive reversed-phase HPLC method to determine intracellular accumulation of hydroxycamptothecin.

  Journal of pharmaceutical and biomedical analysis 20060607

• Apoptosis regulation in tetraploid cancer cells.

  The EMBO journal 20060607

• Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis.

  Life sciences 20060606

• Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.

  Cancer chemotherapy and pharmacology 20060601

• Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.

  International journal of cancer 20060601

• Novel polymeric prodrug with multivalent components for cancer therapy.

  The Journal of pharmacology and experimental therapeutics 20060601

• Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.

  The European journal of health economics : HEPAC : health economics in prevention and care 20060601

• Expression of drug pathway proteins is independent of tumour type.

  The Journal of pathology 20060601

• Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-kappaB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism.

  Apoptosis : an international journal on programmed cell death 20060601

• Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

  Virchows Archiv : an international journal of pathology 20060601

• Camptothecin-mediated apoptosis and antiproliferation effect is accompanied by down-regulation of telomerase activity in HaCaT cells.

  Journal of dermatological science 20060601

• Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis.

  Leukemia 20060601

• Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Response of human macrophage-like cells to stimulation by Fusobacterium nucleatum ssp. nucleatum lipopolysaccharide.

  Oral microbiology and immunology 20060601

• Synchronization in the cell cycle by inhibitors of DNA replication induces histone H2AX phosphorylation: an indication of DNA damage.

  Cell proliferation 20060601

• Expression of the cochaperone HspBP1 is not coordinately regulated with Hsp70 expression.

  Cell biology international 20060601

• Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.

  Anti-cancer drugs 20060601

• [The interactions of antiepileptic drugs in oncology practice].

  Revista de neurologia 20060601

• Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.

  Cancer research 20060601

• FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.

  Prescrire international 20060601

• [Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [A patient with hepatic, pulmonary, and nodal metastases of colon cancer responding to CPT-11/TS-1 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Collision cancer of squamous cell carcinoma and small cell carcinoma of the lung; report of a case].

  Kyobu geka. The Japanese journal of thoracic surgery 20060601

• Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.

  Molecular cancer therapeutics 20060601

• A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

  Digestive diseases and sciences 20060601

• [S-1 for gastric cancer-S-1 monotherapy and its progress].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [S-1 as a single agent for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• [In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060601

• Recent patents therapeutic agents for cancer.

  Recent patents on anti-cancer drug discovery 20060601

• Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins.

  Journal of controlled release : official journal of the Controlled Release Society 20060530

• Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles.

  Journal of controlled release : official journal of the Controlled Release Society 20060530

• Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan.

  Oncogene 20060525

• Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.

  British journal of cancer 20060522

• Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.

  British journal of cancer 20060522

• Irinogenetics: what is the right star?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines.

  Journal of medicinal chemistry 20060518

• Nur77 forms novel nuclear structures upon DNA damage that cause transcriptional arrest.

  Experimental cell research 20060515

• Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.

  Cancer 20060515

• p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.

  Oncogene 20060511

• A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.

  British journal of cancer 20060508

• A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.

  British journal of cancer 20060508

• Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.

  British journal of cancer 20060508

• Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).

  The Medical letter on drugs and therapeutics 20060508

• HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38.

  Journal of pharmaceutical and biomedical analysis 20060503

• Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.

  Investigational new drugs 20060501

• Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.

  Investigational new drugs 20060501

• Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.

  Cancer chemotherapy and pharmacology 20060501

• Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20060501

• Cadmium inhibits both intrinsic and extrinsic apoptotic pathways in renal mesangial cells.

  American journal of physiology. Renal physiology 20060501

• Analysis of common gene expression patterns in four human tumor cell lines exposed to camptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways.

  Frontiers in bioscience : a journal and virtual library 20060501

• Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.

  Head & neck 20060501

• 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity.

  Bioorganic & medicinal chemistry 20060501

• Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.

  European journal of haematology 20060501

• Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.

  Cancer treatment reviews 20060501

• Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer.

  Oncology reports 20060501

• Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.

  Oncology reports 20060501

• Drug delivery across the blood-brain barrier: why is it difficult? how to measure and improve it?

  Expert opinion on drug delivery 20060501

• Individualizing chemotherapeutic treatment of colorectal cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060501

• Pro- and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell lines.

  Diabetes 20060501

• Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501

• [The present state and future of home care for gastric cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Lung carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [A case of gastric cancer presenting with obstructive jaundice and responding to biweekly CPT-11 and CDDP combination administration].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• Gamma-pyranone derivatives and other constituents from Erigeron annuus.

  Die Pharmazie 20060501

• Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

  Current drug metabolism 20060501

• [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20060501

• [Irinotecan for the treatment of metastatic colorectal cancer].

  Bulletin du cancer 20060501

• [Experimental study of hydroxycamptothecine and theprubicine in the treatment of adenoid cystic carcinoma lung metastases].

  Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology 20060501

• Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster.

  Mutation research 20060430

• MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

  Neurology 20060425

• Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.

  British journal of cancer 20060424

• High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.

  Biochemical and biophysical research communications 20060421

• Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.

  Oncogene 20060420

• New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060420

• Caspase inhibition in apoptotic T cells triggers necrotic cell death depending on the cell type and the proapoptotic stimulus.

  Journal of cellular biochemistry 20060415

• Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines.

  Free radical biology & medicine 20060415

• Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060415

• Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.

  Biochemical pharmacology 20060414

• Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.

  British journal of cancer 20060410

• The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA.

  Journal of molecular biology 20060407

• Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20060401

• A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060401

• Proliferation and apoptosis in a neuroblastoma cell line exposed to 900 MHz modulated radiofrequency field.

  Bioelectromagnetics 20060401

• Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors.

  Bioorganic & medicinal chemistry letters 20060401

• Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).

  Lung cancer (Amsterdam, Netherlands) 20060401

• The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer.

  International journal of oncology 20060401

• The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells.

  Oncology reports 20060401

• Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.

  Oncology reports 20060401

• A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  Neuro-oncology 20060401

• Chemotherapy for advanced pancreatic cancer.

  Best practice & research. Clinical gastroenterology 20060401

• Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

  Expert opinion on pharmacotherapy 20060401

• Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.

  American journal of clinical oncology 20060401

• Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.

  American journal of clinical oncology 20060401

• [A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060401

• Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060401

• [Non-surgical treatment for pancreatic cancer].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20060401

• [Effect of hydroxycamptothecin on apoptosis-inducing factor (AIF) expression and on AIF translocation in human hepatocellular cancer cell SMMC-7721].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20060401

• Potent antitumor activity of 10-methoxy-9-nitrocamptothecin.

  Molecular cancer therapeutics 20060401

• [A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--].

  Hinyokika kiyo. Acta urologica Japonica 20060401

• [Prevention of anticancer drug-induced premature ovarian failure].

  Nihon rinsho. Japanese journal of clinical medicine 20060401

• [Molecular targets in colon cancer].

  Therapeutische Umschau. Revue therapeutique 20060401

• Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.

  Drug metabolism and pharmacokinetics 20060401

• Individualizing cancer chemotherapy.

  Clinical advances in hematology & oncology : H&O 20060401

• Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

  Oncology (Williston Park, N.Y.) 20060401

• Nondermatologic adverse events associated with anti-EGFR therapy.

  Oncology (Williston Park, N.Y.) 20060401

• Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.

  Oncology (Williston Park, N.Y.) 20060401

• Triterpenoids and ellagic acid derivatives from in vitro cultures of Camptotheca acuminata Decaisne.

  Plant physiology and biochemistry : PPB 20060401

• Cell type-specific resistance of trigeminal ganglion neurons towards apoptotic stimuli.

  Veterinary microbiology 20060331

• WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization.

  The Journal of biological chemistry 20060331

• DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.

  The Journal of biological chemistry 20060331

• Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.

  British journal of cancer 20060327

• FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).

  British journal of cancer 20060327

• Assembly of a polymeric chain of SUMO1 on human topoisomerase I in vitro.

  The Journal of biological chemistry 20060324

• The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining.

  Oncogene 20060323

• Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells.

  The EMBO journal 20060322

• Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells.

  Journal of molecular biology 20060317

• Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D.

  Cancer research 20060315

• Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

  Cancer research 20060315

• From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• Correspondence re: Cecchin et al., Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005;11:6901-7.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.

  Biochemical pharmacology 20060314

• [Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].

  Deutsche medizinische Wochenschrift (1946) 20060310

• Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.

  Cancer letters 20060308

• Role of pharmacogenetics in irinotecan therapy.

  Cancer letters 20060308

• Suppression of genomic instability by SLX5 and SLX8 in Saccharomyces cerevisiae.

  DNA repair 20060307

• The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

  Biochemistry 20060307

• [The modern treatment of colorectal cancer. Present and future].

  Orvosi hetilap 20060305

• Irinotecan (CPT-11) combined with cisplatin for small cell carcinoma of the nasal cavity.

  Auris, nasus, larynx 20060301

• Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060301

• Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

  International journal of radiation oncology, biology, physics 20060301

• Pharmacogenetics of irinotecan metabolism and transport: an update.

  Toxicology in vitro : an international journal published in association with BIBRA 20060301

• Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade.

  Breast cancer research and treatment 20060301

• Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy.

  The Journal of pharmacology and experimental therapeutics 20060301

• Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats.

  Biopharmaceutics & drug disposition 20060301

• Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060301

• Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2.

  Journal of biomolecular screening 20060301

• The behavior of SATB1, a MAR-binding protein, in response to apoptosis stimulation.

  Cell biology international 20060301

• Recent developments in the use of chemotherapy in brain tumours.

  European journal of cancer (Oxford, England : 1990) 20060301

• Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.

  European journal of cancer (Oxford, England : 1990) 20060301

• Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

  Cancer 20060301

• Direct activation of the human major vault protein gene by DNA-damaging agents.

  Oncology reports 20060301

• Differential involvement of phosphatidylinositol 3-kinase-related protein kinases in hyperphosphorylation of replication protein A2 in response to replication-mediated DNA double-strand breaks.

  Genes to cells : devoted to molecular & cellular mechanisms 20060301

• Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.

  Expert opinion on drug safety 20060301

• [Change of mitochondria during apoptosis of HL-60 cells induced by camptothecine].

  Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20060301

• Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.

  Cancer research 20060301

• XRCC1 genotype and breast cancer: functional studies and epidemiologic data show interactions between XRCC1 codon 280 His and smoking.

  Cancer research 20060301

• [A case of small-cell lung cancer responding remarkably to CPT-11 and CDDP combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060301

• [A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060301

• Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060301

• Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).

  Cancer investigation 20060301

• [Chemotherapy for lung cancer patients].

  Journal of UOEH 20060301

• Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer.

  Cancer science 20060301

• Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.

  Molecular cancer therapeutics 20060301

• Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin.

  Molecular cancer therapeutics 20060301

• The alkaloid alstonine: a review of its pharmacological properties.

  Evidence-based complementary and alternative medicine : eCAM 20060301

• Bioreactor studies on the endophytic fungus Entrophospora infrequens for the production of an anticancer alkaloid camptothecin.

  Canadian journal of microbiology 20060301

• Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.

  Clinical colorectal cancer 20060301

• Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.

  Clinical colorectal cancer 20060301

• Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.

  Clinical lung cancer 20060301

• Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20060301

• Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060301

• Irinotecan for children with relapsed solid tumors.

  Pediatric hematology and oncology 20060301

• Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro.

  Cancer letters 20060227

• Total synthesis and biological evaluation of 22-hydroxyacuminatine.

  Journal of medicinal chemistry 20060223

• Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems.

  International journal of pharmaceutics 20060217

• Activity-guided isolation of cytotoxic constituents from the bark of Aglaia crassinervia collected in Indonesia.

  Bioorganic & medicinal chemistry 20060215

• Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma.

  Cancer 20060215

• A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060215

• Intestinal microflora and digestive toxicity of irinotecan in mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060215

• Polymer therapeutics: concepts and applications.

  Angewandte Chemie (International ed. in English) 20060213

• Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060210

• Practical formal total synthesis of (rac)- and (S)-camptothecin.

  Organic & biomolecular chemistry 20060207

• Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism.

  The Journal of biological chemistry 20060203

• Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability.

  International journal of pharmaceutics 20060203

• A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20060201

• Inhibition of apoptosis by Nur77 through NF-kappaB activity modulation.

  Cell death and differentiation 20060201

• Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.

  Journal of neuro-oncology 20060201

• Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

  International journal of radiation oncology, biology, physics 20060201

• DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.

  The Journal of pharmacology and experimental therapeutics 20060201

• Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis.

  Cell death and differentiation 20060201

• The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.

  Gynecologic oncology 20060201

• A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1.

  PLoS medicine 20060201

• Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma.

  Cancer 20060201

• in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.

  International journal of oncology 20060201

• PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.

  Technology in cancer research & treatment 20060201

• Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.

  Pharmacogenetics and genomics 20060201

• Infection of bovine cells by the protozoan parasite Theileria annulata modulates expression of the ISGylation system.

  Cellular microbiology 20060201

• Identification and immunotherapeutic targeting of antigens induced by chemotherapy.

  Nature biotechnology 20060201

• Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060201

• Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060201

• A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.

  Japanese journal of clinical oncology 20060201

• Central nervous system toxicity induced by irinotecan.

  Journal of the National Cancer Institute 20060201

• Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060201

• Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.

  American journal of clinical oncology 20060201

• Designer combination therapy for cancer.

  Nature biotechnology 20060201

• [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].

  Bulletin du cancer 20060201

• [Progress in therapy for testicular tumors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• Cytotoxic and other compounds from Didymochlaena truncatula from the Madagascar rain forest.

  Journal of natural products 20060201

• A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

  Molecular cancer therapeutics 20060201

• Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/macrophage (CFU-GM) assay.

  Die Pharmazie 20060201

• [Mechanisms of substrate transport by ABC transporter, MRP1/ABCC1].

  Seikagaku. The Journal of Japanese Biochemical Society 20060201

• Novel single nucleotide polymorphism of UGT1A7 gene in Japanese.

  Drug metabolism and pharmacokinetics 20060201

• Novel single nucleotide polymorphism of UGT1A9 gene in Japanese.

  Drug metabolism and pharmacokinetics 20060201

• Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines.

  Journal of gastroenterology 20060201

• Administration of anti-EGFR therapy: a practical review.

  Seminars in oncology nursing 20060201

• [Is small cell lung cancer an orphan disease?].

  Revue de pneumologie clinique 20060201

• [From ASCO and WCLC 2005 to clinical practice: 'conventional' treatments].

  Revue de pneumologie clinique 20060201

• SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

  British journal of cancer 20060116

• Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

  Cancer 20060115

• Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.

  Oncogene 20060112

• Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer.

  Journal of controlled release : official journal of the Controlled Release Society 20060110

• A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines.

  Cancer letters 20060108

• A phase I study of irinotecan administered on a weekly schedule in pediatric patients.

  Pediatric blood & cancer 20060101

• Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.

  Cancer chemotherapy and pharmacology 20060101

• Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.

  Cancer chemotherapy and pharmacology 20060101

• Characterization of secretory intestinal transport of the lactone form of CPT-11.

  Cancer chemotherapy and pharmacology 20060101

• Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.

  Cancer chemotherapy and pharmacology 20060101

• Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.

  Cancer chemotherapy and pharmacology 20060101

• Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs.

  The Journal of pharmacology and experimental therapeutics 20060101

• Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060101

• Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.

  The Journal of clinical endocrinology and metabolism 20060101

• Comparative studies on the camptothecin content from Nothapodytes foetida and Ophiorrhiza species.

  Natural product research 20060101

• Leishmania donovani: differential activities of classical topoisomerase inhibitors and antileishmanials against parasite and host cells at the level of DNA topoisomerase I and in cytotoxicity assays.

  Experimental parasitology 20060101

• Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data.

  Anti-cancer drugs 20060101

• Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.

  Anti-cancer drugs 20060101

• A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20060101

• Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060101

• Rubitecan.

  Expert opinion on investigational drugs 20060101

• Unresectable hepatic colorectal metastases: need for new surgical strategies.

  Annals of surgical oncology 20060101

• Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.

  Annals of surgical oncology 20060101

• Nuclear caspase-3 and caspase-7 activation, and poly(ADP-ribose) polymerase cleavage are early events in camptothecin-induced apoptosis.

  Apoptosis : an international journal on programmed cell death 20060101

• Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.

  Surgery today 20060101

• Adjuvant therapy for colon cancer 2005: new options in the twenty-first century.

  Surgical oncology clinics of North America 20060101

• Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

  Human gene therapy 20060101

• [Management of chemotherapy-induced mucositis and diarrhea].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060101

• [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060101

• Comparative effects of RRR-alpha- and RRR-gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines.

  BMC cancer 20060101

• A novel yeast-based reporter assay system for the sensitive detection of genotoxic agents mediated by a DNA damage-inducible LexA-GAL4 protein.

  Journal of biochemistry 20060101

• Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid.

  Molecular cancer therapeutics 20060101

• Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.

  Molecular cancer therapeutics 20060101

• Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer.

  Japanese journal of clinical oncology 20060101

• Topotecan is a substrate for multidrug resistance associated protein 4.

  Current drug metabolism 20060101

• Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.

  Current pharmaceutical design 20060101

• [Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm].

  Nihon rinsho. Japanese journal of clinical medicine 20060101

• Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions.

  Anticancer research 20060101

• Circumvention of camptothecin-induced resistance during the adaptive cellular stress response.

  Anticancer research 20060101

• Small cell lung cancer: an update on therapeutic aspects.

  The Indian journal of chest diseases & allied sciences 20060101

• Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine.

  BMC cell biology 20060101

• Metastatic ovarian carcinoma one year after surgical removal of colon carcinoma during pregnancy: a case report.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Chylous ascites following operation for para-aortic lymph node dissection in a patient with cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?

  BMC cancer 20060101

• Epigenetic regulation: DNA confers identity but is not enough to maintain it.

  Genome biology 20060101

• Phospholipid fatty acid composition and diamine oxidase activity of intestinal mucosa from rats treated with irinotecan hydrochloride (CPT-11) under vegetable oil-enriched diets: comparison between perilla oil and corn oil.

  JPEN. Journal of parenteral and enteral nutrition 20060101

• Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.

  Drug safety 20060101

• Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

  Bioconjugate chemistry 20060101

• Deciphering cellular states of innate tumor drug responses.

  Genome biology 20060101

• [Myelotoxity of the nuclear enzyme inhibitors irinotecan and etoposide].

  Eksperimental'naia i klinicheskaia farmakologiia 20060101

• Irinotecan as a new agent for urachal cancer.

  Urologia internationalis 20060101

• Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells.

  Journal of drug targeting 20060101

• Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.

  Hepato-gastroenterology 20060101

• A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer.

  Hepato-gastroenterology 20060101

• Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.

  Anticancer research 20060101

• In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.

  Anticancer research 20060101

• Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer.

  Anticancer research 20060101

• Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.

  Anticancer research 20060101

• Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.

  Oncology 20060101

• A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.

  Oncology 20060101

• Cell-based assays for profiling activity and safety properties of cancer drugs.

  Journal of pharmacological and toxicological methods 20060101

• Neoadjuvant chemotherapy in cervical cancer: a 67 patients experience.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.

  Molecular pharmaceutics 20060101

• Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.

  Molecular cancer 20060101

• Reduced expression of top1beta gene induces programmed cell death and alters ascorbate metabolism in Daucus carota cultured cells.

  Journal of experimental botany 20060101

• [Preparation of 10-hydroxycamptothecin semisolid lipid nanoparticles and investigation of its stability].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20060101

• Radiosensitizers in cervical cancer. Cisplatin and beyond.

  Radiation oncology (London, England) 20060101

• Global analysis of gene function in yeast by quantitative phenotypic profiling.

  Molecular systems biology 20060101

• Stable disease in advanced colorectal cancer: therapeutic implications.

  Anticancer research 20060101

• Both bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer.

  Anticancer research 20060101

• Better gene expression by (-)gene than by (+)gene in phage gene delivery systems.

  Biotechnology progress 20060101

• DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy.

  Biochimica et biophysica acta 20060101

• Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20060101

• A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer.

  Cancer investigation 20060101

• Mechanism of central nervous system toxicity by irinotecan.

  Medical hypotheses 20060101

• Tyrosyl-DNA phosphodiesterase (Tdp1) (3'-phosphotyrosyl DNA phosphodiesterase).

  Methods in enzymology 20060101

• Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy.

  Hepato-gastroenterology 20060101

• Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.

  Cancer investigation 20060101

• Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.

  Anticancer research 20060101

• A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.

  Anticancer research 20060101

• Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.

  Anticancer research 20060101

• Review camptothecin: current perspectives.

  Current medicinal chemistry 20060101

• Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases.

  Arthritis research & therapy 20060101

• Camptothecin induces the transit of FasL trimers to the cell surface in apoptotic HEp-2 cells.

  Cellular & molecular biology letters 20060101

• Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20060101

• Non-random clustering of stress-related genes during evolution of the S. cerevisiae genome.

  BMC evolutionary biology 20060101

• Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.

  Chemotherapy 20060101

• BID-deficient breast cancer MCF-7 cells as a model for the study of autophagy in cancer therapy.

  Autophagy 20060101

• Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.

  Drug metabolism reviews 20060101

• Cytotoxicity of organic compounds against ovarian cancer cells: a quantitative structure-activity relationship study.

  Molecular pharmaceutics 20060101

• TBLR1 regulates the expression of nuclear hormone receptor co-repressors.

  BMC cell biology 20060101

• In vitro growth inhibition of bloodstream forms of Trypanosoma brucei and Trypanosoma congolense by iron chelators.

  Kinetoplastid biology and disease 20060101

• Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study.

  Chang Gung medical journal 20060101

• Case-based discussion for the management of metastatic colorectal cancer.

  ONS news 20060101

• Pharmacokinetic considerations in the treatment of CNS tumours.

  Clinical pharmacokinetics 20060101

• Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.

  Molecular neurodegeneration 20060101

• Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20060101

• Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP).

  BMC complementary and alternative medicine 20060101

• HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.

  Bioconjugate chemistry 20060101

• A case report and discussion of cetuximab-induced folliculitis.

  American journal of clinical dermatology 20060101

• Molecular dynamics simulations and experimental studies of binding and mobility of 7-tert-butyldimethylsilyl-10-hydroxycamptothecin and its 20(S)-4-aminobutyrate ester in DMPC membranes.

  Molecular pharmaceutics 20060101

• Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer.

  Journal of hepato-biliary-pancreatic surgery 20060101

• Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience.

  Medical oncology (Northwood, London, England) 20060101

• Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin.

  Tumori 20060101

• Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.

  Tumori 20060101

• Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across Caco-2 cell monolayer.

  Journal of nanoscience and nanotechnology 20060101

• Camptothecin in sterically stabilized phospholipid nano-micelles: a novel solvent pH change solubilization method.

  Journal of nanoscience and nanotechnology 20060101

• TLK1B promotes repair of UV-damaged DNA through chromatin remodeling by Asf1.

  BMC molecular biology 20060101

• Inorganic phosphate nanorods are a novel fluorescent label in cell biology.

  Journal of nanobiotechnology 20060101

• In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C.

  Hepato-gastroenterology 20060101

• Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results.

  Anticancer research 20060101

• Recent progress in target therapy in colorectal cancer.

  Anticancer research 20060101

• New molecular mechanisms of action of camptothecin-type drugs.

  Anticancer research 20060101

• Silvestrol regulates G2/M checkpoint genes independent of p53 activity.

  Anticancer research 20060101

• Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry.

  Bioconjugate chemistry 20060101

• Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.

  The oncologist 20060101

• Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer.

  World journal of surgical oncology 20060101

• Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case.

  Surgery today 20060101

• A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells.

  Urologia internationalis 20060101

• Analyzing the dose-dependence of the Saccharomyces cerevisiae global transcriptional response to methyl methanesulfonate and ionizing radiation.

  BMC genomics 20060101

• Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition.

  Tumori 20060101

• Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.

  Tumori 20060101

• [Advances in the treatment of metastatic colorectal cancer with bevacizumab].

  Tumori 20060101

• Mechanisms of cellular resistance to camptothecins.

  Current medicinal chemistry 20060101

• Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study.

  BMC cardiovascular disorders 20060101

• Development of a tumor-selective approach to treat metastatic cancer.

  PloS one 20060101

• Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer.

  Anticancer research 20060101

• Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.

  Anticancer research 20060101

• Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.

  Anticancer research 20060101

• Hepatic metastases of colorectal cancer: locoregional intra-arterial treatment.

  Anticancer research 20060101

• [Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].

  Magyar onkologia 20060101

• Genome-wide cDNA microarray screening of genes related to the benefits of paclitaxel and irinotecan chemotherapy in patients with advanced non-small cell lung cancer.

  Journal of experimental therapeutics & oncology 20060101

• [Metastatic colorectal cancer: adjournments from ESMO 2006].

  Tumori 20060101

• [A review of chemotherapy for metastatic colon cancer].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.

  Annals of medicine 20060101

• Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.

  International journal of gastrointestinal cancer 20060101

• Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.

  Oncology 20060101

• Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents.

  Bioorganic & medicinal chemistry 20051215

• Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.

  Chemico-biological interactions 20051215

• The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.

  Chemico-biological interactions 20051215

• Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.

  Cancer 20051215

• Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.

  Cancer research 20051215

• Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051215

• A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.

  British journal of cancer 20051212

• Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.

  Journal of controlled release : official journal of the Controlled Release Society 20051210

• Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin.

  International journal of pharmaceutics 20051208

• Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.

  Cancer chemotherapy and pharmacology 20051201

• The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.

  Cell death and differentiation 20051201

• A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20051201

• Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20051201

• [Which role do new therapeutic options play in palliative care of colorectal cancer?].

  Der Internist 20051201

• Distribution of anticancer drug camptothecin in Nothapodytes foetida.

  Fitoterapia 20051201

• Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.

  Cancer biology & therapy 20051201

• Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.

  Investigational new drugs 20051201

• Treatment with hydroxyurea and tyrphostin-1 significantly improves the transduction efficiency of recombinant adeno-associated viruses in human cancer cells.

  Oncology reports 20051201

• Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11.

  European journal of cancer care 20051201

• Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.

  Journal of pharmacokinetics and pharmacodynamics 20051201

• Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.

  Japanese journal of clinical oncology 20051201

• A multicenter phase II study of 'adjuvant' irinotecan following resection of colorectal hepatic metastases.

  American journal of clinical oncology 20051201

• Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.

  American journal of clinical oncology 20051201

• Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).

  American journal of clinical oncology 20051201

• The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Ayurveda and traditional Chinese medicine: a comparative overview.

  Evidence-based complementary and alternative medicine : eCAM 20051201

• [Effect of caffeine on camptothecin-induced apoptosis of Molt-4 cells].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• [Progression of adjuvant chemotherapy for colon cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• [Recent progress of chemotherapy for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051201

• [CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051201

• Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.

  Journal of Korean medical science 20051201

• Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.

  The Laryngoscope 20051201

• Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.

  International journal of clinical oncology 20051201

• Intravenous irinotecan plus oral ciclosporin.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20051201

• Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20051201

• An endophytic fungus from Nothapodytes foetida that produces camptothecin.

  Journal of natural products 20051201

• Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.

  Seminars in oncology 20051201

• The role of bevacizumab as first-line therapy for colon cancer.

  Seminars in oncology 20051201

• Second-line treatment of patients with metastatic colorectal cancer.

  Seminars in oncology 20051201

• Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.

  Seminars in oncology 20051201

• Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.

  Seminars in oncology 20051201

• Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.

  Prescrire international 20051201

• Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.

  Prescrire international 20051201

• A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.

  Digestive diseases and sciences 20051201

• A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.

  Cancer biology & therapy 20051201

• A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin.

  Journal of experimental & clinical cancer research : CR 20051201

• [Synthesis of camptothecin glycosides by phase transfer-catalysis and its inhibitory activity against topo I].

  Yao xue xue bao = Acta pharmaceutica Sinica 20051201

• Management of oxaliplatin-induced peripheral neuropathy.

  Therapeutics and clinical risk management 20051201

• Fluorescence based oxygen uptake analysis in the study of metabolic responses to apoptosis induction.

  Journal of immunological methods 20051130

• Liposomalization of SN-38 as active metabolite of CPT-11.

  Journal of controlled release : official journal of the Controlled Release Society 20051128

• Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

  British journal of cancer 20051128

• The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB.

  Cancer letters 20051118

• Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.

  AIDS (London, England) 20051118

• Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.

  British journal of cancer 20051114

• DNA damage regulates Chk2 association with chromatin.

  The Journal of biological chemistry 20051111

• Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.

  The Journal of organic chemistry 20051111

• [Drug therapy of patients with metastatic colorectal cancer].

  Ugeskrift for laeger 20051107

• Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma.

  AIDS (London, England) 20051104

• Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.

  Cancer chemotherapy and pharmacology 20051101

• Preferential localization of hyperphosphorylated replication protein A to double-strand break repair and checkpoint complexes upon DNA damage.

  The Biochemical journal 20051101

• Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution.

  Cancer chemotherapy and pharmacology 20051101

• S-phase modulation by irinotecan: pilot studies in advanced solid tumors.

  Cancer chemotherapy and pharmacology 20051101

• Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20051101

• Discovery of novel immunostimulants by dendritic-cell-based functional screening.

  Blood 20051101

• The csnD/csnE signalosome genes are involved in the Aspergillus nidulans DNA damage response.

  Genetics 20051101

• Camptothecin binds to a synthetic peptide identified by a T7 phage display screen.

  Bioorganic & medicinal chemistry letters 20051101

• Plant-based anticancer molecules: a chemical and biological profile of some important leads.

  Bioorganic & medicinal chemistry 20051101

• Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.

  Cancer 20051101

• Human multidrug resistance associated protein 4 confers resistance to camptothecins.

  Pharmaceutical research 20051101

• Total and semisynthesis and in vitro studies of both enantiomers of 20-fluorocamptothecin.

  Bioorganic & medicinal chemistry letters 20051101

• Synthesis of a biotinylated camptothecin derivative and determination of the binding sequence by T7 phage display technology.

  Bioorganic & medicinal chemistry letters 20051101

• Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.

  Cancer 20051101

• Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.

  Oncology reports 20051101

• Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro.

  Oncology reports 20051101

• The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.

  Anti-cancer drugs 20051101

• Irinotecan (CPT-11) in the treatment of mycosis fungoides.

  The British journal of dermatology 20051101

• Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.

  Nature clinical practice. Oncology 20051101

• Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B.

  Cancer science 20051101

• Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051101

• Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051101

• [SNPs associated with adverse effects].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• [A case of rectal cancer treated by preoperative chemoradiation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051101

• Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent.

  Journal of pediatric hematology/oncology 20051101

• Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

  Neoplasia (New York, N.Y.) 20051101

• Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.

  Clinical colorectal cancer 20051101

• Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.

  Clinical colorectal cancer 20051101

• Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.

  Clinical colorectal cancer 20051101

• FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.

  Clinical colorectal cancer 20051101

• Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.

  Clinical colorectal cancer 20051101

• Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.

  Clinical colorectal cancer 20051101

• Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.

  Clinical colorectal cancer 20051101

• UGT1A1 genotyping in patients undergoing treatment with irinotecan.

  Clinical advances in hematology & oncology : H&O 20051101

• [Synthesis and spectral characterization of 10-hydroxycamptothecin].

  Guang pu xue yu guang pu fen xi = Guang pu 20051101

• [9-nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo].

  Yao xue xue bao = Acta pharmaceutica Sinica 20051101

• Stealth PEG-PHDCA niosomes: effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake.

  Yao xue xue bao = Acta pharmaceutica Sinica 20051101

• Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

  Gastroenterologie clinique et biologique 20051101

• The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.

  Biochemical pharmacology 20051015

• Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells.

  Cancer research 20051015

• Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.

  British journal of cancer 20051003

• Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20051001

• Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study.

  Lung cancer (Amsterdam, Netherlands) 20051001

• Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).

  Drug metabolism and disposition: the biological fate of chemicals 20051001

• Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate.

  Bioorganic & medicinal chemistry 20051001

• Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

  Cancer 20051001

• MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (beta-D-glucuronate).

  Biochemical pharmacology 20051001

• Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.

  Investigational new drugs 20051001

• A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.

  Investigational new drugs 20051001

• Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design.

  Die Naturwissenschaften 20051001

• Systemic therapy for pancreatic cancer.

  Seminars in radiation oncology 20051001

• Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051001

• Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.

  Cancer research 20051001

• Camptothecins and two new monoterpene glucosides from Ophiorrhiza liukiuensis.

  Chemical & pharmaceutical bulletin 20051001

• [A case of advanced gastric cancer with obstructive jaundice that responded to TS-1/CPT-11 combination therapy after percutaneous transhepatic cholangio drainage].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of small cell carcinoma of the stomach].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• Advanced colorectal cancer: current treatment and nursing management with economic considerations.

  Clinical journal of oncology nursing 20051001

• [Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].

  Kyobu geka. The Japanese journal of thoracic surgery 20051001

• In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.

  International journal of clinical oncology 20051001

• Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.

  The oncologist 20051001

• Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response.

  PLoS pathogens 20051001

• Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.

  IDrugs : the investigational drugs journal 20051001

• Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.

  Clinical breast cancer 20051001

• Phospholipid nanosomes.

  Current drug delivery 20051001

• [Host immunity in colorectal cancer patients treated with TS-1 plus CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Chemotherapy for liver metastasis of colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of peritoneal dissemination disappeared by CPT-11 + TS-1 combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of metastatic colon cancer treated with oxaliplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case of chemoradiation with tissue expander for local reccurence of rectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• [In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats].

  Yao xue xue bao = Acta pharmaceutica Sinica 20051001

• [Pharmacokinetic study of intraperitoneal chemotherapy with HCPT].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20051001

• 1,3-dipolar cycloaddition chemistry for the preparation of novel indolizinone-based compounds.

  The Journal of organic chemistry 20050930

• Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050928

• Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.

  Journal of pharmaceutical and biomedical analysis 20050915

• A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.

  Cancer 20050915

• Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Regulation of hepatocyte engraftment and proliferation after cytotoxic drug-induced perturbation of the rat liver.

  Transplantation 20050915

• Dendritic supramolecular assemblies for drug delivery.

  Chemical communications (Cambridge, England) 20050914

• Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma.

  World journal of gastroenterology 20050907

• Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.

  British journal of cancer 20050905

• Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway.

  Molecular cell 20050902

• Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.

  International journal of cancer 20050901

• Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.

  European urology 20050901

• Gastric cancer. Treatment of advanced disease and new drugs.

  Frontiers in bioscience : a journal and virtual library 20050901

• Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers.

  Bioorganic & medicinal chemistry letters 20050901

• The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.

  Lung cancer (Amsterdam, Netherlands) 20050901

• Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.

  Japanese journal of clinical oncology 20050901

• Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.

  International journal of oncology 20050901

• Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.

  Oncology reports 20050901

• Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.

  Oncology reports 20050901

• p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1.

  Cell cycle (Georgetown, Tex.) 20050901

• Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.

  Anti-cancer drugs 20050901

• In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.

  Anti-cancer drugs 20050901

• Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells.

  Peptides 20050901

• A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.

  Cancer science 20050901

• Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901

• Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).

  Japanese journal of clinical oncology 20050901

• Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.

  Pharmacogenomics 20050901

• DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells.

  Journal of Alzheimer's disease : JAD 20050901

• Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.

  Chemical research in toxicology 20050901

• Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.

  Clinical lung cancer 20050901

• [Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• [A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050901

• Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.

  Journal of neuro-oncology 20050901

• Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.

  Clinical colorectal cancer 20050901

• Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.

  Clinical colorectal cancer 20050901

• Pathophysiological implication of ganglioside GM3 in early mouse embryonic development through apoptosis.

  Archives of pharmacal research 20050901

• [Functional SNPs of the breast cancer resistance protein (ABCG2) gene altering the pharmacokinetics/pharmacodynamics of anticancer agents].

  Seikagaku. The Journal of Japanese Biochemical Society 20050901

• Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.

  Cancer biology & therapy 20050901

• Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.

  The Korean journal of internal medicine 20050901

• [Successful salvage therapy of continuous low-dose irinotecan for a patient with relapsed and refractory diffuse large B-cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050901

• Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy.

  Current drug discovery technologies 20050901

• Plants as a source of anti-cancer agents.

  Journal of ethnopharmacology 20050822

• Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.

  British journal of cancer 20050822

• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells.

  Oncogene 20050818

• 53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage.

  Oncogene 20050818

• Cetuximab therapy and symptomatic hypomagnesemia.

  Journal of the National Cancer Institute 20050817

• Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death.

  Cancer research 20050815

• Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• Cellular profiling of small-molecule bioactivities: an alternative tool for chemical biology.

  Angewandte Chemie (International ed. in English) 20050812

• pH-dependent association of SN-38 with lipid bilayers of a novel liposomal formulation.

  International journal of pharmaceutics 20050811

• [Clinical effects of combination chemotherapy with irinotecan hydrochloride and cisplatin on cervical cancer: study of 46 patients].

  Zhonghua yi xue za zhi 20050810

• HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.

  Cancer chemotherapy and pharmacology 20050801

• Cigarette smoke extract induces DNA damage but not apoptosis in human bronchial epithelial cells.

  American journal of respiratory cell and molecular biology 20050801

• Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Whither irinotecan?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.

  International journal of oncology 20050801

• DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.

  Investigational new drugs 20050801

• Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.

  Lung cancer (Amsterdam, Netherlands) 20050801

• Liposomal encapsulated anti-cancer drugs.

  Anti-cancer drugs 20050801

• Tumor-targeted and activated bioconjugates for improved camptothecin delivery.

  Anti-cancer drugs 20050801

• Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.

  Therapeutic drug monitoring 20050801

• Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.

  European journal of cancer (Oxford, England : 1990) 20050801

• Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas.

  Cancer research 20050801

• Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.

  Cancer research 20050801

• It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.

  Cancer research 20050801

• Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

• A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.

  American journal of clinical oncology 20050801

• Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.

  American journal of clinical oncology 20050801

• [Antitumor effects of ring-closed and ring-opened hydroxycamptothecin on oral squamous carcinoma cell line Tca8113].

  Ai zheng = Aizheng = Chinese journal of cancer 20050801

• [Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].

  Ai zheng = Aizheng = Chinese journal of cancer 20050801

• Hedamycin, a DNA alkylator, induces (gamma)H2AX and chromosome aberrations: involvement of phosphatidylinositol 3-kinase-related kinases and DNA replication fork movement.

  Molecular cancer therapeutics 20050801

• Analysis of incomplete quality of life data in advanced stage cancer: a practical application of multiple imputation.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20050801

• Genome-wide requirements for resistance to functionally distinct DNA-damaging agents.

  PLoS genetics 20050801

• [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050801

• [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050801

• Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.

  Seminars in oncology 20050801

• Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis.

  Journal of chemotherapy (Florence, Italy) 20050801

• Separation of 9-methoxycamptothecin and camptothecin from Nothapodytes foetida by semipreparative HPLC.

  Journal of chromatographic science 20050801

• Patient with angina secondary to capecitabine.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050801

• Iridoids as DNA topoisomerase I poisons.

  Journal of enzyme inhibition and medicinal chemistry 20050801

• [Spontaneous and induced programmed cell death in suspension cell cultures of cotton (Gossypium hirsutum L.)].

  Shi yan sheng wu xue bao 20050801

• Evolutionary trace analysis of eukaryotic DNA topoisomerase I superfamily: identification of novel antitumor drug binding site.

  Science in China. Series C, Life sciences 20050801

• Metastatic colorectal cancer: is there one standard approach?

  Oncology (Williston Park, N.Y.) 20050801

• Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.

  Journal of medicinal chemistry 20050728

• Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050725

• A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.

  The Journal of biological chemistry 20050722

• An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.

  Journal of the American Chemical Society 20050720

• A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response.

  Nature 20050714

• Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

  British journal of cancer 20050711

• A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.

  British journal of cancer 20050711

• Role of genomic markers in colorectal cancer treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050710

• Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with replication protein A in human cells.

  Oncogene 20050707

• A novel, expeditious synthesis of racemic camptothecin.

  Organic letters 20050707

• Solid phase synthesis of anthraquinone peptides and their evaluation as topoisomerase I inhibitors.

  Journal of peptide science : an official publication of the European Peptide Society 20050701

• Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.

  Cancer chemotherapy and pharmacology 20050701

• Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms.

  Drug metabolism and disposition: the biological fate of chemicals 20050701

• Synthesis and antitumor activity of the hexacyclic camptothecin derivatives.

  Bioorganic & medicinal chemistry letters 20050701

• A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20050701

• New cytotoxic agents: a review of the literature.

  Critical reviews in oncology/hematology 20050701

• Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.

  Anti-cancer drugs 20050701

• A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050701

• A mouse model for developing treatment for secondary liver tumors.

  International journal of oncology 20050701

• GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.

  International journal of oncology 20050701

• Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.

  Oncology reports 20050701

• Homogeneous assays for cellular proteases employing the platinum(II)-coproporphyrin label and time-resolved phosphorescence.

  Analytical biochemistry 20050701

• Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).

  IDrugs : the investigational drugs journal 20050701

• Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae.

  Cancer research 20050701

• Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines.

  Biological & pharmaceutical bulletin 20050701

• Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050701

• Anti-apoptotic effects of L-glutamine-mediated transcriptional modulation of the heat shock protein 72 during heat shock.

  Gastroenterology 20050701

• A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20050701

• Rectal cancer clinical practice guidelines in oncology.

  Journal of the National Comprehensive Cancer Network : JNCCN 20050701

• Chemotherapy for metastatic colorectal cancer.

  Journal of the National Comprehensive Cancer Network : JNCCN 20050701

• [Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [A case report of bowel obstruction due to peritonitis carcinomatosa using combined administration with CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050701

• [Childhood rhabdomyosarcoma].

  Nihon Geka Gakkai zasshi 20050701

• Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.

  Clinical colorectal cancer 20050701

• Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.

  Clinical colorectal cancer 20050701

• Camptothecin: roles of the D and E rings in binding to the topoisomerase I-DNA covalent binary complex.

  Current medicinal chemistry. Anti-cancer agents 20050701

• Interfacial inhibitors of protein-nucleic acid interactions.

  Current medicinal chemistry. Anti-cancer agents 20050701

• [Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide].

  Rinsho byori. The Japanese journal of clinical pathology 20050701

• [Favorable response obtained by low dose chemotherapy in an elderly patient with extensive small cell lung cancer and renal dysfunction].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050701

• Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20050701

• Stress-specific signatures: expression profiling of p53 wild-type and -null human cells.

  Oncogene 20050630

• [New oncolytic agents and immunomodulators and their application].

  Nederlands tijdschrift voor geneeskunde 20050625

• [Chemotherapy of patients with colorectal carcinoma].

  Nederlands tijdschrift voor geneeskunde 20050625

• Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.

  British journal of cancer 20050620

• Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.

  Journal of surgical oncology 20050615

• SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity.

  The EMBO journal 20050615

• Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress.

  Cancer research 20050615

• DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells.

  Cancer research 20050615

• Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships.

  Journal of medicinal chemistry 20050602

• Molecular characterization of two anthranilate synthase alpha subunit genes in Camptotheca acuminata.

  Planta 20050601

• Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.

  Cancer chemotherapy and pharmacology 20050601

• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601

• The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.

  Journal of cancer research and clinical oncology 20050601

• The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.

  Molecular pharmacology 20050601

• Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae.

  Genetics 20050601

• Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050601

• A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.

  Investigational new drugs 20050601

• Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.

  Investigational new drugs 20050601

• Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

  Annals of oncology : official journal of the European Society for Medical Oncology 20050601

• Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

  Lung cancer (Amsterdam, Netherlands) 20050601

• Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.

  Lung cancer (Amsterdam, Netherlands) 20050601

• Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.

  Gynecologic oncology 20050601

• Perioperative adjunctive treatment in the management of operable gastric cancer.

  Journal of surgical oncology 20050601

• Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.

  The Journal of clinical investigation 20050601

• [Systemic therapy for colorectal cancer].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20050601

• SDS-aided immobilization and controlled release of camptothecin from agarose hydrogel.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050601

• Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.

  Journal of the American College of Surgeons 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.

  Cancer research 20050601

• A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Camptothecin and its analogues: a review on their chemotherapeutic potential.

  Natural product research 20050601

• [Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].

  Pathologie-biologie 20050601

• St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.

  Pharmaceutical research 20050601

• In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells.

  Molecular cancer therapeutics 20050601

• Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction.

  Molecular cancer research : MCR 20050601

• Indole alkaloids and other constituents of Rauwolfia serpentina.

  Journal of natural products 20050601

• [Chemotherapy for advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [Treatment of small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• [A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050601

• Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma.

  Thyroid : official journal of the American Thyroid Association 20050601

• Modeling antitumor activity in xenograft tumor treatment.

  Biometrical journal. Biometrische Zeitschrift 20050601

• Cathepsins and BID are involved in the molecular switch between apoptosis and autophagy in breast cancer MCF-7 cells exposed to camptothecin.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20050601

• [Molecular biology in clinical cancer research: the example of digestive cancers].

  Revue d'epidemiologie et de sante publique 20050601

• Surface morphology control of polylactide microspheres enclosing irinotecan hydrochloride.

  International journal of pharmaceutics 20050530

• Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints.

  Oncogene 20050526

• Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.

  British journal of cancer 20050523

• A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.

  British journal of cancer 20050523

• Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity.

  Organic & biomolecular chemistry 20050521

• Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Influence of serum and albumins from different species on stability of camptothecin-loaded micelles.

  Journal of controlled release : official journal of the Controlled Release Society 20050518

• Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.

  Blood 20050515

• Purification and characterization of a novel ATP-independent type I DNA topoisomerase from a marine methylotroph.

  Archives of biochemistry and biophysics 20050515

• A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050515

• topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.

  Oncogene 20050512

• Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.

  Journal of chromatography. A 20050506

• 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.

  Journal of medicinal chemistry 20050505

• Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.

  Mutation research 20050502

• Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.

  Cancer chemotherapy and pharmacology 20050501

• Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2.

  Cancer chemotherapy and pharmacology 20050501

• A novel non-toxic camptothecin formulation for cancer chemotherapy.

  Biomaterials 20050501

• Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.

  Blood 20050501

• Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.

  Cancer chemotherapy and pharmacology 20050501

• Caspase- and mitochondrial dysfunction-dependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis.

  Leukemia 20050501

• 4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20050501

• Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells.

  International journal of oncology 20050501

• Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.

  Cancer chemotherapy and pharmacology 20050501

• The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.

  The Journal of surgical research 20050501

• The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20050501

• Inhibition of p53 by lentiviral mediated shRNA abrogates G1 arrest and apoptosis in retinal pigmented epithelial cell line.

  Cell cycle (Georgetown, Tex.) 20050501

• Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity.

  International journal of radiation oncology, biology, physics 20050501

• New combinations in metastatic colorectal cancer: what are our expectations?

  The oncologist 20050501

• 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.

  Journal of clinical pathology 20050501

• Increased susceptibility of spinal muscular atrophy fibroblasts to camptothecin-induced cell death.

  Molecular genetics and metabolism 20050501

• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  The Lancet. Oncology 20050501

• Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

  Pharmacogenetics and genomics 20050501

• Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

• Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.

  Cancer research 20050501

• Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin.

  Cancer research 20050501

• E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.

  Molecular cancer research : MCR 20050501

• Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.

  Chemotherapy 20050501

• The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.

  Chemotherapy 20050501

• Synthesis and pharmacology of new camptothecin drugs.

  Mini reviews in medicinal chemistry 20050501

• Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.

  Molecular cancer therapeutics 20050501

• Determination of camptothecin and 10-hydroxycamptothecin in human plasma using polymer monolithic in-tube solid phase microextraction combined with high-performance liquid chromatography.

  Analytical and bioanalytical chemistry 20050501

• Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

  European journal of cancer (Oxford, England : 1990) 20050501

• FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Adjuvant therapy in colon cancer: which treatment in 2005?

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• Edotecarin: a novel topoisomerase I inhibitor.

  Clinical colorectal cancer 20050501

• Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.

  Clinical colorectal cancer 20050501

• Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.

  Clinical colorectal cancer 20050501

• [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20050501

• Synthesis and biological activity of new class of dioxygenated anticancer agents.

  Current medicinal chemistry. Anti-cancer agents 20050501

• [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20050501

• Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.

  Clinical advances in hematology & oncology : H&O 20050501

• [Successful treatment of refractory mantle cell lymphoma with irinotecan].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050501

• Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.

  Cancer letters 20050428

• Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050425

• Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050425

• HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.

  British journal of cancer 20050425

• N-terminal region of the large subunit of Leishmania donovani bisubunit topoisomerase I is involved in DNA relaxation and interaction with the smaller subunit.

  The Journal of biological chemistry 20050422

• Synthesis and antitumor activity of 7-ethyl-9-alkyl derivatives of camptothecin.

  Bioorganic & medicinal chemistry letters 20050415

• Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships.

  Bioorganic & medicinal chemistry letters 20050415

• Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation.

  Biochimica et biophysica acta 20050415

• Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.

  British journal of cancer 20050411

• Sensitization of stefin B-deficient thymocytes towards staurosporin-induced apoptosis is independent of cysteine cathepsins.

  FEBS letters 20050411

• Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.

  The Journal of biological chemistry 20050408

• [Colon cancer: molecular markers].

  Deutsche medizinische Wochenschrift (1946) 20050408

• Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.

  Journal of medicinal chemistry 20050407

• Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

  Journal of medicinal chemistry 20050407

• Yeast DEL assay detects clastogens.

  Mutation research 20050404

• A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.

  Cancer chemotherapy and pharmacology 20050401

• Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.

  Journal of cancer research and clinical oncology 20050401

• Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.

  Cancer immunology, immunotherapy : CII 20050401

• DNA lesion-specific co-localization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci.

  The Journal of biological chemistry 20050401

• Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells: the role of nuclear factor-kappaB pathway activation.

  Cancer 20050401

• Gefitinib ('Iressa', ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.

  Cancer chemotherapy and pharmacology 20050401

• Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.

  Oncology reports 20050401

• Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050401

• Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.

  Journal of clinical pharmacology 20050401

• Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.

  British journal of clinical pharmacology 20050401

• Regulation of homologous integration in yeast by the DNA repair proteins Ku70 and RecQ.

  Molecular genetics and genomics : MGG 20050401

• Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.

  Cancer research 20050401

• Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050401

• [Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi].

  Ai zheng = Aizheng = Chinese journal of cancer 20050401

• Critical evaluation of current treatments in metastatic colorectal cancer.

  The oncologist 20050401

• Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.

  Molecular cancer therapeutics 20050401

• Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.

  Japanese journal of clinical oncology 20050401

• Complete response of brain metastases to irinotecan-based chemotherapy.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20050401

• [A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050401

• Irinotecan-induced colitis.

  International journal of surgical pathology 20050401

• Cetuximab in previously treated colorectal cancer.

  Clinical colorectal cancer 20050401

• Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.

  Clinical colorectal cancer 20050401

• Biological activities of Ginkgo extracts.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20050401

• [A young patient with invasive small cell carcinoma of the urinary bladder: a case report].

  Hinyokika kiyo. Acta urologica Japonica 20050401

• Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.

  Journal of chemotherapy (Florence, Italy) 20050401

• Current therapies for advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20050401

• Docetaxel in the management of advanced pancreatic cancer.

  Seminars in oncology 20050401

• Experience with docetaxel in the treatment of gastric cancer.

  Seminars in oncology 20050401

• Docetaxel in the treatment of esophageal cancer.

  Seminars in oncology 20050401

• Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.

  Clinical advances in hematology & oncology : H&O 20050401

• Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.

  British journal of cancer 20050328

• Regulation of CHK2 by DNA-dependent protein kinase.

  The Journal of biological chemistry 20050325

• Effect of yerba mate (Ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation.

  Journal of agricultural and food chemistry 20050323

• Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.

  Biochemistry 20050322

• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

• Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

• Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

• Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

  British journal of cancer 20050314

• Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.

  British journal of cancer 20050314

• Neurons exclusively express N-Bak, a BH3 domain-only Bak isoform that promotes neuronal apoptosis.

  The Journal of biological chemistry 20050311

• The Salmonella effector protein SopB protects epithelial cells from apoptosis by sustained activation of Akt.

  The Journal of biological chemistry 20050311

• Tumor suppressor p53 represses transcription of RECQ4 helicase.

  Oncogene 20050303

• Synthesis of 14-azacamptothecin, a water-soluble topoisomerase I poison.

  Organic letters 20050303

• Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1.

  Nature 20050303

• In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy.

  The journal of gene medicine 20050301

• Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.

  Cancer chemotherapy and pharmacology 20050301

• Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Nitric oxide inhibits caspase activation and apoptotic morphology but does not rescue neuronal death.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20050301

• Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050301

• From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells.

  International journal of oncology 20050301

• Quantitative analysis of camptothecin derivatives in Nothapodytes foetida using 1H-NMR method.

  Chemical & pharmaceutical bulletin 20050301

• Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery.

  Trends in pharmacological sciences 20050301

• Gene expression profiling of the irinotecan pathway in colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• [Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20050301

• Advances in colon cancer chemotheapy: nursing implications.

  Home healthcare nurse 20050301

• Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

  Molecular cancer therapeutics 20050301

• Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.

  Chemotherapy 20050301

• Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.

  IDrugs : the investigational drugs journal 20050301

• Gastrointestinal Cancers--Second Annual Symposium. 27-29 January 2005, Hollywood, FL, USA.

  IDrugs : the investigational drugs journal 20050301

• [Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.

  The oncologist 20050301

• The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide.

  Current medical research and opinion 20050301

• Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.

  Clinical therapeutics 20050301

• Synthesis and antitumor activity of A-ring modified hexacyclic analogues of camptothecin.

  Yao xue xue bao = Acta pharmaceutica Sinica 20050301

• Alternative administration of camptothecin analogues.

  Expert opinion on drug delivery 20050301

• Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.

  Nanomedicine : nanotechnology, biology, and medicine 20050301

• Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis.

  British journal of cancer 20050227

• Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

  British journal of cancer 20050227

• Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.

  British journal of cancer 20050227

• Synthesis, antitumor evaluation, and apoptosis-inducing activity of hydroxylated (E)-stilbenes.

  Journal of medicinal chemistry 20050224

• Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220

• Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220

• A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.

  Oncogene 20050217

• Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.

  Cancer 20050215

• Understanding topoisomerase I and II in terms of QSAR.

  Bioorganic & medicinal chemistry 20050215

• On the role of E-ring oxygen atoms in the binding of camptothecin to the topoisomerase I-DNA covalent binary complex.

  Bioorganic & medicinal chemistry 20050215

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

  Cancer research 20050215

• Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.

  Journal of medicinal chemistry 20050210

• Apoptosis-inducing factor is a key factor in neuronal cell death propagated by BAX-dependent and BAX-independent mechanisms.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050209

• A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).

  Journal of pharmaceutical and biomedical analysis 20050207

• Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line.

  The Journal of biological chemistry 20050204

• Systemic therapy for colorectal cancer.

  The New England journal of medicine 20050203

• Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.

  The Prostate 20050201

• The post-translational phosphorylation and acetylation modification profile is not the determining factor in targeting endogenous stress-induced p53 to mitochondria.

  Cell death and differentiation 20050201

• Long-term therapy with recombinant human erythropoietin increases CD8+ T-cell apoptosis in haemodialysis patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050201

• Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.

  Cancer 20050201

• Rotenone-induced caspase 9/3-independent and -dependent cell death in undifferentiated and differentiated human neural stem cells.

  Journal of neurochemistry 20050201

• Synthesis and anti-tumor activity of alkenyl camptothecin esters.

  Acta pharmacologica Sinica 20050201

• DNA topoisomerase I inhibitors from Rinorea anguifera.

  Bioorganic & medicinal chemistry letters 20050201

• The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

  Nature cell biology 20050201

• A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.

  Japanese journal of clinical oncology 20050201

• UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050201

• Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.

  Molecular cancer therapeutics 20050201

• The novel human gene aprataxin is directly involved in DNA single-strand-break repair.

  Cellular and molecular life sciences : CMLS 20050201

• Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.

  Seminars in oncology 20050201

• Adjuvant therapy of colon cancer.

  Seminars in oncology 20050201

• Combined modality treatment for rectal cancer.

  Seminars in oncology 20050201

• Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.

  Seminars in oncology 20050201

• Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.

  Seminars in oncology 20050201

• New colchicinoids from a native Jordanian meadow saffron, colchicum brachyphyllum: isolation of the first naturally occurring dextrorotatory colchicinoid.

  Journal of natural products 20050201

• Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells.

  The journal of medical investigation : JMI 20050201

• [Comparison between two methods for staining DNA of apoptotic spermatozoa].

  Zhonghua nan ke xue = National journal of andrology 20050201

• Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.

  Neoplasia (New York, N.Y.) 20050201

• Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.

  Annals of surgical oncology 20050201

• Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.

  Journal of chemotherapy (Florence, Italy) 20050201

• Dose-response for radiation-induced apoptosis, residual 53BP1 foci and DNA-loop relaxation in human lymphocytes.

  International journal of radiation biology 20050201

• Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts.

  Journal of pharmacokinetics and pharmacodynamics 20050201

• Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.

  British journal of cancer 20050131

• 14-azacamptothecin: a potent water-soluble topoisomerase I poison.

  Journal of the American Chemical Society 20050126

• Comparison of techniques for the extraction of the anti-cancer drug camptothecin from Nothapodytes foetida.

  Journal of chromatography. A 20050121

• Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

  British journal of cancer 20050117

• Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.

  Statistics in medicine 20050115

• Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

  Cancer 20050115

• Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.

  Experimental cell research 20050115

• Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• Antifungal activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca acuminata.

  Journal of agricultural and food chemistry 20050112

• Camptothecin-catalyzed phospholipid hydrolysis in liposomes.

  International journal of pharmaceutics 20050106

• Postsynthetic functionalization of triple helix-forming oligonucleotides.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.

  Biomedical chromatography : BMC 20050101

• Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).

  Cancer 20050101

• Interaction of 14-3-3 protein with Chk1 affects localization and checkpoint function.

  Journal of cell science 20050101

• Functional expression of TWEAK in human colonic adenocarcinoma cells.

  International journal of oncology 20050101

• Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors.

  Biochemical pharmacology 20050101

• Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

  Gynecologic oncology 20050101

• Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks.

  EMBO reports 20050101

• Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer.

  Anti-cancer drugs 20050101

• Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.

  Anti-cancer drugs 20050101

• Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050101

• Disc degeneration in the rabbit: a biochemical and radiological comparison between four disc injury models.

  Spine 20050101

• Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.

  BMC cancer 20050101

• Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.

  The Journal of pharmacy and pharmacology 20050101

• Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates pro-apoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G.

  Cardiovascular diabetology 20050101

• Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan.

  The Journal of international medical research 20050101

• Synergistic antitumor activity of capecitabine in combination with irinotecan.

  Clinical colorectal cancer 20050101

• Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.

  Clinical colorectal cancer 20050101

• [Second-line chemotherapy for advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• [Second-line chemotherapy for recurrent ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.

  Expert opinion on pharmacotherapy 20050101

• Toxicity of the topoisomerase I inhibitors.

  Expert opinion on drug safety 20050101

• The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice.

  Cancer biology & therapy 20050101

• Effects of CKD-602, a new camptothecin anticancer agent, on pregnant does and embryo-fetal development in rabbits.

  Drug and chemical toxicology 20050101

• The impact of tumor physiology on camptothecin-based drug development.

  Current medicinal chemistry. Anti-cancer agents 20050101

• Chemoresistance in non-small cell lung cancer.

  Current medicinal chemistry. Anti-cancer agents 20050101

• New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: a single center's experience before and after their introduction.

  International journal of gastrointestinal cancer 20050101

• Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• Small-cell lung cancer: current therapy and novel agents.

  Oncology (Williston Park, N.Y.) 20050101

• Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.

  Hepato-gastroenterology 20050101

• Apoptosis in infectious mononucleosis: its detection with the Beckman Coulter GenS hematology analyzer.

  Laboratory hematology : official publication of the International Society for Laboratory Hematology 20050101

• Novel camptothecin derivatives.

  In vivo (Athens, Greece) 20050101

• [Optimizing current drugs].

  Annales pharmaceutiques francaises 20050101

• Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats.

  Retina (Philadelphia, Pa.) 20050101

• Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats.

  Reproductive toxicology (Elmsford, N.Y.) 20050101

• First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.

  Oncology 20050101

• Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.

  Anticancer research 20050101

• FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases.

  Anticancer research 20050101

• Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.

  Medical hypotheses 20050101

• Benefit-risk assessment of irinotecan in advanced colorectal cancer.

  Drug safety 20050101

• Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.

  Pharmacogenetics and genomics 20050101

• Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20050101

• New chemotherapeutic strategies in colorectal cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20050101

• Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.

  Anticancer research 20050101

• Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.

  Anticancer research 20050101

• Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy.

  Anticancer research 20050101

• Examination of meningocele induced by the antitumor agent DE-310 in rat fetuses.

  Reproductive toxicology (Elmsford, N.Y.) 20050101

• A simple technique for quantifying apoptosis in 96-well plates.

  BMC biotechnology 20050101

• Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.

  Methods in molecular medicine 20050101

• [Improving longevity in advanced intestinal cancer].

  Krankenpflege Journal 20050101

• (Neo-)adjuvant treatments in colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050101

• Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.

  Medical oncology (Northwood, London, England) 20050101

• Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.

  Cancer journal (Sudbury, Mass.) 20050101

• Novel agents that potentially inhibit irinotecan-induced diarrhea.

  Current medicinal chemistry 20050101

• [p53 gene expression and activation of p53-dependent transcription in melanoma cell lines].

  Molekuliarnaia biologiia 20050101

• Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.

  In vivo (Athens, Greece) 20050101

• The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.

  Oncology 20050101

• Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

  Oncology 20050101

• Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.

  Oncology 20050101

• Cancer cell adaptation to chemotherapy.

  BMC cancer 20050101

• Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

  Acta oncologica (Stockholm, Sweden) 20050101

• Capecitabine as third line therapy in patients with advanced colorectal cancer.

  Acta oncologica (Stockholm, Sweden) 20050101

• Membrane blebbing in cancer cells treated with various apoptotic inducers.

  Acta medica (Hradec Kralove) 20050101

• Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.

  Anticancer research 20050101

• Exogenous expression of hRFI induces multidrug resistance through escape from apoptosis in colorectal cancer cells.

  Anticancer research 20050101

• Pharmacokinetics and metabolism of irinotecan combined with capecitabine in patients with advanced colorectal cancer.

  Anticancer research 20050101

• Nuclear area is a prognostic determinant in advanced colorectal cancer.

  Anticancer research 20050101

• Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.

  Oncology 20050101

• A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.

  Oncology 20050101

• Transfection assays with allele-specific constructs: functional analysis of UDP-glucuronosyltransferase variants.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy.

  Anticancer research 20050101

• Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports.

  Anticancer research 20050101

• Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.

  Anticancer research 20050101

• Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer.

  Anticancer research 20050101

• A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20050101

• Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.

  Medical oncology (Northwood, London, England) 20050101

• Improved tagging strategy for protein identification in mammalian cells.

  BMC genomics 20050101

• Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.

  Breast cancer research : BCR 20050101

• [Utilizing synergism].

  Krankenpflege Journal 20050101

• Clinical trial designs for prospective validation of biomarkers.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

  Cancer cell international 20050101

• A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.

  Clinical chemistry and laboratory medicine 20050101

• Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.

  Acta oncologica (Stockholm, Sweden) 20050101

• DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents.

  Current topics in medicinal chemistry 20050101

• Clinical pharmacogenetics of irinotecan (CPT-11).

  Drug metabolism reviews 20050101

• Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics.

  International journal of toxicology 20050101

• Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

  Nature clinical practice. Oncology 20050101

• Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?

  Nature clinical practice. Gastroenterology & hepatology 20050101

• The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line.

  Acta biochimica Polonica 20050101

• Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG).

  Tumori 20050101

• High salt culture conditions suppress proliferation of rat C6 glioma cell by arresting cell-cycle progression at S-phase.

  Journal of molecular neuroscience : MN 20050101

• An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.

  Oncology 20050101

• [Biotherapy in colorectal cancer].

  Journal de chirurgie 20050101

• Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.

  Oncology 20050101

• Same-day pegfilgrastim and chemotherapy.

  Cancer investigation 20050101

• The inhibition of angiogenesis by antisense oligonucleotides to clusterin.

  Angiogenesis 20050101

• Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.

  Oncology 20050101

• Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients.

  Hepato-gastroenterology 20050101

• [Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].

  Casopis lekaru ceskych 20050101

• SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling.

  Journal of translational medicine 20050101

• Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study.

  European journal of gynaecological oncology 20050101

• Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy.

  Tumori 20050101

• Chemotherapy for colorectal cancer.

  Digestive surgery 20050101

• Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines.

  Oncology research 20050101

• [New chances in therapy of gastrointestinal tumors].

  Krankenpflege Journal 20050101

• [The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].

  Magyar onkologia 20050101

• Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.

  Oncology research 20050101

• TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II.

  The Journal of biological chemistry 20041231

• Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

  The Journal of biological chemistry 20041224

• Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.

  The Journal of biological chemistry 20041224

• Intramolecular hetero Diels-Alder (Povarov) approach to the synthesis of the alkaloids luotonin A and camptothecin.

  Organic letters 20041223

• [Chemotherapy of advanced stomach cancer].

  Zhonghua yi xue za zhi 20041217

• Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

  Cancer research 20041215

• HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.

  Cancer research 20041215

• Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.

  Cancer research 20041215

• Camptothecin-induced imbalance in intracellular cation homeostasis regulates programmed cell death in unicellular hemoflagellate Leishmania donovani.

  The Journal of biological chemistry 20041210

• Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity.

  The Journal of biological chemistry 20041210

• Steady-state fluorescence study on release of camptothecin from agar hydrogel.

  International journal of pharmaceutics 20041209

• GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells.

  Cancer letters 20041208

• Synthesis and cytotoxic activity of substituted luotonin A derivatives.

  Bioorganic & medicinal chemistry letters 20041206

• Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.

  Cancer chemotherapy and pharmacology 20041201

• Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.

  Cancer chemotherapy and pharmacology 20041201

• Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20041201

• Two schedules of second-line irinotecan for metastatic colon carcinoma.

  Cancer 20041201

• Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats.

  Regulatory toxicology and pharmacology : RTP 20041201

• Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.

  International journal of oncology 20041201

• Suppressive effect of CPT-11 on rat esophageal tumorigenesis induced by N-nitrosomethylbenzylamine.

  Oncology reports 20041201

• First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041201

• Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041201

• Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

  Annals of surgery 20041201

• Which drug combination for colorectal cancer?

  Expert opinion on pharmacotherapy 20041201

• Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.

  European journal of cancer (Oxford, England : 1990) 20041201

• Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

  Cancer research 20041201

• [Clinical pathway based on evidence-based medicine (EBM) for chemotherapy for lung cancer].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20041201

• Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38.

  Clinical pharmacology and therapeutics 20041201

• [Colorectal cancer: current treatment options].

  Zeitschrift fur Gastroenterologie 20041201

• [Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20041201

• Sensitization of tumor cells toward chemotherapy: enhancing the efficacy of camptothecin with imidazolines.

  Chemistry & biology 20041201

• Bevacizumab for advanced colorectal cancer.

  Issues in emerging health technologies 20041201

• Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.

  Thrombosis and haemostasis 20041201

• A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

  Bulletin du cancer 20041201

• Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death.

  Molecular cancer therapeutics 20041201

• New camptothecin and ellagic acid analogues from the root bark of Camptotheca acuminata.

  Planta medica 20041201

• [Topoisomerase I inhibitor (irinotecan hydrochloride)].

  Nihon rinsho. Japanese journal of clinical medicine 20041201

• Irinotecan and other agents in the management of multiple tumor types. Highlights from the 6th University of Texas M. D. Anderson Cancer Center Investigators' Workshop. July 16-20, 2003, Amelia Island, Florida, USA.

  Oncology (Williston Park, N.Y.) 20041201

• Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.

  Oncology (Williston Park, N.Y.) 20041201

• Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.

  Oncology (Williston Park, N.Y.) 20041201

• Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.

  Oncology (Williston Park, N.Y.) 20041201

• Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.

  Oncology (Williston Park, N.Y.) 20041201

• Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20041201

• Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.

  Oncology (Williston Park, N.Y.) 20041201

• Combined-modality therapy of rectal cancer with irinotecan-based regimens.

  Oncology (Williston Park, N.Y.) 20041201

• The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells.

  Experimental lung research 20041201

• Future directions of liposome- and immunoliposome-based cancer therapeutics.

  Seminars in oncology 20041201

• [Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041201

• Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer.

  Journal of experimental therapeutics & oncology 20041201

• Genome instability in ataxia telangiectasia (A-T) families: camptothecin-induced damage to replicating DNA discriminates between obligate A-T heterozygotes, A-T homozygotes and controls.

  Bioscience reports 20041201

• Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation.

  Journal of controlled release : official journal of the Controlled Release Society 20041124

• [Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].

  MMW Fortschritte der Medizin 20041118

• Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

  Cancer 20041115

• Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity.

  Bioorganic & medicinal chemistry letters 20041115

• Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041115

• Combined directed ortho metalation/cross-coupling strategies: synthesis of the tetracyclic A/B/C/D ring core of the antitumor agent camptothecin.

  The Journal of organic chemistry 20041112

• Multiple binding modes of the camptothecin family to DNA oligomers.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20041105

• Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.

  Journal of medicinal chemistry 20041104

• Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

  Journal of the National Cancer Institute 20041103

• Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine.

  International journal of colorectal disease 20041101

• Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis.

  Cancer chemotherapy and pharmacology 20041101

• Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.

  Investigational new drugs 20041101

• The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.

  International journal of colorectal disease 20041101

• Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.

  Bioorganic & medicinal chemistry letters 20041101

• GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.

  Experimental cell research 20041101

• Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant.

  British journal of cancer 20041101

• Apoptosis induced kinetic changes in autofluorescence of cultured HL60 cells-possible application for single cell analysis on chip.

  Apoptosis : an international journal on programmed cell death 20041101

• Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells.

  Apoptosis : an international journal on programmed cell death 20041101

• Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• Palliative chemotherapy for advanced gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041101

• Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041101

• A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.

  Clinical pharmacology and therapeutics 20041101

• Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11).

  Clinical pharmacology and therapeutics 20041101

• Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.

  Journal of pediatric hematology/oncology 20041101

• Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.

  Clinical colorectal cancer 20041101

• [A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• [CPT-11 combined chemotherapy for metastatic gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• [A case of liver metastatic recurrence of gastric cancer effectively treated by combined chemotherapy of CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041101

• Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting.

  Pharmaceutical research 20041101

• Hierarchical models for tumor xenograft experiments in drug development.

  Journal of biopharmaceutical statistics 20041101

• Making inferences about projected completors in longitudinal studies.

  Journal of biopharmaceutical statistics 20041101

• Improvement of growth and camptothecin yield by altering nitrogen source supply in cell suspension cultures of Camptotheca acuminata.

  Biotechnology letters 20041101

• Pemetrexed in advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20041101

• Limited potential of hepatic arterial infusion of irinotecan.

  Journal of chemotherapy (Florence, Italy) 20041101

• Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20041101

• Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.

  Journal of chemotherapy (Florence, Italy) 20041101

• Novel autoxidative cleavage reaction of 9-fluoredenes discovered during synthesis of a potential DNA-threading indenoisoquinoline.

  The Journal of organic chemistry 20041029

• Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.

  British journal of cancer 20041018

• A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

  British journal of cancer 20041018

• Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.

  British journal of cancer 20041018

• Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.

  British journal of cancer 20041018

• Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.

  British journal of cancer 20041018

• Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.

  Cancer 20041015

• Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents.

  Cancer research 20041015

• Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.

  Cancer research 20041015

• Bevacizumab in colorectal cancer.

  The New England journal of medicine 20041014

• Effect of hydroxypropyl-beta-cyclodextrin-complexation and pH on solubility of camptothecin.

  International journal of pharmaceutics 20041013

• Antitumor agents. 234. Design, synthesis, and biological evaluation of novel 4beta-[(4' '-benzamido)-amino]-4'-o-demethyl-epipodophyllotoxin derivatives.

  Journal of medicinal chemistry 20041007

• Cetuximab in colon cancer.

  The New England journal of medicine 20041007

• Cetuximab in colon cancer.

  The New England journal of medicine 20041007

• Excited-state proton transfer reactions of 10-hydroxycamptothecin.

  Journal of the American Chemical Society 20041006

• Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.

  Journal of the National Cancer Institute 20041006

• Identification and characterization of the rlp1+, the novel Rad51 paralog in the fission yeast Schizosaccharomyces pombe.

  DNA repair 20041005

• Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.

  British journal of cancer 20041004

• Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

  British journal of cancer 20041004

• Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.

  Cancer chemotherapy and pharmacology 20041001

• The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.

  Cancer chemotherapy and pharmacology 20041001

• Ascorbate modulation of H(2)O(2) and camptothecin-induced cell death in Jurkat cells.

  Cancer chemotherapy and pharmacology 20041001

• New approaches to prevent intestinal toxicity of irinotecan-based regimens.

  Cancer treatment reviews 20041001

• Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.

  Bioorganic & medicinal chemistry 20041001

• New options and old dilemmas in the treatment of patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041001

• Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041001

• A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

  Gynecologic oncology 20041001

• Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.

  Gynecologic oncology 20041001

• Multi-copy suppression of an Aspergillus nidulans mutant sensitive to camptothecin by a putative monocarboxylate transporter.

  Current microbiology 20041001

• Role of eIF5A in TNF-alpha-mediated apoptosis of lamina cribrosa cells.

  Investigative ophthalmology & visual science 20041001

• [Advances in palliative and adjuvant chemotherapy of colon cancer].

  Deutsche medizinische Wochenschrift (1946) 20041001

• Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.

  Anti-cancer drugs 20041001

• Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro.

  Anti-cancer drugs 20041001

• Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

  The Annals of thoracic surgery 20041001

• Pharmacogenetics of irinotecan toxicity.

  Pharmacogenomics 20041001

• Camptothecin, over four decades of surprising findings.

  Phytochemistry 20041001

• Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041001

• High-content screening with siRNA optimizes a cell biological approach to drug discovery: defining the role of P53 activation in the cellular response to anticancer drugs.

  Journal of biomolecular screening 20041001

• [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [Chemotherapy using nedaplatin for advanced gynecologic cancers].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [Treatment of platinum-resistant ovarian cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.

  International journal of clinical oncology 20041001

• Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.

  International journal of clinical oncology 20041001

• [Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [Case report--Complete response of liver metastasis of rectal cancer after combination chemotherapy of CPT-11 + UFT-E].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [CPT-11 hepatic arterial infusion chemotherapy for metastatic liver tumor from gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [Evaluation of bronchial arterial infusion (BAI) for metastatic lung tumor from colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• [A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041001

• Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents.

  The Journal of parasitology 20041001

• Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?

  Journal of chemotherapy (Florence, Italy) 20041001

• Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.

  International journal of clinical practice 20041001

• Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.

  American journal of clinical oncology 20041001

• [The in vitro kinetics of uptake, transport and efflux of 9-nitrocamptothecin in Caco-2 cell model].

  Yao xue xue bao = Acta pharmaceutica Sinica 20041001

• Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.

  Journal of experimental therapeutics & oncology 20041001

• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040915

• Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.

  Cancer research 20040915

• Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.

  Cancer research 20040915

• No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.

  British journal of cancer 20040913

• Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.

  British journal of cancer 20040913

• Reduced Apaf-1 expression in human cutaneous melanomas.

  British journal of cancer 20040913

• Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.

  The Journal of biological chemistry 20040903

• Degradation of camptothecin-20(S)-glycinate ester prodrug under physiological conditions.

  Journal of pharmaceutical and biomedical analysis 20040903

• 2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.

  Cancer biology & therapy 20040901

• Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.

  Oncology reports 20040901

• Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.

  International journal of oncology 20040901

• Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.

  Gut 20040901

• Integration of novel agents in the treatment of colorectal cancer.

  Cancer chemotherapy and pharmacology 20040901

• Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20040901

• Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I.

  Molecular pharmacology 20040901

• DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.

  Molecular pharmacology 20040901

• Pharmacogenomics and stomach cancer.

  Pharmacogenomics 20040901

• ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

• Gefitinib reverses breast cancer resistance protein-mediated drug resistance.

  Molecular cancer therapeutics 20040901

• Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.

  Clinical colorectal cancer 20040901

• Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.

  Current medicinal chemistry. Anti-cancer agents 20040901

• Evidence-based update of chemotherapy options for metastatic colorectal cancer.

  ANZ journal of surgery 20040901

• [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• [A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• [A case of 5-FU-resistant recurrent colon cancer treated with low-dose CPT-11/CDDP on an outpatient basis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040901

• Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.

  Pharmacogenetics 20040901

• Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.

  Anti-cancer drugs 20040901

• Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.

  Anti-cancer drugs 20040901

• The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

  Neoplasia (New York, N.Y.) 20040901

• Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).

  Journal of experimental & clinical cancer research : CR 20040901

• [Distribution of hydroxycamptothecin after aerosol inhalation in rabbits].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040901

• A method to determine the incorporation capacity of camptothecin in liposomes.

  AAPS PharmSciTech 20040901

• The treatment of colorectal carcinoma: standard chemotherapy and beyond.

  Clinical advances in hematology & oncology : H&O 20040901

• Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

  Journal of the National Comprehensive Cancer Network : JNCCN 20040901

• Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.

  International journal of cancer 20040820

• p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress.

  Oncogene 20040819

• Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

  British journal of cancer 20040816

• UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

  British journal of cancer 20040816

• Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

  Cancer research 20040815

• Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin.

  Bioorganic & medicinal chemistry letters 20040802

• Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.

  British journal of cancer 20040802

• ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.

  The Journal of pharmacology and experimental therapeutics 20040801

• Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani.

  Cell death and differentiation 20040801

• A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.

  Investigational new drugs 20040801

• Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.

  Investigational new drugs 20040801

• 9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.

  Investigational new drugs 20040801

• Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.

  Investigational new drugs 20040801

• Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.

  Journal of cancer research and clinical oncology 20040801

• Aggregation properties of a HPMA-camptothecin copolymer in isotonic solutions.

  Biophysical chemistry 20040801

• Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.

  European urology 20040801

• Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins.

  Bioorganic & medicinal chemistry 20040801

• Cisplatin enhances the p53-independent apoptosis induced by a topoisomerase I inhibitor (CPT-11) in the lens epithelial tumors in transgenic mice.

  Oncology reports 20040801

• Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.

  Oncology reports 20040801

• UGT1A1*28 polymorphism in ovarian cancer patients.

  Oncology reports 20040801

• Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta.

  International journal of oncology 20040801

• Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.

  Molecular pharmacology 20040801

• Developments in combination chemotherapy for colorectal cancer.

  Expert review of anticancer therapy 20040801

• Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.

  Journal of the American College of Surgeons 20040801

• Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040801

• A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040801

• Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040801

• Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.

  Clinical chemistry 20040801

• Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.

  Journal of surgical oncology 20040801

• A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040801

• Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

  Journal of clinical pharmacology 20040801

• Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

  Gynecologic oncology 20040801

• Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040801

• Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040801

• Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.

  Molecular cancer therapeutics 20040801

• Treatment issues in pediatric gastric adenocarcinoma.

  Journal of pediatric surgery 20040801

• [Methylated oligonucleotide inhibiting expression of human MRP2 and reversing multidrug resistance in hepatocellular carcinoma Cell HepG2].

  Ai zheng = Aizheng = Chinese journal of cancer 20040801

• Camptothecin-loaded films for the prevention of postsurgical adhesions.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20040801

• [A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040801

• [A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040801

• Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management.

  British journal of cancer 20040801

• Understanding the mechanisms of drug-associated interstitial lung disease.

  British journal of cancer 20040801

• The Aspergillus nidulans npkA gene encodes a Cdc2-related kinase that genetically interacts with the UvsBATR kinase.

  Genetics 20040801

• [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].

  Zentralblatt fur Chirurgie 20040801

• An ent-kaurene diterpene enhances apoptosis induced by tumor necrosis factor in human leukemia cells.

  Planta medica 20040801

• [Synthesis and antitumor activity of 20-O-linked camptothecin ester derivatives].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040801

• [Accumulation and localization of camptothecin in young shoot of Camptotheca acuminata].

  Zhi wu sheng li yu fen zi sheng wu xue xue bao = Journal of plant physiology and molecular biology 20040801

• Current and future strategies for treating metastatic pancreatic cancer.

  Clinical advances in hematology & oncology : H&O 20040801

• The price tag on progress--chemotherapy for colorectal cancer.

  The New England journal of medicine 20040722

• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  The New England journal of medicine 20040722

• New treatment options for colorectal cancer.

  The New England journal of medicine 20040722

• Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.

  International journal of cancer 20040720

• Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.

  Bioorganic & medicinal chemistry letters 20040716

• A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells.

  Biochemical pharmacology 20040715

• Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer.

  Statistics in medicine 20040715

• Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040715

• Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer.

  Cancer research 20040715

• BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.

  Cancer research 20040715

• Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers.

  Journal of controlled release : official journal of the Controlled Release Society 20040707

• Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT).

  British journal of cancer 20040705

• Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells.

  British journal of cancer 20040705

• The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1.

  The Journal of biological chemistry 20040702

• Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.

  Journal of cancer research and clinical oncology 20040701

• Treatment options for small cell lung cancer.

  Current oncology reports 20040701

• An in vitro model system that can differentiate the stages of DNA replication affected by anticancer agents.

  Biochemical pharmacology 20040701

• The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).

  Biochemical pharmacology 20040701

• Synthesis and antitumor activity of 20-O-linked nitrogen-based camptothecin ester derivatives.

  Bioorganic & medicinal chemistry 20040701

• A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study.

  Lung cancer (Amsterdam, Netherlands) 20040701

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.

  Journal of clinical pharmacology 20040701

• Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Irinotecan chemotherapy associated with transient dysarthria and aphasia.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040701

• Gimatecan, a novel camptothecin with a promising preclinical profile.

  Anti-cancer drugs 20040701

• Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.

  Anti-cancer drugs 20040701

• The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.

  European journal of biochemistry 20040701

• Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.

  Expert opinion on pharmacotherapy 20040701

• Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.

  Molecular pharmacology 20040701

• Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.

  Clinical pharmacology and therapeutics 20040701

• [Basic studies for the development of anticancer, antidementia, and taste modifier drugs].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20040701

• Cytotoxic and antimicrobial constituents of the bark of Diospyros maritima collected in two geographical locations in Indonesia.

  Journal of natural products 20040701

• [A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.

  The Israel Medical Association journal : IMAJ 20040701

• Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.

  Current medicinal chemistry. Anti-cancer agents 20040701

• In vitro cytotoxicity of berberine against HeLa and L1210 cancer cell lines.

  Die Pharmazie 20040701

• Inhibitors of topoisomerases as anticancer drugs: problems and prospects.

  Indian journal of experimental biology 20040701

• Circadian rhythm of irinotecan tolerability in mice.

  Chronobiology international 20040701

• [Synthesis and antitumor activities of 10-hydroxy camptothecin derivatives].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040701

• Polymer design and incorporation methods for polymeric micelle carrier system containing water-insoluble anti-cancer agent camptothecin.

  Journal of drug targeting 20040701

• NCCN guideline updates: colon and rectal cancers, version 1.2004.

  Journal of the National Comprehensive Cancer Network : JNCCN 20040701

• A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

  Blood 20040615

• Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

  British journal of cancer 20040614

• A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.

  British journal of cancer 20040614

• Mechanisms of camptothecin resistance by human topoisomerase I mutations.

  Journal of molecular biology 20040611

• Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-beta-D-arabinofuranosylcytosine and bleomycin.

  Experimental cell research 20040610

• Two new drugs for colon cancer.

  The Medical letter on drugs and therapeutics 20040607

• The role of TDP1 from budding yeast in the repair of DNA damage.

  DNA repair 20040603

• The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function.

  DNA repair 20040603

• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20040603

• Heparin/heparan sulfate interacting protein plays a role in apoptosis induced by anticancer drugs.

  Carcinogenesis 20040601

• Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20040601

• Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.

  Cancer chemotherapy and pharmacology 20040601

• Use of cellular glucose-6-phosphate dehydrogenase for cell quantitation: applications in cytotoxicity and apoptosis assays.

  Analytical biochemistry 20040601

• A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040601

• Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040601

• Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.

  Molecular pharmacology 20040601

• An immediate hemolytic reaction induced by repeated administration of oxaliplatin.

  Transfusion 20040601

• Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.

  Cancer 20040601

• Monitoring caspase activity in living cells using fluorescent proteins and flow cytometry.

  The American journal of pathology 20040601

• Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.

  Anti-cancer drugs 20040601

• Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.

  Anti-cancer drugs 20040601

• Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.

  American journal of clinical oncology 20040601

• RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.

  European journal of cancer (Oxford, England : 1990) 20040601

• 'Irinogenetics' and UGT1A: from genotypes to haplotypes.

  Clinical pharmacology and therapeutics 20040601

• UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.

  Clinical pharmacology and therapeutics 20040601

• A novel mouse model of rectal cancer established by orthotopic implantation of colon cancer cells.

  Cancer science 20040601

• In vitro conversion of irinotecan to SN-38 in human plasma.

  Cancer science 20040601

• Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin.

  European journal of medicinal chemistry 20040601

• Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.

  Human pathology 20040601

• [Management of chemotherapy induced diarrhea].

  Zeitschrift fur Gastroenterologie 20040601

• Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.

  Gynecologic oncology 20040601

• Current approaches to first-line treatment of advanced colorectal cancer.

  Clinical colorectal cancer 20040601

• Current status of second-line therapy for metastatic colorectal cancer.

  Clinical colorectal cancer 20040601

• Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.

  Clinical colorectal cancer 20040601

• Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.

  International journal of clinical oncology 20040601

• [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• [Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040601

• [Anti-tumor effects of 10-hydroxycamptothecinc-treated DC-Hepa1-6 fusion vaccines].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20040601

• Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.

  The Journal of pharmacy and pharmacology 20040601

• Camptothecin sensitivity in Werner syndrome fibroblasts as assessed by the COMET technique.

  Annals of the New York Academy of Sciences 20040601

• Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.

  Onkologie 20040601

• [New therapy options in colorectal carcinoma].

  Therapeutische Umschau. Revue therapeutique 20040601

• Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.

  Oncology (Williston Park, N.Y.) 20040601

• Irinotecan in advanced lung cancer: focus on North American trials.

  Oncology (Williston Park, N.Y.) 20040601

• Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.

  Oncology (Williston Park, N.Y.) 20040601

• Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.

  Experimental oncology 20040601

• A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.

  Japanese journal of clinical oncology 20040601

• Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin.

  Journal of controlled release : official journal of the Controlled Release Society 20040531

• Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.

  The Journal of biological chemistry 20040528

• Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism of nucleolar/nucleoplasmic partitioning of topoisomerase I.

  The Journal of biological chemistry 20040521

• Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents.

  Oncogene 20040520

• Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells.

  Journal of agricultural and food chemistry 20040519

• Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

  British journal of cancer 20040517

• Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.

  Cancer research 20040515

• Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040515

• The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons.

  The Journal of biological chemistry 20040514

• Bcl-xES, a BH4- and BH2-containing antiapoptotic protein, delays Bax oligomer formation and binds Apaf-1, blocking procaspase-9 activation.

  Oncogene 20040513

• ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.

  International journal of cancer 20040510

• Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani.

  FEBS letters 20040507

• Synthesis and biochemical properties of E-ring modified luotonin A derivatives.

  Bioorganic & medicinal chemistry letters 20040503

• Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions.

  Carcinogenesis 20040501

• Modeling antitumor activity by using a non-linear mixed-effects model.

  Mathematical biosciences 20040501

• A biodegradable injectable thermoplastic for localized camptothecin delivery.

  Journal of pharmaceutical sciences 20040501

• Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.

  Analytical biochemistry 20040501

• Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.

  Drug metabolism and disposition: the biological fate of chemicals 20040501

• IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.

  Journal of immunology (Baltimore, Md. : 1950) 20040501

• Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells.

  Molecular pharmacology 20040501

• A flow cytometric assay for simultaneous assessment of drug efflux, proliferation, and apoptosis.

  Cytometry. Part B, Clinical cytometry 20040501

• Irinotecan-induced interstitial pneumonia.

  The Lancet. Oncology 20040501

• Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.

  Hepatology (Baltimore, Md.) 20040501

• In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.

  Cancer research 20040501

• Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines.

  The Journal of clinical endocrinology and metabolism 20040501

• The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.

  Cancer science 20040501

• Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.

  Molecular cancer therapeutics 20040501

• Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents.

  Neoplasia (New York, N.Y.) 20040501

• Emerging DNA topisomerase inhibitors as anticancer drugs.

  Expert opinion on emerging drugs 20040501

• Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.

  Critical reviews in oncology/hematology 20040501

• Further bioactive piperidine alkaloids from the flowers and green fruits of Cassia spectabilis.

  Journal of natural products 20040501

• [Chemotherapy for small cell lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040501

• [A case of gastric metastasis of small cell cancer of the lung, regression of the gastric lesion after chemotherapy].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20040501

• [Chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040501

• [A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040501

• Reactivation of hepatitis C virus after chemotherapy for colon cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20040501

• Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.

  Clinical colorectal cancer 20040501

• Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.

  Die Pharmazie 20040501

• Progress in the development of novel treatments for colorectal cancer.

  Oncology (Williston Park, N.Y.) 20040501

• Current strategies in previously untreated advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20040501

• Current status of adjuvant therapy for colorectal cancer.

  Oncology (Williston Park, N.Y.) 20040501

• A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.

  Japanese journal of clinical oncology 20040501

• Apoptotic cell death kinetics in vitro depend on the cell types and the inducers used.

  Apoptosis : an international journal on programmed cell death 20040501

• [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040501

• Rad9 protects cells from topoisomerase poison-induced cell death.

  The Journal of biological chemistry 20040430

• Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

  British journal of cancer 20040419

• Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

  British journal of cancer 20040419

• Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice.

  Journal of controlled release : official journal of the Controlled Release Society 20040416

• Irinotecan pharmacogenetics: is it time to intervene?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Bioactivation of carbamate-based 20(S)-camptothecin prodrugs.

  Bioorganic & medicinal chemistry 20040415

• Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model.

  World journal of gastroenterology 20040415

• Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040415

• Inhibitory activities against topoisomerase I and II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship.

  Bioorganic & medicinal chemistry letters 20040405

• Efficient and chemoselective N-acylation of 10-amino-7-ethyl camptothecin with poly(ethylene glycol).

  Bioorganic & medicinal chemistry letters 20040405

• A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.

  Investigational new drugs 20040401

• Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.

  Journal of cancer research and clinical oncology 20040401

• Human topoisomerase I mediates illegitimate recombination leading to DNA insertion into the ribosomal DNA locus in Saccharomyces cerevisiae.

  Molecular genetics and genomics : MGG 20040401

• Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20040401

• Camptothecin: current perspectives.

  Bioorganic & medicinal chemistry 20040401

• Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.

  Bioorganic & medicinal chemistry 20040401

• Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040401

• Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040401

• A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040401

• Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

  Cancer 20040401

• A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.

  Gynecologic oncology 20040401

• Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040401

• Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

  Cancer research 20040401

• Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040401

• Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040401

• Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.

  Molecular cancer therapeutics 20040401

• [Prospective randomized study of HMVP, MVP, and HVP regimens in treatment of advanced non-small cell lung cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20040401

• Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.

  International journal of clinical oncology 20040401

• [Screening of DNA topoisomerase inhibitors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Screening for inhibitors of tumor invasion into basement membranes].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Structure-activity relationship analysis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

  Neuro-oncology 20040401

• Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

  Neuro-oncology 20040401

• Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.

  International journal of hematology 20040401

• Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.

  Journal of experimental therapeutics & oncology 20040401

• Telomeric DNA damage by topoisomerase I. A possible mechanism for cell killing by camptothecin.

  The Journal of biological chemistry 20040326

• Nanobiohybrids as delivery vehicles for camptothecin.

  Journal of controlled release : official journal of the Controlled Release Society 20040324

• Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040324

• Enhanced stimulation of chromosomal translocations by radiomimetic DNA damaging agents and camptothecin in Saccharomyces cerevisiae rad9 checkpoint mutants.

  Mutation research 20040322

• Camptothecin-sensitive relaxation of supercoiled DNA by the topoisomerase I-like activity associated with poly(ADP-ribose) polymerase-1.

  The Journal of biological chemistry 20040319

• Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.

  Journal of molecular biology 20040319

• Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs.

  International journal of pharmaceutics 20040319

• Subcellular localization of the camptothecin analogues, topotecan and gimatecan.

  Biochemical pharmacology 20040315

• Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin.

  Cancer research 20040315

• Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040315

• Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040315

• Validation study of assay method for DE-310, a novel polymer-bound camptothecin derivative, and the free drug in mouse plasma by liquid chromatography with fluorimetric detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040305

• Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.

  Oncogene 20040304

• A novel role for serum response factor in neuronal survival.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040303

• Prevention of TNF-alpha-induced apoptosis in polyamine-depleted IEC-6 cells is mediated through the activation of ERK1/2.

  American journal of physiology. Gastrointestinal and liver physiology 20040301

• Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.

  Cancer chemotherapy and pharmacology 20040301

• Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin.

  International journal of cancer 20040301

• Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.

  European journal of cancer (Oxford, England : 1990) 20040301

• Comparison of the X-radiation, drug and ultraviolet-radiation responses of clones isolated from a human colorectal tumor cell line.

  Radiation research 20040301

• Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040301

• Quantification of tumor tissue populations by multispectral analysis.

  Magnetic resonance in medicine 20040301

• Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?

  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20040301

• Diflomotecan. Ipsen.

  IDrugs : the investigational drugs journal 20040301

• Camptothecins in clinical development.

  Expert opinion on investigational drugs 20040301

• A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040301

• Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

  Anti-cancer drugs 20040301

• Recent anticancer cytotoxic agents.

  Current medicinal chemistry. Anti-cancer agents 20040301

• Cytotoxic constituents of the twigs and leaves of Aglaia rubiginosa.

  Journal of natural products 20040301

• [Two cases of metastatic or recurrent rectal cancer responding to combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040301

• Chemotherapy-induced lung disease.

  Clinics in chest medicine 20040301

• Chemotherapy of small cell lung cancer: state of the art.

  Current opinion in oncology 20040301

• Systemic treatment of advanced colorectal carcinoma.

  European journal of gastroenterology & hepatology 20040301

• [Resection of liver metastasis of colorectal origin following chemotherapy with irinotecan].

  Annales de chirurgie 20040301

• Murine lupus autoantibodies identify distinct subsets of apoptotic bodies.

  Autoimmunity 20040301

• Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.

  The Journal of biological chemistry 20040227

• Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin.

  Journal of medicinal chemistry 20040226

• Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.

  Biochemistry 20040224

• N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx.

  British journal of cancer 20040223

• Mode of binding of camptothecins to double helix oligonucleotides.

  Organic & biomolecular chemistry 20040221

• Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.

  Journal of the American Chemical Society 20040218

• Alteration in copy numbers of genes as a mechanism for acquired drug resistance.

  Cancer research 20040215

• Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival.

  Cancer research 20040215

• Pheophorbide a is a specific probe for ABCG2 function and inhibition.

  Cancer research 20040215

• Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications.

  Cancer research 20040215

• p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.

  Oncogene 20040212

• Development and characterization of a novel liposome-based formulation of SN-38.

  International journal of pharmaceutics 20040211

• Regions within the N-terminal domain of human topoisomerase I exert important functions during strand rotation and DNA binding.

  Journal of molecular biology 20040206

• Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons.

  Organic letters 20040205

• PR-39, a porcine antimicrobial peptide, inhibits apoptosis: involvement of caspase-3.

  Developmental and comparative immunology 20040201

• Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.

  Cancer chemotherapy and pharmacology 20040201

• Inhibitory effect of IGF-I on induced apoptosis in mouse preimplantation embryos cultured in vitro.

  Theriogenology 20040201

• Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells.

  Kidney international 20040201

• Synthesis of condensed quinolines and quinazolines as DNA ligands.

  Bioorganic & medicinal chemistry 20040201

• New method for the analysis of cell cycle-specific apoptosis.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20040201

• Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.

  American journal of clinical oncology 20040201

• First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?

  Annals of oncology : official journal of the European Society for Medical Oncology 20040201

• Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

  Cancer research 20040201

• Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex.

  Cancer research 20040201

• DNA repair functions that control sensitivity to topoisomerase-targeting drugs.

  Eukaryotic cell 20040201

• Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models.

  Cancer science 20040201

• Special issue for Monroe Wall and Mansukh Wani. A Festschrift.

  Journal of natural products 20040201

• Camptothecin and taxol: historic achievements in natural products research.

  Journal of natural products 20040201

• A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy.

  Journal of natural products 20040201

• Focus on gastric cancer.

  Cancer cell 20040201

• Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.

  Internal medicine (Tokyo, Japan) 20040201

• A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.

  Journal of neuro-oncology 20040201

• New developments in the treatment of esophageal cancer.

  Clinical advances in hematology & oncology : H&O 20040201

• UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.

  British journal of cancer 20040126

• Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.

  British journal of cancer 20040126

• The role of lysine 532 in the catalytic mechanism of human topoisomerase I.

  The Journal of biological chemistry 20040123

• Biliary excretion of irinotecan and its metabolites.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20040123

• Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.

  International journal of cancer 20040120

• Glutathione S-transferase P1 has protective effects on cell viability against camptothecin.

  Cancer letters 20040120

• A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks.

  Human molecular genetics 20040115

• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040115

• Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.

  Cancer 20040115

• Novel mode of action of tylophorine analogs as antitumor compounds.

  Cancer research 20040115

• Cancer pharmacogenetics.

  British journal of cancer 20040112

• Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).

  British journal of cancer 20040112

• Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105

• Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105

• Camptothecin and 10-hydroxycamptothecin from Camptotheca acuminata hairy roots.

  Plant cell reports 20040101

• Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.

  Cancer chemotherapy and pharmacology 20040101

• A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

  Cancer chemotherapy and pharmacology 20040101

• Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

  International journal of cancer 20040101

• Chondrocyte apoptosis induced by collagen degradation: inhibition by caspase inhibitors and IGF-1.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040101

• Biosynthesis of camptothecin. In silico and in vivo tracer study from [1-13C]glucose.

  Plant physiology 20040101

• Enzyme-prodrug systems: carboxylesterase/CPT-11.

  Methods in molecular medicine 20040101

• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040101

• Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

  Biochemical pharmacology 20040101

• A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.

  Antiviral research 20040101

• Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040101

• RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult.

  Nucleic acids research 20040101

• A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.

  Investigational new drugs 20040101

• A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer.

  Investigational new drugs 20040101

• First-line treatment strategies to improve survival in patients with advanced colorectal cancer.

  Drugs 20040101

• Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines.

  Chemical research in toxicology 20040101

• Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.

  European journal of cancer (Oxford, England : 1990) 20040101

• Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• [Principles of postoperative therapy in rectal carcinoma].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20040101

• Biological characterization of MLN944: a potent DNA binding agent.

  Molecular cancer therapeutics 20040101

• Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

  Gynecologic oncology 20040101

• FDA drug approval summaries: oxaliplatin.

  The oncologist 20040101

• Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.

  Molecular cancer research : MCR 20040101

• Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

  Neuro-oncology 20040101

• Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  Neuro-oncology 20040101

• DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.

  Archives of pharmacal research 20040101

• Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer.

  Surgery today 20040101

• Treatment of colorectal cancer metastasis: the role of chemotherapy.

  Cancer metastasis reviews 20040101

• Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.

  Japanese journal of clinical oncology 20040101

• The role of new agents in the treatment of colorectal cancer.

  Oncology 20040101

• Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.

  Oncology 20040101

• Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine.

  Nucleic acids research 20040101

• [Combined treatment of esophageal cancer: a review].

  Medicina (Kaunas, Lithuania) 20040101

• [The guidelines for diagnostics and treatment of cervical cancer].

  Medicina (Kaunas, Lithuania) 20040101

• Cytotoxicity, cytoprotection and neurotoxicity of novel deprenyl-related propargylamines, stable nitroxide free radicals, in vitro and in vivo.

  In vivo (Athens, Greece) 20040101

• Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).

  BMC medicine 20040101

• Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).

  Oncology 20040101

• Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.

  Oncology 20040101

• Effect of human noxa on irinotecan-induced apoptosis in human gastric carcinoma cell lines.

  Hepato-gastroenterology 20040101

• 5-Fluorouracil: identification of novel downstream mediators of tumour response.

  Anticancer research 20040101

• Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.

  Anticancer research 20040101

• Combined effect of sodium selenite and campthotecin on cervical carcinoma cells.

  Neoplasma 20040101

• [Capecitabine and irinotecan].

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20040101

• A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.

  Oncology 20040101

• New treatments for colorectal cancer.

  FDA consumer 20040101

• Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro.

  Scandinavian journal of immunology 20040101

• Systematic quantification of gene interactions by phenotypic array analysis.

  Genome biology 20040101

• Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.

  BMC cancer 20040101

• Evaluation of the acid-cleavable isotope-coded affinity tag reagents: application to camptothecin-treated cortical neurons.

  Journal of proteome research 20040101

• Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2.

  Neoplasma 20040101

• Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.

  The International journal of biological markers 20040101

• Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.

  BMC cancer 20040101

• The comet assay differentiates efficiently and rapidly between genotoxins and cytotoxins in quiescent cells.

  Cell biology international 20040101

• Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.

  BMC cancer 20040101

• Two-stage normalization using background intensities in cDNA microarray data.

  BMC bioinformatics 20040101

• Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.

  Anticancer research 20040101

• [Liver resection after downstaging with neoadjuvant chemotherapy for 'unresectable' colorectal metastases].

  Chirurgia italiana 20040101

• [Present-day potential of medication for disseminated cervical carcinoma].

  Voprosy onkologii 20040101

• Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells.

  Breast cancer research : BCR 20040101

• Translocation of Bax and Bid to mitochondria, endoplasmic reticulum and nuclear envelope: possible control points in apoptosis.

  Journal of molecular histology 20040101

• First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.

  Oncology 20040101

• A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.

  Oncology 20040101

• Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.

  Drugs in R&D 20040101

• Assay development for high throughput screening of p21(Waf1/Cip1) protein expression in intact cells using fluorometric microvolume assay technology.

  Drugs under experimental and clinical research 20040101

• Magneto/optical annexin V, a multimodal protein.

  Bioconjugate chemistry 20040101

• Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents.

  Drug delivery 20040101

• Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.

  Medical oncology (Northwood, London, England) 20040101

• Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.

  Journal of liposome research 20040101

• 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

  Urologic oncology 20040101

• Role of DNA mismatch repair in apoptotic responses to therapeutic agents.

  Environmental and molecular mutagenesis 20040101

• Apoptosis and necrosis increase antigenicity of proteins recognized by antinuclear antibodies.

  Reumatismo 20040101

• Current perspectives in the treatment of metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.

  Cancer investigation 20040101

• Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy.

  Anticancer research 20040101

• Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20040101

• UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers.

  Anticancer research 20040101

• Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.

  Oncology 20040101

• In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain.

  Bioconjugate chemistry 20040101

• Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.

  The oncologist 20040101

• Kinetics of Smac/DIABLO release from mitochondria during apoptosis of MCF-7 breast cancer cells.

  Cell biology international 20040101

• Role of new agents in the treatment of colorectal cancer.

  Surgical oncology 20040101

• Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.

  BMC pharmacology 20040101

• Mapping and mutation of the conserved DNA polymerase interaction motif (DPIM) located in the C-terminal domain of fission yeast DNA polymerase delta subunit Cdc27.

  BMC molecular biology 20040101

• Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.

  Cancer investigation 20040101

• Cellular localisation of the anti-cancer drug camptothecin in Camptotheca acuminata Decne (Nyssaceae).

  European journal of histochemistry : EJH 20040101

• Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial.

  Cancer investigation 20040101

• [Recent results of irinotecan therapy in colorectal cancer].

  Magyar onkologia 20040101

• Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan.

  Tumori 20040101

• Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.

  Oncology 20040101

• Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.

  Anticancer research 20040101

• Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.

  Anticancer research 20040101

• Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates.

  Molecular pharmaceutics 20040101

• Synthesis of a macromolecular camptothecin conjugate with dual phase drug release.

  Molecular pharmaceutics 20040101

• Cloning and identification of two unique genes involved in UV induced apoptosis on human keratinocyte (HaCaT) cell line.

  Toxicology mechanisms and methods 20040101

• Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria.

  Neuroreport 20031219

• Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.

  Journal of medicinal chemistry 20031218

• Progress in treatment of small-cell lung cancer: role of CPT-11.

  British journal of cancer 20031215

• Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.

  Cancer research 20031215

• Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.

  International journal of cancer 20031210

• Caenorhabditis elegans dna-2 is involved in DNA repair and is essential for germ-line development.

  FEBS letters 20031204

• Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export.

  Oncogene 20031204

• Mechanisms of caspase-independent neuronal death: energy depletion and free radical generation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20031203

• Precursor peptide progastrin(1-80) reduces apoptosis of intestinal epithelial cells and upregulates cytochrome c oxidase Vb levels and synthesis of ATP.

  American journal of physiology. Gastrointestinal and liver physiology 20031201

• Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.

  Cancer chemotherapy and pharmacology 20031201

• Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.

  Cancer chemotherapy and pharmacology 20031201

• Promyelocytic HL60 cells express NADPH oxidase and are excellent targets in a rapid spectrophotometric microplate assay for extracellular superoxide.

  Toxicological sciences : an official journal of the Society of Toxicology 20031201

• Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

  Journal of cancer research and clinical oncology 20031201

• Stable overexpression of specific segments of the P2P-R protein in human MCF-7 cells promotes camptothecin-induced apoptosis.

  Journal of cellular physiology 20031201

• Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells.

  International journal of oncology 20031201

• A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

  Annals of oncology : official journal of the European Society for Medical Oncology 20031201

• Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.

  Expert opinion on investigational drugs 20031201

• Nitric oxide levels in human preneoplastic colonocytes determine their susceptibility toward antineoplastic agents.

  Molecular pharmacology 20031201

• Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.

  Pharmacogenetics 20031201

• A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).

  Biomedical chromatography : BMC 20031201

• Docetaxel: promising and novel combinations in ovarian cancer.

  British journal of cancer 20031201

• Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.

  International journal of clinical oncology 20031201

• Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.

  International journal of clinical oncology 20031201

• Antitumour potential of a polysaccharide-rich substance from the fruit juice of Morinda citrifolia (Noni) on sarcoma 180 ascites tumour in mice.

  Phytotherapy research : PTR 20031201

• Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20031201

• Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20031201

• A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031201

• Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I.

  Cancer research 20031201

• Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.

  Cancer research 20031201

• Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

  Cancer research 20031201

• Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

  International journal of clinical pharmacology and therapeutics 20031201

• [Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies].

  Ai zheng = Aizheng = Chinese journal of cancer 20031201

• [Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031201

• [Novel molecular approaches in the therapy of advanced colorectal carcinoma].

  Onkologie 20031201

• Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression.

  Apoptosis : an international journal on programmed cell death 20031201

• In vitro sensitivity of human gastric cancer cells (HGC-27) to Helicobacter pylori cytotoxin.

  Scandinavian journal of gastroenterology 20031201

• CKD-602. Chong Kun Dang.

  Current opinion in investigational drugs (London, England : 2000) 20031201

• 2070-DTI, a topoisomerase inhibitor produced by Streptomyces sp. strain No. 2070.

  Journal of enzyme inhibition and medicinal chemistry 20031201

• The toxicity rates of two different regimens of irinotecan.

  Hepato-gastroenterology 20031201

• Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling.

  The Journal of biological chemistry 20031128

• Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons.

  Oncogene 20031127

• A phase II irinotecan-cisplatin combination in advanced pancreatic cancer.

  British journal of cancer 20031117

• A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.

  British journal of cancer 20031117

• Defects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cells.

  British journal of cancer 20031117

• Cell-cycle-dependent three-dimensional redistribution of nuclear proteins, P 120, pKi-67, and SC 35 splicing factor, in the presence of the topoisomerase I inhibitor camptothecin.

  Experimental cell research 20031115

• Isodiospyrin as a novel human DNA topoisomerase I inhibitor.

  Biochemical pharmacology 20031115

• Luotonin A. A naturally occurring human DNA topoisomerase I poison.

  Journal of the American Chemical Society 20031112

• Enhanced prediction of potential rodent carcinogenicity by utilizing comet assay and apoptotic assay in combination.

  Mutation research 20031110

• Regioselective synthesis and cytotoxicities of camptothecin derivatives modified at the 7-, 10- and 20-positions.

  Bioorganic & medicinal chemistry letters 20031103

• c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis.

  British journal of cancer 20031103

• Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.

  British journal of cancer 20031103

• OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.

  Leukemia research 20031101

• Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.

  Cancer chemotherapy and pharmacology 20031101

• Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.

  Cancer chemotherapy and pharmacology 20031101

• Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis.

  Journal of cell science 20031101

• Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment.

  Current medicinal chemistry. Anti-cancer agents 20031101

• Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.

  Clinical chemistry 20031101

• Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.

  Investigational new drugs 20031101

• Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes.

  Investigational new drugs 20031101

• A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.

  Investigational new drugs 20031101

• Werner protein stimulates topoisomerase I DNA relaxation activity.

  Cancer research 20031101

• Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.

  Cancer research 20031101

• Lamellarin D: a novel potent inhibitor of topoisomerase I.

  Cancer research 20031101

• Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.

  Cancer research 20031101

• Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

• Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.

  Molecular cancer therapeutics 20031101

• [Chemotherapy for gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• [Chemotherapy for colorectal carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• [A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• [A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• Presentations from the Walter Reed Army Medical Center. Case 1: rectal carcinoma.

  Oncology (Williston Park, N.Y.) 20031101

• [Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20031101

• Overview of chemotherapy-induced diarrhea.

  Seminars in oncology nursing 20031101

• Development of new agents for the treatment of advanced colorectal cancer.

  Clinical colorectal cancer 20031101

• A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.

  Clinical colorectal cancer 20031101

• Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.

  Clinical colorectal cancer 20031101

• Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.

  Japanese journal of clinical oncology 20031101

• [A case of isolated hepatic malignant lymphoma representing characteristic findings on radiological imaging].

  Fukuoka igaku zasshi = Hukuoka acta medica 20031101

• Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.

  The Journal of biological chemistry 20031031

• Liquid chromatography determination of 10-hydroxycamptothecin in human serum by a column-switching system containing a pre-column with restricted access media and its application to a clinical pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031025

• Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1.

  The Journal of biological chemistry 20031024

• Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

  British journal of cancer 20031020

• Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells.

  British journal of cancer 20031020

• Mechanisms of resistance to topoisomerase I-targeting drugs.

  Oncogene 20031020

• Total synthesis of mappicine ketone (nothapodytine B) by means of sulfur-directed 5-exo-selective aryl radical cyclization onto enamides.

  The Journal of organic chemistry 20031017

• Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031015

• Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031015

• The inhibition of MAPK pathway is correlated with down-regulation of MMP-9 secretion induced by TNF-alpha in human keratinocytes.

  Experimental cell research 20031015

• A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031015

• Connexins and apoptotic transformation.

  Biochemical pharmacology 20031015

• Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031015

• A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.

  Cancer research 20031015

• Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions.

  DNA repair 20031007

• Down modulation of topoisomerase I affects DNA repair efficiency.

  DNA repair 20031007

• Sensory neurons from mice lacking the Brn-3b POU family transcription factor are resistant to death-inducing stimuli both in vitro and in vivo.

  Brain research. Molecular brain research 20031007

• In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope.

  British journal of cancer 20031006

• Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031005

• Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031005

• A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.

  Cancer chemotherapy and pharmacology 20031001

• A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20031001

• Colorectal cancer: integrating oxaliplatin.

  Current treatment options in oncology 20031001

• Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.

  The Journal of pharmacology and experimental therapeutics 20031001

• Effects of 50 Hz electromagnetic field exposure on apoptosis and differentiation in a neuroblastoma cell line.

  Bioelectromagnetics 20031001

• A gel electrophoresis assay for the simultaneous determination of topoisomerase I inhibition and DNA intercalation.

  Analytical biochemistry 20031001

• Acquisition of drug resistance by constitutive suppression of NF-kappaB in ras-transformed NIH3T3 mouse fibroblasts.

  International journal of oncology 20031001

• Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).

  Annals of oncology : official journal of the European Society for Medical Oncology 20031001

• Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin.

  Biochemical pharmacology 20031001

• Review article: colorectal cancer chemotherapy.

  Alimentary pharmacology & therapeutics 20031001

• Optical forces for noninvasive cellular analysis.

  Applied optics 20031001

• Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.

  Gynecologic oncology 20031001

• Apoptotic pathways of epothilone BMS 310705.

  Gynecologic oncology 20031001

• Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?

  Anti-cancer drugs 20031001

• Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.

  Anti-cancer drugs 20031001

• Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan.

  Southern medical journal 20031001

• Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.

  Molecular cancer research : MCR 20031001

• [Development of the protein therapeutics using the super anti-cell death factor FNK].

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20031001

• [Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].

  Nihon Geka Gakkai zasshi 20031001

• [The platelet-sparing effect of carboplatin and docetaxel combination chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• The DNA synthesome: its potential as a novel in vitro model system for studying S-phase specific anticancer agents.

  Critical reviews in oncology/hematology 20031001

• Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.

  Seminars in radiation oncology 20031001

• Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.

  Seminars in radiation oncology 20031001

• Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.

  Journal of chemotherapy (Florence, Italy) 20031001

• Irinotecan (Campto) in the treatment of pancreatic cancer.

  Expert review of anticancer therapy 20031001

• Advanced pancreatic cancer: is there a role for combination therapy?

  Expert review of anticancer therapy 20031001

• [Experimental study on intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [A case of spinal infarction related to hepatic arterial infusion chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [Long-term survival after neck lymph node metastases from sigmoid colon cancer--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• [Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031001

• Current treatment and future directions in neuroblastoma.

  Indian journal of pediatrics 20031001

• TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways.

  Brain pathology (Zurich, Switzerland) 20031001

• Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.

  Methods and findings in experimental and clinical pharmacology 20031001

• Are there any better camptothecins than the ones we have?

  Clinical advances in hematology & oncology : H&O 20031001

• Pharmacogenomics: road to anticancer therapeutics nirvana?

  Oncogene 20030929

• Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030925

• Nitric oxide suppresses apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions.

  International journal of cancer 20030920

• ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation.

  Oncogene 20030918

• Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030917

• Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.

  British journal of cancer 20030915

• Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.

  British journal of cancer 20030915

• Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.

  British journal of cancer 20030915

• Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1.

  British journal of cancer 20030915

• Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

  British journal of cancer 20030915

• Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915

• Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030915

• Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030915

• Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.

  Cancer research 20030915

• Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray.

  Oncogene 20030904

• Cellular apoptosis is associated with increased caveolin-1 expression in macrophages.

  Journal of lipid research 20030901

• The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.

  Cancer chemotherapy and pharmacology 20030901

• Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis.

  Oral oncology 20030901

• Induced cell death of preimplantation mouse embryos cultured in vitro evaluated by comet assay.

  Theriogenology 20030901

• Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

  Journal of gastroenterology and hepatology 20030901

• Comment: Usefulness of herbal and dietary supplement references.

  The Annals of pharmacotherapy 20030901

• A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.

  Cancer 20030901

• Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030901

• Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030901

• Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030901

• Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.

  Journal of clinical pharmacology 20030901

• Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.

  Biomedical chromatography : BMC 20030901

• Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.

  Cancer research 20030901

• Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.

  Anti-cancer drugs 20030901

• New bioactive diterpene polyesters from Euphorbia decipiens.

  Journal of natural products 20030901

• [Controversial issues in chemotherapy for inoperable gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030901

• [Controversy of treatment for advanced colorectal cancer--intermedisine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030901

• PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.

  Molecular cancer therapeutics 20030901

• Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.

  Leukemia & lymphoma 20030901

• Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20030901

• Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.

  Oncology (Williston Park, N.Y.) 20030901

• Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report.

  Oncology (Williston Park, N.Y.) 20030901

• Irinotecan in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20030901

• Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.

  Oncology (Williston Park, N.Y.) 20030901

• [Polymorphism in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Chemotherapy for colon cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Application and problems in hepatic arterial infusion chemotherapy].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Home chemotherapy and outpatient treatment for metastatic colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [5-fluorouracil and leucovorin therapy for advanced colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Present status of chemotherapy for colorectal cancer in countries outside of Japan].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Toxicities associated with chemotherapy in colorectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Radiotherapy for locally relapsed rectal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Guidance and informed consent in colon cancer therapy].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.

  Japanese journal of clinical oncology 20030901

• [Current status of camptothecin derivatives as natural antitumor agents].

  Yao xue xue bao = Acta pharmaceutica Sinica 20030901

• Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.

  Journal of controlled release : official journal of the Controlled Release Society 20030828

• Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.

  Journal of controlled release : official journal of the Controlled Release Society 20030828

• Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.

  Journal of the National Cancer Institute 20030820

• Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.

  Bioorganic & medicinal chemistry letters 20030818

• Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.

  British journal of cancer 20030818

• Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.

  British journal of cancer 20030818

• Nat3p and Mdm20p are required for function of yeast NatB Nalpha-terminal acetyltransferase and of actin and tropomyosin.

  The Journal of biological chemistry 20030815

• Irinotecan pathway genotype analysis to predict pharmacokinetics.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030815

• Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

  British journal of cancer 20030804

• Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.

  The Journal of pharmacology and experimental therapeutics 20030801

• Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.

  Cancer chemotherapy and pharmacology 20030801

• Advanced NSCLC: new cytostatic agents.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.

  Molecular pharmacology 20030801

• Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.

  Journal of clinical gastroenterology 20030801

• Camptothecins and lung cancer: improved delivery systems by aerosol.

  Current cancer drug targets 20030801

• Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study.

  International journal of radiation oncology, biology, physics 20030801

• Oxidative stress is generated via the mitochondrial respiratory chain during plant cell apoptosis.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030801

• A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030801

• Missing evidence for the adequacy of a 1-cm distal margin in resected rectal cancer.

  Annals of surgical oncology 20030801

• Tailoring chemotherapy in advanced colorectal cancer.

  Current opinion in pharmacology 20030801

• Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin.

  Drug development and industrial pharmacy 20030801

• Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.

  Biochemical pharmacology 20030801

• Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.

  Cancer research 20030801

• Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Expression and functional analyses of breast cancer resistance protein in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• [A case of multiple lung metastases from colon cancer after sigmoidectomy treated effectively by chemotherapy].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030801

• [A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030801

• [A case of effective weekly paclitaxel administration for metastatic gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030801

• Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.

  Molecular cancer therapeutics 20030801

• Validation of the role of angiogenesis as a chemotherapeutic target.

  Clinical colorectal cancer 20030801

• Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.

  Clinical colorectal cancer 20030801

• Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.

  Clinical colorectal cancer 20030801

• Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.

  Anti-cancer drugs 20030801

• 5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.

  Anti-cancer drugs 20030801

• CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.

  Journal of chemotherapy (Florence, Italy) 20030801

• New perspectives in the management of pancreas cancer.

  Seminars in oncology 20030801

• Current and ongoing trials with irinotecan in the United States.

  Seminars in oncology 20030801

• Alternative schedules with irinotecan.

  Seminars in oncology 20030801

• Induction therapy in patients with metastatic colorectal cancer.

  Seminars in oncology 20030801

• Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.

  Seminars in oncology 20030801

• [Improved camptothecin production by cell lines of Camptotheca acuminata].

  Shi yan sheng wu xue bao 20030801

• Nucleolus in apoptosis-induced mouse preimplantation embryos.

  Zygote (Cambridge, England) 20030801

• Evolving role of irinotecan in small-cell lung cancer.

  Clinical advances in hematology & oncology : H&O 20030801

• Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.

  European journal of pharmacology 20030725

• Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.

  Journal of medicinal chemistry 20030717

• Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.

  Statistics in medicine 20030715

• Calpains mediate p53 activation and neuronal death evoked by DNA damage.

  The Journal of biological chemistry 20030711

• Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705

• Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20030701

• Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11).

  Medical and pediatric oncology 20030701

• A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.

  International journal of colorectal disease 20030701

• Yeast histone 2A serine 129 is essential for the efficient repair of checkpoint-blind DNA damage.

  EMBO reports 20030701

• Hypoxia induces p53 through a pathway distinct from most DNA-damaging and stress-inducing agents.

  Carcinogenesis 20030701

• Is liver disease an octreotide side effect?

  Journal of clinical gastroenterology 20030701

• Some new bi- and ter-benzimidazole derivatives as topoisomerase I inhibitors.

  Farmaco (Societa chimica italiana : 1989) 20030701

• TNF increases camptothecin-induced apoptosis by inhibition of NF-kappaB.

  European journal of cancer (Oxford, England : 1990) 20030701

• A phase II study of irinotecan in patients with advanced renal cell carcinoma.

  Cancer 20030701

• Human Spy1 promotes survival of mammalian cells following DNA damage.

  Cancer research 20030701

• Interactions between antiepileptic and chemotherapeutic drugs.

  The Lancet. Neurology 20030701

• A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030701

• Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030701

• Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC.

  Anti-cancer drugs 20030701

• Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• The Schizosaccharomyces pombe cdt2(+) gene, a target of G1-S phase-specific transcription factor complex DSC1, is required for mitotic and premeiotic DNA replication.

  Genetics 20030701

• Identification of a topoisomerase I mutant, scsA1, as an extragenic suppressor of a mutation in scaA(NBS1), the apparent homolog of human nibrin in Aspergillus nidulans.

  Genetics 20030701

• A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin.

  Pharmaceutical research 20030701

• Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.

  Chemotherapy 20030701

• Population-based maximum tolerated dose of irinotecan and carboplatin.

  Oncology (Williston Park, N.Y.) 20030701

• Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20030701

• The global role of irinotecan in the treatment of lung cancer: 2003 update.

  Oncology (Williston Park, N.Y.) 20030701

• Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.

  IDrugs : the investigational drugs journal 20030701

• Campto effective and flexible chemotherapy for advanced colorectal cancer.

  International journal of palliative nursing 20030701

• A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.

  The Journal of surgical research 20030701

• Pharmacology of intraperitoneal CPT-11.

  Surgical oncology clinics of North America 20030701

• Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

  The Netherlands journal of medicine 20030701

• Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.

  Clinical lung cancer 20030701

• The camptothecins.

  Lancet (London, England) 20030628

• Validation of a novel assay for checkpoint responses: characterization of camptothecin derivatives in Saccharomyces cerevisiae.

  Mutation research 20030619

• Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

  British journal of cancer 20030616

• Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent.

  Biochemical pharmacology 20030615

• Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.

  Cancer research 20030615

• Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.

  The Journal of biological chemistry 20030613

• Tripartate poly(ethylene glycol) prodrugs of the open lactone form of camptothecin.

  Bioorganic & medicinal chemistry 20030612

• Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.

  The Journal of biological chemistry 20030606

• In vivo evolution of tumour cells after the generation of double-strand DNA breaks.

  British journal of cancer 20030602

• Double-stranded RNA activates a p38 MAPK-dependent cell survival program in biliary epithelia.

  American journal of physiology. Gastrointestinal and liver physiology 20030601

• Identification of the metabolites of 9-nitro-20(S)-camptothecin in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20030601

• Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells.

  Journal of Asian natural products research 20030601

• Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.

  Cancer 20030601

• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601

• Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030601

• Different roles of the Mre11 complex in the DNA damage response in Aspergillus nidulans.

  Molecular microbiology 20030601

• Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030601

• Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030601

• Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030601

• Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.

  American journal of clinical oncology 20030601

• Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

  Gynecologic oncology 20030601

• Optimal use of the combination of irinotecan and 5-fluorouracil.

  Seminars in oncology 20030601

• Antinuclear antibodies recognize cellular autoantigens driven by apoptosis.

  Joint, bone, spine : revue du rhumatisme 20030601

• Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

  Pharmaceutical research 20030601

• [Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030601

• [Chemotherapy-induced diarrhea].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030601

• [A case of gastric cancer with multiple liver metastasis responding to combination therapy of CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030601

• Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.

  Journal of chemotherapy (Florence, Italy) 20030601

• Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.

  Journal of chemotherapy (Florence, Italy) 20030601

• DNA topoisomerases I and II inhibitory activity of constituents isolated from Juglans mandshurica.

  Archives of pharmacal research 20030601

• Advances in colon cancer.

  Drug news & perspectives 20030601

• Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion.

  The Journal of biological chemistry 20030530

• Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.

  The Journal of biological chemistry 20030530

• Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.

  Journal of medicinal chemistry 20030522

• HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

  Oncogene 20030522

• IPM chemotherapy in cytokine refractory renal cell cancer.

  British journal of cancer 20030519

• Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro.

  British journal of cancer 20030506

• High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030505

• LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway.

  American journal of physiology. Gastrointestinal and liver physiology 20030501

• The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.

  International journal of oncology 20030501

• Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20030501

• Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo.

  Cancer chemotherapy and pharmacology 20030501

• Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

  Annals of oncology : official journal of the European Society for Medical Oncology 20030501

• Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030501

• Macrophage recognition of externalized phosphatidylserine and phagocytosis of apoptotic Jurkat cells--existence of a threshold.

  Archives of biochemistry and biophysics 20030501

• Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.

  Cancer 20030501

• The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.

  Cancer 20030501

• Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.

  Cancer 20030501

• Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.

  Cancer 20030501

• Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

  Cancer 20030501

• Inhibition of cholangiocarcinoma growth by tannic acid.

  Hepatology (Baltimore, Md.) 20030501

• Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.

  Cancer gene therapy 20030501

• Induction of apoptosis in estrogen dependent and independent breast cancer cells by the marine terpenoid dehydrothyrsiferol.

  Biochemical pharmacology 20030501

• Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.

  Annals of surgical oncology 20030501

• Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030501

• Dual fluorescence analysis of DNA apoptosis in sperm.

  American journal of obstetrics and gynecology 20030501

• Pharmacogenetics of irinotecan.

  Current medicinal chemistry. Anti-cancer agents 20030501

• [A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030501

• Irinotecan: promising activity in the treatment of malignant glioma.

  Oncology (Williston Park, N.Y.) 20030501

• Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.

  Oncology (Williston Park, N.Y.) 20030501

• Rationale for mitomycin and irinotecan use in advanced breast cancer.

  Oncology (Williston Park, N.Y.) 20030501

• Japanese ovarian trials: focus on irinotecan.

  Oncology (Williston Park, N.Y.) 20030501

• Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.

  Oncology (Williston Park, N.Y.) 20030501

• Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

  Oncology (Williston Park, N.Y.) 20030501

• Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.

  Oncology (Williston Park, N.Y.) 20030501

• Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.

  Oncology (Williston Park, N.Y.) 20030501

• Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.

  Oncology (Williston Park, N.Y.) 20030501

• Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20030501

• Phlebitis due to irinotecan.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20030501

• Biochemical and microarray analyses of bupivacaine-induced apoptosis.

  The Journal of toxicological sciences 20030501

• [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20030501

• [Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].

  Gastroenterologie clinique et biologique 20030501

• Concurrent radiation therapy and irinotecan in stage IIIB cervical cancer.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20030501

• Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

  British journal of cancer 20030422

• Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.

  British journal of cancer 20030422

• Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents.

  Bioorganic & medicinal chemistry 20030417

• Antitumor agents 216. Synthesis and evaluation of paclitaxel-camptothecin conjugates as novel cytotoxic agents.

  Bioorganic & medicinal chemistry 20030417

• Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.

  Biochemical pharmacology 20030415

• Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030401

• A simple, informative, and quantitative flow cytometric method for assessing apoptosis in cultured cells.

  Progress in neuro-psychopharmacology & biological psychiatry 20030401

• Lipid membrane with low proton permeability.

  Biochimica et biophysica acta 20030401

• Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.

  Lung cancer (Amsterdam, Netherlands) 20030401

• Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.

  Diseases of the colon and rectum 20030401

• Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

  Molecular cancer therapeutics 20030401

• [Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide].

  Ai zheng = Aizheng = Chinese journal of cancer 20030401

• [Inhibition of hydroxycamptothecin on laryngeal squamous carcinoma cell line].

  Ai zheng = Aizheng = Chinese journal of cancer 20030401

• Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.

  American journal of clinical oncology 20030401

• Camptothecin biosynthetic genes in hairy roots of Ophiorrhiza pumila: cloning, characterization and differential expression in tissues and by stress compounds.

  Plant & cell physiology 20030401

• [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030401

• A novel method of eliminating non-neuronal proliferating cells from cultures of mouse dorsal root ganglia.

  Cellular and molecular neurobiology 20030401

• Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.

  Japanese journal of clinical oncology 20030401

• Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.

  Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al 20030401

• [Effect of the change of caspase-3 activity on the neoadjuvant chemotherapy-induced apoptosis of large-intestinal carcinoma cells].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20030401

• Design, synthesis and pharmacological evaluation of new anticancer fused pentacycles.

  Journal of enzyme inhibition and medicinal chemistry 20030401

• Indolizino[1,2-b]quinolines derived from A-D rings of camptothecin: synthesis and DNA interaction.

  Journal of enzyme inhibition and medicinal chemistry 20030401

• Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition.

  The Journal of biological chemistry 20030328

• Early changes in metabolism of leukemic cell lines upon induction of apoptosis by cytotoxic drugs.

  European journal of pharmacology 20030328

• Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.

  British journal of cancer 20030324

• Cancer pharmacogenomics: current and future applications.

  Biochimica et biophysica acta 20030317

• Down-regulation of proinflammatory capacity during apoptosis in human polymorphonuclear leukocytes.

  Journal of immunology (Baltimore, Md. : 1950) 20030315

• Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030315

• Dykellic acid inhibits drug-induced caspase-3-like protease activation.

  Biochemical and biophysical research communications 20030314

• Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.

  Journal of medicinal chemistry 20030313

• Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle.

  Oncogene 20030313

• Antiproliferative activity of apples is not due to phenolic-induced hydrogen peroxide formation.

  Journal of agricultural and food chemistry 20030312

• An adjustable release rate linking strategy for cytotoxin-peptide conjugates.

  Bioorganic & medicinal chemistry letters 20030310

• Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.

  Bioorganic & medicinal chemistry letters 20030310

• Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin.

  The Journal of biological chemistry 20030307

• CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.

  Leukemia research 20030301

• Overexpression of the anti-apoptotic caspase-2 short isoform in macrophage-derived foam cells of human atherosclerotic plaques.

  The American journal of pathology 20030301

• Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030301

• An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030301

• Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases.

  Journal of neurochemistry 20030301

• Differential effects of catalase on apoptosis induction in human promonocytic cells. Relationships with heat-shock protein expression.

  Molecular pharmacology 20030301

• Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030301

• An age-related increase in resistance to DNA damage-induced apoptotic cell death is associated with development of DNA repair mechanisms.

  Journal of neurochemistry 20030301

• Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.

  Cancer research 20030301

• Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.

  Acta pharmacologica Sinica 20030301

• Concern about similarity of manuscripts.

  Clinical pharmacology and therapeutics 20030301

• Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030301

• E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.

  Cancer gene therapy 20030301

• Camptothecin analogs in malignant gliomas: comparative analysis and characterization.

  Journal of neurosurgery 20030301

• [A case of metastatic liver tumor of colorectal cancer responding to low-dose CPT-11 chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030301

• Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.

  Japanese journal of clinical oncology 20030301

• Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.

  Japanese journal of clinical oncology 20030301

• Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

  Cancer cell 20030301

• Glucuronides in anti-cancer therapy.

  Current medicinal chemistry. Anti-cancer agents 20030301

• [Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].

  Gastroenterologie clinique et biologique 20030301

• Potato disc tumor induction assay: a multiple mode of drug action assay.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20030301

• [A case of paraneoplastic syndrome improved following chemoradiotherapy for lung cancer].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20030301

• [A symphony for the camptothecins].

  Bulletin du cancer 20030301

• Synthesis of 6-formyl-pyridine-2-carboxylate derivatives and their telomerase inhibitory activities.

  Bioorganic & medicinal chemistry letters 20030224

• NFBD1, a novel nuclear protein with signature motifs of FHA and BRCT, and an internal 41-amino acid repeat sequence, is an early participant in DNA damage response.

  The Journal of biological chemistry 20030221

• 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents.

  Bioorganic & medicinal chemistry 20030220

• gamma-Irradiation-induced DNA damage enhances NO production via NF-kappaB activation in RAW264.7 cells.

  Biochimica et biophysica acta 20030217

• Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.

  The Prostate 20030215

• Revealing the mode of action of DNA topoisomerase I and its inhibitors by atomic force microscopy.

  Biochemical and biophysical research communications 20030214

• Selective phenolic acylation of 10-hydroxycamptothecin using poly (ethylene glycol) carboxylic acid.

  Bioorganic & medicinal chemistry letters 20030210

• Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.

  British journal of cancer 20030210

• Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways.

  The Journal of biological chemistry 20030207

• Semisynthesis of DB-67 and other silatecans from camptothecin by thiol-promoted addition of silyl radicals.

  Bioorganic & medicinal chemistry 20030206

• Successful clinical response to irinotecan in relapsed neuroblastoma.

  Medical and pediatric oncology 20030201

• Limited stage small cell lung cancer: treatment and therapy.

  Current treatment options in oncology 20030201

• p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11).

  The Journal of pharmacology and experimental therapeutics 20030201

• Structure-activity relationship of alkyl 9-nitrocamptothecin esters.

  Acta pharmacologica Sinica 20030201

• High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.

  Therapeutic drug monitoring 20030201

• Effect of Ca2+-dependent cell death on the release of herpes simplex virus.

  Archives of virology 20030201

• Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

  Cancer research 20030201

• Hepatic artery infusion for liver metastases from colorectal cancer.

  Lancet (London, England) 20030201

• Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study.

  Lung cancer (Amsterdam, Netherlands) 20030201

• Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3.

  Carcinogenesis 20030201

• Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.

  Leukemia 20030201

• Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.

  International journal of clinical oncology 20030201

• [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030201

• [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030201

• The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.

  Clinical colorectal cancer 20030201

• Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.

  Clinical colorectal cancer 20030201

• Metabolite profiling of alkaloids and strictosidine synthase activity in camptothecin producing plants.

  Phytochemistry 20030201

• Chemotherapy for small cell lung cancer.

  Seminars in oncology 20030201

• [Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].

  Bulletin du cancer 20030201

• Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.

  Journal of neuro-oncology 20030201

• [Chemotherapy for colorectal cancers].

  Journal de chirurgie 20030201

• [Determination of 9-nitrocamptothecin in rat plasma and tissues by high performance liquid chromatography].

  Yao xue xue bao = Acta pharmaceutica Sinica 20030201

• Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

  British journal of cancer 20030127

• A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.

  British journal of cancer 20030127

• Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030125

• Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.

  Life sciences 20030124

• Monitoring of apoptosis of HL60 cells by Fourier-transform infrared spectroscopy.

  The Biochemical journal 20030115

• Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030115

• Staurosporine-induced apoptosis and hydrogen peroxide-induced necrosis in two human breast cell lines.

  British journal of cancer 20030113

• Massive telomere loss is an early event of DNA damage-induced apoptosis.

  The Journal of biological chemistry 20030110

• Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A.

  The Journal of biological chemistry 20030103

• Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin.

  Journal of medicinal chemistry 20030102

• Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.

  Oncology reports 20030101

• Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.

  Critical reviews in oncology/hematology 20030101

• Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20030101

• Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.

  Drug metabolism and disposition: the biological fate of chemicals 20030101

• Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.

  Drug metabolism and disposition: the biological fate of chemicals 20030101

• A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.

  Cancer 20030101

• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.

  International journal of radiation oncology, biology, physics 20030101

• A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030101

• Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.

  Cancer research 20030101

• Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents.

  Cancer research 20030101

• Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).

  Biological & pharmaceutical bulletin 20030101

• Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.

  Molecular cancer therapeutics 20030101

• Induction of DNA damage responses by adozelesin is S phase-specific and dependent on active replication forks.

  Molecular cancer therapeutics 20030101

• Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.

  Anti-cancer drugs 20030101

• The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.

  Breast cancer research : BCR 20030101

• Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20030101

• Assessment of the intestinal permeability following postoperative chemotherapy for human malignant disease.

  European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20030101

• Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.

  Oncology 20030101

• Lessons learned from the irinotecan metabolic pathway.

  Current medicinal chemistry 20030101

• Dual topoisomerase I/II inhibitors in cancer therapy.

  Current topics in medicinal chemistry 20030101

• A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).

  Japanese journal of clinical oncology 20030101

• Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents.

  Pharmaceutical research 20030101

• The effect of inhibiting topoisomerase I and II on the anti-apoptotic response associated with pro-inflammatory crystals of calcium pyrophosphate dihydrate in human neutrophils.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030101

• Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.

  Naunyn-Schmiedeberg's archives of pharmacology 20030101

• The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.

  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20030101

• Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.

  Bioconjugate chemistry 20030101

• Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer.

  Medical oncology (Northwood, London, England) 20030101

• Defective Brca2 influences topoisomerase I activity in mammalian cells.

  Acta biochimica Polonica 20030101

• CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data.

  Advances in experimental medicine and biology 20030101

• Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.

  Anticancer research 20030101

• The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells.

  Anticancer research 20030101

• Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.

  Urologic oncology 20030101

• Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.

  Oncology reports 20030101

• Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.

  Oncology reports 20030101

• The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.

  Oncology reports 20030101

• [Cytoreductive surgery of liver metastasis from colorectal cancer: principles of intra-arterial regional chemotherapy].

  Khirurgiia 20030101

• GoMiner: a resource for biological interpretation of genomic and proteomic data.

  Genome biology 20030101

• Palliative treatment of patients with colorectal cancer.

  Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 20030101

• A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.

  Hepato-gastroenterology 20030101

• Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer.

  Oncology 20030101

• Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.

  Oncology 20030101

• Safety pharmacology of CKD-602, a novel anticancer agent.

  Arzneimittel-Forschung 20030101

• Metastatic colorectal cancer: systemic treatment in the new millennium.

  Cancer control : journal of the Moffitt Cancer Center 20030101

• Role of granulocyte-macrophage colony-stimulating factor on apoptosis induced by ischemia-reperfusion in the intestinal epithelium.

  European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20030101

• Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.

  European journal of gynaecological oncology 20030101

• Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Irinotecan in the treatment of gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Current treatments and future perspectives in colorectal and gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• [Kinetics of the lactone-carboxylate transition of hybrid camptothecin-netropsin molecules].

  Biofizika 20030101

• Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study.

  Anticancer research 20030101

• Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.

  Anticancer research 20030101

• Chemotherapy for advanced pancreatic cancer.

  International journal of radiation oncology, biology, physics 20030101

• Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors.

  Tumori 20030101

• Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer.

  The International journal of biological markers 20030101

• Irinotecan enhances IL-12 production by OK-432-activated murine macrophages.

  Anticancer research 20030101

• Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.

  Anticancer research 20030101

• Epidermal growth factor receptor inhibition induces trichomegaly.

  Acta oncologica (Stockholm, Sweden) 20030101

• Treatment of advanced disease and new drugs.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20030101

• Ursolic acid inhibits proliferation and stimulates apoptosis in HT29 cells following activation of alkaline sphingomyelinase.

  Anticancer research 20030101

• Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer.

  Anticancer research 20030101

• Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.

  Anticancer research 20030101

• Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.

  Oncology 20030101

• Current chemotherapy for glioblastoma.

  Cancer journal (Sudbury, Mass.) 20030101

• Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates.

  Bioconjugate chemistry 20030101

• DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.

  Cell cycle (Georgetown, Tex.) 20030101

• SNP analysis by using ferrocenyl naphthalene diimide (FND)-based electrochemical hybridization assay (EHA).

  Nucleic acids research. Supplement (2001) 20030101

• Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101

• The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.

  Oncology reports 20030101

• [The update on pancreatic cancer chemotherapy].

  Medicina (Kaunas, Lithuania) 20030101

• Herpes simplex virus UL14 protein blocks apoptosis.

  Microbiology and immunology 20030101

• Antiblastic drug combinations with ifosfamide: an update.

  Oncology 20030101

• Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.

  Biopolymers 20030101

• Clinical studies of camptothecin and derivatives.

  The Alkaloids. Chemistry and biology 20030101

• Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study.

  Tumori 20030101

• Single-agent irinotecan as second-line treatment for advanced gastric cancer.

  Tumori 20030101

• Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.

  Cancer investigation 20030101

• Combined modality therapy in esophageal cancer: the Memorial experience.

  Seminars in surgical oncology 20030101

• Potential role of macrophages as immunoregulators of pregnancy.

  Reproductive biology and endocrinology : RB&E 20030101

• Palliative cytostatic treatment of cervical carcinoma.

  European journal of gynaecological oncology 20030101

• Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.

  Anticancer research 20030101

• Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models.

  Anticancer research 20030101

• Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.

  Anticancer research 20030101

• A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.

  Cancer investigation 20030101

• New developments in systemic chemotherapy in advanced colorectal cancer.

  Scandinavian journal of gastroenterology. Supplement 20030101

• The use of housekeeping genes (HKG) as an internal control for the detection of gene expression by quantitative real-time RT-PCR.

  Folia biologica 20030101

• [Systemic treatment of colorectal cancers--factual standards and perspectives].

  Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20030101

• [Novel combinations of irinotecan with molecular-targeted drugs in the treatment of colorectal carcinoma].

  Tumori 20030101

• A modified chorioallantoic membrane assay allows for specific detection of endothelial apoptosis induced by antiangiogenic substances.

  Angiogenesis 20030101

• Topoisomerase I interactive agents.

  Cancer chemotherapy and biological response modifiers 20030101

• MAPK signaling is involved in camptothecin-induced cell death.

  Molecules and cells 20021231

• Molecular characterization of ABC transporter-encoding genes in Aspergillus nidulans.

  Genetics and molecular research : GMR 20021231

• Formaldehyde-induced DNA cross-link of indolizino[1,2-b]quinolines derived from the A-D rings of camptothecin.

  Journal of medicinal chemistry 20021219

• Erbitux trial flawed from the beginning, committee finds.

  Journal of the National Cancer Institute 20021218

• Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021215

• Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling.

  Current biology : CB 20021210

• Recent advances in topoisomerase I-targeting agents, camptothecin analogues.

  Mini reviews in medicinal chemistry 20021201

• Hyperbaric oxygen enhances apoptosis in hematopoietic cells.

  Apoptosis : an international journal on programmed cell death 20021201

• The fate of monocytes during 24 h of culture as revealed by flow cytometry and electron microscopy.

  Journal of immunological methods 20021201

• Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest.

  Journal of cell science 20021201

• Apoptosis: biochemical aspects and clinical implications.

  Clinica chimica acta; international journal of clinical chemistry 20021201

• Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.

  Journal of biomolecular structure & dynamics 20021201

• Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.

  Archives of gynecology and obstetrics 20021201

• Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20021201

• Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

  Cancer chemotherapy and pharmacology 20021201

• Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021201

• Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021201

• Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021201

• Pharmacokinetics of irinotecan and its metabolites.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021201

• Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.

  Expert opinion on investigational drugs 20021201

• Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.

  Cancer research 20021201

• Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.

  Pharmacogenetics 20021201

• Novel therapeutic approaches in the treatment of children with hepatoblastoma.

  Journal of pediatric hematology/oncology 20021201

• Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021201

• Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).

  American journal of clinical oncology 20021201

• Challenging the platinum combinations in the chemotherapy of NSCLC.

  Lung cancer (Amsterdam, Netherlands) 20021201

• Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20021201

• Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.

  Clinical pharmacology and therapeutics 20021201

• Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells.

  Carcinogenesis 20021201

• Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.

  Oncology (Williston Park, N.Y.) 20021201

• Current status of capecitabine in the treatment of colorectal cancer.

  Oncology (Williston Park, N.Y.) 20021201

• [Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan].

  Ai zheng = Aizheng = Chinese journal of cancer 20021201

• [Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021201

• Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.

  Zeitschrift fur Gastroenterologie 20021201

• The role of pemetrexed in the treatment of colorectal cancer.

  Seminars in oncology 20021201

• Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.

  Seminars in oncology 20021201

• Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus.

  Cancer letters 20021128

• A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis.

  Oncogene 20021128

• Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.

  Cytokine 20021124

• Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.

  British journal of cancer 20021118

• Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.

  The Journal of biological chemistry 20021115

• SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.

  Oncogene 20021114

• Evidence of functional modulation of the MEKK/JNK/cJun signaling cascade by the low density lipoprotein receptor-related protein (LRP).

  The Journal of biological chemistry 20021108

• Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives.

  Journal of medicinal chemistry 20021107

• Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis.

  British journal of cancer 20021104

• Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.

  International journal of oncology 20021101

• The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.

  The Journal of pharmacology and experimental therapeutics 20021101

• DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.

  Molecular pharmacology 20021101

• Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors.

  Cancer 20021101

• Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021101

• New drugs for patients with pancreatic cancer.

  Current opinion in oncology 20021101

• Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors.

  Cancer research 20021101

• Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021101

• Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021101

• Non-platinum gemcitabine combinations in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20021101

• Unexpected pleural effusions in 3 pediatric patients treated with STI-571.

  Journal of pediatric hematology/oncology 20021101

• Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.

  Anti-cancer drugs 20021101

• High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.

  Cancer chemotherapy and pharmacology 20021101

• [Glutamate transporter mediated increase of antitumor activity by theanine, an amino acid in green tea].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021101

• Antimycin A-induced apoptosis of HL-60 cells.

  Cytometry 20021101

• Exposure of cells to static magnetic field accelerates loss of integrity of plasma membrane during apoptosis.

  Cytometry 20021101

• Autocrine/paracrine regulation of apoptosis in epithelial cells by prostaglandin E2.

  Prostaglandins, leukotrienes, and essential fatty acids 20021101

• Camptothecin accumulation and variations in camptotheca.

  Planta medica 20021101

• [A case of AFP-producing gastric cancer with multiple liver metastases responding to CPT-11 and cisplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Dysarthria during irinotecan administration].

  La Revue de medecine interne 20021101

• Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.

  Clinical colorectal cancer 20021101

• Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.

  Clinical colorectal cancer 20021101

• Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.

  Clinical colorectal cancer 20021101

• Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.

  Clinical colorectal cancer 20021101

• [A case of postoperative liver metastasis of alpha-fetoprotein producing gastric cancer successfully treated with intrahepatic chemotherapy (adriamycin, cisplatin, irinotecan hydrochloride)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Hepatic arterial infusion with irinotecan for the colorectal cancer patient with liver metastasis--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021101

• [Gastrointestinal toxicity caused by irinotecan in the case of preexistent passage problems].

  Nederlands tijdschrift voor geneeskunde 20021026

• Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin.

  The Journal of biological chemistry 20021018

• Addition of ester enolates to N-alkyl-2-fluoropyridinium salts: total synthesis of (+/-)-20-deoxycamptothecin and (+)-camptothecin.

  The Journal of organic chemistry 20021018

• Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.

  Biochemical pharmacology 20021015

• The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.

  Biochemical pharmacology 20021015

• A novel apoptosis research method with imaging-combined flow cytometer and HITC or IR-125 staining.

  Cytometry 20021015

• Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

  Cancer research 20021015

• Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.

  Cancer research 20021015

• Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation.

  Cancer research 20021015

• Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.

  British journal of cancer 20021007

• Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities.

  Molecular pharmacology 20021001

• Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.

  Cancer 20021001

• Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021001

• Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.

  Cancer chemotherapy and pharmacology 20021001

• Detection of in situ activation of transglutaminase during apoptosis: correlation with the cell cycle phase by multiparameter flow and laser scanning cytometry.

  Cytometry 20021001

• SN-38 induces cell cycle arrest and apoptosis in human testicular cancer.

  European urology 20021001

• Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20021001

• Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021001

• A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021001

• Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study.

  American journal of clinical oncology 20021001

• Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.

  American journal of clinical oncology 20021001

• Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts.

  Anti-cancer drugs 20021001

• Accelerated apoptotic DNA laddering protocol.

  BioTechniques 20021001

• [A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].

  Gan to kagaku ryoho. Cancer & chemotherapy 20021001

• The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.

  Seminars in oncology 20021001

• Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.

  Seminars in oncology 20021001

• Camptothecin delivery methods.

  Pharmaceutical research 20021001

• In vitro pharmacodynamics of CKD-602 in HT-29 cells.

  Archives of pharmacal research 20021001

• Epithelial growth factor receptor interacting agents.

  Hematology/oncology clinics of North America 20021001

• Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells.

  Acta medica Okayama 20021001

• Detection of anti-CD3 mAbs-induced mitogenesis and caspase-3 activity as a method for the evaluation of T-cell reactivity in clinical and experimental investigations.

  Russian journal of immunology : RJI : official journal of Russian Society of Immunology 20021001

• Chromosomal instability in B-lymphoblasotoid cell lines from Werner and Bloom syndrome patients.

  Mutation research 20020926

• Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.

  Mutation research 20020926

• Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.

  British journal of cancer 20020923

• Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of embryonic cortical neurons evoked by DNA damage.

  The Journal of biological chemistry 20020920

• Palladium-promoted cascade reactions of isonitriles and 6-iodo-N-propargylpyridones: synthesis of mappicines, camptothecins, and homocamptothecins.

  Organic letters 20020919

• Synthesis and cytotoxic activity of pyridazino[1',6':1,2]pyrido[3,4-b]indol-5-inium derivatives as anti-cancer agents.

  Bioorganic & medicinal chemistry letters 20020916

• Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915

• Poly(L-glutamic acid)--anticancer drug conjugates.

  Advanced drug delivery reviews 20020913

• A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.

  British journal of cancer 20020909

• DNA topoisomerase I and II expression in drug resistant germ cell tumours.

  British journal of cancer 20020909

• Secreted and tumour targeted human carboxylesterase for activation of irinotecan.

  British journal of cancer 20020909

• Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.

  British journal of cancer 20020909

• Mus81-Eme1 and Rqh1 involvement in processing stalled and collapsed replication forks.

  The Journal of biological chemistry 20020906

• Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin.

  Bioorganic & medicinal chemistry letters 20020902

• Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.

  The Biochemical journal 20020901

• Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer.

  Panminerva medica 20020901

• Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity.

  Molecular pharmacology 20020901

• Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).

  Molecular pharmacology 20020901

• Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20020901

• Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.

  Cancer research 20020901

• Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.

  International journal of cancer 20020901

• Effects of caspase inhibition on camptothecin-induced apoptosis of HL-60 cells.

  Cytometry 20020901

• Disruption of a DNA topoisomerase I gene affects morphogenesis in Arabidopsis.

  The Plant cell 20020901

• Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells.

  Laboratory investigation; a journal of technical methods and pathology 20020901

• Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.

  Chemotherapy 20020901

• Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.

  Biometrics 20020901

• Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20020901

• Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.

  Clinical pharmacology and therapeutics 20020901

• Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

  Journal of neuro-oncology 20020901

• Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.

  Journal of cancer research and clinical oncology 20020901

• [Randomized controlled trials in Japan--lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020901

• Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs.

  Japanese journal of cancer research : Gann 20020901

• Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Camptothecin and taxane regimens for small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Irinotecan plus cisplatin in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Current role of irinotecan in the treatment of non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020901

• Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.

  Anti-cancer drugs 20020901

• Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore.

  Annals of the Academy of Medicine, Singapore 20020901

• Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

  Pharmaceutical research 20020901

• O6-benzylguanine-mediated enhancement of chemotherapy.

  Molecular cancer therapeutics 20020901

• Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.

  Human cell 20020901

• Different sensitivities to apoptotic induction by camptothecin between normal and senescent lens epithelial cells.

  Yan ke xue bao = Eye science 20020901

• St. John's Wort: more implications for cancer patients.

  Journal of the National Cancer Institute 20020821

• Effects of St. John's wort on irinotecan metabolism.

  Journal of the National Cancer Institute 20020821

• Nitric oxide-induced Cl- secretion in isolated rat colon is mediated by the release of thromboxane A2.

  The Journal of physiology 20020815

• Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020805

• Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells.

  The international journal of biochemistry & cell biology 20020801

• Modulation of G(2) arrest enhances cell death induced by the antitumor 1-nitroacridine derivative, Nitracrine.

  Apoptosis : an international journal on programmed cell death 20020801

• Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.

  Journal of pharmaceutical sciences 20020801

• Focus-formation of replication protein A, activation of checkpoint system and DNA repair synthesis induced by DNA double-strand breaks in Xenopus egg extract.

  Journal of cell science 20020801

• Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.

  International journal of oncology 20020801

• In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton.

  International journal of oncology 20020801

• Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.

  Lung cancer (Amsterdam, Netherlands) 20020801

• Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020801

• Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway.

  European journal of biochemistry 20020801

• Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

  Cancer research 20020801

• Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020801

• Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020801

• Immature and mature cortical neurons engage different apoptotic mechanisms involving caspase-3 and the mitogen-activated protein kinase pathway.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20020801

• Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.

  Cancer chemotherapy and pharmacology 20020801

• Studies on fertilization in the teleost IV. Effects of aphidicolin and camptothecin on chromosome formation in fertilized medaka eggs.

  Development, growth & differentiation 20020801

• Targeting vascular endothelial growth factor in colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020801

• Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report.

  Oncology (Williston Park, N.Y.) 20020801

• Mitomycin as a modulator of irinotecan anticancer activity.

  Oncology (Williston Park, N.Y.) 20020801

• Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.

  Oncology (Williston Park, N.Y.) 20020801

• Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.

  Oncology (Williston Park, N.Y.) 20020801

• Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.

  Internal medicine (Tokyo, Japan) 20020801

• [Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020801

• [CPT-11 hepatic arterial injection plus oral UFT administration for liver metastasis of rectal cancer--report of two cases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020801

• Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.

  Onkologie 20020801

• In vitro cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes and neutrophils.

  The Journal of toxicological sciences 20020801

• Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin.

  Pharmaceutical research 20020801

• Inhibitory properties of antitumor prostaglandins against topoisomerases.

  Bioscience, biotechnology, and biochemistry 20020801

• [Gemcitabine-based combinations in inoperable pancreatic cancers].

  Bulletin du cancer 20020801

• Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.

  Clinical colorectal cancer 20020801

• N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.

  Clinical colorectal cancer 20020801

• The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.

  Clinical colorectal cancer 20020801

• Irinotecan in 5-fluorouracil-refractory colorectal cancer.

  Clinical colorectal cancer 20020801

• Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.

  Clinical colorectal cancer 20020801

• [Clinical study on patients with advanced gastric cancer treated with oxaliplatin combining with hydroxycamptothecine].

  Ai zheng = Aizheng = Chinese journal of cancer 20020801

• Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

  British journal of cancer 20020729

• Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines.

  British journal of cancer 20020729

• Silkworm hemolymph as a potent inhibitor of apoptosis in Sf9 cells.

  Biochemical and biophysical research communications 20020726

• Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.

  The Journal of biological chemistry 20020719

• The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.

  Experimental cell research 20020715

• Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

  British journal of cancer 20020715

• Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.

  Statistics in medicine 20020715

• Modulation of irinotecan metabolism by ketoconazole.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020715

• Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

  Cancer research 20020715

• Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.

  Biochemical and biophysical research communications 20020712

• Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis.

  Oncogene 20020704

• A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs.

  Journal of the American Chemical Society 20020703

• GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.

  International journal of oncology 20020701

• Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.

  International journal of oncology 20020701

• Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.

  Drug metabolism and disposition: the biological fate of chemicals 20020701

• Lymphocyte apoptosis after exhaustive and moderate exercise.

  Journal of applied physiology (Bethesda, Md. : 1985) 20020701

• Assay of caspase activation in situ combined with probing plasma membrane integrity to detect three distinct stages of apoptosis.

  Journal of immunological methods 20020701

• Fission yeast chk1 mutants show distinct responses to different types of DNA damaging treatments.

  Genes to cells : devoted to molecular & cellular mechanisms 20020701

• Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.

  European journal of cancer (Oxford, England : 1990) 20020701

• Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.

  Cancer research 20020701

• Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.

  Cancer research 20020701

• Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis.

  Gastroenterology 20020701

• DNA structural alterations induced by bis-netropsins modulate human DNA topoisomerase I cleavage activity and poisoning by camptothecin.

  Biochemical pharmacology 20020701

• Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020701

• Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020701

• Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.

  International journal of cancer 20020701

• Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives.

  Medical science monitor : international medical journal of experimental and clinical research 20020701

• SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase I.

  European journal of biochemistry 20020701

• Another NICE mess.

  The Lancet. Oncology 20020701

• [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020701

• Chemotherapy for metastatic colorectal cancer.

  Drug and therapeutics bulletin 20020701

• Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin.

  Anti-cancer drugs 20020701

• Non-linear pharmacokinetics of irinotecan in mice.

  Anti-cancer drugs 20020701

• Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.

  British journal of cancer 20020617

• Potent inhibition of DNA unwinding and ATPase activities of pea DNA helicase 45 by DNA-binding agents.

  Biochemical and biophysical research communications 20020607

• Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells.

  Biochemical and biophysical research communications 20020607

• Simultaneous determination of the carboxylate and lactone forms of 10-hydroxycamptothecin in human serum by restricted-access media high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020605

• Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.

  British journal of cancer 20020605

• Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics.

  International journal of pharmaceutics 20020604

• Polyamine depletion prevents camptothecin-induced apoptosis by inhibiting the release of cytochrome c.

  American journal of physiology. Cell physiology 20020601

• The tumour suppressor p33ING1 does not enhance camptothecin-induced cell death in melanoma cells.

  International journal of oncology 20020601

• Determination of drug interactions occurring with the metabolic pathways of irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20020601

• Heterogeneous susceptibility to spontaneous and induced apoptosis characterizes two related transplantable melanomas with different biological properties.

  Pigment cell research 20020601

• Induction of apoptosis by nitric oxide in macrophages is independent of apoptotic volume decrease.

  Cell death and differentiation 20020601

• Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.

  Cancer research 20020601

• Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020601

• Thalidomide and irinotecan-associated diarrhea.

  American journal of clinical oncology 20020601

• Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.

  European journal of cancer (Oxford, England : 1990) 20020601

• Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.

  Anti-cancer drugs 20020601

• Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.

  Japanese journal of cancer research : Gann 20020601

• High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.

  Carcinogenesis 20020601

• [A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020601

• Phase I studies of nogitecan hydrochloride for Japanese.

  International journal of clinical oncology 20020601

• New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.

  Expert review of anticancer therapy 20020601

• ERBITUX as a single agent and in combination in colorectal carcinoma.

  Expert review of anticancer therapy 20020601

• Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020601

• Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.

  Seminars in oncology 20020601

• Proteome analysis of camptothecin-treated cortical neurons using isotope-coded affinity tags.

  Electrophoresis 20020601

• Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

  Current cancer drug targets 20020601

• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  Molecular cancer therapeutics 20020601

• [Cytokine-induced killer cells induce apoptosis of K562 cells expressed bcr-abl].

  Zhongguo shi yan xue ye xue za zhi 20020601

• Loss of one allele of the p53 gene in the lens epithelial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT-11).

  Cancer letters 20020528

• [Irinotekan in spread small cell lung cancer. More studies are required to change the practice].

  Lakartidningen 20020523

• Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.

  British journal of cancer 20020520

• Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.

  Oncogene 20020516

• Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin.

  The Journal of biological chemistry 20020510

• Novel camptothecin derivatives. Part 1: oxyalkanoic acid esters of camptothecin and their in vitro and in vivo antitumor activity.

  Bioorganic & medicinal chemistry letters 20020506

• Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.

  British journal of cancer 20020506

• Caspase-mediated parkin cleavage in apoptotic cell death.

  The Journal of biological chemistry 20020503

• Changes in mobility account for camptothecin-induced subnuclear relocation of topoisomerase I.

  The Journal of biological chemistry 20020503

• Irinotecan in small-cell lung cancer.

  The New England journal of medicine 20020502

• An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry.

  Biomedical chromatography : BMC 20020501

• New developments in the treatment of esophageal cancer.

  Current oncology reports 20020501

• Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells.

  The Journal of pharmacology and experimental therapeutics 20020501

• Structural insights into CPT-11 activation by mammalian carboxylesterases.

  Nature structural biology 20020501

• Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment.

  Cancer research 20020501

• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

• Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.

  Chemotherapy 20020501

• Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.

  Japanese journal of cancer research : Gann 20020501

• [Current status of the chemotherapy for lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• [A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• [Usefulness of low-dose irinotecan for multiple lung metastases of cholangiocellular carcinoma after operation--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.

  Breast cancer research and treatment 20020501

• [Small cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [Irinotecan].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [Recent progress in the treatment of ED small cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• [New treatment strategy for stage III non-small-cell lung cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• Irinotecan, cisplatin, and radiation in esophageal cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan and gemcitabine in patients with solid tumors: phase I trial.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan in epithelial ovarian cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Irinotecan for the treatment of cervical cancer.

  Oncology (Williston Park, N.Y.) 20020501

• Combined-modality therapy for rectal cancer using irinotecan.

  Oncology (Williston Park, N.Y.) 20020501

• Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies.

  Oncology (Williston Park, N.Y.) 20020501

• A novel flow cytometric technique for drug cytotoxicity gives results comparable to colony-forming assays.

  Cytometry 20020501

• Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.

  Clinical colorectal cancer 20020501

• Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20020501

• Lessons learned from the Saltz and Mayo Clinic regimens.

  Clinical colorectal cancer 20020501

• Chemoradiation with novel agents for rectal cancer.

  Clinical colorectal cancer 20020501

• [Experimental study on the viricidal effect of rough extracts of camptothecine fruit on herpes simplex virus-2 in vitro].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20020428

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.

  Cancer 20020415

• Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.

  British journal of cancer 20020408

• Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

  International journal of oncology 20020401

• Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells.

  International journal of oncology 20020401

• Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.

  Drug metabolism and disposition: the biological fate of chemicals 20020401

• Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.

  Molecular pharmacology 20020401

• Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.

  Cancer chemotherapy and pharmacology 20020401

• Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.

  Cancer chemotherapy and pharmacology 20020401

• Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

  Neuro-oncology 20020401

• Evidence of an association between human papillomavirus and impaired chemotherapy-induced apoptosis in cervical cancer cells.

  Gynecologic oncology 20020401

• Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.

  European journal of cancer (Oxford, England : 1990) 20020401

• Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

  American journal of clinical oncology 20020401

• Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.

  Clinical pharmacology and therapeutics 20020401

• A novel ABC transporter gene, PMR5, is involved in multidrug resistance in the phytopathogenic fungus Penicillium digitatum.

  Molecular genetics and genomics : MGG 20020401

• [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020401

• [A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020401

• [Chemotherapy for the patients with esophageal cancer].

  Nihon Geka Gakkai zasshi 20020401

• Update on European adjuvant trials with irinotecan for colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Irinotecan/thalidomide in metastatic colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Capecitabine/irinotecan combination regimens in colorectal cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Irinotecan therapy for small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20020401

• Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

  Molecular medicine (Cambridge, Mass.) 20020401

• [Anticancer effect of hydroxycampothecin on oral squamous carcinoma cell line].

  Ai zheng = Aizheng = Chinese journal of cancer 20020401

• Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice.

  British journal of cancer 20020318

• Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.

  British journal of cancer 20020318

• Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides.

  The Journal of biological chemistry 20020315

• Stability of irinotecan hydrochloride in aqueous solutions.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020315

• Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.

  Cancer research 20020315

• DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

  Cancer research 20020315

• Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.

  Lung cancer (Amsterdam, Netherlands) 20020301

• Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20020301

• Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Combined chemotherapy trials require combined pharmacogenetic approaches.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020301

• Promising drug is victim of bad business.

  Nature medicine 20020301

• Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

  Nature medicine 20020301

• Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination.

  Mutagenesis 20020301

• Fighting wars, winning battles.

  Annals of surgical oncology 20020301

• Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.

  Annals of surgical oncology 20020301

• Kinetics of HL-60 cell entry to apoptosis during treatment with TNF-alpha or camptothecin assayed by the stathmo-apoptosis method.

  Cytometry 20020301

• Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

• Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

• [A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020301

• Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

  Japanese journal of cancer research : Gann 20020301

• Factors influencing the cellular accumulation of SN-38 and camptothecin.

  Cancer chemotherapy and pharmacology 20020301

• Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.

  Gene therapy 20020301

• [Cell cycle block and apoptosis in rabbit lens epithelial cells induced by hydroxycamptothecine].

  [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20020301

• Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma.

  Transfusion 20020301

• [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20020301

• Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020301

• Preparation and characterization of camptothecin solid lipid nanoparticles.

  Drug development and industrial pharmacy 20020301

• Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles.

  Current medicinal chemistry. Anti-cancer agents 20020301

• Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells.

  Experimental cell research 20020215

• Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020215

• Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells.

  Cancer research 20020215

• Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

  Biochemical pharmacology 20020215

• The modulation of the DNA-damaging effect of polycyclic aromatic agents by xanthines. Part I. Reduction of cytostatic effects of quinacrine mustard by caffeine.

  Biochemical pharmacology 20020215

• p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family.

  Oncogene 20020214

• Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer.

  British journal of cancer 20020212

• Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe.

  The Journal of biological chemistry 20020208

• Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.

  The Journal of biological chemistry 20020208

• Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.

  Biochemistry 20020205

• Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I.

  The Journal of biological chemistry 20020201

• Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain.

  The Journal of biological chemistry 20020201

• Activation of chymotrypsin-like serine protease(s) during apoptosis detected by affinity-labeling of the enzymatic center with fluoresceinated inhibitor.

  International journal of oncology 20020201

• Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.

  International journal of oncology 20020201

• Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

  Therapeutic drug monitoring 20020201

• Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes.

  Toxicological sciences : an official journal of the Society of Toxicology 20020201

• Nothing succeeds like failure.

  Nature biotechnology 20020201

• Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.

  American journal of clinical oncology 20020201

• An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.

  Cancer research 20020201

• Potentiation of cell killing by low-dose-rate radiation by camptothecin is related to an increase in the level of DNA double-strand breaks.

  Radiation research 20020201

• Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020201

• Future treatment options with capecitabine in solid tumours.

  European journal of cancer (Oxford, England : 1990) 20020201

• Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells.

  Neurosurgery 20020201

• ImClone BLA is declined.

  Nature biotechnology 20020201

• Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.

  Cancer 20020201

• CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.

  Cancer 20020201

• Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus-dependent.

  British journal of pharmacology 20020201

• Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line.

  Cancer chemotherapy and pharmacology 20020201

• [Globalization of anti-cancer therapies].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• [Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.

  Gan to kagaku ryoho. Cancer & chemotherapy 20020201

• Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.

  Journal of chemotherapy (Florence, Italy) 20020201

• Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure.

  Onkologie 20020201

• Gemcitabine-based combination treatment of pancreatic cancer.

  Seminars in oncology 20020201

• Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.

  Seminars in oncology 20020201

• Altered irinotecan metabolism in a patient receiving phenytoin.

  Anti-cancer drugs 20020201

• Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.

  Anti-cancer drugs 20020201

• Prediction of the response of colorectal cancer to systemic therapy.

  The Lancet. Oncology 20020201

• [Developed new agents for lung cancer].

  Nihon Geka Gakkai zasshi 20020201

• [Drug delivery systems for cancer chemotherapy].

  Nihon Geka Gakkai zasshi 20020201

• A critical role for ethylene in hydrogen peroxide release during programmed cell death in tomato suspension cells.

  Planta 20020201

• Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.

  Journal of pediatric hematology/oncology 20020201

• Influence of phenytoin on the disposition of irinotecan: a case report.

  Journal of pediatric hematology/oncology 20020201

• Clinical trials using irinotecan.

  Journal of pediatric hematology/oncology 20020201

• Phase I study of irinotecan in pediatric patients with malignant solid tumors.

  Journal of pediatric hematology/oncology 20020201

• Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

  Investigational new drugs 20020201

• Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy.

  Journal of neuro-oncology 20020201

• Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.

  Journal of neuro-oncology 20020201

• A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.

  Hematology/oncology clinics of North America 20020201

• 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs.

  Inhalation toxicology 20020201

• Adjuvant therapy of colon cancer: a review.

  Clinical colorectal cancer 20020201

• Werner and Bloom helicases are involved in DNA repair in a complementary fashion.

  Oncogene 20020131

• [The new chemotherapy of colorectal cancers].

  Presse medicale (Paris, France : 1983) 20020126

• Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.

  The Journal of biological chemistry 20020125

• Synthesis of an immunoconjugate of camptothecin.

  Bioorganic & medicinal chemistry letters 20020121

• Recurrent growth factor starvation promotes drug resistance in human leukaemic cells.

  British journal of cancer 20020121

• Cell-based assays for identification of novel double-strand break-inducing agents.

  Journal of the National Cancer Institute 20020116

• X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.

  Cancer research 20020115

• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  The New England journal of medicine 20020110

• Lung cancer--time to move on from chemotherapy.

  The New England journal of medicine 20020110

• Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.

  Journal of medicinal chemistry 20020103

• The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.

  Oncogene 20020103

• Monoclonal antibody to human chronic myeloid leukemia cell line MOLM-7 specifically reacts with an antigen of apoptotic cells.

  Leukemia research 20020101

• Synthesis and evaluation of a novel E-ring modified alpha-hydroxy keto ether analogue of camptothecin.

  Bioorganic & medicinal chemistry 20020101

• Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).

  International journal of oncology 20020101

• Increased frequency of DNA deletions in pink-eyed unstable mice carrying a mutation in the Werner syndrome gene homologue.

  Carcinogenesis 20020101

• Irinotecan dosing: does the CPT in CPT-11 stand for 'Can't Predict Toxicity'?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique.

  Cytometry 20020101

• Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.

  Cancer research 20020101

• Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.

  The Journal of thoracic and cardiovascular surgery 20020101

• Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.

  Japanese journal of cancer research : Gann 20020101

• Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells.

  Acta neurochirurgica 20020101

• MMS1 protects against replication-dependent DNA damage in Saccharomyces cerevisiae.

  Molecular genetics and genomics : MGG 20020101

• Characterization of BTBD1 and BTBD2, two similar BTB-domain-containing Kelch-like proteins that interact with Topoisomerase I.

  BMC genomics 20020101

• Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20020101

• Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test.

  Oncology reports 20020101

• Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

  Cancer investigation 20020101

• Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.

  BMC cancer 20020101

• In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.

  Anti-cancer drugs 20020101

• Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.

  Anti-cancer drugs 20020101

• Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.

  Clinical & experimental metastasis 20020101

• Potential antimutagenic activity of berberine, a constituent of Mahonia aquifolium.

  BMC complementary and alternative medicine 20020101

• Transforming growth factor-beta1 blocks the enhancement of tumor necrosis factor cytotoxicity by hyaluronidase Hyal-2 in L929 fibroblasts.

  BMC cell biology 20020101

• Chronomodulated chemotherapy and irradiation: an idea whose time has come?

  Chronobiology international 20020101

• Chronotherapy of colorectal cancer.

  Chronobiology international 20020101

• Third Wave, Daiichi to develop personalized cancer treatment.

  Expert review of molecular diagnostics 20020101

• Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.

  BMC cancer 20020101

• UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

  The pharmacogenomics journal 20020101

• Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20020101

• Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.

  Journal of neuro-oncology 20020101

• An HIV treatment the world may never see.

  Positively aware : the monthly journal of the Test Positive Aware Network 20020101

• In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line.

  Anticancer research 20020101

• Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.

  Anticancer research 20020101

• F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells.

  Anticancer research 20020101

• Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin.

  BMC cell biology 20020101

• A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.

  Oncology 20020101

• Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil.

  Oncology reports 20020101

• Computer automated prediction of potential therapeutic and toxicity protein targets of bioactive compounds from Chinese medicinal plants.

  The American journal of Chinese medicine 20020101

• Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.

  Acta biochimica Polonica 20020101

• Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases.

  Hepato-gastroenterology 20020101

• Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer.

  Hepato-gastroenterology 20020101

• A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.

  Anticancer research 20020101

• DNA strand-breaks induced by the topoisomerase I inhibitor camptothecin in unstimulated human white blood cells.

  Cell biology international 20020101

• Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.

  Oncology 20020101

• Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.

  Oncology 20020101

• DNA binding induces conformational transition within human DNA topoisomerase I in solution.

  Biopolymers 20020101

• Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.

  Cancer detection and prevention 20020101

• Camptothecins: a review of their chemotherapeutic potential.

  Drugs 20020101

• Current status and perspectives in the development of camptothecins.

  Current pharmaceutical design 20020101

• Efficacy of combination chemotherapy for stage IV colon cancer with extensive peritoneal dissemination and multiple liver metastases: a case report.

  Oncology reports 20020101

• Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

  Oncology 20020101

• [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].

  Molekuliarnaia biologiia 20020101

• Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.

  Clinical & experimental metastasis 20020101

• Induction of hRAD9 is required for G2/M checkpoint signal transduction in gastric cancer cells.

  Pathobiology : journal of immunopathology, molecular and cellular biology 20020101

• In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats.

  Journal of experimental therapeutics & oncology 20020101

• CDK inhibitors: cell cycle arrest versus apoptosis.

  Cell cycle (Georgetown, Tex.) 20020101

• Sequential activation of caspases and serine proteases (serpases) during apoptosis.

  Cell cycle (Georgetown, Tex.) 20020101

• CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity.

  Cell cycle (Georgetown, Tex.) 20020101

• Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells.

  Journal of biomedical science 20020101

• Fractionation and characterization of a conjugate between a polymeric drug-carrier and the antitumor drug camptothecin.

  Bioconjugate chemistry 20020101

• The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.

  Cancer investigation 20020101

• Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases.

  Surgery today 20020101

• Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.

  Anticancer research 20020101

• Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer.

  Anticancer research 20020101

• Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.

  Anticancer research 20020101

• Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations.

  Anticancer research 20020101

• [Studies on the preparation of camptothecin niosomes].

  Yao xue xue bao = Acta pharmaceutica Sinica 20020101

• [Effect of ladasten on proliferative activity and apoptosis in peripheral blood T-lymphocytes ].

  Eksperimental'naia i klinicheskaia farmakologiia 20020101

• The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients.

  Journal of liposome research 20020101

• Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

  Cancer biology & therapy 20020101

• Inhibition of cyclin A kinase activity in E2F-1 chemogene therapy of colon cancer.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20020101

• Topoisomerase I interactive agents.

  Cancer chemotherapy and biological response modifiers 20020101

• Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.

  Drug metabolism and drug interactions 20020101

• Nanomolar level of resveratrol (trans-3,5,4'-trihydroxystilbene) is required, but is not sufficient, to inhibit the growth of human monocytoid tumor cells through an apoptotic-like mechanism.

  Drugs under experimental and clinical research 20020101

• CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.

  International journal of gastrointestinal cancer 20020101

• A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.

  International journal of gastrointestinal cancer 20020101

• Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI.

  Molecular imaging 20020101

• A practical six-step synthesis of (S)-camptothecin.

  Organic letters 20011227

• Camptothecin and Zeocin can increase p53 levels during all cell cycle stages.

  Biochemical and biophysical research communications 20011221

• Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.

  The Journal of biological chemistry 20011214

• Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells.

  Brain research 20011207

• Nuclear translocation of PDCD5 (TFAR19): an early signal for apoptosis?

  FEBS letters 20011207

• Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver.

  International journal of oncology 20011201

• Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20011201

• Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011201

• Apoptosis-induced release of mature sterol regulatory element-binding proteins activates sterol-responsive genes.

  Journal of lipid research 20011201

• Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.

  Toxicology and applied pharmacology 20011201

• Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011201

• Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011201

• Radiosensitization with chemotherapeutic agents.

  Lung cancer (Amsterdam, Netherlands) 20011201

• CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.

  Japanese journal of cancer research : Gann 20011201

• The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.

  Carcinogenesis 20011201

• Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20011201

• [Phase I study with irinotecan hydrochloride (CPT-11) for advanced neuroblastoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011201

• [Chemotherapy of colorectal carcinoma].

  Der Internist 20011201

• Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.

  Cancer chemotherapy and pharmacology 20011201

• Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011201

• IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes.

  Oncogene 20011129

• Telomerase protects developing neurons against DNA damage-induced cell death.

  Brain research. Developmental brain research 20011126

• Quantitation of camptothecin and related compounds.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• Separation methods for camptothecin and related compounds.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents.

  Journal of medicinal chemistry 20011122

• Human bcl-2 gene attenuates the ability of rabbit lens epithelial cells against H2O2-induced apoptosis through down-regulation of the alpha B-crystallin gene.

  The Journal of biological chemistry 20011116

• Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011115

• Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.

  Biochemical and biophysical research communications 20011109

• High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.

  Journal of chromatography. B, Biomedical sciences and applications 20011105

• 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.

  The Journal of biological chemistry 20011102

• A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20011101

• Unique action determinants of double acting topoisomerase inhibitor, TAS-103.

  International journal of oncology 20011101

• The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification.

  International journal of oncology 20011101

• Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.

  Cancer research 20011101

• Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair.

  Carcinogenesis 20011101

• Thrombogenic role of cells undergoing apoptosis.

  British journal of haematology 20011101

• Prostaglandin D(2) synthase induces apoptosis in pig kidney LLC-PK1 cells.

  Kidney international 20011101

• Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis.

  British journal of pharmacology 20011101

• Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

• Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

• The role of apoptosis in the pathogenesis of Fuchs endothelial dystrophy of the cornea.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20011101

• Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.

  Japanese journal of cancer research : Gann 20011101

• [A case of lung metastasis from colon cancer treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011101

• Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.

  Cancer immunology, immunotherapy : CII 20011101

• A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma.

  Cancer chemotherapy and pharmacology 20011101

• Toxicity of irinotecan in patients with colorectal cancer.

  The New England journal of medicine 20011101

• A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011101

• Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011101

• [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].

  Revue de pneumologie clinique 20011101

• Perspectives in colorectal cancer meeting. Miami, Florida. September 28-29, 2001.

  Clinical colorectal cancer 20011101

• Capecitabine combinations in the treatment of advanced colorectal cancer.

  Clinical colorectal cancer 20011101

• Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.

  Clinical colorectal cancer 20011101

• Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex.

  Molecular cancer therapeutics 20011101

• Design of new anti-cancer agents based on topoisomerase poisons targeted to specific DNA sequences.

  Current medicinal chemistry. Anti-cancer agents 20011101

• The POU domain transcription factor Brn-3a protects cortical neurons from apoptosis.

  Neuroreport 20011029

• Evaluation of cell survival, DNA double strand breaks, and DNA synthesis during concurrent camptothecin and X-radiation treatments.

  International journal of cancer 20011020

• Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011015

• Downregulation of topoisomerase I in differentiating human intestinal epithelial cells.

  International journal of cancer 20011015

• [New therapeutic options in chemotherapy of advanced colorectal cancer].

  Medizinische Klinik (Munich, Germany : 1983) 20011015

• Switching enantiofacial selectivities using one chiral source: catalytic enantioselective synthesis of the key intermediate for (20S)-camptothecin family by (S)-selective cyanosilylation of ketones.

  Journal of the American Chemical Society 20011010

• Advances in cancer therapy with plant based natural products.

  Current medicinal chemistry 20011001

• Molecular characterization of the Rep protein of the blackgram isolate of Indian mungbean yellow mosaic virus.

  The Journal of general virology 20011001

• Stathmo-apoptosis: arresting apoptosis by fluorochrome-labeled inhibitor of caspases.

  International journal of oncology 20011001

• High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.

  Analytical biochemistry 20011001

• Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.

  The British journal of surgery 20011001

• Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).

  Cancer research 20011001

• Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.

  Cancer research 20011001

• Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.

  Anti-cancer drugs 20011001

• Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

• [Standard therapy of CPT-11 for colorectal cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.

  Xenobiotica; the fate of foreign compounds in biological systems 20011001

• [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Sigmoid colon cancer with multiple liver metastasis (H3) effectively treated with CPT-11 and DSM (degradable starch microsphere) HAI therapy and intensive high dosage 5-FU HAI therapy--a case report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• [Two cases of multiple liver metastases of colon cancer with systemic irinotecan and hepatic arterial injection of 5-FU].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Co-amplification of dhfr and a homologue of hmsh3 in a Chinese hamster methotrexate-resistant cell line correlates with resistance to a range of chemotherapeutic drugs.

  Cancer chemotherapy and pharmacology 20011001

• Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.

  Journal of medicinal chemistry 20010927

• Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.

  Journal of medicinal chemistry 20010927

• Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation.

  Oncogene 20010920

• Irinotecan-induced dysarthria.

  Journal of the National Cancer Institute 20010919

• Down-regulation of CD28 expression by TNF-alpha.

  Journal of immunology (Baltimore, Md. : 1950) 20010915

• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  Cancer research 20010915

• Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010915

• Sequence-specific trapping of topoisomerase I by DNA binding polyamide-camptothecin conjugates.

  Journal of the American Chemical Society 20010912

• Phosphorylation-induced activation of tilapia nonspecific cytotoxic cells by serum cytokines.

  Diseases of aquatic organisms 20010912

• Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells.

  FEBS letters 20010907

• Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis.

  Journal of cellular physiology 20010901

• Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells.

  Molecular pharmacology 20010901

• Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20010901

• Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance.

  International journal of cancer 20010901

• The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.

  Cancer research 20010901

• Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis.

  The Journal of physiology 20010901

• Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.

  Chemistry & biology 20010901

• Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).

  British journal of pharmacology 20010901

• Detection of caspase activation in situ by fluorochrome-labeled caspase inhibitors.

  BioTechniques 20010901

• [A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010901

• Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function.

  Molecular cell 20010901

• S phase dependence and involvement of NF-kappaB activating kinase to NF-kappaB activation by camptothecin.

  Biochemical pharmacology 20010901

• A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.

  Cancer chemotherapy and pharmacology 20010901

• Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.

  Cancer chemotherapy and pharmacology 20010901

• Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.

  British journal of cancer 20010901

• Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010901

• Relationship between lactone ring forms of HCPT and their antitumor activities.

  Acta pharmacologica Sinica 20010901

• The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.

  Human cell 20010901

• Phosphatidylserine induces apoptosis in CHO cells without mitochondrial dysfunction in a manner dependent on caspases other than caspases-1, -3, -8 and -9.

  FEBS letters 20010824

• Antiangiogenic potential of 10-hydroxycamptothecin.

  Life sciences 20010824

• A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.

  Biochemistry 20010821

• Resistance to topoisomerase poisons due to loss of DNA mismatch repair.

  International journal of cancer 20010815

• A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

  Cancer research 20010815

• Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin.

  Journal of controlled release : official journal of the Controlled Release Society 20010810

• Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine.

  Journal of chromatography. B, Biomedical sciences and applications 20010805

• The DNA helicase activity of yeast Sgs1p is essential for normal lifespan but not for resistance to topoisomerase inhibitors.

  Mechanisms of ageing and development 20010801

• Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.

  Molecular pharmacology 20010801

• Phase I clinical trial of weekly combined topotecan and irinotecan.

  American journal of clinical oncology 20010801

• Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.

  Cancer research 20010801

• Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Two unusual sites of colon cancer metastases and a rare thyroid lymphoma. Case 2. Chemotherapy-responsive right artial metastasis from colon carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying.

  Pharmaceutical development and technology 20010801

• Subcellular redistribution of BAX during apoptosis induced by anticancer drugs.

  Anti-cancer drugs 20010801

• Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction.

  Anti-cancer drugs 20010801

• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

• High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.

  Biomedical chromatography : BMC 20010801

• Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.

  Japanese journal of cancer research : Gann 20010801

• High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors.

  Cell proliferation 20010801

• Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae.

  Genes to cells : devoted to molecular & cellular mechanisms 20010801

• A mutation in subunit B of the DNA polymerase alpha-primase complex from Novikoff hepatoma cells concomitant with a conformational change and abnormal catalytic properties of the DNA polymerase alpha-primase complex.

  Molecular carcinogenesis 20010801

• Temozolomide in combination with other cytotoxic agents.

  Seminars in oncology 20010801

• Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20010801

• [Oxaliplatin in combination with non fluoropyrimidine drugs in colorectal cancer].

  Bulletin du cancer 20010801

• Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.

  Japanese journal of clinical oncology 20010801

• Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20010801

• Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.

  Acta pharmacologica Sinica 20010801

• Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20010801

• Irinotecan in the treatment of small cell lung cancer.

  Expert review of anticancer therapy 20010801

• Therapeutic advances in the management of metastatic colorectal cancer.

  Expert review of anticancer therapy 20010801

• Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.

  Clinical colorectal cancer 20010801

• Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.

  Clinical colorectal cancer 20010801

• Review of the role of CPT-11 in the treatment of colorectal cancer.

  Clinical colorectal cancer 20010801

• Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010715

• Characterization of DNA damage-stimulated self-interaction of Saccharomyces cerevisiae checkpoint protein Rad17p.

  The Journal of biological chemistry 20010713

• Downregulation of free ubiquitin: a novel mechanism of p53 stabilization and neuronal cell death.

  Brain research. Molecular brain research 20010713

• Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

  The New England journal of medicine 20010712

• Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

  The New England journal of medicine 20010712

• Biodegradable polymer implants to treat brain tumors.

  Journal of controlled release : official journal of the Controlled Release Society 20010706

• Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo.

  Journal of controlled release : official journal of the Controlled Release Society 20010706

• The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.

  Journal of controlled release : official journal of the Controlled Release Society 20010706

• Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC).

  Journal of controlled release : official journal of the Controlled Release Society 20010706

• p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner.

  Oncogene 20010705

• c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells.

  Molecular pharmacology 20010701

• UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.

  International journal of oncology 20010701

• beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.

  Experimental cell research 20010701

• 9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy.

  Journal of medical virology 20010701

• A series of enediynes as novel inhibitors of topoisomerase I.

  Bioorganic & medicinal chemistry 20010701

• Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.

  Cancer research 20010701

• A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.

  Cancer research 20010701

• Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer.

  European journal of cancer (Oxford, England : 1990) 20010701

• Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.

  British journal of cancer 20010701

• Researchers urge caution with standard regimen for metastatic colorectal cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010701

• Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.

  Journal of natural products 20010701

• [Usefulness of chemotherapy with CPT-11 in clinic for three colorectal cancer in terminal stage].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010701

• A tomato homologue of the human protein PIRIN is induced during programmed cell death.

  Plant molecular biology 20010701

• Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.

  Cancer chemotherapy and pharmacology 20010701

• The emerging world role of irinotecan in lung cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Irinotecan and radiation in combined-modality therapy for solid tumors.

  Oncology (Williston Park, N.Y.) 20010701

• Rationale for non-platinum chemotherapy in advanced NSCLC.

  Oncology (Williston Park, N.Y.) 20010701

• Topoisomerase I inhibitors in the treatment of head and neck cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.

  Oncology (Williston Park, N.Y.) 20010701

• Role of topoisomerase I inhibitors in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Recent advances in the chemotherapy of non-small cell lung cancer.

  Japanese journal of clinical oncology 20010701

• Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.

  Annals of hematology 20010701

• [Mitochondrial mechanisms of CPT-induced apoptosis in nasopharyngeal carcinoma cells].

  Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology 20010701

• Camptothecin suppresses nitric oxide biosynthesis in RAW 264.7 macrophages.

  Life sciences 20010629

• ELF magnetic field affects proliferation of SPD8/V79 Chinese hamster cells but does not interact with intrachromosomal recombination.

  Mutation research 20010627

• Inhibition of epithelial cell apoptosis by Porphyromonas gingivalis.

  FEMS microbiology letters 20010625

• pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.

  FEBS letters 20010615

• Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.

  Journal of medicinal chemistry 20010607

• Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver.

  Journal of pharmaceutical sciences 20010601

• Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.

  Anti-cancer drugs 20010601

• Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.

  Anti-cancer drugs 20010601

• Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.

  American journal of clinical oncology 20010601

• Control of irinotecan-induced diarrhea by octreotide after loperamide failure.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20010601

• [A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010601

• [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010601

• [The effect of EB virus bhrfl gene expressing on the topoisomerase I expression in nasopharyngeal carcinoma cell line].

  Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology 20010601

• Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

  Seminars in oncology 20010601

• Differentiation between inducers of apoptosis and nonspecific cytotoxic drugs by means of cell analyzer and immunoassay.

  Die Pharmazie 20010601

• [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20010601

• Rapid micro-assay of camptothecin in Camptotheca acuminata.

  Planta medica 20010601

• Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.

  Cancer chemotherapy and pharmacology 20010601

• Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.

  The Surgical clinics of North America 20010601

• Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

  Pharmaceutical research 20010601

• Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.

  Seminars in oncology 20010601

• In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.

  Osaka city medical journal 20010601

• Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20010601

• New developments in the treatment of ovarian cancer.

  Expert opinion on investigational drugs 20010601

• Activation of p53 by roscovitine-mediated suppression of MDM2 expression.

  Oncogene 20010531

• Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).

  Journal of medicinal chemistry 20010524

• Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.

  International journal of cancer 20010515

• Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515

• Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.

  Journal of medicinal chemistry 20010510

• Molecular characterisation of camptothecin-induced mutations at the hprt locus in Chinese hamster cells.

  Mutation research 20010509

• Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death.

  Biochemical and biophysical research communications 20010504

• Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

  International journal of oncology 20010501

• Detection of caspases activation by fluorochrome-labeled inhibitors: Multiparameter analysis by laser scanning cytometry.

  Cytometry 20010501

• Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.

  European journal of cancer (Oxford, England : 1990) 20010501

• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  Cancer research 20010501

• Impact on survival following successful neoadjuvant chemotherapy and radical surgery for Stage IIb bulky and Stage IIIb cervical cancer.

  Gynecologic oncology 20010501

• Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.

  Japanese journal of cancer research : Gann 20010501

• Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51.

  Genes to cells : devoted to molecular & cellular mechanisms 20010501

• Suppression of the radiation-sensitive phenotype of hamster irs1 and irs2 strains selected for resistance to 3-aminobenzamide.

  International journal of radiation biology 20010501

• [Platinum compounds in cancer therapy--past, present, and future].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• [A modified administrated schedule for combination therapy with irinotecan and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical cancer--a report of 2 cases as a pilot study].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010501

• Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.

  Cancer chemotherapy and pharmacology 20010501

• Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies.

  Cancer chemotherapy and pharmacology 20010501

• Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.

  The Lancet. Oncology 20010501

• 25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.

  Clinical colorectal cancer 20010501

• Advances in the treatment of metastatic colorectal cancer.

  Clinical colorectal cancer 20010501

• Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.

  Clinical colorectal cancer 20010501

• Topoisomerase I inhibitors in the combined modality therapy of lung cancer.

  Clinical lung cancer 20010501

• Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.

  International journal of cancer 20010415

• Monochloramine inhibits etoposide-induced apoptosis with an increase in DNA aberration.

  Free radical biology & medicine 20010415

• DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.

  Journal of molecular biology 20010413

• Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.

  Cancer letters 20010410

• A link between apoptosis and degree of phosphorylation of high mobility group A1a protein in leukemic cells.

  The Journal of biological chemistry 20010406

• Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.

  Oncogene 20010405

• Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.

  Drug metabolism and disposition: the biological fate of chemicals 20010401

• Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.

  Biomedical chromatography : BMC 20010401

• A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide.

  Journal of neurochemistry 20010401

• Caspase-mediated suppression of glutamate (AMPA) receptor channel activity in hippocampal neurons in response to DNA damage promotes apoptosis and prevents necrosis: implications for neurological side effects of cancer therapy and neurodegenerative disorders.

  Neurobiology of disease 20010401

• Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells.

  Cancer research 20010401

• Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.

  Cancer research 20010401

• Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010401

• [Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010401

• Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan.

  Cancer chemotherapy and pharmacology 20010401

• The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.

  Oncology (Williston Park, N.Y.) 20010401

• Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro.

  The Journal of steroid biochemistry and molecular biology 20010401

• Sensitivity to camptothecin in Aspergillus nidulans identifies a novel gene, scaA+, related to the cellular DNA damage response.

  Molecular genetics and genomics : MGG 20010401

• A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

  Journal of cellular biochemistry 20010401

• [Chemotherapy of irinotecan (CPT-11) combined with cisplatin in patients with advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [Irinotecan (CPT-11) therapy for advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• [Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• Changes in gene expression during programmed cell death in tomato cell suspensions.

  Plant molecular biology 20010401

• [New chemotherapies for colorectal cancer treatment].

  Gastroenterologie clinique et biologique 20010401

• Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.

  Prescrire international 20010401

• Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.

  The Journal of biological chemistry 20010316

• Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.

  Journal of controlled release : official journal of the Controlled Release Society 20010312

• Inhibition of Flp recombinase by the topoisomerase I-targeting drugs, camptothecin and NSC-314622.

  The Journal of biological chemistry 20010309

• p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.

  Oncogene 20010308

• Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity.

  Brain research. Molecular brain research 20010305

• Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.

  Cytometry 20010301

• Determinants of prognosis and response to therapy in colorectal cancer.

  Current oncology reports 20010301

• Oxaliplatin: a new agent for colorectal cancer.

  Current oncology reports 20010301

• Topoisomerase I targeting agents in small-cell lung cancer.

  Current oncology reports 20010301

• Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

• Irinotecan in the treatment of colorectal cancer: clinical overview.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

• Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons.

  Annals of neurology 20010301

• [A case of AFP-producing gastric cancer responding to low-dose CPT-11 and low-dose cisplatin combination chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20010301

• Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.

  Cancer research 20010301

• Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.

  Anti-cancer drugs 20010301

• Camptothecin schedule and timing of administration with irradiation.

  Oncology (Williston Park, N.Y.) 20010301

• Cisplatin and irinotecan in upper gastrointestinal malignancies.

  Oncology (Williston Park, N.Y.) 20010301

• Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.

  Oncology (Williston Park, N.Y.) 20010301

• Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.

  Oncology (Williston Park, N.Y.) 20010301

• Growth and production of camptothecin by cell suspension cultures of Nothapodytes foetida.

  Planta medica 20010301

• Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.

  Expert opinion on pharmacotherapy 20010301

• [Evaluation of quality of life in patients with advanced colorectal cancer treated with topotecan].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20010301

• Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement.

  The Journal of biological chemistry 20010216

• Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis.

  The Journal of biological chemistry 20010216

• Effect of bile acids on the uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.

  Biochimica et biophysica acta 20010216

• Continuous measurement of targeted promoter activity by a secreted bioluminescence reporter, Vargula hilgendorfii luciferase.

  Analytical biochemistry 20010215

• Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.

  Cancer 20010215

• Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.

  Cancer 20010215

• Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

  Cancer research 20010215

• Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin.

  Bioorganic & medicinal chemistry letters 20010212

• Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

  Biochemical and biophysical research communications 20010209

• Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.

  International journal of oncology 20010201

• Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1.

  Biochemical pharmacology 20010201

• Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.

  British journal of cancer 20010201

• High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.

  Biological & pharmaceutical bulletin 20010201

• Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.

  Japanese journal of cancer research : Gann 20010201

• Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.

  American journal of clinical oncology 20010201

• Why drugs fail: of mice and men revisited.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010201

• Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010201

• [Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20010201

• Adjuvant therapy of colon cancer.

  Seminars in oncology 20010201

• Modulation of camptothecin analogs in the treatment of cancer: a review.

  Anti-cancer drugs 20010201

• North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.

  Seminars in oncology 20010201

• Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba.

  Journal of natural products 20010201

• [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].

  Onkologie 20010201

• A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.

  Anti-cancer drug design 20010201

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  The New England journal of medicine 20010125

• Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.

  Cancer research 20010115

• Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.

  Cancer research 20010115

• The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

  Cancer research 20010115

• Mesityllithium as a reagent for chemoselective halogen-lithium exchange reaction.

  Organic letters 20010111

• Flow cytometric fluorescence lifetime measurements.

  Methods in cell biology 20010101

• Analysis of cleavage complexes using reactive inhibitor derivatives.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Drug toxicity in E. coli cells expressing human topoisomerase I.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Analysis of drug uptake-flow cytometry.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Cell-cycle analysis of drug-treated cells.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Assaying drug-induced apoptosis.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Drug-induced stabilization of covalent DNA topoisomerase I-DNA intermediates. DNA cleavage assays.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Apoptosis enhancement by the HIV-1 Nef protein.

  Journal of immunology (Baltimore, Md. : 1950) 20010101

• The changing face of chemotherapy in colorectal cancer.

  British journal of cancer 20010101

• Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.

  British journal of cancer 20010101

• A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.

  Cancer 20010101

• Gemcitabine: progress in the treatment of pancreatic cancer.

  Oncology 20010101

• Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.

  British journal of pharmacology 20010101

• Irinotecan: a new agent comes of age.

  The oncologist 20010101

• Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.

  The oncologist 20010101

• Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

  The oncologist 20010101

• The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer.

  Critical reviews in oncology/hematology 20010101

• Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

  Clinical and experimental immunology 20010101

• [A case of small cell carcinoma of esophagus successfully treated by chemotherapy with CPT-11 and CDDP].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20010101

• Pharmacological determinants of 9-aminocamptothecin cytotoxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Irinotecan in small-cell lung cancer: the US experience.

  Oncology (Williston Park, N.Y.) 20010101

• Establishment of the standard regimen for non-small-cell lung cancer in Japan.

  Oncology (Williston Park, N.Y.) 20010101

• Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.

  Oncology (Williston Park, N.Y.) 20010101

• Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20010101

• Docetaxel followed by gemcitabine and irinotecan in solid tumors.

  Oncology (Williston Park, N.Y.) 20010101

• Irinotecan: summary and future directions.

  Oncology (Williston Park, N.Y.) 20010101

• Current status of irinotecan in lung cancer.

  Oncology (Williston Park, N.Y.) 20010101

• New state of the art in small-cell lung cancer.

  Oncology (Williston Park, N.Y.) 20010101

• Chemoradiation in locally advanced non-small cell lung cancer.

  Cancer treatment and research 20010101

• Lung cancer: therapeutic options for stage IV and recurrent NSCLC.

  Cancer treatment and research 20010101

• Treatment of extensive stage small cell lung cancer.

  Cancer treatment and research 20010101

• Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.

  Oncology 20010101

• A novel genetic screen identifies checkpoint-defective alleles of Schizosaccharomyces pombe chk1.

  Current genetics 20010101

• The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

  Anti-cancer drugs 20010101

• Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

  Investigational new drugs 20010101

• Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.

  Investigational new drugs 20010101

• Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.

  Anticancer research 20010101

• [Irinotecan in colorectal cancer].

  Tumori 20010101

• [Molecular factors predictive of response to chemotherapy in advanced stages of colorectal cancer].

  Tumori 20010101

• Adjuvant therapy for colon cancer: the European experience.

  Tumori 20010101

• Urinary metabolites of DX-8951, a novel camptothecin analog, in rats and humans.

  Arzneimittel-Forschung 20010101

• Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.

  Neuro-oncology 20010101

• A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.

  Oncology 20010101

• A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.

  Farmaco (Societa chimica italiana : 1989) 20010101

• The DRAG test: an assay for detection of genotoxic damage.

  Alternatives to laboratory animals : ATLA 20010101

• Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.

  Anticancer research 20010101

• Morphological classification of dental lesions induced by various antitumor drugs in mice.

  Toxicologic pathology 20010101

• Elevations of DNA topoisomerase I in invasive carcinoma of the breast.

  The breast journal 20010101

• Expression of BAX in cell nucleus after experimentally induced apoptosis revealed by immunogold and embedment-free electron microscopy.

  Cell biology international 20010101

• Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model.

  Anticancer research 20010101

• 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies.

  Anticancer research 20010101

• The anti-proliferative effect of inhibitor of telomerase on cultured retinal pigment epithelial cells.

  Journal of Tongji Medical University = Tong ji yi ke da xue xue bao 20010101

• The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.

  Arthritis research 20010101

• Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma.

  Investigational new drugs 20010101

• A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.

  Investigational new drugs 20010101

• Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.

  Investigational new drugs 20010101

• New adjuvant therapies for esophageal cancer.

  Advances in surgery 20010101

• Optimizing the use of irinotecan in colorectal cancer.

  The oncologist 20010101

• Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.

  Oncology 20010101

• Nonspecific cytotoxic cells and innate immunity: regulation by programmed cell death.

  Developmental and comparative immunology 20010101

• Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report.

  Tumori 20010101

• Topoisomerase I interactive agents.

  Cancer chemotherapy and biological response modifiers 20010101

• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  Anticancer research 20010101

• Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.

  Bioconjugate chemistry 20010101

• Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11 by increasing Th1-cytokine production in mice.

  Anticancer research 20010101

• Inhibitors of trypsin-like serine proteases prevent DNA damage-induced neuronal death by acting upstream of the mitochondrial checkpoint and of p53 induction.

  Neuroscience 20010101

• Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

  The oncologist 20010101

• The development of camptothecin analogs in childhood cancers.

  The oncologist 20010101

• Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.

  Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20010101

• [Irinotecan and fluorouracil in combination in colorectal carcinoma: a little clarity].

  Tumori 20010101

• Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.

  European journal of gynaecological oncology 20010101

• UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.

  AAPS pharmSci 20010101

• Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases--a pilot experience.

  Hepato-gastroenterology 20010101

• [Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].

  Voprosy onkologii 20010101

• Simultaneous determination of apoptosis and surface antigen expression in tumor adherent cells.

  Journal of biological regulators and homeostatic agents 20010101

• [Genetic information under control--role of eukaryotic topoisomerase I].

  Postepy biochemii 20010101

• Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma.

  Anticancer research 20010101

• DNA binding properties of the indolocarbazole antitumor drug NB-506.

  Anti-cancer drug design 20010101

• Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: results of a phase I clinical study.

  Tumori 20010101

• A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

  Health technology assessment (Winchester, England) 20010101

• [Proceedings of the 3rd National Conference of Medical Oncology. Irinotecan: present and future. Napoli, Italy, 5 November 2001].

  Tumori 20010101

• [Colorectal cancer: irinotecan in combination with newer drugs].

  Tumori 20010101

• [Irinotecan in the treatment of stomach cancer].

  Tumori 20010101

• [Role of irinotecan in the treatment of small cell carcinoma].

  Tumori 20010101

• The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.

  Anti-cancer drug design 20010101

• Irinotecan hydrochloride.

  Clinical journal of oncology nursing 20010101

• Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.

  Cancer research 20001201

• The super anti-apoptotic factor Bcl-xFNK constructed by disturbing intramolecular polar interactions in rat Bcl-xL.

  The Journal of biological chemistry 20001124

• The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity.

  Journal of medicinal chemistry 20001019

• New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.

  International journal of cancer 20001015

• Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.

  The Journal of biological chemistry 20001013

• Analysis of stereoelectronic properties of camptothecin analogues in relation to biological activity.

  Bioorganic & medicinal chemistry 20000701

• [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20000701

• Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells.

  Cancer research 20000401

• p53-dependent apoptosis in melanoma cells after treatment with camptothecin.

  The Journal of investigative dermatology 20000301

• Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.

  Molecular pharmacology 20000301

• Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.

  Cancer research 20000301

• Uncoupling of apoptosis and Jun/AP-1 activity in human promonocytic cells treated with DNA-damaging and stress-inducing agents.

  European journal of cell biology 20000101

• Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.

  Cancer chemotherapy and pharmacology 20000101

• Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.

  Antimicrobial agents and chemotherapy 19991201

• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  Cancer research 19991201

• Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.

  Cancer research 19990801

• Derivatives of the new ring system indolo[1,2-c]benzo[1,2,3]triazine with potent antitumor and antimicrobial activity.

  Journal of medicinal chemistry 19990715

• Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells.

  The Prostate 19990615

• Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives.

  Journal of medicinal chemistry 19990520

• 9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells.

  AIDS research and human retroviruses 19990210

• Bradycardia induced by irinotecan: a case report.

  Japanese journal of clinical oncology 19981101

• Synthesis and anti-human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon-3-yl esters.

  Antiviral chemistry & chemotherapy 19981101

• Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling.

  Journal of medicinal chemistry 19981008

• Activation of JNK pathway and induction of apoptosis by manganese in PC12 cells.

  Journal of neurochemistry 19981001

• Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.

  Cancer research 19981001

• 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.

  Clinical & experimental metastasis 19981001

• The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells.

  International journal of oncology 19980801

• Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities.

  Cancer research 19980715

• Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.

  The Journal of pharmacology and experimental therapeutics 19980701

• Proteolytic cleavage of HsRad51 during apoptosis.

  FEBS letters 19980508

• Preparation and imaging of nuclear spreads from cells of the zebrafish embryo. Evidence for large degradation intermediates in apoptosis.

  Chromosoma 19980301

• Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.

  Anticancer research 19980101

• Pentoxifylline stimulates drug-induced apoptosis in leukemic cells.

  Neoplasma 19980101

• Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.

  The Journal of biological chemistry 19971212

• Clinical pharmacokinetics of irinotecan.

  Clinical pharmacokinetics 19971001

• Discovery of selective, small-molecule inhibitors of RNA complexes--I. The Tat protein/TAR RNA complexes required for HIV-1 transcription.

  Bioorganic & medicinal chemistry 19970601

• Efficacy of camptothecin in progressive multifocal leucoencephalopathy.

  Lancet (London, England) 19970510

• Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.

  Antimicrobial agents and chemotherapy 19970501

• Actin cleavage by CPP-32/apopain during the development of apoptosis.

  Oncogene 19970306

• An overview of the clinical pharmacology of topotecan.

  Seminars in oncology 19970201

• Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.

  British journal of cancer 19960801

• Clinical pharmacokinetics of topotecan.

  Clinical pharmacokinetics 19960801

• Camptothecin and taxol: from discovery to clinic.

  Journal of ethnopharmacology 19960401

• Bioactive steroidal alkaloids from Solanum umbelliferum.

  Journal of natural products 19960301

• Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs.

  Journal of medicinal chemistry 19950331

• Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.

  Cancer research 19950215

• Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

  Journal of the National Cancer Institute 19940601

• Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.

  Journal of medicinal chemistry 19930903

• Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

  Antimicrobial agents and chemotherapy 19930701

• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

  Cancer research 19930615

• Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay.

  Toxicology letters 19930401

• Inhibitors of human immunodeficiency virus integrase.

  Proceedings of the National Academy of Sciences of the United States of America 19930315

• Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.

  Proceedings of the National Academy of Sciences of the United States of America 19930301

• Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery.

  Antimicrobial agents and chemotherapy 19921001

• Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor.

  AIDS research and human retroviruses 19910101

• Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.

  Journal of natural products 19910101

• Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

  Molecular pharmacology 19900701

• Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.

  Cancer chemotherapy and pharmacology 19880101

• Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

  Cancer chemotherapy and pharmacology 19880101

• Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

  Cancer research 19871115

• Antiviral action of camptothecin.

  Antimicrobial agents and chemotherapy 19721101

• Plant antitumor agents. IV. An approach toward the synthesis of camptothecin.

  The Journal of organic chemistry 19691201